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Glossary of terms 
Abbreviated progressive muscle relaxation (APRT): An abbreviated form of the 
progressive muscle relaxation technique (PMR) 
Adho mukha svanasana: Downward facing dog pose. 
Alpha rhythm: “An EEG pattern consisting of trains of sinusoidal 8-13 Hz activity” 
(AASM, 2007, p. 59). 
Ardha chandrasana: Half moon pose. 
Ardha kurmasana: Tortoise pose. 
Ardha pavana muktasana: Half wind removing pose. 
Ardha shalbhasana: Half locust pose. 
Ardha chandrasana: Half moon pose. 
Apnoea: “An interruption of airflow lasting at least 10 seconds in adults or the 
equivalent of two breaths in children” (AASM, 2007, p. 59). 
Asana: The third limb of in Patanjali‟s eightfold path of yoga („Ashtanga yoga‟) 
translated as postures, poses, and stable sitting positions. 
Ashtanga vinyasa yoga: A dynamic system of yoga introduced to the west in the early 
20
th
 century by K. Pattabhi Jois. This form of yoga incorporates a series of 51 traditional 
static yoga poses linked by a „Vinyasa‟, which is a dynamic connective flow of poses 
that links a series of static asanas.  
Ashtanga yoga: The eightfold path of yoga as outlined by Patanjali. The eight branches 
include: Yama, Niyama, Asana, Pranayama, Pratyahara, Dharana, Dhyana and Samadhi. 
Autonomic nervous system (ANS): The part of the peripheral nervous system that 
mainly controls subconscious involuntary functions such as heart rate, digestion, 
respiration rate etc. 
B. K. S. Iyengar: A contemporary yoga master. Founder of 'Iyengar yoga'. 
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Balasana: Child‟s pose. 
Bastrika pranayama: Bellows breathing technique - breathing forcibly in and out 
through the nose in equal proportions. 
Beta rhythm: “An EEG rhythm consisting of 13-30 Hz activity” (AASM, 2007, p. 59). 
Bhujangasana: Cobra pose. 
Bikram Choudhury: A contemporary yoga master founder of 'Bikram yoga' 
Bikram yoga: A system of yoga synthesized by Bikram Choudhury from traditional 
hatha yoga techniques and introduced in the west in the early 1970s. Bikram beginners 
yoga class incorporates a series of 26 postures and two short breathing exercises, and is 
ideally practiced in ambient temperature of 105°F (40.5°C), which is approximately 
3.5° C - 4°C above normal body temperature, and in humidity of 40%. Practicing yoga 
in such conditions results in an aerobic effect as well as considerable sweating. 
Bitilasana: Cow pose 
Body mass index (BMI): A measure of obesity calculated by dividing body mass (in 
Kg) by the square of the height (in meter) as follows: BMI = body mass/(height)
2
 
Chakra: A wheel-like vortex energetic centre which, according to yogic philosophy 
and traditional Indian medicine, are believed to exist on the surface of the human energy 
body. The seven main chakras are positioned along the body from the top of the head to 
the base of the spine. 
Continuous positive airway pressure (CPAP): A device used for treating sleep apnea 
by maintaining a constant, continuous positive airway pressure to help keep the airway 
open.  
Cyclic meditation (CM): A yogic practice introduced by Swami Vivekananda and the 
Vivekananda yoga anusandhana samsthana (VYASA). CM is based on cycles of static 
yoga postures followed by supine relaxation periods of several minutes each. 
xv 
 
Delta rhythm: “An EEG rhythm consisting of 1-4 Hz activity” (AASM, 2007, p. 59). 
Dharana: The sixth limb of Patanjali‟s eightfold path of yoga, translated as 
concentration, keeping the mind focused. 
Dhyana: The seventh limb of Patanjali‟s eightfold path of yoga translated as 
meditation, contemplation, reflection, awareness. 
Electrocardiogram (ECG): Recording of the electrical activity of the heart. 
Electroencephalogram (EEG): Recording of the electrical activity of the brain. 
Electromyogram (EMG): Recording of muscle electrical potentials. 
Electromyogram (EOG): “Recording of eye movements by means of changes in the 
electrical potentials between the retina and the cornea” (Pollak et al., 2010, p 77). 
Gamma-amino butyric Acid (GABA): A key neurotransmitter distributed throughout 
the central nervous system and also believed linked to the endocrine system and 
affecting sleep quality.  
Garurasana: Eagle pose. 
Goolf Chakra: Ankle rotations. 
Guru: A spiritually evolved teacher, who can dispel ignorance and illusion from the 
mind of a devotee/disciple. 
Hatha yoga: An ancient yoga system aiming at purifying the entire physical body using 
Shatkarma (cleansing practices), Asana (posture), Pranayama (breath/energy 
regulation), Mudra, (hand gestures) Banda (energy locks) and Dharana 
(focus/concentration). 
Heart Rate Variability (HRV): The variability of the time interval between 
consecutive heart beats.  
Hypopnea: “A specified reduction in airflow lasting at least 10 seconds in adults or the 
equivalent of two breaths in children” (AASM, 2007, p. 59). 
xvi 
 
Ida nadi: One of the main energy channels which, according to yogic philosophy, runs 
on the left side of the spine intersecting various chakras on the way. 
K complex: “An EEG event consisting of a well delineated negative sharp wave 
immediately followed by a positive component standing out from the background EEG 
with total duration ≥0.5 second, usually maximal in amplitude over the frontal regions” 
(AASM, 2007, p. 59). 
Kapalabati: A rapid breathing technique done with more emphasis on exhalation. 
Kosha: A layer or sheath in Sanskrit. Yogic philosophy describes five sheaths, 
sometimes likened to layers of an onion that surround the soul, including a physical 
layer, a pranic (energetic) layer, an instinctive thinking/emotional layer, a 
mental/intellectual layer and a super- consciousness layer. 
Kriya: Activity, dynamic yogic practice. 
Kriya yoga: An ancient yoga system reintroduced by Mahavatar Babaji and his disciple 
Lahiri Mahasaya in the 19th century and popularised by Paramhansa Yogananda. It 
includes several levels of Pranayama and intended to facilitate accelerated spiritual 
development. 
Kundalini: Retained energy or potential energy/ consciousness in human beings. 
Kundalini yoga (KY): A yoga practice based on a philosophy expounding the 
awakening of potential energy and inherent consciousness within the human body and 
mind. KY as introduced by Yogi Bhajan utilises meditation and breathing techniques, 
Mudras and some postures.  
Kurmasana: Tortoise Pose. 
Manibandha Chakra: Wrist rotations. 
Mantra: A subtle sound vibration, that aims through repetition at expanding one's 
awareness or consciousness. 
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Marjaryasana: Cat pose. 
Matsyendrasana: Half lord of the fish pose. A spine twisting pose. 
Mindfulness based stress reduction (MBSR): a non sectarian program established by 
Jon Kabat-Zinn at the University of Massachusetts Medical School. It aims at 
cultivating mindfulness, defined as a moment-to-moment non-judgmental awareness of 
mental and emotional processes and states, and using it as a tool for self transformation 
and self healing. 
Mudra: A symbolic (hand) gesture used for directing energetic and spiritual focus 
Nadi: Subtle energy channels which, according to yogic philosophy, run throughout the 
body. 
Nadi Shodana Pranayama: Alternate nostril breathing' or 'balanced breathing'.  
Nidra: Sleep in Sanskrit 
Niyama: The second limb of in Patanjali‟s eightfold path of yoga which deals with 
fixed observances, values and precepts. 
Oxygen desaturation: A drop below normal (90%) in the amount of oxygen in blood 
haemoglobin. 
Oxygen desaturation index (ODI): A measure of mean oxygen desaturation 
Padmasana: Lotus pose; a seated meditative pose. 
Paschimottanasana: A seated forward bend pose. 
Patanjali: Author of the „Yoga Sutra‟ who systematised the eightfold path of yoga. 
Pattabhi Jois: Contemporary yoga master who promoted the „Ashtanga vinyasa yoga‟ 
method. 
Pavana muktasana: Wind removing pose. 
Periodic leg movements of sleep (PLMD): Movements of the legs during sleep 
occurring with a specified frequency, duration and amplitude. 
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Pingala nadi: One of the main energy channels, which, according to yogic philosophy, 
runs on the right side of the spine intersecting various chakras on the way. 
Prana: A vital energy force, which, according to yogic philosophy, sustains life and 
creation. 
Pranayama: The fourths limb of Patanjali‟s eightfold path of yoga that deals with 
regulation of breath for cultivating and regulating energy flow in the body. 
Progressive muscle relaxation (PMR): A relaxation technique based on sequential 
tensing and relaxing of various muscle groups. PMR was introduced by American 
physician Edmund Jacobson in the early 1920s. 
Pratyahara: The fifth limb of Patanjali‟s eightfold path of yoga that deals with 
withdrawal of the senses and directing them inwardly. 
Qi Gong: Also called Qigong or Chi kung is a Chinese Mandarin term describing 
diverse methods of physical and mental training for health, martial arts and spiritual 
advancement. Qi can be interpreted as energy, breathing or air and Gong as a method 
for achieving results. Together they can be translated as an energy cultivation practice 
method. 
Raja yoga: Translated from Sanskrit as „royal yoga‟ or royal union. Deals mainly with 
cultivation of the mind using meditative techniques leading towards deeper self 
knowledge with the ultimate goal of achieving spiritual liberation. Raja yoga was first 
described in the ‟Yoga Sutra‟ of Patanjali. 
Rapid Eye Movements (REM): “EOG events consisting of trains of conjugate, 
irregular, sharply peaked eye movements with an initial deflection usually lasting <500 
milliseconds” (AASM, 2007, p. 59). 
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Respiratory effort related arousal (RERA): “A sequence of breaths lasting at least 10 
seconds which does not meet criteria for an apnea or hypopnea and is characterised by 
increasing respiratory effort leading to an arousal from sleep” (AASM, 2007, p. 59). 
Samadhaya: The eighth limb of Patanjali‟s eightfold path of yoga. Deals with 
absorption of consciousness in the self, profound meditation, super-consciousness 
Samadhi: see Samadhaya  
Sankalpa: Spiritual resolve. 
Savasana: Corpse pose; a supine relaxation pose. 
Shalbhasana: Locust pose. 
Shatkarma: Yogic purification practices for cleaning the upper digestive system and 
colon, nasal passages, eyes etc. 
Shushumna: The central subtle energy channel, which according to yogic philosophy 
flow along the spinal column 
Siddhasana: A meditative sitting pose. 
Skandh Chakra: Shoulder rotations 
Sleep efficiency: The ratio between the actual sleep time in a sleep episode to the total 
available time for sleep. 
Sleep spindle: “An EEG event consisting of a train of distinct waves with frequency 11-
16 Hz (most commonly 12 – 14 Hz) with a duration ≥0.5 seconds, usually maximal in 
amplitude over the central regions” (AASM, 2007, p. 59). 
Slow Wave Sleep (SWS): SWS is the deepest sleep phase and is characterised by low 
frequency high amplitude brain waves that are 75 microvolt or greater as observed on 
EEG recordings. 
Sudarshan kriya yoga (SKY): A contemporary yoga system formalised by Sri Sri 
Ravi Shankar, founder of the Art of living Foundation. The SKY protocol incorporates a 
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sequence of specific yogic breathing techniques, including ujai pranayama, bastrika 
pranayama, and a special SKY breathing sequence. 
Swastikasana: The „auspicious‟ pose;  a meditative pose similar to Siddhasana. 
Tadasana: Mountain pose. 
Theta rhythm: “An EEG rhythm consisting of 4-8 Hz activity” (AASM, 2007, p. 59). 
Tiryaka tadasana: Swaying palm tree pose 
Transcendental meditation (TM): A meditation technique, using internal silent 
mantra repetition. The TM technique and TM movement were introduced in India in the 
mid-1950s by Maharishi Mahesh Yogi (1914–2008) and has achieved worldwide reach 
since the 60's.  
Ujai pranayama: A kind of yogic breathing technique which produces a light sonorous 
sound. 
Utkatasana: Squatting pose. 
Uttankoormasana: Tortoise pose. 
Vajrasana: The 'thunderbolt' pose. 
Virasana: Hero's pose. 
Vinyasa: Breath-synchronized yogic movement sequence. 
Vipassana meditation: Vipassana (Insight - in Pali) in the Buddhist tradition refers to 
insight into the true nature of reality. Vipassana meditation is an insight or mindfulness 
method of self-observation which focuses on the close interconnection between mind 
and body. This interconnection is experienced directly by paying close attention to the 
physical sensations throughout the body. Vipassana Meditation in the tradition of 
Sayagyi U Ba Khin as taught by S.N. Goenka and hundreds of his assistant teachers 
runs regular courses worldwide.  
Virabhadrasana: Warrior‟s pose 
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Yama: The first limb of Patanjali‟s eightfold path of yoga; translated from Sanskrit as 
moral injunctions, self restraint, and abstention. 
Yoga Nidra: Yogic sleep - in Sanskrit; a deep relaxation and meditation technique 
aiming to bring the body to a state of complete rest and the mind to a state of full 
awareness. 
Zen meditation: Zazen in Japanese - is the core practice in Zen Buddhism. Specific 
choice of practice methods depend on the specific school with the first step usually 
involving a concentration practice for anchoring the mind by observing or counting the 
breath or by focusing on an area below the navel. The two main schools of Zen 
Buddhism differ in main meditation method. In the Rinzai school pondering of 'Koans' 
is the main practice method where as in the Soto school whole-hearted sitting 
(Shikantaza) is the main practice method. Koans are stories, dialogues, questions or 
statements that cannot be understood by rational thinking and intended to lead the 
practitioner to transcend the rational mind. Shikantaza, on the other hand, is a practice 
of alert attention/mindfulness in which the mind does not attach to any particular 
thoughts or objects, but rather involves observing whatever arises in the mind without 
attaching to it. 
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Summary 
The aging process is associated with a significant increase in the prevalence of 
sleep disorders, the most common being insomnia and obstructive sleep apnea (OSA). 
Insomnia is associated with daytime sleepiness and drowsiness, reduced attention, poor 
memory, slowed reaction time and reduced problem solving capacity. Insomnia is 
recognised as a major cause of morbidity in the elderly population and is associated 
with diminished mental and physical health and reduced quality of life along with 
increased likelihood of nursing home placement and increased risk of accidents and 
falls. Effective management of insomnia may contribute significantly to the reduction of 
morbidity and enhancement of quality of life in older adults and may help reduce health 
resource utilisation and related costs. While sedative-hypnotic drugs are currently the 
main form of treatment of insomnia, they have limited effectiveness and are associated 
with various side-effects, including daytime drowsiness, that further increase the risk of 
accidents and falls in the elderly population. Therefore, finding alternative, safe, non-
drug interventions is highly desirable.  
Yoga encompasses a wide range of practices, including physical exercises, breath 
exercises, meditation exercises and relaxation exercises. Studies have shown that yoga 
provides various physical and mental health benefits including reduction of stress, 
anxiety, depression, somatic and mental hyper-arousal. These conditions have been 
found to be strongly associated with insomnia. Therefore, the present study 
hypothesised that yoga intervention may be of benefit in alleviating geriatric insomnia. 
Little research has been published (by early 2007) on yoga as an intervention for 
improving sleep quality and quality of life of older people in a western cultural setting. 
A single study conducted in India (Manjunath & Telles, 2005) and two studies 
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conducted in Taiwan (Chen et al., 2008; Chen et al., 2009; Chen et al., 2010) have 
shown yoga improved some subjective sleep quality and quality of life measures of 
older people. The aim of the present study was to fill a gap in existing research and 
evaluate whether a yoga intervention could improve sleep quality and quality of life of 
elderly people living in a western cultural setting. The study was designed to be 
ecologically valid in that it followed current clinical guidelines regarding patients 
presenting with insomnia complaints and included typical older people presenting with 
insomnia symptoms and excluded those presenting with other morbid or co-morbid 
conditions which may affect sleep.  
A mixed „waiting list control‟ (WLC) study design (n =74) was used, with 
participants‟ ages ranging from 60 to 87 (M = 74.4, SD = 7.1). The yoga intervention 
included two weekly classes incorporating physical and meditative yoga, and daily 
home practice of meditative yoga for 12 weeks. Subjective measures included reliable 
and valid self-reported questionnaire that assessed sleep quality, mental health and 
physical health. These included the Pittsburgh Sleep Quality index (PSQI), Karolinska 
Sleepiness Scale (KSS), Epworth Sleepiness Scale (ESS), Multivariate Apnea 
Prediction Index (MAP), Profile of Mood States (POMS), Depression Anxiety and 
Stress Scale (DASS), Short Form Health Survey (SF36) and daily sleep and practice 
logs. Objective measures were derived from sleep studies conducted using portable 
monitoring in each of the participants‟ home environment.  
Overall, the results indicate that yoga appears to be a safe, easy to implement, and 
well accepted, non-drug intervention for insomnia in the elderly in a western urban 
cultural setting. Practicing yoga for at least 25 minutes a day for twelve weeks improved 
most aspects of subjective sleep status and many aspects of psychological and emotional 
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well being. Practice compliance was found to be an essential factor in the outcomes of 
the yoga intervention with high practice compliance being related to improvements in 
sleep quality measures and some quality of life measures. In comparison to the control 
group the treatment group showed significant improvements in a range of subjective 
factors including overall sleep quality (p=.011), sleep efficiency (p=.045), sleep latency 
(p=.004), sleep duration (p=.042), self assessed sleep quality (p=.002) and fatigue 
(p=.010). Improvements were also seen in general well being (p=.008), overall mental 
health (p=.009), depression (p=.019), anxiety (p=.011), stress (p=.022), tension (p=.044) 
anger (p=.005), vitality (p=.053) and daily function in physical (p=.035), emotional 
(p=.043), and social (p=.030) roles. Improvements were also seen in some objective 
sleep quality factors including duration of the deep sleep (SWS) stage (p=.042). 
However, no significant change was found in the use of sedative-hypnotic medications 
in the study population. 
It was also found that obstructive sleep apnea (OSA) appears to be present to 
varying degrees in the majority of elderly people presenting with insomnia symptoms. 
While the results suggest that yoga practice did not result in a significant change in 
OSA status, the presence of co-morbid OSA reduced the efficacy of yoga in improving 
overall sleep quality and sleep efficiency and some aspects of quality of life including 
carrying out daily roles and social function, but did not affect most other measures. 
Currently, recommended diagnostic procedures for patients presenting with insomnia 
symptoms appear inadequate to diagnose OSA reliably in elderly patients presenting 
with insomnia symptoms, suggesting they should be screened for OSA using objective 
sleep studies prior to prescribing sedative-hypnotics.  
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Chapter 1. Introduction 
1.1 Overview 
The following review is intended to provide background on key issues related to 
the present study‟s aims, design, intervention, outcome measures, analysis and 
discussion of results. It is not intended to serve as a comprehensive review of aging, 
sleep, sleep disorders, sleep study technology or yoga. Accordingly, this review will 
briefly describe sleep physiology, sleep staging and sleep disorders. The review will 
then focus mainly on insomnia and geriatric insomnia. The review will more briefly 
discuss obstructive sleep apnea (OSA) and geriatric OSA due to the part OSA played in 
the present study. The review will also discuss traditional polysomnography versus 
novel methods for sleep analysis such as those used in the present study. Next, the 
review will briefly discuss yoga from ancient and modern perspectives in order to 
facilitate better understanding of the considerations guiding the design and 
implementation of the intervention. Since the body of evidence on some aspects of yoga 
is relatively limited in scope and quality, the review will also include some evidence on 
related practices that are aligned with yogic techniques incorporated in the present 
study. The review will then focus on aspects of yoga relevant to the intervention applied 
in the present study. 
1.2 The aging population 
In most developed countries the population is aging. A decline in fertility and a 20 
year increase in average life span over the second half of the 20th century combined 
with elevated fertility over the 20 years following World War II (nicknamed the "Baby 
Boom"), will increase the proportion of those aged 65 years and over during 2010-2030 
(Centers for Disease Control and Prevention [CDC], 2003). Thus, the average life span 
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is expected to increase by an additional 10 years by 2050 worldwide (CDC, 2003) with 
the number of older Americans being expected to reach 71 million, or roughly 20% of 
the US population by 2030 (CDC, 2007). Like that of most developed countries, 
Australia's population is ageing rapidly. From mid 1989 to mid 2009, the proportion in 
the population of those aged 65 years and over increased from 11.0% to 13.3% 
(Australian Bureau of Statistics [ABS], 2009) while the proportion of the Australian 
population aged less than 15 years old is projected to fall from 19.3% at June 2006 to 
15.0% at June 2056 and the proportion of the population aged 65 years and over is 
projected to grow from 13.3% at June 2006 to 26.4% at June 2056 (Australian 
Government -Department of Health and Aging [DHA], 2006).  
Elderly populations suffer from a much higher proportion of chronic diseases, 
ensuing disabilities and reduced quality of life (CDC, 2003). In the US it is estimated 
that 80% of older adults have at least one chronic health condition (CDC, 2007) and 
50% have at least two chronic health conditions (CDC, 2003). Thus, amongst 
Americans aged 65 and over it is estimated that 55% of women and 42% of men have 
arthritis, 58 % of women and 43% of men have high blood pressure, 27 % of women 
and 38% of men have heart disease, 21 % of women and 24% of men have cancer, 30 % 
of women and 42% of men have trouble hearing, 19 % of women and 15% of men have 
trouble seeing (Federal Inter-agency Forum on Aging Related Statistics [FIFARS], 
2010) and 30% of post menopausal women have osteoporosis (Office of the Surgeon 
General, US Dept. of Health and Human Services [OSG], 2004).  
The prevalence of sleep disorders including insomnia and obstructive sleep apnea 
(OSA) also increases significantly with age (Wolkove et al., 2007; Ancoli-Israel et al., 
1991). The growing elderly population increases demands on public and private health 
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systems and social services. This translates to increased healthcare related costs, and 
requires increasing infrastructure and human resources to maintain healthcare systems 
and public health programs (CDC, 2003).  
1.3 Sleep 
1.3.1 Defining Sleep 
“The Principles and Practice of Sleep Medicine” defines sleep as follows: 
“According to a simple behavioural definition, sleep is a reversible behavioural state of 
perceptual disengagement from and unresponsiveness to the environment. It is also true 
that sleep is an amalgam of physiologic and behavioural processes. Sleep is typically 
(but not necessarily) accompanied by postural recumbence, behavioural quiescence, 
closed eyes and all the other indicators one commonly associates with sleeping” 
(Carskadon, M. A. & Dement, W. C., 2010, p. 16). 
1.3.2 Sleep physiology and staging 
Sleep timing is closely related to the circadian rhythm, a roughly 24-hour cycle 
affecting many life processes. Sleep timing is regulated by a light-entrainable circadian 
pacemaker located in the suprachiasmatic nucleus of the hypothalamus portion of the 
brain (Dijk & Duffy, 1999) which regulates the secretion of melatonin from the pineal 
gland. Melatonin‟s  primary physiological function is to convey information related to 
the light/darkness cycle to body physiology and there is evidence that melatonin plays 
an important part in the coupling of circadian rhythms, especially core body temperature 
and sleep-wake rhythms (Claustrata, et al., 2005). 
Sleep staging criteria has been standardized and is described in “A Manual of 
Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human 
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Subjects” (Rechtschaffen and Kales, 1968) and more recently revised and updated by 
the American Academy of Sleep Medicine (AASM) in the “AASM Manual for the 
Scoring of Sleep and Associated Events: Rules, Terminology and Technical 
Specifications” (Iber et al., 2007). Sleep cycles several times during the total sleep 
period. Each cycle usually lasts 90 minutes on average in young adults (Pollak et al., 
2010, p. 156) and includes Non Rapid Eye Movement (NREM) sleep followed by Rapid 
Eye Movement (REM) sleep (Pollak et al., 2010, pp. 228-229). Non-rapid eye 
movement (NREM) sleep constitutes approximately 80% of total sleep time and has 
been subdivided by Rechtschaffen & Kales into four stages, NREM stages 1, 2, 3 and 4 
(Silber et al., 2007). NREM Stage 1, sometimes called the somnolence or drowsy stage, 
is a transitional period between sleep and wakefulness where sleep is light, and slow 
rolling eye movements may often be detected. It constitutes about 4 -5 percent of total 
sleep time and is characterised by medium amplitude combination of alpha (8-13 Hz) 
and low frequency (2-7 Hz) brain waves, (Pollak et al., 2010, p. 228; Silber et al., 2007). 
NREM stage 2 constitutes about 45 -50 percent of total sleep time. In NREM stage 2 the 
sleep becomes deeper and brain activity shows typical superimposed wave formations 
called K-complexes and sleep spindles (Pollak et al., 2010, p. 228; Silber et al., 2007). 
K-complexes are well-defined negative sharp wave-forms, followed immediately by a 
slower positive complex with the total duration of at least 0.5 seconds (Silber et al., 
2007). Sleep spindles are bursts of 11-16 Hz (usually 12-14 Hz) waves that occur for at 
least 0.5 seconds (Silber et al., 2007). NREM Stages 3 and 4 are referred to jointly as 
Slow Wave Sleep (SWS) or deep sleep. SWS is the deepest sleep phase and is 
characterised by low frequency high amplitude brain waves that are 75 microvolt or 
greater as observed on EEG recordings (Pollak et al., 2010, p. 228; Silber et al., 2007). 
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The SWS stage is believed to contribute to the restorative processes that occur 
during sleep and is related to Growth Hormone (GH) secretion with  studies reporting a 
linear relationship between amounts of SWS and amounts of GH secretion (Van Cauter 
et al., 1998) and a close temporal and quantitative relationship between GH secretion 
and SWS (Gronfier et al., 1996; Holl, 1991). Furthermore, pharmacologically 
stimulated SWS sleep, via oral administration of gamma-hydroxybutyrate (GHB), an 
effective stimulant of SWS in normal subjects, has been shown to result in increased 
GH secretion (Van Cauter et al., 1998; Van Cauter et al., 1997; Gronfier et al., 1996). 
Studies have also shown that selective suppression of SWS in healthy adults results in 
marked decreases in insulin sensitivity without adequate compensatory increase in 
insulin release, leading to reduced glucose tolerance and increased diabetes risk (Tasali 
et al., 2008). In rats the occurrence of SWS, but not REM sleep nor wakefulness, was 
associated with higher rates of protein synthesis throughout the brain, suggesting that 
SWS favours the restoration of cerebral proteins (Ramm & Smith, 1990). 
REM sleep is characterised by rapid eye movements, a reduction or inhibition of 
voluntary muscle tone and increased mixed frequency low voltage brain activity, 
(Pollak et al., 2010, pp. 228-229; Silber et al., 2007). Most dreaming occurs during 
REM sleep and dreams are more vivid and more easily recalled then those which may 
occur in non-REM sleep (Pollak et al., 2010, p. 68),  
The American Academy of Sleep Medicine (AASM) Visual Scoring Task Force 
has proposed a modified sleep staging scheme: Stage W (Wakefulness), Stage N1 
(equivalent to NREM 1 sleep stage), Stage N2 (equivalent to NREM 2 sleep stage), 
Stage N3 (equivalent to SWS), and Stage R (equivalent to REM sleep) (Silber et al., 
2007). The AASM Task Force found no evidence to indicate validity or biological 
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significance in subdividing the SWS stages into the two separate stages NREM 3 and 
NREM4 (Silber et al., 2007). The results of the objective sleep staging measures used in 
the present study have been further simplified and divide sleep into light sleep (which 
includes stages N1 and N2), SWS and REM.  
1.3.3 Sleep studies 
Polysomnography (PSG), also referred to as a sleep study, is a comprehensive 
multi-parameter recording of changes in various physiological variables that occur 
during sleep and is used to measure, diagnose or exclude, various sleep disorders 
(Pollak et al, 2010, pp. 176-178). In full traditional PSG these variables usually include 
brain electrical activity, eye movement, muscle electrical activity, electrical activity of 
the heart, limb movements, oral and nasal airflow, respiratory related movement (chest 
and abdominal movement), blood oxygen saturation and body position (Pollak et al, 
2010, pp. 176-178; American Psychiatric Association [APA], 2000, p. 598). These 
variables are measured using non-invasive sensors that are applied to the patient‟s body 
and connected via leads to a central computerised monitoring and recording system. The 
technologies used to measure and analyse these signals are: 
1. Electroencephalography (EEG) for measuring, recording and evaluating the 
brain's spontaneous electrical activity. 
2. Electrooculography – (EOG) for measuring, recording and evaluating the 
resting potential of the eye retina. 
3. Electromyography (EMG) - for measuring, recording and evaluating the 
electrical activity produced by skeletal muscles.  
4. Electrocardiography (ECG or EKG) for measuring, recording and evaluating 
the electrical activity of the heart. 
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5.  Peripheral Pulse Oximetry for measuring, recording and evaluating the 
oxyhaemoglobin saturation level in the patient's blood. 
 (Pollak et al, 2010, pp. 176-178; APA, 2000, p. 598). 
Traditional Polysomnography (PSG) is generally conducted overnight in a sleep 
laboratory facility which is monitored by one or more sleep scientists. This is still the 
preferred method for diagnosis of sleep disorders, but it is expensive, inconvenient for 
patients, and because demand is greater than available supply, there are long waits and 
delays in diagnosis (Morgenthaler et al., 2010). In the United States the average time 
from a referral to a sleep specialist to a diagnosis in a sleep lab is 2-10 months 
(Morgenthaler et al., 2010). Therefore, PSG is gradually being supplemented or 
replaced by other techniques that allow at-home measurements, including portable 
monitoring and actigraphy (Morgenthaler et al., 2010). 
Portable monitoring often has fewer data channels than traditional PSG, but is 
easier to use and interpret, and reduces costs by at least 35% compared to PSG 
(Morgenthaler et al., 2010). While the accuracy and reliability of portable monitoring 
technologies have been questioned in the past (Flemons et al., 2003), recent 
advancements have significantly narrowed the performance gap between traditional 
PSG and portable monitoring. For example, the positive predictive value of PSG in 
patients with moderate to severe obstructive sleep apnea is 99%, compared with 95% 
for portable monitoring (Morgenthaler et al., 2010). This constitutes a modest reduction 
in diagnostic power which is counterbalanced by portable monitoring‟s timeliness, 
greater patient comfort and substantial cost reduction (Morgenthaler et al., 2010). The 
Portable Monitoring Task Force of the American Academy of Sleep Medicine has 
published specific guidelines for the use of unattended portable monitoring in the 
diagnosis of obstructive sleep apnea in adult patients (Collop et al., 2007). According to 
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these guidelines portable monitoring should be performed only in conjunction with a 
comprehensive sleep evaluation supervised by a certified sleep medicine practitioner. 
Portable monitoring can be used as an alternative to PSG for diagnosing OSA in 
patients with a high pre-test probability of moderate to severe OSA but it is not 
considered appropriate for the for general screening for OSA of asymptomatic 
populations or the diagnosis of OSA in patients with significant comorbid medical 
conditions that may degrade its accuracy (Collop et al., 2007). Portable monitoring has 
been used in the present study (see section 3.4.3.2). 
Actigraphy is occasionally used in conjunction with a sleep logs and a medical 
interview for the limited aim of studying sleep-wake patterns and circadian rhythms. It is 
based on assessing movement, most often of the wrist, using an actimetry sensor mounted 
in a wrist-watch like package, to measure and record gross motor activity. The data are 
then downloaded to a computer system for further analysis. Actigraphy offers significant 
cost reduction compared to PSG and simple portable monitoring and also allows longer 
monitoring periods (Littner et al., 2003; Thorpy et al., 1995; Morgenthaler et al., 2007). 
Studies of Electrocardiography (ECG) and Heart Rate Variability (HRV) signal 
analysis have culminated in the development of mathematical algorithms for extraction 
of variables related to sleep directly from HRV data itself. These studies have shown 
that HRV analysis by time-dependant spectral analysis can be used to give information 
on the function of the autonomic nervous system (ANS) - specifically shifts between 
sympathetic and parasympathetic dominance and associated sleep stages (Baharav et al., 
1995; Keselbrener et al., 1996). Later studies have revealed features related to 
awakenings and sleep stages can be extracted from HRV analysis (Ehrhart et al., 2000; 
Shinar et al., 2001; Shinar et al., 2003a; Shinar et al., 2006). Research has further 
demonstrated that ECG waveform analysis can be used to extract features related to 
12 
 
body position and EMG (Shinar et al., 2003b; Shinar et al., 1999). Extensive research 
into the link between obstructive sleep apnea (OSA) and the ECG has resulted in the 
development of algorithms for detecting OSA by analysing ECG data (Moody et al., 
1985; Shinar et al., 2000; Baharav et al., 2001; Baharav et al., 2004; Dorfman-Furman 
et al., 2005). These studies have provided the theoretical foundation for the 
development of a comprehensive computerised sleep analysis system which enables 
using a smaller number of data channels, thus significantly reducing costs and enabling 
rapid, reliable and consistent analysis within a short time span (Hypnocore, 2010) (Used 
in the present study. See section 3.4.3.3). 
1.4 Sleep disorders  
A sleep disorder (somnipathy) is a condition that leads to a disruption of sleep 
patterns or abnormal behaviour occurring during sleep, or excessive daytime sleepiness 
and/or fatigue. The cause can be physiological, psychological, environmental or 
lifestyle factors. The disorder can be primary or secondary (i.e., a by-product of another 
primary disorder) or co-morbid (i.e., independent of, and coexisting with, another 
disorder). There are at least 77 recognised separate sleep disorders (Pollak et al., 2010, 
p. 212). The most prevalent are insomnia, sleep apnea, restless leg syndrome (RLS) and 
narcolepsy (Pollak et al., 2010, p. 212). The exact number of sleep disorders varies 
depending upon the particular classificatory system used. The main classificatory 
systems can be found in the “International Classification of Sleep Disorders (ICSD-2)” 
published by the American Academy of Sleep Medicine (American Academy of Sleep 
Medicine [AASM], 2005), the sleep disorders section of the “Diagnostic and Statistical 
Manual of Mental Disorders” (DSM IV-TR) published by the American Psychiatric 
Association (APA, 2000, pp. 597-661), and the non-organic sleep disorders section 
(general classification no.F-51) of the “International Classification of Disease” (ICD-
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10) published by the World Health Organisation (WHO, 2007). In general sleep 
disorders can be divided into three major categories: Dyssomnias, Parasomnias and 
secondary sleep disorders, which may be caused by another primary medical or 
psychiatric disorder or by substance abuse (APA, 2000, pp. 597; The National Center 
for Biotechnology Information [NCBI-Mesh], 2010). Dyssomnias are primary disorders 
of sleep initiation or sleep maintenance or excessive sleepiness and are therefore mainly 
characterised by a disturbance in quantity, quality or timing of sleep (APA, 2000, pp. 
598). They include primary insomnia, primary hypersomnia, narcolepsy, breathing 
related sleep disorders (BRSD) and circadian rhythm disorders (APA, 2000, p. 599). 
Insomnia is characterized by persistent difficulty falling asleep and/or difficulty 
maintaining sleep and/or non-restorative sleep (APA, 2000, p. 599), where as 
hypersomnia is characterized by excessive daytime sleepiness (APA, 2000, p. 604). 
Dyssomnias in general can be further subdivided into three subcategories based on the 
cause of the disorder, namely, intrinsic (i.e., the cause is from within the body), extrinsic 
(i.e., an environmental or pathogenic cause external to the body), and disturbances of 
the circadian rhythm (AASM, 2001, p. 15), which is the clock driven 24-hour cycle of 
physiological, biochemical and behavioural processes (Pollak et al., 2010, pp. 51-52). 
Parasomnias are abnormal movements or behaviours occurring during sleep. They are 
caused by inappropriate activation of the autonomic nervous system (ANS), motor 
system or cognitive process during sleep or sleep-wakefulness transition stages (APA, 
2000, pp. 630-631). Parasomnias can be subdivided into arousal disorders (that include 
sleepwalking, sleep terrors and confusional arousals), sleep-wake transition disorders 
(that include sleep starts, sleep talking, nocturnal leg cramping and rhythmic movement 
disorders), parasomnias of REM sleep (such as nightmares, sleep paralysis, REM sleep 
behaviour disorder etc.) and a fourth group of all other non specific parasomnias (that 
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include sleep bruxism, primary snoring, sleep enuresis, abnormal swallowing syndrome 
etc.) (Pollak et al., 2010, pp. 51-52).  
1.5 Insomnia 
1.5.1 Insomnia - overview 
Insomnia is mainly characterised by difficulty to initiate or maintain sleep, or 
complaints of non restorative sleep, which cause significant daytime impairment or 
distress (APA, 2000, p. 599). Insomnia is the most prevalent, chronic sleep disorder in 
the general population and has potentially serious consequences (Mai & Buysse, 2008; 
Harvey, 2001; Ford & Kamerow; 1989; NIH, 2005, p. 3). Insomnia has been considered 
both a symptom and a disorder in its own right. This distinction may have affected how 
it has been treated both in research and in clinical settings (Mai & Buysse, 2008). 
Insomnia has a major impact on individuals and society. Chronic insomnia is 
associated with reduced quality of life, fatigue, mood disturbances, occupational 
performance impairment and decreased productivity (Mai & Buysse, 2008). Chronic 
insomnia sufferers may have poorer general health and use health care services more 
often (Mai & Buysse, 2008; Simon & Vonkroff, 1997). Also, they are more likely to be 
involved in industrial and motor vehicle accidents (Mai & Buysse, 2008; Chilcot & 
Shapiro, 1996; Balter & Uhlenhuth, 1992). All these consequences result in 
considerable direct and indirect economic burden (Mai & Buysse, 2008; Walsh & 
Englehardt, 1999; Chilcot & Shapiro, 1996). 
The aging process is associated with physiological changes which may affect 
sleep (Van Someren, 2000). Diminished subjective sleep quality is one of the most 
frequent health complaints in the elderly (Prinz, 1995) with more than 80 percent 
reported having experienced some sleep disturbance and 50 percent reported frequent 
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occurrence of sleep disturbances (Foley et al., 1995, as cited in Schneider, 2002). In the 
elderly, undiagnosed and untreated insomnia may cause impaired daily function and 
reduced quality of life and is a risk factor for accidents and falls (Ancoli-Israel, 2009; 
Vitiello, 1999; Ancoli-Israel & Ayalon, 2006; Brassington et al., 2000; Byles et al., 
2000). Benzodiazepines are currently the preferred pharmacologic intervention for 
insomnia (Holbrook et al., 2000a) but their use is associated with increase in adverse 
events (Nowell et al., 1997) and existing data supports only short-term use (Soldatos et 
al., 1999; Kupfer & Reynolds, 1997; Holbrook et al., 2000b; Nowell et al., 1997; Bain, 
2006). 
1.5.2 Insomnia - definitions and main classifications  
Insomnia is a complex condition associated with diverse complaints including 
difficulty initiating and/or maintaining sleep and/or early morning final awakening 
and/or non-restorative sleep resulting in daytime fatigue, low energy, distress, 
functional, and social or work-related impairment. Insomnia may be transient, 
intermittent or chronic, lasting days or years. It can manifest as a primary, co-morbid or 
secondary disorder, resulting from another medical or psychiatric disorder or from drug 
use/abuse. It can be triggered by stressful personal circumstance or environmental 
factors. The symptoms may manifest separately or in various combinations (Pollak et 
al., 2010, pp. 111-114). All these factors have resulted in a lack of uniformity in 
definition and diagnostic criteria for insomnia. 
The definition and diagnosis of insomnia are guided by the “International 
Classification of Sleep Disorders” (ICSD-2) by the American Academy of Sleep 
Medicine (AASM, 2005), the “Diagnostic and Statistic Manual of Mental Disorders” - 
(DSM IV-TR) by the American Psychiatric Association (APA, 2000), and the 
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“International Classification of Disease” (ICD-10) by the World Health Organisation 
(World Health Organisation [WHO], 2007). These classification systems differ 
somewhat in defining insomnia with regards to emphasis on frequency, severity, 
duration and consequences of symptoms (Mai & Buysse, 2008; Ohayon, 2002). Mai & 
Buysse summarise the three main definitions of insomnia as follows: 
1. “ICSD-2 Main Criteria and definitions for Insomnia: 
1. A complaint of difficulty initiating sleep, difficulty maintaining sleep, or 
waking up too early or sleep that is chronically unrestorative or poor in quality. 
In children, the sleep difficulty is often reported by the caretaker and may 
consist of observed bedtime resistance or inability to sleep independently. 
2. The above sleep difficulty occurs despite adequate opportunity and 
circumstances for sleep. 
3. At least one of the following forms of daytime impairment related to the 
night-time sleep difficulty is reported by the patient: fatigue or malaise; 
attention, concentration, or memory impairment; social or vocational 
dysfunction or poor school performance; mood disturbance or irritability; 
daytime sleepiness; motivation, energy, or initiative reduction; proneness for 
errors or accidents at work or while driving; tension, headaches, or 
gastrointestinal symptoms in response to sleep loss; concerns or worries about 
sleep” (Mai & Buysse, 2008).  
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2. “DSM-IV-TR Criteria for Primary Insomnia: 
1. The predominant complaint is difficulty initiating or maintaining sleep, or 
non-restorative sleep, for at least one month.  
2. The sleep disturbance, or associated daytime fatigue, causes clinically 
significant distress or impairment in social, occupational, or other important 
areas of functioning. 
3. The sleep disturbance does not occur exclusively during the course of 
Narcolepsy, Breathing-Related Sleep Disorder, Circadian Rhythm Sleep 
Disorder, or a Parasomnia. 
4. The disturbance does not occur exclusively during the course of another 
mental disorder (e.g., Major Depressive Disorder, Generalized Anxiety 
Disorder, a delirium). 
5. The disturbance is not due to the direct physiological effects of a substance 
(e.g., a drug of abuse, a medication) or a general medical condition” (Mai & 
Buysse, 2008). 
3. “ICD-10 Criteria for Nonorganic Insomnia 
A condition of unsatisfactory quantity and/or quality of sleep, which persists for 
a considerable period of time, including difficulty falling asleep, difficulty 
staying asleep, or early final wakening. Insomnia is a common symptom of 
many mental and physical disorders, and should be classified in addition to the 
basic disorder only if it dominates the clinical picture. (Mai & Buysse, 2008)” 
The definitions above touch upon various aspects of insomnia, some of which 
deserve further deliberation, namely: relationship to other disorders (secondary 
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insomnia), duration (transient, intermittent or chronic insomnia), symptoms and effects. 
These will be discussed in the following sections. 
1.5.3 Primary, secondary and co-morbid insomnia  
Insomnia can manifest as a primary disorder, a co-morbid disorder or secondary 
disorder (Mai & Buysse, 2008; Harvey, 2001). Chronic insomnia may coexist with 
other chronic medical or psychiatric conditions and may relate to these conditions in 
various ways (Ancoli-Israel, 2006). Sleep complaints may be a symptom of a primary 
disorder, such as congestive heart failure or conversely, may be a factor in the etiology 
of other disorders such as diabetes mellitus (Ancoli-Israel, 2006). The prevalence of 
insomnia is higher amongst patients with other chronic conditions than in the general 
population and evidence suggests that secondary insomnia which is a symptom of 
chronic disorders tends to be more severe and persistent than insomnia which is not a 
consequence of another chronic disorder (Ancoli-Israel, 2006) 
The distinction between primary, secondary and co-morbid insomnia has 
importance in both clinical and research settings as it affects diagnosis, treatment 
strategy, study design and result analysis. The DSM-IV definition of primary insomnia 
(see above) centres on difficulty in initiating and/or maintaining sleep, or unrestorative 
sleep, lasting at least one month and resulting in daytime impairment or distress which 
does not occur exclusively together with other medical or psychiatric or substance 
use/abuse problems. A diagnosis of primary insomnia requires sleep disturbance to be 
the primary complaint (APA, 2000, p. 599), while secondary insomnia is a consequence 
of another sleep disorder, medical or psychiatric condition, or the use/abuse of drugs 
(Pollak et al., 2010, pp. 111-113). Secondary insomnia has to be etiologically related to 
a primary condition which predates the onset of the insomnia (Lichstein, et al., 2001; 
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Pollak et al., 2010, pp. 111-113). Co-morbid insomnia, although co-existing with 
another condition (i.e., medical or psychiatric condition, sleep disorder or substance 
use/abuse), is not etiologically related to it (Lichstein, et al., 2001). Following these 
definitions, diagnosis of primary or co-morbid insomnia would indicate a need to treat it 
directly. On the other hand, it has often been implied that the causative primary disorder 
should be treated effectively first in order to alleviate a secondary type insomnia 
(Lichstein, et al., 2000). However, studies suggest that secondary insomnia can also be 
treated successfully by direct intervention, and therefore patients suffering from 
secondary insomnia should not be excluded from direct insomnia treatment (Lichstein et 
al., 2000). Furthermore, the discrimination between secondary insomnia and co-morbid 
insomnia often relies mainly on evidence provided by the patient with regards to the 
course of the disorder and this may result in misdiagnosis (Lichstein et al., 2000; 
Lichstein et al., 2001).  
1.5.4 Insomnia differentiation by duration 
Insomnia can also be differentiated based on the time scale as transient, 
intermittent or chronic insomnia defined as follows: 
1. Transient insomnia –occurs from one day to several weeks 
2. Intermittent insomnia – is transient insomnia which occurs occasionally 
3. Chronic insomnia – occurs most nights over a one month period 
(NIH, 2003; Schneider, 2002) 
Transient and intermittent-transient insomnia may be triggered by fluctuating 
environmental conditions (e.g., extreme temperatures, noise, light and other disturbances), 
transitory life style factors and sleep hygiene factors (e.g.,- work-related, travel-related, 
holiday-related events), stress caused by transitory life circumstances, and transitory side-
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effects of drug use/abuse (Pollak et al., 2010, pp. 112-114; APA, 2000, pp. 599-603). The 
cause of chronic insomnia is frequently a combination of factors, including physiological 
and mental health disorders, regular drug use/abuse, chronic stress, and other sleep/wake 
cycle disorders (Pollak et al., 2010, pp. 112-113; Schneider, 2002). 
1.5.5 Insomnia differentiation by symptoms 
The following night-time symptoms may manifest separately or in combination: 
1. Difficulty in initiating sleep 
2. Difficulty in maintaining sleep, frequent awakenings, and difficulty 
resuming sleep  
3. Difficulty in resuming sleep after awakening early in the morning 
Accordingly, insomnia can be further classified based on symptom dominance as 
sleep onset insomnia, sleep maintenance insomnia, and terminal/early morning insomnia 
(NIH, 2003, p. 5; Schneider, 2002). This classification may have clinical relevance as sleep 
onset difficulty is often associated with anxiety and/or stress and/or heightened nocturnal 
mental or physiological arousal (Schneider, 2002; APA, 2000, p. 599). Conversely, sleep 
maintenance difficulty may be related to a range of psychiatric or physiological conditions 
such as depression, chronic stress, chronic pain, illnesses and also life style /sleep hygiene 
factors, which may affect circadian rhythms (e.g., shift work) (Pollak,et al., 2010, p. 112; 
APA, 2000, p. 600; Schneider, 2002).  
Insomnia may result in various daytime symptoms including fatigue, lack of 
energy, sleepiness, irritability and mood disturbances, reduced concentration and 
reduced ability to perform various tasks (APA, 2000, p. 600; Schneider, 2002). These 
symptoms are not used to diagnose insomnia on their own as they may also be 
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associated with other conditions such as obstructive sleep apnea (OSA) (APA, 2000, 
p.617). 
1.5.6 Diagnosis of insomnia in clinical settings 
In clinical settings insomnia is primarily diagnosed by a clinical evaluation based 
on a systematic review of medical history, psychiatric history, substance use history and 
sleep history. This information may be acquired by patient interview, review of medical 
history and by administering medical/psychiatric questionnaires, a sleepiness 
assessment tool, sleep logs, measures of subjective sleep quality, daytime function, and 
quality of life and psychological assessment scales (AASM, 2010; Schutte-Rodin et al., 
2008; Mai & Buysse, 2008; Littner et al., 2003) (All of these are used in the present 
study. See section 3.4.2). According to the 2003 practice parameters established by the 
American Academy of Sleep Medicine (AASM), PSG is not indicated for the routine 
evaluation of transient insomnia, chronic insomnia, or insomnia associated with 
psychiatric disorders. However, PSG is indicated in cases when a sleep-related 
breathing disorder (SRDB) or periodic limb movement disorder (PLMD) is suspected, 
or when initial diagnosis is inconclusive, initial treatment fails, or precipitous arousals 
occur with violent or injurious behaviour (Littner et al., 2003; Schutte-Rodin et al., 
2008). 
1.5.7 Prevalence and risk factors of insomnia  
A study by the National Sleep Foundation found about one-third of Americans 
reported some type of sleep problem with approximately 25 percent reporting 
occasional insomnia and nine percent reporting sleep difficulties every night. This study 
is consistent with other national studies (Ancoli-Israel & Roth, 1999). Estimates of the 
prevalence of insomnia in the general population vary greatly from 10 percent to up to 
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40 percent, depending on what diagnostic criteria and definitions are used (Mai & 
Buysse, 2008; Roth, 2007; Buysse et al., 2005; Holbrook et al., 2000a; Montgomery, 
2002). This is demonstrated by a review of 50 insomnia studies based on data collected 
in various representative community-dwelling samples that compares insomnia 
prevalence estimates using four different definitions: (1) insomnia symptoms; (2) 
insomnia symptoms with daytime consequences; (3) sleep dissatisfaction; and (4) 
insomnia diagnoses with prevalence estimates using these four definitions found to be 
as follows: 
1. Approximately one-third of a general population presented with at least one of 
DSM-IV insomnia diagnostic criteria  
2. Adding the criteria of daytime consequences of insomnia reduces the prevalence 
estimate to between 9 and 15 percent.  
3. Using the sleep dissatisfaction criteria yields an estimate of between 8 and 18 
percent of the general population.  
4. Finally, using a precise/stringent process based on all DSM-IV classification 
criteria, corresponding to a clinical diagnostic procedure, yields prevalence 
estimate of six percent for the general population (Ohayon, 2002).  
Similarly, a more recent study estimated insomnia prevalence of approximately 30 
percent based on several population-based studies with a variety of adult samples from 
different countries with diagnostic criteria of one or more of the following symptoms of 
insomnia: Difficulty initiating sleep, difficulty maintaining sleep, waking up too early and 
in some studies the additional requirement of non restorative or poor quality sleep. 
However, by adding a diagnostic requirement of perceived daytime impairment or distress 
which was caused by the sleep disturbance, prevalence estimate dropped to 10 percent 
(NIH State-of-the-Science Conference Statement, 2005, as cited in Roth, 2007). Finally, 
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when using the stricter DSM-IV diagnostic criteria, estimates again dropped to 
approximately six percent (Roth, 2007).  
An important factor affecting insomnia prevalence estimation is the distinction 
between primary and secondary insomnia, since many people suffering from insomnia 
also suffer from various other conditions, including other sleep disorders, medical 
conditions, psychiatric conditions, and conditions related to substance use/abuse. 
Insomnia has been associated with arthritis, cancer, kidney disease, pulmonary disease, 
hypertension, cardiovascular disease, stroke, dementia, asthma, sleep apnea, narcolepsy, 
neurological conditions (e.g., Parkinson‟s disease, Restless Legs Syndrome), endocrine 
system conditions (e.g., diabetes, hyperthyroidism, hypothyroidism), anxiety, 
depression, and mental illnesses, such as schizophrenia, and substance abuse disorders 
(Buysse et al., 2005; Lichstein et al., 2001; Schneider, 2002). A study based on data 
from the US National Ambulatory Medical Care Survey of Office Based Physicians 
(1989 - 1990) found only 31 percent of insomnia patients were diagnosed with primary 
insomnia; 30 percent also suffered depression; 20 percent also suffered from other 
mental disorders, and 19 percent also suffered from other medical conditions (Radecki 
& Brunton, 1993, as cited in Holbrook et al., 2000a). 
Insomnia has also been associated with demographic and social factors. Higher 
rates of insomnia complaints were found in women (Ohayon, 2002) with a higher 
frequency of insomnia being reported in post menopausal women and in the elderly (65 
year of age and older) (Schneider, 2002; Holbrook et al., 2000a). Elderly females in 
particular report sleep disturbances more frequently than elderly males. This may be 
related to some extent to postmenopausal hormonal changes such as estrogen deficiency 
which has been suggested to contribute to sleep problems and is often experienced 
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during the peri and post menopausal period and increases with age (Vitiello et al., 2004; 
Moe, 1999). 
Studies have also found a strong association between various psychological 
conditions and insomnia. Recent research suggests an extensive overlap between 
anxiety and insomnia among the elderly is a result of a common vulnerability to 
negative emotionality and at times may act as risk factors for each other (Magee, & 
Carmin 2010). A review on determinants of geriatric insomnia, based on 18 relevant 
studies, concluded that bad sleepers had significantly higher scores for anxiety, 
neuroticism and depression than good sleepers and that anxiety and depression 
correlated positively with insomnia and negatively with sleep duration. In addition, 
depression, anxiety or neuroticism were often better predictors of insomnia than health 
indicators such as perceived health and number of prescribed drugs. These findings 
imply that there is a stronger association between primary geriatric insomnia and 
psychological factors than between primary geriatric insomnia and lifestyle or health 
indicators (Beullens, 1999).  
The strong association between psychological factors, arousal and insomnia was 
further demonstrated in a large study of a randomly selected sample from the general 
population (n=3600, duration - one year) that revealed that anxiety, depression, arousal 
and beliefs in the long-term negative consequences of insomnia, were significantly 
related to the maintenance of insomnia (Jansson & Linton, 2007). 
An association has been found between chronic pain and insomnia. A study of 
close to 19,000 individuals, representative of approximately 206 million Europeans, 
concluded that chronic pain is as important as mood disorders in contributing to 
insomnia. Chronic pain was associated with a worsening of insomnia as measured by a 
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greater number of insomnia symptoms, more severe daytime consequences and a more 
chronic insomnia condition (Ohayon, 2005). Another study found that 53 percent of 
chronic pain patients had scores suggestive of clinical insomnia on the Insomnia 
Severity Index versus three percent of subjects with no pain. Affective pain was also 
revealed as a significant predictor of insomnia severity (Tang et al., 2007). 
History of insomnia is a risk factor for insomnia with 31 percent reporting 
insomnia at first interview also reporting insomnia at one year follow-up (Ford & 
Kamerow, 1989). Family history of insomnia is another risk factor with close to 27 
percent reporting insomnia having at least one relative with insomnia complaints 
(Bastien et al., 2000). 
With age, the prevalence of various sleep disorders increases. Sleep disorders such 
as primary and secondary insomnia, snoring and obstructive sleep apnea (OSA) occur 
more frequently in the elderly population (Wolkove et al., 2007). Objective sleep 
studies reveal sleep impairment, including increased wakefulness, arousal from sleep 
and decreased slow wave sleep (SWS) duration, even in healthy elderly (Prinz, 1995). 
Research has also shown that with age the ability to sleep decreases but not the need for 
sleep (Ancoli-Israel, 1997) and that diminished subjective sleep quality is one of the 
most frequent health complaints in the elderly (Prinz, 1995). Often, sleep disorders in 
the elderly are overlooked and undertreated by physicians and the complaints or 
symptoms attributed to coexistent medical or psychiatric conditions (Wolkove et al., 
2007). 
In a National Institute of aging study of 9000 elderly 65 year of age and older, 
more than 80 percent reported having experienced some sleep disturbance and 50 
percent reported frequent occurrence of difficulty falling asleep, or difficulty 
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maintaining sleep or waking up too early, or needing a daytime nap, or daytime fatigue. 
Common complaints, confirmed by objective sleep studies, included sleep 
fragmentation, decreases in total sleep time, and increases in daytime sleepiness (Foley 
et al., 1995, as cited in Schneider, 2002). Using the broad diagnostic criteria of 
difficulty in initiating or maintaining sleep, insomnia affects up to half of elderly over 
65 with the prevalence being higher in elderly women than in elderly men (Moan, 
1992). A German survey of 330 elderly patients aged over 65 years treated in general 
practice, applied DSM-III-R diagnostic criteria and found 23 percent had severe 
insomnia, 17 percent had moderate insomnia and 17 percent had mild insomnia with 
more than 80 percent of the patients reporting chronic insomnia for one to five years or 
longer (Hohagen et al., 1994).  
In institutionalised elderly, sleep disorders severity and frequency is even greater 
than in the general elderly population (Ancoli-Israel, 2009). Institutionalization of the 
elderly by itself is associated with reduced sleep quality. A study reported that 83 
percent of residents in „low care‟ housing considered themselves as poor sleepers 
compared to 60 percent living independently (Middlekoop et al., 1994). Several 
environmental and life style factors that have been shown to affect circadian rhythms 
and degrade sleep quality, such as low levels of sunlight exposure and lack of physical 
activity (Dijk & Duffy, 1999) are more common in „aged care‟ facilities (Hood et al., 
2004). In addition, longer than average time in bed, typical of aged care institutions, 
increases sleep fragmentation (Fetveit & Bjorvatn, 2002). Anxiety and depression, often 
associated with transition from one‟s home into an aged care facility, may also have a 
significant negative effect on sleep (Middlekoop et al., 1994; Sukegawa, 2003). 
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1.5.8 Insomnia - aetiology and pathogenesis 
Primary psycho-physiological insomnia is thought to develop because of learned 
associations that have a detrimental impact on sleep (Pollak et al., 2010, p.183). It has 
been considered as either a predominantly psychological condition or as a 
predominantly physiological condition. Typically life stresses cause an increased level 
of tension and agitation which may manifest physiologically as muscular tension and 
vasoconstriction (Pollak et al., 2010, p.183) and/or manifest psychologically as an over 
concern about the inability to fall asleep, which creates a vicious circle of increased 
difficulty in falling asleep that in turn increases the preoccupation and concern about not 
being able to fall asleep (Pollak et al., 2010, p.183). 
The physiological hyper arousal model theory is often used to explain a possible 
cause of insomnia on the physiological level. This theory postulates that a constant 
elevated level of alertness is a major cause of sleep difficulties. It has been supported by 
several studies using a range of subjective self-reported hyper-arousal scales and 
objective measures. These showed a tendency towards physiological hyper-arousal in 
individuals with chronic insomnia. This tendency may in turn be aggravated by other 
factors (e.g., psychiatric disorders or other sleep disorders) also associated with 
insomnia (Stepanski et al., 1988; Pavlova et al., 2001). Insomnia patients scored higher 
than normal sleepers on self reported hyper-arousal total scale score (Pavlova et al., 
2001). Insomnia sufferers have also been found to have an elevated metabolic rate 
(measured by overall oxygen consumption) compared with normal sleepers (Bonnet & 
Arand, 2003). Other studies have shown that inducing higher physiological arousal 
levels for a week (by means of high caffeine intake) in normal sleepers also produced 
insomnia symptoms. However, inducing disturbed sleep in normal sleepers did not 
result in increased physiological arousal levels (Bonnet & Arand, 2003; Bonnet & 
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Arand, 1997) indicating that hyper arousal results in insomnia but that insomnia does 
not result in hyper-arousal. 
Primary insomnia is associated with altered brainwave activity. Increased EEG 
beta wave activity has been found in subjects with primary insomnia compared to 
subjects with secondary insomnia and normal sleepers and this increased beta activity 
was negatively associated with the perception of sleep quality (Perlis et al., 2001). A 
study comparing the EEG frequency spectra of normal sleepers to those sub-typed 
subjective insomnia sufferers (with relatively long total sleep time coupled with relative 
underestimation of sleep time) and to those sub-typed objective insomnia sufferers (with 
relatively short actual total sleep time) found lower delta NREM EEG activity and 
higher alpha, beta and sigma (sleep spindles) NREM EEG activity in subjective 
insomnia patients, but not in objective insomnia patients compared to normal sleepers. 
There were no differences amongst the groups for REM EEG activity (Krystal et al., 
2002). In addition, a significant correlation was found between NREM EEG frequency 
spectral indices and sleep complaints in patients with subjective insomnia, which may 
reflect heightened autonomic arousal during sleep (Krystal et al., 2002). 
In addition to altered EEG activity, insomniacs have been found to exhibit greater 
pre-sleep Central Nervous System (CNS) arousal than normal sleepers (Jacobs et al., 
1993). A study using functional neuro-imaging, found increased brain glucose 
metabolism both during sleep and wake states in insomnia patients compared to normal 
sleepers indicating that insomnia is associated with greater brain metabolism (Nofzinger 
et al., 2004). Several studies have also found that neuro-endocrine and clinical 
similarities exist between primary insomnia and major depressive disorder, related to 
abnormal corticotrophin releasing factor (CRF) activity. CRF hyperactivity seems to 
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mediate the hyper-arousal seen in primary insomnia. These findings imply 
hypothalamic-pituitary-adrenal (HPA) axis and CRF over activity in both disorders 
(Roth et al., 2007).  
1.5.9 Insomnia and aging 
Typically, the following changes in sleep may occur with aging: 
1. A phase advance in the normal circadian sleep cycle (i.e., going to sleep earlier and 
waking up earlier). 
2. Total nocturnal sleep time decreases (6.5 hours average for people over 60 
compared to 7-8 hours in younger adults). 
3. Delayed sleep onset. 
4. Decrease in slow wave sleep (SWS) phase duration. 
5. Decrease in rapid eye movement (REM) phase duration. 
6. Decrease in arousal threshold. 
7. Sleep becomes more fragmented with increased frequency of arousals and 
awakenings.  
(Wolkove et al., 2007; Holbrook et al., 2000a; Reidel et al.,1995; Reidel & 
Lichstein, 1998; Schneider, 2002; Prinz, 1995).  
The aging process is associated with physiological changes which may affect 
sleep. With age, a lack of input to the suprachiasmatic nucleus (SCN), which is the 
brain‟s biological clock, may accelerate de-activation of neurons involved in the 
generation of circadian rhythm or output of this rhythm. These alterations appear to 
contribute strongly to sleep problems (Van Someren, 2000). This is supported by 
evidence of an age-related decline in production of melatonin. Melatonin has several 
claimed neurobiological roles, namely -an anti-ageing agent; a free-radical scavenger; a 
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regulator of circadian rhythm; and an endogenous sleep-inducer and it is suggested that 
a decline in melatonin production may also affect sleep quality (Rikkert
 
& Rigaud, 
2001). Circadian rhythms in the elderly also become more affected by daytime napping 
and low levels of exposure to sunlight, which are both more prevalent in the elderly 
population (Van Someren, 2000) and there is a decrease in arousal threshold in the 
elderly which in turn increases the sensitivity to environmental factors such as noise, 
light, temperature and results in higher probability of sleep disturbance occurring 
(Bliwise, 2000, as cited in Ellis et al., 2002) 
Ageing is associated with sleep phase alterations. A meta analysis of 65 studies 
representing 3,577 subjects aged 5 years to 102 years, concluded that sleep efficiency, 
percentage of slow-wave sleep (SWS), percentage of REM sleep, and REM latency all 
significantly decreased with age, while sleep latency (SOL), percentage of stage 1 
NREM sleep, percentage of stage 2 NREM sleep, and wake after sleep onset (WASO) 
significantly increased with age (Ohayon et al., 2004). 
In addition to age-related physiological changes, which contribute to a higher 
prevalence of insomnia amongst the elderly, the elderly may also be more vulnerable to 
the effects of poor sleep hygiene and the effects of medications, including those 
prescribed for sleep problems and for other co-morbid medical conditions that are also 
more prevalent with age (Reidel & Lichstein, 1998; Schneider, 2002). The physiological 
and metabolic changes associated with aging affect the pharmacokinetics of drugs 
(Higbee, 2000) and may increase the time taken to metabolise stimulants such as coffee 
so that caffeine consumption after 2 PM in the afternoon is associated with longer 
duration of insomnia in the elderly (Ellis et al., 2002). With aging, total body fat also 
increases so that fat-soluble drugs, such as benzodiazepines have an increased volume 
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of distribution and decreased clearance rates (Schneider, 2002). In addition, drug 
metabolism may be altered due to impaired oxidation, reduction and hydroxylation. 
Reduced hepatic blood flow and glomerular filtration may also result in decreased drug 
excretion from the body. These changes result in increased central nervous system 
(CNS) sensitivity to effects of depressants (Schneider, 2002).  
1.5.10 Insomnia - prognosis 
Despite its high prevalence, insomnia symptoms may be attributed to various co-
morbid conditions and insomnia is often misdiagnosed and may persist untreated for 
years, long after the original causative factors have resolved. Patients with primary 
insomnia, with typical onset at early adulthood, often do not present for treatment until 
middle adulthood. As a result, patients often resort to various self-help remedies 
including over the counter medications, alcohol, „natural products‟, and various 
unproven treatments (Morin et al., 2006; Wolkove et al., 2007; APA, 2000, pp. 601-
602; AASM, 2001, p. 29). 
Findings regarding the prognosis of insomnia are inconclusive, however if left 
untreated insomnia is likely to become chronic. In a prospective study with a cohort of 
13,563 participants aged 45 to 69 years, neither insomnia complaints nor hypnotic use 
predicted increased mortality over a 6.3 years period (Phillips & Mannino, 2005). On 
the other hand, a review of 16 studies reporting an association between insomnia and 
sleeping pills usage and mortality, concluded that the evidence linking insomnia and/or 
hypnotic consumption and mortality is suggestive but inconclusive and additional 
higher quality research is necessary (Nuhic & Kramer, 2007). Another review of 
insomnia epidemiological research, reported that sleep medication use is predictive of 
mortality but the evidence for insomnia as a risk factor for mortality is inconclusive 
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(Taylor et al., 2003). A large study (n=3445) of patients suffering at least one of five 
physician-identified chronic conditions (hypertension, diabetes, congestive heart failure, 
myocardial infarction, or depression) found 16 percent had severe insomnia and 34 
percent had mild insomnia at baseline. A follow-up conducted after two years found 59 
percent of patients with mild insomnia and 83 percent of patients with severe insomnia 
at baseline still suffered sleep problems (Katz & McHorney, 1998). 
1.5.11 Insomnia’s impact 
1.5.11.1 Insomnia’s impact on general quality of life 
Comorbid insomnia may have a major negative impact on quality of life and 
overall functioning (Ancoli-Israel, 2006). A study of 1913 German adults found that 
quality of life was rated as bad in 22 percent and good in 28 percent of severe 
insomniacs compared to three percent (bad) and 68 percent (good) in normal sleepers 
(Hajak et al., 2001). Several Studies have compared the quality of life of insomnia 
patients to control groups of individuals with no sleep complaints using SF-36 
questionnaire. This questionnaire measures general health and quality of life using eight 
scales representative of mental, physical and social functioning, physical and emotional 
well-being (SF36 was used in the present study; please refer to section 3.4.2.7 and to 
appendix 5.7). Patients with severe insomnia had lower scores on all eight scales
 
of the 
SF-36 than those with mild insomnia or good sleepers while patients with mild 
insomnia had lower scores than good sleepers on all eight scales
 
of the SF-36. Overall, 
the insomnia group had lower mean scores on all SF-36 subscales compared with the 
control group indicating impairment across diverse aspects of quality of life (Zammit et 
al., 1999; Leger et al., 2001). Insomnia has also been shown to be independently 
associated with poorer health-related quality of life comparable to that found with 
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chronic disorders such as congestive heart failure and clinical depression (Katz & 
McHorney, 2002). 
1.5.11.2 Insomnia’s impact on mental health 
Insomnia is associated with a range of psychiatric disorders, and it is estimated 
that 40% of insomnia patients have a comorbid psychiatric condition, although the exact 
nature of the relationship has not been established. Insomnia is a risk factor for the 
development of anxiety disorder, depression and other psychiatric disorders (Ancoli-
Israel, 2006; Ford & Kamerow, 1989; Breslau et al., 1996) as well as being a key 
symptom for various psychiatric disorders - depressive disorders in particular (Ford & 
Kamerow, 1989; McCall, 2001; Riemann et al., 2001). In a review of eight 
epidemiological studies, a very strong correlation was found between insomnia and later 
development of depression within one to three years, implying insomnia symptoms on 
their own have predictive value of depression onset in later years (Riemann & 
Voderholzer, 2003). Another review of epidemiological studies found that insomnia was 
consistently predictive of depression, anxiety disorders, other psychological disorders, 
alcohol abuse/dependence, drug abuse/ dependence, and suicide, indicating insomnia is 
a risk factor for these conditions (Taylor et al., 2003). Furthermore, a study showed that 
psychiatric history has been found to be closely related to the severity and chronicity of 
existing insomnia and also that chronic insomnia may be a residual symptom of a past 
mental disorder putting the patient at a higher risk of relapse (Ohayon & Roth, 2003). 
Results from a study using epidemiological data from a survey of over 10,000 
community dwelling adults in the US suggest that uncomplicated insomnia is associated 
with an increase in a risk for a first onset of major depression, panic disorder, and 
alcohol abuse in the following year. These results further suggest that insomnia, even in 
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the absence of psychiatric disorders, was associated with increased utilisation of general 
medical and mental health services for emotional problems (Weisman et al., 1997). 
1.5.11.3 Insomnia’s impact on physical health 
Insomnia is associated with a range of medical disorders with chronic insomnia 
patients reporting a higher frequency of various medical conditions compared to normal 
sleepers including heart disease (21.9% vs. 9.5%), high blood pressure (43.1% vs. 
18.7%), neurologic disease (7.3% vs. 1.2%), breathing problems (24.8% vs. 5.7%), 
urinary problems (19.7% vs. 9.5%), chronic pain (50.4% vs. 18.2%), and 
gastrointestinal problems (33.6% vs. 9.2%) (Taylor et al., 2007). On the other hand, 
people suffering the following medical conditions also reported a higher frequency of 
chronic insomnia than those not suffering from these medical conditions: heart disease 
(44.1% vs. 22.8%), cancer (41.4% vs. 24.6%), high blood pressure (44.0% vs. 19.3%), 
neurologic disease (66.7% vs. 24.3%), breathing problems (59.6% vs. 21.4%), urinary 
problems (41.5% vs. 23.3%), chronic pain (48.6% vs. 17.2%), and gastrointestinal 
problems (55.4% vs. 20.0%) (Taylor et al., 2007). 
In a cross-sectional study of 30,397 participants aged 18 years and older involved 
in the 2005 US National Health Interview Survey a positive association was found 
between both shorter and longer sleep durations and cardio vascular disease (CVD) 
suggesting that sleep duration may be an important marker of CVD (Sabanayagam, & 
Shankar, 2010). This is supported by a 12 year prospective study of 1870 subjects in 
Sweden which found an association between difficulty falling asleep and death from 
coronary artery disease in men but not in women (Mallon et al., 2002). There is further 
evidence to suggest that sleep complaints may actually be a factor in the etiology of 
some disorders, such as diabetes mellitus (Ancoli-Israel, 2006). 
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1.5.11.4 Socio-economical impact of insomnia 
Insomnia is associated with considerable socio-economical impact as sleep 
disturbances may impact daytime activities and often result in daytime fatigue, memory 
deficits and other cognitive deficits, which may have substantial impact on daytime 
functioning in critical tasks such as driving and work, resulting in an increase in work 
absenteeism and accidents (some with catastrophic consequences) (Chilcott & Shapiro, 
1996). Studies in the US and in France found insomniacs had double the rate of work 
absenteeism, took more sick leaves, showed reduced work performance and more 
frequent work-related accidents in comparison to good sleepers. Insomniacs also 
reported poor work related self-esteem, less job satisfaction, and reduced efficiency at 
work, compared with good sleepers (Leger et al., 2002; Leger et al., 2006; Novak et al., 
2004). A study in France found that drivers with insomnia had a higher road accident 
rate and a threefold greater risk of having two or three serious road accidents compared 
to good sleepers (Leger et al., 2006). 
Insomnia is also associated with increased health care utilisation and it is reported 
that compared to good sleepers, people with insomnia consult physicians more often, 
report more medical problems, consume more medications, have more emergency visits 
to hospitals and are hospitalised twice as often (Leger et al., 2002; Novak et al., 2004). 
Insomnia is also associated with greater functional impairment, reduced productivity, 
and higher health care utilization among primary care patients (Simon & Von Korff, 
1997).  
Insomnia results in substantial direct and indirect costs to individuals, the health 
care system and society. Estimates of insomnia‟s economic impact vary widely 
depending on the methodology used. In general, two main cost categories are analysed - 
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direct and indirect costs. Direct costs are those mostly related to application of medical 
intervention for treating insomnia and its side effects and consequences. These include 
costs of treatment, examinations, medicines, hospitalizations and other medical costs 
due to increased morbidity and mortality, depression related to insomnia, and increased 
insomnia related alcohol consumption. Indirect costs are related to disorders and/or 
conditions induced as consequences of insomnia including costs resulting from death, 
accidents, reduced productivity, increased absenteeism etc. (Drummond et al., 2005; 
Ozminkowski et al., 2007). A US study of 138,820 younger adults (aged 18 - 64) and 
75,558 elderly (aged 65 and above) suffering from insomnia, with equivalently-sized 
control groups, revealed average direct and indirect costs for younger adults with 
insomnia over a six months period were about $1,253 greater than for good sleepers. 
For the elderly, direct costs were about $1,143 greater for insomniacs than for good 
sleepers (Ozminkowski et al., 2007). An estimation of direct health care costs of 
insomnia in 1995 in the US was $13.9 billion. Total cost for medications alone was 
$1.97 billion, of which less than half was for prescription medication. Health care 
services for insomnia totalled $11.96 billion, 91% of which was for nursing home care 
(Walsh & Engelhardt, 1999). Direct health care costs of insomnia in 1995 in France was 
estimated to be $2.07 billion (Leger et al., 1999). An estimate of the total annual cost of 
insomnia in the US in 1996 was between $92.5 and $107.5 billion US dollars (Chilcott 
& Shapiro, 1996). A more conservative estimate of total direct, indirect and related 
costs of insomnia in the US in 1994 was between 30 to 35 billion US dollars (Stoller, 
1994).  
1.5.11.5 Insomnia’s impact on older adults 
In the elderly, undiagnosed and untreated insomnia may cause impaired daily 
function and reduced quality of life. It is associated with diminished attention, 
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concentration, memory, reaction time, problem solving, cognition and overall decreased 
sense of well-being. It is also a risk factor for accidents and falls (Ancoli-Israel, 2009; 
Vitiello, 1999; Ancoli-Israel & Ayalon, 2006; Brassington et al., 2000; Byles et al., 
2000). Falls are the leading cause of injury-related visits to emergency departments in 
the US and the main cause of accidental deaths in elderly patients (65 years and older) 
(Fuller, 2000). More than 90 % of hip fractures occur as a result of falls, the majority in 
individuals 70 and older. One third of community-dwelling elderly and 60 percent of 
nursing home residents fall each year (Fuller, 2000). The mortality rate for falls 
increases significantly with age across genders, racial and ethnic groups, with falls 
accounting for 70% of all accidental deaths in elderly aged 75 years and older (Fuller, 
2000). Therefore, it is not surprising that diminished sleep quality is associated with 
higher morbidity and mortality rates in the elderly population (Hays et al., 1996; 
Ancoli-Israel, 2009). Sleep disturbances are often a factor in the decision taken by 
family members to move an older adult into an aged care facility and are associated 
with an increased likelihood of nursing home placement (Pollak et al., 1990; Pollak & 
Perlick, 1991) Taken together the research findings presented above emphasise the 
urgent need to address insomnia in the elderly population. 
1.5.12 Treatments for insomnia 
1.5.12.1 Overview 
Due to the diverse nature and causation of insomnia, a variety of treatment 
approaches are used. In some cases, treating a primary physiological or mental disorder 
may result in improvement of the secondary sleep disorder (insomnia), while in other 
cases, treating the secondary sleep disorder (insomnia) symptoms may improve the 
primary disorder (Ancoli-Israel, 2006). Interventions for insomnia fall into two main 
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categories: pharmacological and non-pharmacological. Pharmacotherapy can be carried 
out on the symptomatic management level or by specific diagnosis and treatment. 
Pharmacological intervention relies mostly on sedative hypnotic drugs and in some 
cases on antidepressants. Benzodiazepines are most often prescribed and to a lesser 
extent non-benzodiazepines sedative agents (Kramer, 1999). Non-pharmacological 
treatments for primary and secondary insomnia include various combinations of 
cognitive behavioural therapies (CBT), various forms of relaxation training, 
phototherapy (Petit et al., 2003) and also several less researched interventions for sleep 
disturbance such as exercise and acupuncture.  
1.5.12.2 Pharmacological treatment for insomnia 
Benzodiazepines are currently the preferred pharmacologic intervention for 
insomnia. They are widely used because to date, no other class of drugs has been proven 
superior to benzodiazepines in terms of benefit to risk ratio (Holbrook et al., 2000a). 
Studies have revealed short-term treatment (2-4 weeks) of chronic insomnia using 
benzodiazepines or Zolpidem (a non-benzodiazepine hypnotic) produced reliable 
improvements, most notably, a significantly increased total
 
sleep duration (Nowell et al., 
1997). However, benzodiazepine treatment was also associated with an increase in 
adverse events,
 
particularly daytime drowsiness and dizziness or light-headedness 
(Nowell et al., 1997). Several meta-analyses suggest intermediate and long-term 
pharmacotherapy for insomnia is associated with diminished benefits, tolerance, and 
insomnia rebound effects (Soldatos et al., 1999; Nowell et al., 1997). Furthermore, 
existing data supports only short-term use as data on long-term usage and consequences 
is lacking (Soldatos et al., 1999; Kupfer & Reynolds, 1997; Holbrook et al., 2000b; 
Nowell et al., 1997; Bain, 2006). 
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One meta-analysis using data from 45 randomised, controlled trials, representing a 
total of 2672 patients, (including 15 studies of patients over 65 years of age), concluded 
the overall benefit of benzodiazepines appears to be minor because they do not provide 
a major advantage over placebo in the treatment of insomnia. This meta-analysis also 
found that benzodiazepines use was often associated with adverse cognitive effects. The 
authors therefore recommended non-pharmacological interventions for insomnia 
(Holbrook et al., 2000b). Another study found sleep medication use was predictive of 
mortality although it did not suggest a direct causative link (Taylor et al., 2003). 
Melatonin (N-acetyl-5-methoxytryptamine), is produced by the pineal gland in 
response to reduced photo-input. The dim light melatonin onset (DLMO) is a standard 
marker for the human circadian pattern (Kramer, 1999) and plays a role in regulation of 
the circadian cycle, and other physiological processes. Melatonin is a broad-spectrum 
antioxidant and a potent free radical scavenger with a particular role in protection of 
nuclear and mitochondrial DNA and a preventive role in oncogenesis (Altun & Ugur-
Altun, 2007; Reiter et al., 2001). Newer melatonin based medications mimic 
physiological pattern of the endogenous hormone by prolonged release (PR) throughout 
the night. A study of PR melatonin intervention in primary insomnia patients aged 55 
years and older has shown significant improvement in sleep latency and quality of sleep, 
as well as next morning alertness with no evidence of abuse potential or rebound 
insomnia or withdrawal effects following treatment discontinuation. This study also 
found a low incidence of adverse events, most side-effects of minor severity, and no 
evidence of impairment of cognitive and/or psychomotor skills, compared to placebo 
(Lemonie et al., 2007; Zisapel, 2009). 
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In case of co-morbid depression and insomnia, anti-depressants and sleep hygiene 
manipulation may serve a dual role. As described earlier, sleep disturbances are 
associated with depression and are typical of depressed patients. Various studies have 
demonstrated that in depressed patients there is reduction of slow wave sleep (SWS) 
and disinhibition of REM sleep. Most of the effective antidepressant agents have been 
found to suppress REM sleep. In addition, manipulations of the sleep-wake cycle, such 
as sleep deprivation or a phase advance of the sleep period, have been shown to 
alleviate depressive symptoms. These findings imply a strong bi-directional relationship 
between sleep, sleep modification, and depression (Riemann et al., 2001). However, 
antidepressants have been found to have variable effects on sleep and some 
antidepressants seem to worsen sleep in patients with depression (Jindal & Thase, 
2004).  
Benzodiazepines have respiratory depressant effects and may worsen sleep-related 
breathing disorders (SRDB). Long-term use may cause complete obstructive sleep 
apnea (OSA) in heavy snorers or short repetitive central sleep apnea in patients with 
recent myocardial infarction and for this reason benzodiazepines use is contraindicated 
in patients with sleep apnea (Guilleminault, 1990; Wagner et al., 1998). Non-
benzodiazepines drugs for insomnia cause minimal respiratory depression, and therefore 
may be safer than benzodiazepines in patients with respiratory disorders (Wagner & 
Wagner, 2000).  
1.5.12.3 Non-pharmacological treatments for insomnia 
1.5.12.3.1 Introduction 
Due to pharmacotherapy‟s limitations and side effects, a wide range of alternative 
therapies for treating insomnia have been tried. An AASM appointed expert task force 
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reviewed the scientific evidence on non-pharmacological interventions for insomnia from 
1999- 2006 (Morgenthaler et al., 2006a). The task force found psychological and 
behavioural interventions to be effective in the treatment of both chronic primary and 
secondary insomnia. Specifically, stimulus control therapy, relaxation training, cognitive 
behavioural therapy, sleep restriction therapy, multi-component therapy (that does not 
include cognitive therapy), biofeedback and paradoxical intention were found to be 
individually effective interventions for chronic insomnia (Morgenthaler et al., 2006a). 
However, psychological and behavioural interventions require the involvement of a health 
care professional, are usually administered individually and are therefore costly in terms of 
health-care utilisation. On the other hand, like yoga, relaxation and physical exercise, also 
discussed below, are more applicable to both individual self-help practice, as well as group 
practice and arguably, this makes them more cost-effective and widely accessible than 
most other non-drug treatments for insomnia. Furthermore, relaxation and exercise share 
some common elements with meditative and physical yoga exercises respectively (see 
sections 1.5.12.3.9 and 1.5.12.3.13) and therefore evidence on their effect on sleep quality 
and quality of life is also reviewed below. Overall, there is some evidence on the positive 
effects of some relaxation techniques and some types of exercise on sleep quality however 
evidence on their effect on geriatric insomnia is lacking and more research is required.  
1.5.12.3.2 Cognitive behavioural therapy (CBT) 
Cognitive behavioural therapy (or CBT) refers to a wide range of 
psychotherapeutic methods aimed at resolving dysfunctional emotions, behaviours and 
cognitions. CBT in the broad sense may refer to any combination of cognitive therapies 
and behavioural therapies. A review of 16 meta-analyses supports the efficacy of CBT 
for diverse psychological and psychosomatic disorders (Butlera et al., 2006). A 
systematic review on the efficacy of cognitive behavioural therapy (CBT), bright light, 
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and physical exercise for treating insomnia in older adults reported that CBT only had a 
mild effect on sleep problems in older adults, most markedly in sleep maintenance 
insomnia and evidence on the efficacy of bright light and exercise interventions was too 
limited to enable drawing any conclusions (Montgomery & Dennis, 2004). A systematic 
review of seven studies of CBT intervention for primary insomnia concluded CBT was 
superior to any single-component therapy such as stimulus control, relaxation training, 
and sleep hygiene education, however more research was required to determine optimal 
multi therapy configuration (Wang et al., 2005) 
1.5.12.3.3 Behavioural therapy 
Behaviour therapy, or behavioural modification, is a form of psychotherapy that 
focuses on treatment of human behavioural disorders by reinforcing acceptable 
behaviour and suppressing of undesirable behaviour (The Columbia Electronic 
Encyclopaedia, 2007). A review of 12 studies of non-pharmacological interventions for 
treating insomnia in community-dwelling older adults reports behavioural approaches 
have produced reliable and durable therapeutic benefits including improved sleep 
efficiency and continuity and enhanced satisfaction with sleep patterns with reduced 
dependence on hypnotics. This review further reports that stimulus control and sleep 
restriction are more effective compared to relaxation methods (Morin et al., 1999 a). 
1.5.12.3.4 Sleep restriction  
Sleep restriction is a behavioural therapy method reported as one of the most 
effective non-pharmacological interventions for insomnia (Hastings & Long, 1994; 
Holbrook et al., 2000a; Smith et al., 2002). Sleep restriction is especially suited for 
insomniacs who tend to spend extended periods in bed, trying to fall asleep with limited 
success. The aim of this approach is to increase sleep efficiency (the ratio between 
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actual sleep time and total time spent in bed) (Morin et al., 1999a; Spielman et al., 1987; 
Glovinsky & Spielman. 1991, pp. 49-63; Hoche et al., 2001). Initially sleep restriction is 
often achieved by delaying bed time, which may result in mild sleep deprivation. As 
sleep latency and frequency of awakening decrease, bed time may be adjusted to earlier 
timing. The rationale behind this method is that extended time in bed leads to 
fragmented sleep and perpetuates insomnia. The advantage of sleep restriction is that it 
can be implemented easily compared to other interventions although patient compliance 
can be difficult (Morin et al., 1999a) and it may result in daytime sleepiness in elderly 
patients. 
Sleep restriction protocol normally includes preliminary filling out preliminary 
sleep diaries (for at least 2 weeks) and restricting bedtime is then restricted to the 
average estimated Total Sleep Time (TST). The patient then continues to enter data into 
sleep diaries which are to monitor sleep efficiency. Total time in bed is modified in 
order to keep sleep efficiency in the range of 80–90% and is reduced by 15–20 minutes 
when sleep efficiency exceeds 90%. In contrast, it is decreased by 15–20 minutes when 
sleep efficiency is below 80% (some recommend 75% for elderly). Thus, total bedtime 
is thus adjusted weekly until an ideal steady state is reached but this should not fall 
below 5 hours. Short daytime naps are permissible especially in the early stages of 
therapy (Glovinsky & Spielman, 1991).  
1.5.12.3.5 Stimulus control 
Stimulus control is a behavioural therapy method which aims at creating an 
association between the bed/bedroom and rapid sleep onset by avoiding any non-sleep 
related activities in the bedroom (Morin et al., 1999a). The protocol generally 
incorporates several rules that need to be followed by the patient including: 
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1. Going to bed only when feeling tired. 
2. Using the bed and bedroom for sleep (and possibly sex) but not for reading, 
watching TV, eating, drinking or pursuing mental activities (such as studying or 
lying awake and worrying about not being able to fall asleep). 
3. Leaving the bedroom if sleep onset does not occur within 15–20 min. and returning 
to the bedroom only when feeling sleepy again. 
4. Repeating step no. 3 again if sleep onset does not occur within 15–20 min. 
Repeating this procedure again throughout the night when necessary. 
5. Getting up at the same time every morning regardless of amount of sleep achieved 
during the previous night (using an alarm clock for this purpose if necessary). 
6. Avoiding daytime napping. 
The advantage of this method is its relative simplicity, which enables family physicians 
and other health professionals to administer it with ease (Petit et al., 2003). 
1.5.12.3.6 Sleep hygiene education 
Poor sleep hygiene is a common cause of primary insomnia and good sleep 
hygiene is considered an essential component of insomnia treatment strategy (Morin et 
al., 1999a). Sleep hygiene education aims at teaching the patient how to modify lifestyle 
and environment to improve sleep quality (Morin et al., 1999a); however there is not 
enough evidence to support using it on its own to treat insomnia (Chesson et al., 1999). 
One study found sleep hygiene education resulted in improved sleep continuity and 
depth and better mood in the morning; however it also found sleep restriction therapy 
improved sleep efficiency more than sleep hygiene education (Hoch et al., 2001). Sleep 
hygiene education advice may typically include: 
1. Avoiding caffeine, nicotine and alcohol, especially later in the day. 
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2. Avoiding heavy meals within two to three hours of bedtime. 
3. Avoiding fluid consumption after dinner to reduce night-time urination frequency. 
4. Avoiding excessive stimulation after 5 PM (noisy exciting places or situations). 
5. Using the bed for sleep only and not for relaxation, reading, nor watching TV. 
6. Establishing a routine for getting ready to go to bed. 
7. Winding down and relaxing before going to bed. 
8. Getting all the worrying done before going to bed and postponing remaining issues 
to the next day. 
9. Maintaining comfortable bedroom temperatures; use enough but not too many 
blankets. 
10.  Trying to sleep in a quiet room or using earplugs. 
11. Trying to keep the room dark; otherwise, using a sleep mask if maintaining a dark 
room is not possible. 
12. Keeping fixed wakeup and bedtime schedule seven days a week. 
13. Avoiding daytime naps as much as possible and if a nap is required – then napping 
before 3 PM and for no longer than one hour 
14. Exercising regularly but not in the evening before going to bed  
(Petit et al., 2003) 
1.5.12.3.7 Paradoxical intention  
Paradoxical intention aims at removing performance anxiety associated with 
falling asleep by asking the patient to try to remain awake as long as possible in bed in a 
darkened room without engaging in any other activity or turning on the lights. 
Paradoxical intention is supported empirically by the American Psychological 
Association (Morin et al., 1999) and it has the advantage that it can be administered 
with ease by family physicians (Chesson et al., 1999). Studies of paradoxical intention 
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however, all focus on sleep onset insomnia and have variable results that suggest that it 
is less effective than relaxation or stimulus control treatments (Morin et al., 1999).  
1.5.12.3.8 Cognitive therapy 
Cognitive therapy is based on the premise that emotional disturbances (e.g., 
anxiety and depression) are a direct consequence of dysfunctional, maladaptive beliefs 
and thought patterns which affect how individuals interpret and react to external events; 
therefore, by identifying and challenging these beliefs and thought patterns,  patients 
can learn to modify them, and minimise associated emotional disturbances (Corey, 
2009, pp. 288-289).  
It has been suggested that pre-sleep cognitive activity of insomniacs can be 
distinguished from that of good sleepers as being more focused on worries, problems 
and environmental noises and that insomniacs are more likely to think about 
sleeplessness or daily events (Harvey, 2000). Insomniacs have also been found to have 
higher negative beliefs and attitudes about sleep than good sleepers (Carneya et al., 
2010).  
When applied to sleep disturbances, cognitive therapy aims at identifying 
detrimental beliefs and attitudes about sleep and then challenging, modifying or 
replacing them with beliefs more conducive to better sleep (Morin et al., 1999a). The 
therapist normally prepares the patient by explaining the relationships between 
cognition, affect and behaviour and the therapy‟s main objectives. Dysfunctional 
maladaptive beliefs and attitudes are then identified and replaced (Petit et al., 2003). 
Cognitive therapy may help empower patients and give them a sense of control over the 
disorder. However it requires considerable time and professional involvement that 
family physicians may not be able to provide. There is also insufficient evidence to 
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support using cognitive therapy to treat insomnia on its own (Chesson et al., 1999) yet, 
cognitive therapy may be effective as part of multifaceted intervention strategy (Morin 
et al., 1999a) and several studies consider cognitive therapy an essential component of 
insomnia treatment strategy that may be especially beneficial for elderly chronic 
insomniacs (Morin et al., 1999a; Edinger et al., 1992). 
1.5.12.3.9 Relaxation therapies 
A broad range of relaxation methods can be used to improve sleep (Morin et al., 
1999a) although some lack evidence to support their efficacy (Petit et al., 2003). 
Various muscle relaxation methods such as progressive muscle relaxation (PMR) 
(Freeman, 2009, pp. 130-133; Cancini et al., 1983), and autogenic training (Linden, 
1994; Stetter et al., 2002) methods aim at reducing somatic arousal. Most relaxation 
methods can be self-administered, thus reducing health resource utilisation and involve 
teaching patients how to voluntarily and sequentially relax tension from muscle groups 
in order to induce physiological relaxation (Pollak et al., 2010, p. 181). Progressive 
muscular relaxation therapy (PMR), later named Jacobson Progressive Relaxation 
Therapy (JPRT) (Freeman, 2009; pp. 130-132) is the name first given to a technique 
developed in the 1930s by American physician Edmund Jacobson for reduction of stress 
and anxiety (Freeman, 2009; p. 131). JPRT involves observing muscular tension in a 
specific part of the body, learning to relax the tension away and then observing the 
difference before and after the relaxation. This process is applied systematically to all 
major muscle groups in the body (Freeman, 2009; p. 131) and may take up to 90 days to 
complete as it focuses on a single muscle group and a single body position in each one 
hour session. Limb position is modified from session to session in order to learn to work 
with subtler levels of tension with the ultimate goal of developing an ability to 
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unconsciously monitor and eliminate somatic tensions (Freeman, 2009; p. 131). The 
original process seemed too time consuming to many and various shortened versions of 
progressive muscle relaxation have been developed, often too short to allow intense and 
detailed observation as intended by Jacobson (Freeman, 2009; p. 132). A shorter form 
of progressive relaxation named Abbreviated Progressive Relaxation Techniques 
(APRT) was developed by Wolpe in the 1950s (Freeman, 2009; pp. 132-133). In APRT 
relaxation of several of the 16 major muscle groups may be practiced in a single session, 
thereby requiring a maximum of 10 sessions to complete the entire process (Freeman, 
2009; pp. 132-133). Autogenic training is a form of self relaxation procedure that trains 
the practitioner to focus on sensations such as heaviness and warmth in various body 
parts with the aim of eliciting a psycho-physiological relaxation response (Stetter & 
Kupper, 2002; Pollak et al., 2010, p. 31). The yogic relaxation/meditation methods used 
in the present study, included a yogic muscle relaxation component and a yogic 
meditative awareness component, in which practitioners focus on opposing body 
sensations, such as heat and cold (see sections 1.7.12, and 3.3.10) and therefore research 
findings on the effect of PMR, APRT and autogenic training are arguably of relevance 
to the present study. Unlike PMR and APRT, the yogic relaxation technique 
incorporated in the present study can be learned and executed within a single one hour 
session (see sections 3.3.10.4),. 
A review of 29 studies found favourable outcomes of Abbreviated Progressive 
Muscle Relaxation (APRT) interventions compared to psychotherapy outcomes. APRT 
delivered on an individual basis in conjunction with providing APRT training tapes to 
subjects for self-practice had the strongest association to favourable outcomes. The 
treatment duration and number of sessions were also positively associated with 
improvement (Carlson & Hoyle, 1993). A meta-analysis of three studies found positive 
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effects of autogenic training intervention versus control for a range of conditions 
including functional sleep disorders, tension headache/migraine, mild-to-moderate 
essential hypertension, coronary heart disease, asthma, pain disorder, Raynaud‟s 
disease, anxiety disorders and mild-to-moderate depression (Stetter & Kupper, 2002). 
Another study that compared effects of a single session of PMR, meditation and control 
found participants in the meditation and PMR groups decreased more in cognitive, 
somatic, and general state anxiety than controls with the PMR group having the greatest 
reduction in somatic anxiety (Rausch et al., 2006). 
Several underlying physiological mechanisms may be involved in relaxation 
techniques including modulation of the autonomic nervous system (ANS) and endocrine 
system. A study comparing relaxation training, beta-adrenergic blockers and sham 
training found reduced excitatory autonomic response to mental and physical 
stimulation, and increased vagal activity in both the relaxation and beta blocker 
intervention groups compared to a sham intervention group (Lucini et al., 1997). 
Another study indirectly demonstrated relaxation training increased endorphin 
production by using the opioid receptor blocking drug Naltrexone which resulted in 
counteracting the diastolic pressure reducing effects of relaxation training in response to 
mental stress (McCubbin et al., 1996). 
1.5.12.3.10 Multi component therapy 
Multi component therapy for insomnia combines several of the above 
interventions (Jacobs et al., 1993) with specific protocols being individually tailored to 
suit the patient. The American Psychological Association consider multi component 
therapy as probably efficacious (Morin et al., 1999a) and multi-component therapy has 
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been shown to produce better results than no treatment, but it is not always more 
effective than stimulus control or sleep restriction on their own (Morin et al., 1999a). 
Multifactor behavioural interventions combining sleep restriction, modified 
stimulus control, and relaxation response training, has been found highly effective in 
moving individuals with chronic sleep-onset insomnia into the range of normal sleepers. 
The effect may have been achieved, in part, by reducing pre-sleep CNS arousal (Jacobs 
et al., 1993).  
1.5.12.3.11 Phototherapy 
The circadian cycle is usually 24 hours and is normally entrained to be aligned 
with the external environmental rhythm of day/night changes in light levels. Light is the 
chief stimulus responsible for coordinating the internal circadian rhythm with the 
environmental 24-hour light/dark cycle and is perceived by the retina which transoms 
signals via the retino-hypothalamic tract to the brain (Marieb & Hoehn, 2010, p. 566; 
Zisapel, 2001). Absence of adequate and timely light input may result in misalignment 
of the circadian clock with the environmental cycle and this may result in sleep 
disorders. These may include insomnias associated with the endogenous clock running 
slower or faster than the norm, or in an irregular rhythm; periodic insomnias caused by 
disturbances in light perception (e.g., in blind people); and transient insomnias due to 
life circumstances (e.g., shift-work sleep disorder), or travel (i.e., jet-lag) (Zisapel, 
2001).  
Phototherapy aims at advancing or delaying the inner circadian clock using 
exposure to bright light in specific dosages and time intervals, and high exposure 
avoidance at other times. For patients with delayed sleep-phase syndrome (DSPS), 
exposure to bright light in early morning and avoidance of bright light in the evening is 
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prescribed. Conversely, for patients with advanced sleep phase syndrome (ASPS), 
exposure to bright light in the evening is prescribed in attempt to delay sleep onset 
(Zisapel, 2001). Several studies suggest that exposure to bright light in the evening is 
beneficial in alleviating sleep maintenance insomnia in healthy elderly subjects 
(Campbell et al., 1995). Phototherapy involves administering light via light boxes or 
head mounted visors with an intensity f greater than 1000 Lux being recommended for 
the elderly (Zisapel, 2001). 
1.5.12.3.12 Acupuncture 
A recent Cochrane systematic review evaluating acupuncture for insomnia found 
that the available body of evidence included only a small number of randomised 
controlled trials with poor methodological quality and significant clinical heterogeneity. 
The reviewers therefore concluded that the available evidence is insufficient to support 
use of acupuncture as an intervention for insomnia, and that larger higher quality 
clinical trials are needed (Cheuk et al., 2007). 
1.5.12.3.13 Exercise 
Existing evidence indicates that exercise is associated with improvement in sleep 
quality in the normal population and that aerobic type exercise may improve insomnia 
symptoms. However, more research is required to understand the relationship between 
exercise types and sleep quality and identify the most suitable exercise interventions for 
insomnia in general and in the elderly insomniac population in particular.  
Two meta-analyses examining the effects of exercise on sleep found that while the 
relative efficacy of specific exercise interventions for improving sleep in normal and 
clinical populations could not be established based on available data (Kubitz et al., 
1996; Driver & Taylor, 2000), acute and chronic exercise increased slow wave sleep 
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(SWS) and total sleep time (TST) and decreased sleep onset latency (SOL), REM sleep 
latency and REM sleep duration. Moderating variables included sex, age, fitness level 
and exercise type, duration and timing (Kubitz et al., 1996; Driver & Taylor, 2000).  
A Cochrane review of physical exercise intervention for primary insomnia, where 
80% or more of participants were over the age of 60, found little high quality evidence 
on the relationship between exercise and insomnia symptoms. Reviewers concluded that 
exercise, although not appropriate for all elderly, may improve sleep and quality of life, 
but further research was required as these conclusions were based on a single relatively 
small study (n=43) (Montgomery and Dennis, 2002). A more recent study comparing 
aerobic exercise and resistance training as interventions for insomnia found acute 
moderate-intensity aerobic exercise reduced pre-sleep anxiety and improved sleep in 
patients with chronic primary insomnia while resistance training exercise did not 
(Passos et al., 2010). Conversely, a recent retrospective study of young adults (n=862, 
mean age= 24.67 +/- 5.91) using self reported questionnaires on perception of exercise 
level, fitness level, and sleep quality, concluded that perceived high physical fitness, but 
not exercise level itself, was associated with favourable scores for various sleep quality 
measures and suggested that it was the cognitive processes manifested by these self 
perceptions, rather than the exercise itself, that played a major role in sleep quality 
(Gerber et al., 2010).  
1.5.12.4 Pharmacotherapy versus other interventions 
Overall, evidence suggests that pharmacotherapy is effective for short term or 
periodic use and may be associated with adverse effects, while alternative treatments for 
insomnia are suitable for both short and long term use and should be attempted as first 
line of intervention, prior to prescribing hypnotics. 
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A comparative meta-analysis of 21 studies totalling 470 subjects of 
pharmacotherapy and behaviour therapy for persistent insomnia found that overall 
behaviour therapy and pharmacotherapy produce similar short-term
 
treatment outcomes 
in primary insomnia (Smith et al., 2002). Another review concluded that non-
pharmacological treatments such as stimulus control, sleep restriction, sleep hygiene 
education, cognitive therapy, multi-component therapy and paradoxical intention, used 
for primary and secondary insomnia in elderly patients, are feasible and effective 
alternatives to benzodiazepines (Petit et al., 2003). Vitiello (1999) concludes that 
despite being widely used, hypnotics are best suited for periodic use rather than for 
treatment of chronic sleep disorder symptoms and should be used only if sleep hygiene 
intervention as first-line therapy proves unsuccessful. In another study Holbrook et al. 
(2000 a) concluded that the overall benefit of benzodiazepines appears to be minor and 
is associated with adverse affects. They recommend trying non-pharmacological 
interventions for insomnia including sleep hygiene modifications and exercise. Another 
study found that in chronic insomniacs, the addition of medication to CBT produced 
added benefits during the acute phase, but the best long-term outcome was achieved 
when medication was discontinued during the maintenance phase of CBT (Morin et al., 
2009). A study comparing behavioural and pharmacological interventions for late life 
insomnia (mean age 65) found that both were effective for the short term management 
of insomnia but improvements in sleep were better sustained with the behavioural 
intervention compared to pharmacotherapy (Morin et al., 1999b). 
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1.6 Sleep related breathing disorders (SRBD)  
1.6.1 Introduction 
The present study which aimed at examining the effectiveness of a yoga 
intervention for improving sleep and life quality in elderly people presenting with 
complaints of insomnia attempted to exclude people with OSA. Candidates were 
screened using a standard clinical procedure recommended for patients presenting with 
insomnia complaints in line with the 2003 practice parameters established by the 
American Academy of Sleep Medicine (AASM), where PSG is not indicated for the 
routine evaluation of transient insomnia, chronic insomnia, or insomnia associated with 
psychiatric disorders (Littner et al., 2003). Those suspected of suffering from other 
sleep disorders were excluded. Nevertheless, as described in section 4.6, additional 
participants were later diagnosed with previously undetected co-morbid obstructive 
sleep apnea (OSA). Therefore, SRBD and specifically OSA have been included in this 
review. 
1.6.2 SRBD definitions and classifications 
SRBD is a term which encompasses a group of disorders characterized by 
disturbed respiratory patterns during sleep, including pauses in breathing, or reduction 
in the volume of ventilation during sleep (Wolkove et al., 2007). These events are called 
apneas, hypopneas and RERAs. A hypopnea event is associated with very shallow or 
slow breathing, resulting in a reduction in volume of ventilation and a fall in the blood 
oxygen saturation level (Pollak et al, 2010, pp. 102-103). This is distinguished from an 
apnea event where there is a complete pause in breathing, lasting for at least 10 seconds 
(Pollak et al, 2010, p. 26). A more elaborate definition is used in the context of scoring 
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apnea and hypopnea events in a sleep study with a clinically significant apnea event 
being scored in an adult patient, when all of the following criteria are met:  
1. A drop in the peak excursion of oro-nasal thermal sensor ( signal) by ≥ 90% of 
baseline 
2. Duration of the event is ≥ 10 seconds 
3. At least 90% of the apnea event duration meets the amplitude reduction criteria for 
apnea (AASM, 2007, p. 45). 
A clinically significant hypopnea event is scored in a sleep study of an adult 
patient when all of the following criteria are met: 
1. A drop in the peak excursion of oro-nasal thermal sensor ( signal) by ≥ 30% of 
baseline 
2. Duration of the event is  ≥ 10 seconds 
3. An oxygen desaturation of  ≥ 4% from pre event baseline occurs 
4. At least 90% of the hypopnea event duration meets the amplitude reduction criteria 
for hypopnea (AASM, 2007, p. 46). 
Alternatively, a clinically significant hypopnea event can also be scored in a sleep 
study when all of the following criteria occur: 
1. A drop in the peak excursion of oro-nasal thermal sensor ( signal) of ≥ 50% of 
baseline 
2. Duration of the event is  ≥ 10 seconds 
3. A desaturation of ≥ 3% from pre event baseline occurs associated with an arousal. 
4. At least 90% of the hypopnea event duration meets the amplitude reduction criteria 
(AASM, 2007, p. 46). 
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Increased respiratory effort that does not meet the criteria for hypopnea or apnoea 
may result in an arousal event termed a Respiratory Effort Related Arousal (RERA). An 
event is scored as a RERA if there is a sequence of breaths that lasts for at least 10 
seconds and is characterised by increased respiratory effort and negative esophageal 
pressure (as manifested by the flattening of the nasal pressure waveform) that leads to 
an arousal from sleep and yet does not meet the criteria for apnoea or hypopnea (as 
specified above) (AASM, 2007, p. 45; Pollak et al., 2010, p. 194). 
An apnea event is classified as obstructive, central or mixed type apnoea event 
depending on the presence or absence of respiratory effort (Pollak et al, 2010, p. 26) and 
is scored as an obstructive apnea event if it meets apnoea scoring criteria (as specified 
above) and there is continued or increased respiratory effort during the entire period of 
absent airflow (AASM, 2007, p. 45). It is scored as a central apnea event if it meets 
apnoea scoring criteria (as specified above) and respiratory effort is absent during the 
entire period of absent airflow (AASM, 2007, p. 45). It is considered a mixed apnea 
event if it meets apnoea scoring criteria (as specified above) and respiratory effort is 
absent in the first part of the event followed by a resumption of respiratory effort in the 
second part of the event (AASM, 2007, p. 45). 
A task force by the American Academy of sleep medicine (AASM), the European 
Respiratory Society (ERS), the Australasian Sleep Association (ASA), and the 
American Thoracic Society, recommended the following classification of SRBD:  
1. Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) 
2. Central Sleep Apnea-hypopnea syndrome (CSA)  
3. Cheyne-Stokes syndrome. 
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4.  Some patients may have a complex sleep apnea syndrome for example 
OSAHS and CSA (AASM, 1999, as cited in Morgenthaler et al., 2006b). 
Unlike OSAHS, which is caused by an obstruction to the air flow, CSA and 
Cheyne-Stokes syndrome are caused by an imbalance in the brain‟s respiratory control 
centres. In CSA this causes the patient to miss one or more breaths (Morgenthaler et al., 
2006b). Cheyne-Stokes syndrome, on the other hand, is characterised by a regular 
crescendo and decrescendo fluctuation in respiratory rate and volume. This breathing 
pattern causes a wide fluctuation in blood oxygen and carbon dioxide levels that may 
trigger an arousal at the peak of the crescendo phase of this breathing pattern. This in 
turn may result in sleep maintenance insomnia with frequent awakenings (Pollak et al., 
2010, pp. 48-49). OSAHS is a much more common disorder. A retrospective review of 
data of one month sample of patients referred to the Mayo clinic for objective studies in 
2004 revealed the following distribution of apnoea cases: OSAHS – 84%, CSA - 0.4%, 
and15% of the cases presented with complex apnoea (Morgenthaler et al., 2006b). 
A wider definition of obstructive SRBD disorders related to upper airway 
resistance includes snoring in addition to upper airway resistance syndrome (UARS), 
and Obstructive Sleep Apnea–hypopnea syndrome (OSAHS). Snoring is defined as loud 
upper airway breathing sounds in sleep, without episodes of apnea or hypoventilation, 
arousals or other evidence of sleep disturbance. Snoring is very common, occurring in 
up to 40-50% of adults aged over 65. Snoring is strongly associated with SRDB 
however many snorers do not have SRBD (Kushida, 2005; Netzer et al., 2003; AASM, 
2001, pp. 195-196). And many clinicians regard SRBD as a spectrum or continuum of 
disorders so that snoring may gradually deteriorate into OSAHS as a consequence of 
additional risk factors or deterioration in existing risk factors (such as weight, alcohol 
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consumption, use of sedatives/hypnotics etc.) (Wolkove et al., 2007; Collop & Cassel, 
2002; Guilleminiault et al., 1993; Lugaresi et al., 1994; Kushida, 2005).  
1.6.3 Measuring and expressing SRBD severity 
A range of indexes is used in conjunction with PSG data in order to diagnose and 
express sleep related breathing disturbances. The following are the most common 
currently in use: 
1. The Apnea index (AI) expresses average apnea events per hour (Pollak et al., 
2010, p. 26). 
2. The Apnea Hypopnea index (AHI) combines apnea and hypopnea events per 
hour (Pollak et al., 2010, p. 26). Revision of scoring guidelines using this 
measures has been recommended as using different standard hypopnea 
definitions can yield considerable differences in the Apnea Hypopnea index 
(AHI) (Ruehland et al., 2009; Kushida et al., 2005).  
3. The Respiratory Disturbance Index (RDI) has usually been used 
synonymously with AHI (Pollak et al., 2010, p. 193; AASM, 2001, p. 347). 
4. Respiratory Effort Related Arousal index (RERA index) is the number of 
RERAs per hour (see glossary and section 1.6.2). 
Other measures which may also assist in assessing severity level of SRDB include 
blood oxygen saturation levels (Pollak et al., 2010, p. 166) and number of arousals 
(AASM, 2001, p. 56).  
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1.6.4 Obstructive sleep apnea (OSA) 
1.6.4.1 OSA - symptoms and diagnosis 
OSA is the most common SRBD and is characterised by repeated episodes of complete 
cessation of breathing called apnea (defined above). It may also include partial 
reductions in ventilation volume called hypopnea (defined above) (Bassiri & 
Guilleminault, 2000). Other symptoms include, snoring, waking up gasping for air or 
feeling choked, frequent arousals from sleep associated with the apnea, dry throat or 
mouth upon awakening, morning headaches or nausea, mild to severe daytime 
sleepiness and decreased cognitive functioning (AASM, 2001, p. 57; Berg, 2008; 
Mendelson, 1987, p. 194). Currently the standard clinical diagnosis of OSA relies on 
full PSG (Berg, 2008). The evaluation of the severity of OSA relies on PSG data and 
information regarding daytime sleepiness levels with AHI in the range of 5–15 
considered mild, AHI in the range of 15–30 considered moderate and AHI>30 
considered severe. Sleepiness levels are also classified as mild (unwanted daytime 
sleepiness in situations requiring little attention), moderate (unwanted daytime 
sleepiness in situations requiring some degree of attention) or severe (uncontrollable 
daytime sleepiness causing significant daytime impairment) (Berg, 2008).  
1.6.4.2 OSA - aetiology and pathophysiology 
OSA is characterised by episodes of apnea and hypopnea. These are caused by the 
interaction between sleep-related changes in upper airway muscle function and subtle 
narrowing of the oropharyngeal lumen. This results in an occlusion of one or more 
structures along the upper airways including the nose, palate and base of the tongue. 
This in turn  results in the reduction or cessation of airflow. This phenomena is often 
most noticeable during the rapid eye movement (REM) sleep and may explain why 
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OSA often first progresses and is most severe during REM sleep (Bradley & Phillipson, 
1985). Apnea and hypopnea episodes lead to decrease in blood oxygen levels (hypoxia) 
and increase in blood carbon dioxide level (carbocemia). Hypoxia may lead to asphyxia, 
a condition of deficient supply of oxygen to body tissues. Asphyxia may then lead to 
increased inspiratory effort. The combination of increased respiratory effort and 
collapse of the airway leads to creation of negative pressure (i.e., partial vacuum) within 
the thorax (Pepperell et al., 2002) which results in additional increase in inspiratory 
effort (Bradley & Phillipson, 1985). The increasing respiratory effort eventually leads to 
an arousal that results in a restoration of the muscle tone in the upper airway thus 
terminating the obstructive event (Bradley & Phillipson, 1985). There is some evidence 
that the increased respiratory effort itself and not the hypoxia or hypercapnia is the main 
factor that acts as the stimulus for the arousal from sleep (Gleeson et al., 1990). The 
arousal usually involves going into a lighter stage of sleep or partial awakening and 
once the normal breathing is restored, blood gases levels normalise, and the patient may 
go into a deeper sleep again. However, this again leads to an apnea event and a vicious 
circle is set up that may repeat itself hundreds of times during the night, leading to 
significant disruption of sleep and degrading of sleep quality (Bradley & Phillipson, 
1985). The recurrent episodes of nocturnal asphyxia followed by recurrent arousals 
from sleep also induce various secondary physiological responses, such as increased 
sympathetic tone and elevated blood pressure that may eventually produce clinical 
cardiovascular, hemodynamic, and neuropsychiatric symptoms associated with OSA 
(Bradley & Phillipson, 1985; Douglas, 2002).  
The exact pathophysiology of OSA is not fully understood. However, various 
studies have shown both anatomical and neurological abnormalities in OSA patients. 
Various imaging techniques have revealed that compared to normal subjects, OSA 
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patients have enlarged tongues and soft palates and inferiorly positioned hyoid bones, 
retro-positioned mandibles and maxillae, increased mandibular plane angle, increased 
facial height, narrow posterior airway spaces and shorter cranial base (Low et al., 1996; 
Hochban & Brandenburg 1994; Battagel & L'Estrange,1996). Obese OSA patients have 
additional structural abnormalities which are usually absent in non-obese OSA patients. 
A study found that compared with the controls, non-obese OSA patients had aberrations 
of the cervico-craniofacial skeleton while obese OSA patients also had abnormalities of 
upper airway soft tissue, head posture and position of the hyoid bone (Tangugsorn et al., 
2000). 
The fact that OSA patients are able to maintain unobstructed airway in the waking 
state indicates that anatomical abnormalities are only partially responsible and suggests 
an existence of a neuromuscular component. EMG studies have shown that in OSA 
patients the pharyngeal dilator muscles are more active in the waking state compared to 
normal subjects (Mezzanotte et al., 1992). The activity of these muscles is reduced 
shortly after sleep onset, indicating they receive input from brainstem neurons involved 
in sleep regulation. In apnea patients, this may lead to the collapse of the pharyngeal 
airway (Jordan & White, 2008). It has been suggested that the initial sleep onset 
reduction in upper airway muscle activity is due to loss of a „wakefulness‟ stimulus, 
rather than to loss of responsiveness to negative airway pressure, and that this stimulus 
may be greater in the OSA patient than in healthy controls. Furthermore, this increased 
stimulus in the waking state may be a compensatory mechanism for overcoming 
pharyngeal abnormality (Fogel et al., 2005; Mezzanotte et al., 1992). Other studies 
suggest that chronic intermittent hypoxia/asphyxia contributes to the pathophysiology of 
SRDB by reducing upper airway muscle endurance and selectively impairing 
pharyngeal dilator EMG responses to physiological stimulation, and in this way 
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perpetuating a vicious circle of airway muscle collapse and hypoxia/asphyxia (Bradford 
et al., 2005). 
1.6.4.3 Risk factors for OSA 
OSA risk factors include obesity, anatomical upper airway abnormalities, age, 
gender, smoking, excessive alcohol intake, use of muscle relaxants, nasal congestion, 
estrogen depletion in menopause and family history (Young et al., 1993; Young et al., 
2002a; Berg, 2008). Population based studies reveal that the risk of OSA in males is two 
to three times greater than in females (Young et al., 1993; Young et al., 2002).Obesity, 
is probably the single most predictive factor for OSA, observed in 60% of patients with 
OSA in developed countries (Strobel & Rosen, 1996). Obesity is usually expressed in 
body mass index (BMI), which is calculated by dividing body mass (in Kg) by the 
square of the height (in meter) as follows: BMI = body mass/ (height)
 2. 
A strong 
correlation exists between BMI, OSA and excessive daytime sleepiness (EDS) in 
professional drivers (Dagan, et al., 2006) and in the elderly the best predictors of sleep-
disordered breathing were found to be BMI, falling asleep at inappropriate times, male 
gender, alcohol consumption within two hours of bedtime and daytime napping (Ancoli-
Israel et al., 1991).  
1.6.4.4 Prevalence of OSA 
Population-based epidemiologic studies have revealed a high prevalence and wide 
spectrum of severity for undiagnosed obstructive sleep apnea (OSA). The prevalence of 
mild to moderate OSA was found to be particularly high (Young et al., 2002b). A study 
conducted to estimate the prevalence of undiagnosed sleep-disordered breathing among 
adults aged 30 to 60 years evaluated by PSG, used data extracted from the Wisconsin 
Sleep Cohort Study, a longitudinal study of the natural history of cardiopulmonary 
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disorders of sleep. This study estimated the prevalence of SRBD (defined as an AHI 
score of 5 or higher) as 9% for women and 24% for men (Young et al., 1993). A large 
study (n=1741) of men and women between the ages of 20 and 100 revealed that,
 
for 
clinically defined sleep apnea (AHI ≥ 10 with daytime symptoms), men had a 
prevalence of 3.9% and women
 
1.2%. In premenopausal women the prevalence of sleep 
apnea was found to be 0.6% and in postmenopausal
 
women with hormone replacement 
therapy (HRT) 0.5% while in  postmenopausal women without HRT the prevalence of 
sleep
 
apnea was 2.7%. These results reveal male gender and menopause as significant 
risk factors
 
for sleep apnea, and that in women HRT is associated with reduced
 
risk 
(Bixler et al., 2001). 
With age, upper airway muscles weaken and lose tone during sleep, predisposing 
the patient to airway obstruction. This may lead to snoring and obstructive sleep apnea 
(Wolkove et al., 2007). Indeed, the frequency of sleep apnea increases with age and is 
substantial amongst the elderly. A survey of 461 randomly selected elderly aged over 65 
in the US found 24% had Apnea index (AI) ≥ 5 and 62% had Respiratory Disturbance 
Index (RDI) ≥ 10 (Ancoli-Israel et al., 1991). In another study of 1389 community 
dwellers aged 60 to 70 years, 49.5% of subjects reported snoring, and 10.8% reported 
breathing stoppages during sleep. Both disorders were significantly higher in males and 
those with high BMI (Dealbarto et al., 1996). 
1.6.4.5 Impact of OSA 
A consistent association exists between OSA, including mild OSA, and significant 
morbidity. Undiagnosed OSA, with or without symptoms, is independently associated 
with increased likelihood of hypertension, cardiovascular disease, and stroke and these 
conditions are all leading causes of morbidity in adults. In addition, a consistent 
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association exists between OSA and between daytime sleepiness, drowsiness, motor 
vehicle accidents, and diminished quality of life (Young et al., 2002b). 
Multiple studies support the hypothesis that intermittent hypoxia induced by OSA, 
and not sleep fragmentation, causes persistent hypertension and that the long-term 
consequences of
 
chronic intermittent hypoxia may also include cerebral and coronary 
vascular problems, developmental
 
and neuro-cognitive deficits, and neuro-degeneration; 
however more research is required to better understand the underlying mechanisms and 
the relation to OSA (Neubauer, 2001). OSA-induced frequent arousals cause sleep 
fragmentation which results in excessive daytime sleepiness (EDS) (Pepperell, et al. 
2002). Both nocturnal hypoxia and sleepiness seem to contribute to various deficits 
shown in various cognitive functions including memory, general intellectual tasks and 
executive psychomotor tasks (Bedard et al., 1991). EDS may result in periods of „micro 
sleep‟ lasting several seconds, causing lapses of attention, which may result in motor 
vehicle accidents (Williamson et al., 2000). 
1.6.4.6 Treatments for OSA 
Various interventions are used to treat OSA including weight loss, continuous 
positive airway pressure (CPAP), pharyngeal surgery, medication and oral appliances 
(Berg, 2008). In obese patients, a long term solution also involves weight reduction 
strategies; however, continuous positive airway pressure (CPAP) is generally 
considered the treatment of choice. There is growing evidence on the efficacy of oral 
appliances (OA) but these are mainly indicated when CPAP cannot be tolerated since 
CPAP seems more effective than OA in most cases. Evidence to date does not support 
drug therapy and surgical procedures as interventions for OSA (Berg, 2008; Busetto et 
al., 2005; Smith & Lasserson, 2009; Lim et al., 2006; Smith et al., 2006).  
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Weight loss is recommended as it significantly reduces OSA in obese patients 
(Shochat & Pillar, 2003) and a strong association has been shown between OSA and 
obesity (Young et al., 1993; Ancoli-Israel et al., 1991). The main mechanism by which 
weight loss helps reduce OSA seems to be reduction in adipose tissue deposited 
adjacent to the pharyngeal airway. The volume of this tissue is related to the presence 
and degree of OSA (Shelton et al., 1993) with obese patients having significantly lower 
pharyngeal cross-sectional areas compared to non obese male control subjects (Busetto 
et al., 2005). Indeed, weight loss in obese OSA patients has been shown to be associated 
with a marked decrease in the pharyngeal adipose tissue volume (Shelton et al., 1993), 
and an increase in the size of the upper airway passage (Busetto et al., 2005), fewer 
apneas and hypopneas, reduction of oxygen desaturation and sleep fragmentation 
(Shelton et al., 1993). Even a weight reduction of 15% may substantially increase the 
pharyngeal cross-sectional area and substantially improve the severity of OSAS in very 
obese patients (Busetto et al., 2005).  
The most commonly recommended and applied intervention for OSA is a 
continuous positive airway pressure (CPAP) device designed to deliver positive air 
pressure, usually, via a nose mask. The increased pressure keeps the airway 
unobstructed (Shochat & Pillar, 2003). A recent Cochrane systematic review concluded 
CPAP can be an effective treatment for OSA but compliance is the main problem with 
this intervention because many people cannot tolerate it, or do not use it every night. 
Attempts to improve compliance have included various mechanical design 
modifications. However, none has led to significant increases in compliance (Smith & 
Lasserson, 2009). 
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Oral appliances (OA) are designed to keep the upper airway open by either 
advancing the lower jaw forward or by keeping the mouth open during sleep. A 
Cochrane systematic review of OA for OSA found that there is increasing evidence to 
suggest that OA improved subjective sleepiness and sleep disordered breathing 
compared with a control. When comparing effectiveness of OA to CPAP, the latter 
appears to be more effective in improving sleep disordered breathing and OA therapy is 
considered appropriate for patients with mild symptomatic OSA, and those unwilling or 
unable to tolerate CPAP therapy. Further research is required on the effectiveness of OA 
for OSA patients with more severe symptoms of sleepiness (Lim et al., 2006). 
Surgical intervention has had some reported success in treating OSA but a 
Cochrane systematic review of surgery for OSA suggests that for mixed levels of AHI, 
with mostly moderate daytime sleepiness, current evidence does not support the use of 
surgery in sleep apnea/hypopnea syndrome and that long-term follow-up of patients 
who undergo surgical correction of upper airway obstruction is required (Sundaram et 
al., 2005). Furthermore, in the elderly, there is an increased risk of surgery related 
complications (Shochat & Pillar, 2003). 
Pharmacotherapy has been proposed as an alternative to CPAP in some patients 
intolerant of CPAP with mild to moderate sleep apnea. Pharmacotherapy may work in 
several ways to reduce the severity of OSA, including an increase in the tone in the 
upper airway dilator muscles, an increase in ventilatory drive, a reduction in the 
proportion of REM sleep, an increase in cholinergic tone during sleep, a reduction in 
airway resistance and a reduction in surface tension in the upper airway. A recent 
Cochrane review of pharmacotherapy for OSA concluded that to date there is 
insufficient evidence to recommend drug therapy in the treatment of OSA and suggests 
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that better matching of drugs to individual patients according to their dominant OSA 
mechanism is required (Smith et al., 2006).  
Positional therapy, which involves avoiding the supine sleeping position, may be 
partially effective in patients who usually have apnoea events mainly in that position 
Evidence is lacking however, regarding the prevalence of positional apnoea (Shochat & 
Pillar, 2003). 
Currently there is a lack of good quality evidence on the use of alternative 
methods for treating OSA. A single small study (n=25) of Didgeridoo (an ancient wind 
instrument developed by indigenous Australians of northern Australia) playing as 
alternative treatment for OSA in adult OSA patients with moderate OSA and snoring, 
reported that four months of private practice with a didgeridoo instructor resulted in 
significant reduction in AHI and significant improvement in subjective sleep quality 
measures compared to control. The suggested mechanism of action was improving 
muscle tone and reducing collapsibility of the upper airways (Puhan et al., 2006). 
1.6.4.7 The relationship between OSA and insomnia 
A recent review points to an association between insomnia and sleep disordered 
breathing (SDB) that has mostly been overlooked by researchers and medical 
professionals in the last few decades (Beneto et al., 2009). The review further reports on 
findings from several studies that had estimated the frequency of insomnia in OSA 
patients to be between 24.2% and 54.9% with recent data reporting a frequency of 
between 42% and 54.9% (Beneto et al., 2009). Reviewers conclude that patients with 
co-morbid SDB and insomnia are characterised by three main features including 
significant presence of psychological and psychiatric disorders, more sleep disruptions 
and an association with other sleep disorders such as the restless leg syndrome (RLS) 
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(Beneto et al., 2009). Reviewers also suggest a hypothetical metabolic/endocrine link 
between OSA and insomnia whereby OSA results in autonomic modulation leading to 
activation of the hypothalamic–pituitary–adrenal (HPA) axis which then causes 
increased sleep fragmentation. This in turn increases the secretion of cortisol which 
leads to further deterioration in sleep quality and so on. However reviewers suggest 
more research is required to understand the interaction and bi-directional relationship 
between OSA and insomnia (Beneto et al., 2009).  
Findings of several studies suggest that there is a stronger association between 
OSA and sleep maintenance insomnia and early morning awakening type insomnia than 
between OSA and sleep onset insomnia (Beneto et al., 2009). In a study of 157 
predominantly male OSA patients, 42% were found to have at least one insomnia 
symptom. However, insomnia subtypes differed in daytime sleepiness measures, Apnea 
Hypopnea Index (AHI) and Arousal Index (AI). The sleep onset insomnia subtype 
group had significantly lower AHI and AI and lower daytime sleepiness while the sleep 
maintenance insomnia subgroup had similar AHI and AI levels to those of OSA-only 
subjects and also had more severe daytime sleepiness levels than those found in the 
sleep onset insomnia subtype (Chung, 2005). The association between OSA and 
insomnia may also depend on the degree/severity level of OSA. A retrospective study of 
105 patients, referred to PSG for OSA evaluation, reported a strong positive correlation 
between OSA and insomnia symptom severity (Smith et al., 2004). Conversely, another 
similar retrospective study of 255 patients suggests that insomnia is not strongly 
associated with SDB. This study found insomnia complaints more prevalent in patients 
with AHI<10 than in those with AHI≥10 and no association between AHI, Desaturation 
index (DI) and the severity of insomnia symptoms in a subset of 228 patients with 
significant SDB (Krell & Kapur, 2005). 
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The differentiation between SDB patients with or without insomnia complaints 
has clinical relevance as SDB patients with insomnia complaints were found to have a 
significantly higher frequency of psychiatric disorders, cognitive-emotional symptoms, 
physical symptoms and mental symptoms that further degraded sleep quality. These 
patients also reported greater use of sedative hypnotic drugs (Krakow et al., 2001). 
Another study of 99 elderly with and without insomnia found that those with comorbid 
insomnia and SRBD had the greatest functional impairment including significantly 
lower daytime functioning and slower reaction time (Gooneratne et al., 2006). 
The overall higher prevalence of both OSA and insomnia in the elderly population 
(see sections 1.5.9 and 1.6.4.3) also increases the likelihood of concurrent OSA and 
insomnia as well as the likelihood of undiagnosed OSA to be present in elderly 
presenting with insomnia complaints. One study reported a high prevalence of 
undiagnosed sleep apnea in elderly insomniacs that had previously undergone an 
interview to screen for sleep apnoea. This study reported an AHI >5 in 43 percent and 
an AHI >15 in 29 percent of study population. Since OSA may be a confounding factor 
in studies on insomnia, this study suggested using PSG as a screening tool when 
recruiting older adults for research on insomnia (Lichstein et al., 1999). 
The implications of the above findings in relation to the screening process utilised 
in the present study are discussed in section 3.2.2.  
1.7 Yoga 
1.7.1 Introduction 
The use of complementary therapies, including mind-body practices, is becoming 
increasingly prevalent in western cultural settings. One of the most popular mind-body 
methods is yoga. Yoga encompasses diverse philosophical systems and practice 
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methods that have evolved mainly in the Indian subcontinent since ancient times. Yoga 
practices may include various combinations of physical exercises, breathing exercises, 
relaxation and meditation exercises, as well as devotional and lifestyle practices. Studies 
have shown yoga may provide various physical health and mental health benefits and 
may reduce stress, anxiety, somatic and mental hyper-arousal, that have all been shown 
to be strongly associated with primary insomnia. Up until early 2007, when the present 
study was initiated, there had been little published research on the use of yoga for 
improving quality of sleep in older people within western cultural settings.  
Yoga Nidra, (translated from Sanskrit as „yogic sleep‟), is a special, yet simple 
and accessible form of yogic guided meditation technique, that incorporates several 
meditation and relaxation components derived from ancient yogic and Tantric practices. 
In Yoga Nidra the practitioner enters into a state that approximates sleep, while 
maintaining alertness and awareness throughout the entire process. Despite its 
suggestive name and its simplicity there is no published research on Yoga Nidra‟s effect 
on geriatric insomnia. 
There are however, a number of published studies on the effect of various non-
yogic meditation techniques, such as Transcendental meditation (TM) (Ospina et al., 
2007), Zen-Buddhist meditation (Chiesa, 2009; Chiesa & Serretti, 2010; Ospina et al., 
2007), Vipassana meditation (Chiesa & Serretti, 2010; Chiesa & Serretti, 2009) and 
various contemporary forms of mindfulness meditation (Ospina et al., 2007; Chiesa & 
Serretti, 2009). Although these methods are not yogic in the limited sense, they have 
much in common with yogic meditation techniques in general and with Yoga Nidra in 
particular. Various studies have also been conducted on the effect of non-yogic 
contemporary muscle relaxation techniques (Carlson & Hoyle, 1993) as well as 
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stretching (Thacker et al., 2004; Herbert & Gabriel, 2002; Andersen, 2005; Shrier, 
2004) and isometric training techniques (Millar et al., 2007; Peters et al., 2006; Taylor 
et al., 2003). These methods have arguably been influenced by and have much in 
common with similar yogic exercises. Due to the similarities, research on these non-
yogic techniques may help obtain better insight into the mechanisms underlying yogic 
practices and their potential benefits. Therefore, they are reviewed briefly within this 
context. The present study‟s yoga protocol has incorporated yogic physical, relaxation 
and meditation exercises and the protocol design process was based on traditional and 
contemporary yogic texts and the existing scientific evidence on the effect of various 
yogic practices as well as similar non-yogic techniques. 
1.7.2 Use of yoga and complementary and alternative medicine (CAM) 
The use of complementary and alternative medicine (CAM) including mind-body 
practice methods such as yoga is on the rise. The 2007 National Health Interview 
Survey (NHIS) published by the National Center for Complementary and Alternative 
Medicine (NCCAM) and the National Center for Health Statistics of the Centers for 
Disease Control and Prevention (CDC) reported 38.3% of US adults have used CAM in 
the past 12 months (compared to 36% in the 2002 survey) (Barnes et al., 2008). CAM 
use among adults was greater among women, people with higher levels of education and 
higher incomes. Deep breathing, meditation, yoga, progressive relaxation and guided 
imagery were among the ten most common CAM therapies used by adults and their use 
has increased from 2002 to 2007 as follows: Deep breathing exercises from 11.6% to 
12.7%, meditation from 7.6% to 9.4%, massage therapy from 5% to 8.3%, and yoga 
from 5.1% to 6.1% (Barnes et al., 2008). Anxiety/depression and insomnia were among 
the ten conditions for which CAM was most frequently used (4.5% and 2.2% 
respectively) (Barnes et al., 2008). A 1998 US survey estimated 15.0 million adults 
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(7.5% of US adult population) had used yoga at least once in their lifetime and 7.4 
million (3.8%) during the previous year. Yoga was used both for general wellness (64% 
of yoga practitioners) and for specific health conditions (48% of yoga practitioners) 
such as neck and back pain (21% of yoga practitioners). Factors independently 
associated with yoga usage were female gender, metropolitan area dwelling, education 
level above high school, use of other CAM modalities and age, with the age group of 
34-53 reporting highest use. 90% of respondents thought yoga was very or somewhat 
helpful and 76% did not report spending money related to their yoga practice (Saper et 
al., 2004).  
1.7.3 What is yoga? 
In western cultural settings the word „Yoga‟ is often associated with physical yoga 
exercises. However, the term „Yoga‟ has a much wider context. Yoga is a Sanskrit word 
derived from the root “Yuj” that has various connotations including binding, joining, 
attaching, yoking, harnessing and focusing the mind. From ancient times the root “Yuj” 
has also been used in spiritual practice context, often to denote the control of the mind 
and the senses. It can also be translated as union, usually referring to union between 
man and the divine (Iyengar, 2001, p. 1; Feuerstein, 2000, p. 342).Yoga may encompass 
diverse psycho- physical practices associated with various cultures, spiritual traditions 
and body cultivation methods (Butera, 2006, p. 202). Yoga philosophy deals with 
physical, mental and spiritual wellness. It views the body and the mind holistically as 
one; whereby physical health depends on mental health and mental health depends on 
physical health (Butera, 2006, p. 202).Yoga instruction may include physical practices, 
breathing exercises, relaxation and meditation practices (Butera, 2006, p. 202), as well 
as internal and external hygiene and cleansing practices (Yogendra, 2003, chap. III -
XII). 
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Yoga is one of six traditional systems of Indian philosophy (Iyengar, 2001, p. 1) 
and is thought to date back more than 4000 years (Feurstein, 1990, p. VII). Patanjali, the 
great Indian sage who according to tradition lived around 200 -500 BC, collated, 
systematised and codified yoga in his classical work the “Yoga Sutra” (translated from 
Sanskrit as yoga aphorisms or verses) (Feurstein, 1990, p. 3; Feurstein, 2000, p. 342; 
Iyengar, 2002, p. XVII). In the second verse of the of the “Yoga Sutra” Patanjali states 
that “Yoga is the cessation of movement in the consciousness” („Ýogah Citta Vrtti 
nirodah‟ in Sanskrit) (Iyengar, 2002, p. 50; Feurstein, 1990, p. 26), or in other words, 
the goal of yoga according to Patanjali is the restraining of the fluctuations of the 
consciousness. In the 13
th
 verse of the “Yoga Sutra” Patanjali states that “Yoga practice 
is the steadfast effort to still these fluctuations” (Iyengar, 2002, p. 63) and the goal is 
achieved through practice and dispassion which are the two poles of yoga practice 
(Feurstein, 1990, p. 34). Overall yoga provides the practitioner with various methods of 
understanding the functioning of the mind in order to gradually restrain its activity and 
achieve an undisturbed state of silence (Iyengar, 2002, p.62). Patanjali set out an 
eightfold path of yoga („Ashtanga Yoga‟ in Sanskrit) for the practitioner to achieve this 
goal (Iyengar, 2002, pp. 31-32; Iyengar, 2002, pp.140-142). The eightfold path includes 
these eight components: 
1. „Yama‟ - Sanskrit term for moral injunctions, self restraint, abstention 
2. „Niyama‟ - Sanskrit term for fixed observances, values and precepts 
3. „Asana‟- Sanskrit term for postures, poses, stable sitting positions 
4. „Pranayama‟ - translated as regulation of breath/energy 
5. „Pratyahara‟ - Sanskrit term for directing the senses inwardly 
6. „Dharana‟ – Sanskrit term for concentration, keeping the mind focused  
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7. „Dhyana‟ - Sanskrit term for meditation, contemplation, reflection, 
awareness 
8. Samadhaya - Sanskrit term for absorption of consciousness in the self, 
profound meditation, super consciousness (Iyengar, 2002, pp. 31-32; Iyengar, 
2002, pp.140-142).  
Several of these foundation yogic components have been incorporated into the 
yoga protocol of the present study (see section 3.3). 
„Hatha Yoga‟ (Hathayoga in Sanskrit) is one of the major ancient yoga systems 
and the most prevalent form of yoga currently practiced in western cultural settings. 
Hatha yoga was introduced in India in the 15th century by the great yoga sage 
Svatmarama who consolidated his own experience and now lost ancient texts, in his key 
yoga text “Hatha Yoga Pradipika” (Svatmarama, 2002, p. IX). The Sanskrit word Hatha 
is a combination of „Ha‟ (sun in Sanskrit) and „Tha‟ (moon in Sanskrit). Some interpret 
this as alluding to the combination of solar and lunar energy, which are two main forms 
of energy described in yoga philosophy. These energies were believed to flow in the 
human mind-body and govern life. Hatha Yoga practice was believed to bring these two 
energies into balance (Maheshwarananda, 2009). In the 10
th
 verse of “Hatha Yoga 
Pradipika” Svatmarama explains that hatha yoga is the foundation for any type of yoga 
practice, and also provides the means for curing the body from any pain and illness 
(Svatmarama, 2002, p. 4). In the opening verses of the “Hatha Yoga Pradipika”, 
Svatmarama states that hatha yoga is the first step leading to the heights of „Raja Yoga‟ 
(Royal Yoga – in Sanskrit) (Svatmarama, 2002, p.1). 
Traditional hatha yoga is subdivided into seven and sometimes eight limbs, which 
are similar, although not identical, to Patanjali‟s eightfold path of yoga.. The great yoga 
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sages Patanjali, Svatmarama and Gheranda, author of the “Gheranda Samhita”, the 
most encyclopaedic of all root texts of hatha yoga (Gheranda, 2004, p. IX), are in 
agreement on the primary role of physical poses (Asana), breath regulation exercises 
(Pranayama), directing the senses inwardly (Pratyahara), meditation (Dhyana) and the 
ultimate goal of absorption of consciousness in the self or self realization (Samadhi) 
(Iyengar, 2002, pp. 31-32; Iyengar, 2002, pp.140-142; Svatmarama, 2002, p. X; 
Gheranda, 2004, pp. IX-XI). The first four of these components have become essential 
elements of contemporary yoga practice and will be discussed in more detail below to 
provide the background for the yoga protocol used in the present study (see section 3.3) 
1.7.4 Asana  
Asana practice is the third limb of the eightfold path of yoga as outlined in 
Patanjali‟s “Yoga Sutra” (Iyengar, 2002, pp. 31-32; Iyengar, 2002, pp.140-142; 
Feuerstein, 2000, p. 34). The Sanskrit word „Asana‟ can be translated as sitting, a seat, 
or a sitting posture. In yoga practice asana originally referred to a posture or pose 
(Feuerstein, 2000, p. 34; Buhnemann, 2007, p. 17) used for prolonged meditation 
practice but was later developed within the framework of hatha yoga to refer to poses 
for building strength and suppleness and serving a range of therapeutic functions 
(Feuerstein, 2000, p. 34; Buhnemann, 2007, p. 20). Svatmarama explains that asana 
practice is the first step of hatha yoga as it builds physical strength, helps attain good 
health and assists in developing self control (Svatmarama, 2002, p. 8). Other traditional 
core yoga texts also view the asanas mainly as a foundation yogic practice intended to 
improve and maintain practitioners' well-being, flexibility, strength and vitality. Unlike 
some contemporary yoga schools classical texts do not view asana practice as an 
exclusive or primary yogic practice, but rather as a subordinate and preparatory practice 
intended to provide a good foundation for meditative practice by developing the ability 
76 
 
to remain in seated position for extended periods (Buhnemann, 2007, pp. 21- 22; 
Feuerstein, 2000, p. 34). Contemporary yoga master Iyengar further explains that in 
order to achieve body- mind integration, the body, which is the foundation for any 
practice, must be kept healthy (Iyengar, 2009, p. 204). Furthermore, because of the 
close connection between body and mind, they affect each other (Iyengar 2009, p. 228). 
Asana practice, therefore, affects not only the body but the mind as well (Iyengar 2009, 
p. 204).  
The number of basic asanas mentioned in traditional texts varies greatly 
(Buhnemann, 2007, p. 25). Two seminal traditional hath yoga texts, the “Hatha Yoga 
Pradipika” and the “Gheranda Samhitta”, mention the existence of 84 major poses 
(Svatwarama, 2002, p. 16; Gheranda, 2004, p. 16). The “Gheranda Samhitta” further 
explains that out of these, 32 are useful and essential for building strength (Gheranda, 
2004, p. 16). Yoga asanas can be classified as standing poses, sitting poses, twists, 
forward bends, back bends, arm balances, core strength postures, inversions, and 
restorative poses (Yoga Journal, 2010; Raub, 2002). The design of the present study‟s 
asana protocol strived to incorporate poses from most of the above categories and adapt 
them, where necessary, to suit older adults (see section 3.3.9). 
Each of the poses is claimed to provide specific physiological and mental benefits 
such as building strength, flexibility and mobility of spine and joints, improving 
postural alignment, improving balance, toning internal organs, improving circulation, 
digestion and elimination, preventing or alleviating specific health conditions and 
calming the mind (Iyengar, 2001, pp. 39-353; Buhnemann, 2007, p. 20). However, there 
is currently a lack of high quality evidence to substantiate claims made regarding the 
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physiological effects or health benefits of specific poses and this remains an important 
subject for future research. 
1.7.5 Pranayama  
Pranayama is the fourth limb of the eightfold path of yoga as outline by Patanjali 
(Iyengar, 2002, pp. 31-32; Iyengar, 2002, pp.140-142; Feuerstein, 2000, p. 225). 
„Pranayama‟ is a Sanskrit word constructed of two separate words, „Prana‟ and 
„Ayama‟. „Prana‟ can be translated as breath, respiration, life, vitality and energy. 
„Ayama‟ can be translated as restraint, control and regulation. Put together „Pranayama‟ 
means regulation of breath and/or energy (Feuerstein, 2000, p. 225; Iyengar, 2010, pp. 
13-14). Yoga texts describe subtle energy channels called „nadi‟ (tube or pipe in 
Sanskrit), through which the prana flows. The practice of pranayama is claimed to clear 
„blockages‟ from these channels and thus achieve better flow of vital energy and 
improved health (Iyengar, 2010, p. 15). Pranayama is considered by core ancient and 
contemporary yoga texts an important tool for improving health, preventing and curing 
diseases and also for facilitating concentration and calming the mind as an essential 
foundation practice for higher spiritual practice, as in pranayama practice the breath and 
the mind are closely interlinked (Svatmarama, 2002, pp. 33 - 35; Iyengar, 2010, p. 14; 
Feuerstein, 2000, p. 225; Iyengar, 2006, p. 32). 
Several key ancient and contemporary yoga texts caution that incorrect or 
untimely pranayama practice may be harmful. In the “Hatha Yoga Pradipika” 
Svatmarama maintains that only after asana practice is consolidated, self control is 
attained, and moderate suitable dietary practices adopted, the practitioner may 
commence practice of pranayama. He adds that correct and timely pranayama practice 
can cure disease, but conversely, improper and untimely practice may cause disease 
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(Svatmarama, 2002, pp. 36-37). Contemporary Yoga master B.K.S. Iyengar, in his 
encyclopaedic manual “Light on Pranayama”, emphasises that pranayama practice 
should only be attempted once the yoga asana have been mastered and that there can be 
no short cuts in this respect (Iyengar, 2010, p. 53; Iyengar 2006, p. 33). In addition, 
Iyengar explains that before attempting pranayama practice, the practitioner  needs to 
learn correct use of the intercostal muscles and diaphragmatic muscles via proper 
practice of the asana and warns that premature or improper practice of pranayama may 
severely harm the practitioner‟s health (Iyengar, 2010, p. 54). 
Despite the above mentioned cautions, some contemporary schools of yoga 
incorporate substantial pranayama practice at the beginner‟s level and have 
demonstrated various health benefits with no reported adverse effects. One such yogic 
practice, is „Sudarshan Kriya Yoga‟ (SKY) formalised by Sri Sri Ravi Shankar (Art of 
Living Foundation [ALF], 2010; SKY, 2010). SKY protocol incorporates a sequence of 
classic yogic breathing techniques and a special SKY breathing sequence (Brown & 
Gerbarg, 2005a; Brown & Gerbarg, 2005b). A review of studies on SKY intervention 
does not report adverse events (Brown & Gerbarg, 2005a; Brown & Gerbarg, 2005b). 
Another yogic system which incorporates breathing techniques at the beginner‟s level is 
Kundalini Yoga (KY). Several studies using KY intervention have not reported any 
adverse effects (Shannahoff-Khalsa, 2004; Khalsa, 2004b). It seems that more research 
is required to establish the safety, efficacy and correct application of other pranayama 
practices. The present study‟s protocol was designed for an elderly population with no 
previous yoga experience and therefore a conservative cautious approach was taken and 
pranayama practice was excluded. However, awareness of natural unregulated breath 
was used as one of the main tools in the meditative component of the protocol (see 
section 3.3.10). 
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1.7.6 Pratyahara  
„Pratyahara‟ is a Sanskrit word translated as withdrawal of the senses or directing 
the senses inwardly. It is the fifth limb of the eightfold path of yoga as outlined by 
Patanjali in his “Yoga Sutra”. Patanjali does not provide many details how to practice 
and achieve pratyahara (Iyengar, 2002, pp. 31-32; Iyengar, 2002, pp.140-142). 
Pratyahara is the connecting link between external aspects and internal aspects of yoga 
as withdrawing the five senses (i.e. tactile, taste, smell, auditory and visual) inwards and 
away from external objects and bringing them under control paves the way to 
concentration practices (Iyengar, 2001, pp. 25 -27).  
1.7.7 Dharana 
„Dharana‟ is a Sanskrit word translated as concentration, practice with continuous 
single pointed focus of the mind, binding the consciousness (Feuerstein, 200, p. 85). It 
is the sixth limb of the eightfold path of yoga as outlined by Patanjali in is his “Yoga 
Sutra” (Iyengar, 2002, pp. 31-32; Iyengar, 2002, pp.140-142). Patanjali explains that in 
order to counteract the multitude of distractions, the practitioner should resort to the 
practice of concentration on a single principle (Feuerstein, 1990, p. 47). Dharana is 
accompanied by increased sensory inhibition and slowing down of the thought process 
which precedes entering into a full state of meditation (Dhyana) (Feuerstein, 2000, p. 
85). In the present study the breath has been used as the main internal object of 
concentration (see section 3.3.10.3). 
1.7.8 Dhyana 
„Dhyana‟ is the seventh limb of the eightfold path of yoga as outlined by Patanjali 
is his “Yoga Sutra” (Iyengar, 2002, pp. 31-32; Iyengar, 2002, pp.140-142) and is a 
Sanskrit word translated as meditation, contemplation or meditative state (Feuerstein, 
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2000, p. 88). Dhyana is the most common term both for the meditative state of 
consciousness and the yogic techniques by which to reach it (Feuerstein, 2006 and is a 
central advanced technique common to all yogic paths (Feuerstein, 2000, p. 88) as it 
constitutes a deepening of the preceding process of concentration, or one-pointed-
mindedness (Dharana) (Feuerstein, 2006). Indeed, as outlined by Patanjali in his “Yoga 
Sutra”, all limbs of yoga are part of a general effort to restructure the practitioner‟s 
consciousness and all lead in the same direction. However, in Dhyana the inner 
restructuring of the mind is greatly enhanced, as it is considered the foundation for the 
ecstatic breakthrough to a state of „Samadhi‟ (Feuerstein, 2006). According to Iyengar 
(2009, p. 160) Patanjali provides a variety of practice methods based on his 
understanding that meditation is not suitable or possible for all levels of practitioners. In 
the present study, the practice of Yoga Nidra was chosen as the main meditative 
practice. One of the considerations behind this choice was the fact that it incorporates a 
variety of practice tools to accommodate individual difference and practice levels (see 
section 3.3.10.5). 
1.7.9 Samadhi 
„Samadhi‟ is a Sanskrit word translated as absorption of consciousness in the self, 
profound meditation or super consciousness. It is the eighth limb of the eightfold path of 
yoga as outlined by Patanjali is his “Yoga Sutra” (Iyengar, 2002, pp. 31-32; Iyengar, 
2002, pp. 140-142; Feuerstein, 2006). Ultimately, the traditional spiritual goal of 
meditation is „Samadhi‟, the final ecstatic merging with the object of meditation, and 
breakthrough towards higher state of consciousness. Furthermore, the ultimate goal of 
„Samadhi‟ is achieving self-realization (Feuerstein, 2006).  
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1.7.10 Objects of meditation in yogic meditation techniques 
Yoga practitioners consider that anything can serve as an object of meditation, 
from the most gross to the most subtle, from the most mundane to the divine including 
things that are internal or external, concrete or abstract, real or imagined (Feuerstein, 
2006). Patanjali, in the “Yoga Sutra” leaves the choice of meditation object open and 
accepts a wide range of meditation objects for focusing consciousness including body 
parts, planets and stars, various abstract concepts, feelings and processes (Feuerstein, 
2006).  
The “Hatha Yoga Pradipika” recommends meditating upon the inner sound 
(„Nada‟ in Sanskrit) (Feuerstein, 2006). The practice of „Mantra-yoga‟ can be found in 
many spiritual traditions and incorporates regular and prolonged recitation („japa‟ in 
Sanskrit) of a specific „mantra‟. Mantras are considered to be sacred sounds, syllables, 
words or word combinations with the best known example being the sacred syllable 
„Om‟, which symbolizes the absolute and is often used in conjunction with other sounds 
or combination of sounds (Feuerstein, 2006). 
In „Guru-yoga‟, the object of meditation is a fully enlightened teacher („sad -
Guru‟ in Sanskrit). The disciple, who constantly keeps the Guru in his mind in thought, 
worship, and meditation, aims to align himself with the teacher and duplicate within 
himself the teacher's illumined state (Feuerstein, 2006). 
The “Gheranda-Samhita”, distinguishes between sthula ("coarse"), jyotir- 
("luminous"), and sukshma-dhyana ("subtle meditation"). In Sthula-dhyana the 
practitioner visualises a particular form, such as a guru or a deity, in great detail. In 
Jyotir-dhyana the practitioner contemplates on the Divine and visualizes it as a mass of 
light in specific energy centres of the body („chakra‟ in Sanskrit). In Sukshma-dhyana 
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the practitioner meditates upon the awakened „Kundalini‟ energy - an unconscious, 
instinctive or libidinal force claimed to be lying dormant coiled at the base of the spine 
(Feuerstein, 2006) and is a meditation object favoured by many Hatha-yoga and Tantric 
schools (Feuerstein, 2006).  
The yoga nidra practice incorporated in the present study provides a range of 
meditation objects, including various parts of the body, the natural breath, opposing 
physical sensations and various visualised images (see sections 1.7.12 and 3.3.10.5). 
1.7.11 Meditation and related practices - modern versus traditional 
perspectives 
The English term meditation was derived from the Indo-European root „med‟ 
whose main meaning was that of „measuring‟. Its Latin equivalent „meditor‟ originally 
meant „exercise‟ in general but then restricted to mental or spiritual exercise (Bader, 
1990, pp. 25-26). The current common usage of the term meditation is somewhat 
broader than that represented by term „Dhyana‟ in Patanjali‟s “Yoga Sutra” or in the 
“Gheranda Samhita”. The “oxford online dictionary” defines the verb to „meditate‟ as: 
to “focus one's mind for a period of time, in silence or with the aid of chanting, for 
religious or spiritual purposes or as a method of relaxation” (Oxford Online dictionary, 
2010). In a comprehensive analysis of recent meditation research Shapiro et al. (2003) 
define meditation as: “A family of practices that train attention and awareness, usually 
with the aim of fostering psychological and spiritual well being and maturity”. 
According to Shapiro et al. (2003) meditation achieves this aim by training the mind 
and increasing the amount of voluntary control over mental processes in such a way that 
they can be directed in beneficial ways, including the development of qualities of 
concentration, calm, joy, love, compassion, and heightened awareness. Heightened 
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awareness, in turn, results in better self knowledge and understanding of how one 
relates to the world. It also leads to a better knowledge of consciousness and reality. 
According to Shapiro et al. (2003) meditation methods are commonly classified as 
concentration type meditation or awareness type meditation, where concentration type 
practices are designed to focus awareness on a single object such as the breath or an 
internal sound (mantra in Sanskrit), and awareness type practices allow attention to be 
directed at a wider variety of objects Shapiro et al. (2003). It seems therefore, that the 
current use of the term meditation may include elements of the fifth, sixth and seventh 
limbs of Patanjali‟s eightfold path of yoga, namely, Pratyahara (withdrawal of the 
senses), Dharana (concentration) and Dhyana (meditation), as well as relaxation 
practices. In traditional yoga texts, on the other hand, meditation is considered an 
advanced stage which requires adequate preparation. Pratyahara leads to Dharana which 
leads to Dhyana which eventually may lead to Samadhi (Iyengar, 2002, pp. 31-32; 
Iyengar, 2002, pp. 140-142; Feuerstein, 2006). The Pratyahara, Dharana and Dhyana 
elements as well as a relaxation element are incorporated in the meditation techniques 
used in the present study (see section 3.3.10) 
1.7.12 Yoga Nidra 
„Yoga Nidra‟ (translated from Sanskrit as yogic sleep), is a form of yogic guided 
meditation technique. Yoga nidra originated in India from the ancient teachings of yoga 
and „Tantra‟- a philosophical system incorporating a vast array of spiritual practices and 
ritual forms aiming at attaining spiritual liberation (Miller, 2005a, pp. 3-4; Satyananda, 
1976, pp. 1-3). Several yoga masters have revitalised the practice of yoga nidra during 
the 20th century, mainly Swami Sivananda and his disciples including Satyananda 
Swaraswati of the Bihar school of yoga, Swami Satchyananda of Integral Yoga, and 
swami Vishnudevananda of the Sivananda Yoga Vedanta centre; but also Swami Rama 
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of the Himalayan Institute and his direct disciple, Swami Veda Bharati of the Swami 
Rama Sadhaka Grama and Sri Brahamananda Swaraswati(Rammurti S. Mishra), an 
initiate of the Radhaswami school of Surrat Shabd Yoga and others (Miller, 2005a, pp. 
3-4). 
„Yoga Nidra‟ is usually performed lying supine and motionless in „Savasana‟ 
(translated from Sanskrit as „dead corpse pose‟) and mentally following a series of 
instructions read out by a yoga teacher (Satyananda, 1976, p. 69) (in person, or using an 
audio CD for home- practice. Both methods have been applied in the present study - see 
3.3.10.2 -3.3.10.5). A single yoga nidra sequence may incorporate several yogic 
techniques including relaxation, withdrawal of the senses, concentration, and 
awareness/mindfulness, autosuggestion, and visualisation. Furthermore, it uses a range 
of meditation objects including the natural breath, various parts of the body, opposing 
physical sensations (e.g. hot and cold, heavy and light etc.) and images generated by 
inner visualisation (Satyananda, 1976, pp. 70-73). This allows tailoring a range of 
meditation protocols with varying duration and meditative emphasis to suit beginner to 
advanced students with different needs and abilities. In his book and accompanying CD 
“Yoga Nidra: The Meditative Heart of Yoga”, Miller has added psychological 
components (Miller, 2005, pp. 79-82) designed to help in dealing with negative feeling 
and emotions (Miller, 2005b, track 3), negative thought and belief patterns and negative 
self perceptions (Miller, 2005b, track 4). 
Yoga nidra practice is claimed to provide many benefits including somatic and 
mental relaxation, improved memory, reduction of stress, anxiety, fear, anger, 
depression and insomnia, and also improved learning ability and memory (Satyananda, 
1976, p. 2). Satyananda explains that in yoga Nidra, the practitioner enters a state which 
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constitutes some aspects of Patanjali‟s yogic elements of „Pratyahara‟ (Satyananda, 
1976, p. 2), „Dharana‟ (Satyananda, 1976, p. 72), and in advanced levels of practice also 
„Dhyana‟ (Satyananda, 1976, p. 72). According to Miller (2010, p.38) each of the 
components of yoga nidra, directs the practitioner‟s awareness to a different „sheath‟ 
(„Kosha‟ in Sanskrit – see glossary) or yogic aspect of the mind-body phenomenon. 
Miller lists the following sheaths/layers/levels, and respective yoga nidra practice 
elements: On the physical level - awareness of physical sensations. On the energy level 
- awareness of breath and energy flow. On the emotional level - awareness of feelings 
and emotions. On the intellectual level - awareness of thoughts, beliefs and images. On 
the sensual level - awareness of joy, pleasure and desire. On the ego level - awareness of 
the witness or ego. On the natural blissful level - awareness of the changeless body. 
According to Miller, a yoga nidra session may focus on a single aspect, several aspects 
or all of the above aspects of the mind-body (Miller, 2010, p.38). Indeed, yoga nidra 
allows tailoring various protocols varying in duration and number of meditative 
components (Satyananda, 1976, pp. 81-150). Arguably, by using an external „directive‟ 
in the form of the teacher‟s voice, the practitioner is given a chance to let go further and 
reach a deeper level of relaxation. All these aspects of yoga nidra make it a multifaceted 
and versatile meditation tool that is easy to learn and follow. 
There are various variants of yoga nidra sequences (Satyananda, 1976, pp. 81-
150; Miller, 2005b) and the yoga nidra protocol used in the present study was based on 
several Yoga Nidra protocols as taught by Swami Satyananda Swaraswati of the Bihar 
school of yoga (Satyananda, 1976, pp. 81-150). A typical protocol may include the 
following components in this order:  
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1. Preparation:  the practitioner is instructed to lie down comfortably on a mat in the 
supine position, feet apart and palms facing upwards. If necessary, the body is 
covered with a blanket to keep warm and once comfortable, the practitioner is 
instructed to stay still until the end of the practice (if the supine position is not 
comfortable other horizontal or sitting positions are permissible). The practitioner 
is then instructed to focus on external sounds and direct his/her attention from 
sound to sound („Antar Mouna‟ in Sanskrit) (Satyananda, 1976, pp. 69). 
2. Relaxation : The practitioner is instructed to scan the entire body and feel if there 
is any tension in the muscles and then feel the tension dissolving away while 
relaxing the whole body (part by part or all at once) (Satyananda, 1976, pp. 142-
143).This component resembles some western muscle relaxation techniques 
described earlier (see section 1.5.12.3.9). 
3. Resolve („Sankalpa‟ in Sanskrit):  The practitioner is instructed to make a wish for 
any positive change in his/her life, health, relationships etc. and this is repeated 
three times (Satyananda, 1976, p.70). This element of Yoga Nidra resembles 
„autosuggestion‟ techniques as introduced by Emil Coue in the early 20th century 
(Coue, 2006, pp. 21-28), although in a more concise format. 
4. Rotation of consciousness: The names of various body parts are called out by the 
teacher, sequentially in a rapid succession, from top to bottom and from right to 
left. The practitioner is instructed to direct his/her awareness to the body part called 
out and to mentally repeat the name of the body part (Satyananda, 1976, p.70) and 
focus on any sensation there (Miller, 2005b, track 1). In yoga nidra, the practitioner 
is passive and the rate and direction of the body scan is dictated by the teacher or 
the recording. Arguably, this allows the yoga nidra practitioner to let go further and 
achieve a deeper level of relaxation. 
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5. Awareness of the contact between body and floor. The practitioner is instructed 
to be aware of the contact points between body and floor, whole body at once or 
part by part (Satyananda, 1976, p.132; Satyananda, 1976, p. 148). 
6. Awareness of subtle body movements – The practitioner is instructed to be aware 
of muscle twitches or subtle movements in the body in conjunction with the breath 
(Satyananda, 1976, p. 143). 
7. Breath awareness: The practitioner is instructed to direct the awareness to the 
natural (uncontrolled) breath as it manifests in the movement of the navel, chest, 
throat, nostrils eyebrow centre (Satyananda, 1976, p.132). Usually this practice is 
done while mentally counting the breaths. For example, the practitioner maintains 
focus and counts down from a certain number to zero (or vice versa) (Satyananda, 
1976, p. 71).  
8.  Awareness of opposing sensations: The practitioner is instructed to sense 
opposite sensations in the body, such as heat and then cold, lightness and then 
heaviness, painful and then pleasant sensation etc. (Satyananda, 1976, p. 72).  
9. Focusing on the ‘inner space’ (Chidakasha – in Sanskrit): The practitioner is 
instructed to focus on the inner space between the eyebrows (with the eyes closed) 
and observe whatever appears there such as colours, patterns etc. (Satyananda, 
1976, p. 132). 
10. Visualisations: The practitioner is instructed to visualise a rapid sequence of 
objects such as natural scenery, building, flowers, people, etc. The practitioner tries 
to visualise them as vividly as possible as they are called out by the teacher 
(Satyananda, 1976, p. 72; Satyananda, 1976, p. 132). 
11. Repeating the Resolve: The practitioner is instructed to repeat the initial resolve (a 
wish for any positive change in his/her life, health, relationship etc.) three times 
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(Satyananda, 1976, pp. 72-73). At this point in the meditation the practitioner is 
immersed deeper in the meditation, the mind is calmer and arguably the level of 
suggestibility to the resolve statement is increased.  
12. Movement in time: The practitioner is instructed to mentally review/visualise the 
events which have occurred during the day (Satyananda, 1976, p. 72; Satyananda, 
1976, p. 132). 
13. Completion: The practitioner is instructed to gradually become aware of his/her 
body, the room and its surroundings and thereby finish the practice. (Satyananda, 
1976). 
In summary, it seems that yoga nidra represents a broad range of meditative yogic 
techniques and also fits Shapiro et al.‟s (2003) contemporary definition of meditation. 
Yoga nidra‟s flexibility and range of meditative tools allow creating protocols of 
varying length and emphasis to suit beginner to advanced students. Yoga Nidra‟s well 
structured guided meditation format makes it accessible and applicable using audio CDs 
and MP3 players and thus advantageous for home-based self-practice. 
1.7.13 Research on the effects and benefits of yoga practice 
1.7.13.1 Introduction 
There is a growing body of evidence on the effects and benefits of yoga practice; 
however, studies vary greatly in quality, methodology, yoga protocols, and populations. 
Most studies on yoga intervention employ composite protocols that incorporate several 
yogic practice elements (e.g. asana and relaxation or pranayama and meditation). A 
small number of studies examine the effects of a single yogic practice element on its 
own (i.e. asana, pranayama, relaxation or yogic meditation on their own). This section 
will include a general review on the effects of yoga interventions followed by a short 
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review on the effects of specific yogic practice components (i.e. asana, pranayama, 
relaxation or meditation). The section on the effects of yogic meditation techniques will 
also include a brief review of the effects of similar non-yogic meditation techniques that 
are aligned with yogic meditation techniques. 
1.7.13.2 Research on effects of composite yoga practices  
1.7.13.2.1 Introduction 
Most published studies to date have investigated the effect of composite yoga 
intervention protocols that incorporate at least two yogic practice components. Often the 
relative proportion of each of the components is not clearly stated and/or the protocol is 
described only in very general terms. Identifying the effects of specific components of 
yoga (i.e. yoga poses, breathing, relaxation, meditation, chanting etc.) within a protocol 
and comparing protocols with different mixes of yogic practice elements needs to be 
addressed in future research.  
1.7.13.2.2 Yoga’s effect on sleep quality  
A small number of studies have shown that yoga may improve a range of sleep 
quality measures with most studies investigating the effects on normal sleepers and not 
those suffering from a sleep disturbance. Most studies to date have only used subjective 
sleep quality measures and at the inception of present study (early 2007) only one 
published study investigated yoga as an intervention for improving sleep quality in an 
elderly population (Manjunath & Telles, 2005). 
This study involved a six months trial conducted in Bangalore India, in 
collaboration with the Vivekanada Yoga research foundation. The study, which 
recruited healthy subjects from a single aged care facility and did not exclude normal 
sleepers or use objective sleep measures, compared self rated sleep quality outcomes of 
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normal subjects randomised into three groups: yoga intervention, traditional Indian 
medicine („Ayurveda‟) and control. The study population consisted of 69 out of 120 
residents of a single aged care facility and the inclusion criteria did not require a 
diagnosed or self reported sleep disturbance. A very extensive yoga intervention 
protocol, that is unlikely to be suitable for the lifestyle of elderly people in western 
cultural settings, was used. This protocol included two daily guided yoga sessions six 
days a week. The morning session protocol included 60 minutes of regulated breathing 
exercises („Pranayama‟), physical warm-up exercise („Shilikarna Vayama‟), physical 
yoga poses („Asana‟), and guided relaxation. The evening session protocol included 
devotional songs („Bhajan‟), lectures on the theory and philosophy of yoga and a 
practice of „Cyclic Meditation‟ (CM), which incorporates cycles of physical yoga poses 
followed by supine rest. Results revealed that the yoga group, but not the control group, 
showed significant improvement in various subjective sleep quality measures including 
sleep latency, total sleep time and feeling refreshed in the morning (Manjunath & 
Telles, 2005). 
Shannahoff-Khalsa describes several yogic meditation and breathing techniques 
with a specific effect on insomnia and other sleep disorders (Shannahoff-Khalsa, 2006, 
pp. 164-179; Shannahoff-Khalsa, 2004). Some of these techniques were applied in a 
study (n =20) of Kundalini Yoga (KY) as an intervention for primary and secondary 
insomnia. This study used an intervention which included breathing exercises (some in 
conjunction with inward silent mantra recitation) and a breath awareness meditation and 
incorporated an initial guided session followed by home-based self-practice sessions for 
eight weeks. The study results, derived from self-reported sleep-wake diary, revealed a 
significant pre- to post-intervention improvement in Sleep Efficiency (SE), Total Sleep 
Time (TST), Total Wake Time (TWT), Sleep Onset Latency (SOL), Wake time After 
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Sleep Onset (WASO), number of awakenings, and other sleep quality measures. 
(Khalsa, 2004b). 
A study of Tibetan Yoga (TY) for supporting cancer patients included a weekly 
session of meditation, visualization and gentle postures over a period of seven weeks 
with 98% of the TY intervention group completing 2-3 sessions and 58% at least five 
sessions. The results showed significant improvement in various subjective sleep quality 
measures but no significant difference in various mental health measures in the 
intervention compared to the control group (Cohen et al., 2004). 
Three studies have been conducted in Taiwan to measure the effect of a six 
months intervention of hatha yoga adapted for the needs of the elderly (“Silver Yoga”). 
Subjects included community dwelling elderly (two studies) and elderly living in 
assisted living facilities (one study). The intervention included gentle yoga postures, 
relaxation exercises and guided imagery. Results revealed a significant improvement in 
various subjective mental health and sleep quality measures (Chen et al., 2008; Chen et 
al., 2009; Chen et al., 2010a) 
The association between autonomic hyper arousal and insomnia has been 
discussed above (see section 1.5.8). Three short studies have shown yoga practice may 
affect autonomic modulation and also improve sleep quality pointing to a possible 
mechanism by which yoga practice may contribute to improved sleep quality. These 
studies, which compared the immediate effects of Cyclic Meditation (CM) and 
relaxation in the yogic shavasana („corpse‟) pose (SR) in normal subjects found a shift 
in sympatho-vagal balance in favour of parasympathetic dominance in the CM group 
but not the SR group. A significant decrease in oxygen consumption and breath rate and 
an increase in breath volume were seen in both groups but, the magnitude of change on 
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all three measures was greater following a CM session. Furthermore, the proportion of 
slow-wave sleep (SWS) increased significantly, whereas proportion of rapid-eye-
movement (REM) sleep and the number of awakenings decreased in the night that 
followed practice in the CM group compared to the SR group. The CM group also 
showed an improvement in a range of self reported subjective sleep quality measures 
including feeling more refreshed in the morning, increase in sleep duration, and 
decrease sleep disruptions. (Patra, & Telles, 2010; Patra, & Telles, 2009; Telles et al., 
2000).  
1.7.13.2.3 Yoga’s effect on stress, anxiety and depression 
Stress, anxiety and depression may have a significant negative impact on quality 
of life. The association between stress, anxiety and depression and between insomnia 
was discussed above (see section 1.5.7). Several studies have shown yoga practice may 
alleviate stress, anxiety and depression pointing to a possible mechanism by which yoga 
practice may improve sleep quality in individuals suffering from stress, anxiety or 
depression and comorbid sleep disturbance. However additional high quality research is 
required. 
A recent critical review of the effect of yoga on depression found eight studies 
with poor methodology but encouraging results and concluded that additional research 
is required (Uebelacker et al., 2010). Another systematic review of the effect of yoga on 
depression implied that yoga interventions may have some positive effects on 
depressive disorders but additional research is required due to the heterogeneity of 
intervention protocols and poor methodological quality (Pilkington et al., 2005). A 
systematic review of the effectiveness of yoga for the treatment of anxiety and anxiety 
disorders, found eight poor quality studies reporting positive results, and recommends 
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further better quality research focused on specific anxiety disorders. (Kirkwood et al., 
2005). 
A study of an Iyengar yoga intervention for stress reduction in 24 self referred 
females found that two weekly classes over a period of three months led to significant 
improvements on self reported measures of stress, psychological and physical well 
being outcomes. Salivary cortisol hormone was found to decrease significantly after 
participating in a yoga class and those complaining of back pain or headache prior to the 
intervention reported marked improvement in pain levels (Michalsen et al., 2005). 
A study (n=57) comparing the immediate effects of a 22.5 minutes session of CM 
to a similar session of relaxation in shavasana (SR) found that both techniques improved 
memory scores immediately after and decreased anxiety with the practice of CM having 
a greater effect than SR (Subramanya & Telles, 2009).  
A 12 months study (n=21) of yoga as an intervention for obsessive compulsive 
disorder (OCD) compared „Relaxation Response‟ plus „Mindfulness Meditation‟ to 
Kundalini Yoga (KY) which included breath synchronized Sanskrit mantra chanting, 
shoulder shrugs, gentle flexing and relaxing movements of the spine in the sitting 
position, focusing on the “third eye” (point between eyebrows), and regulated four part, 
very slow breath through the left nostril only. Results showed that the KY group had 
greater improvement on several related psychological measures. (Shannahoff-Khalsa, 
2004) 
A single study suggests that stimulation of Gamma-amino butyric Acid (GABA) 
production is a possible mediating mechanism by which yoga improves mood and 
anxiety. The study compared Iyengar yoga intervention to walking intervention for 60 
minutes three times a week for 12 weeks in metabolically matched subjects and found 
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greater improvements in mood and anxiety measures and a nearly significant (p=.09) 
increase in acute thalamic GABA levels in the yoga group compared to the walking 
group with a positive correlation between improved mood and decreased anxiety and 
thalamic GABA levels. The researchers suggest a possible role of GABA in mediating 
the beneficial effects of yoga on mood and anxiety as pharmacologic drugs prescribed 
to improve mood and decrease anxiety also stimulate GABA production (Streeter et al., 
2010). 
1.7.13.2.4 Yoga’s effect on pain and musculoskeletal health  
Pain and physical discomfort may have a detrimental impact on sleep by causing 
increased sensory stimulation that may result in higher somatic arousal (see section 
1.5.7 -1.5.8). Yoga practices have been found to improve musculoskeletal conditions 
and alleviate a range of musculoskeletal complaints and reduce pain and tenderness 
(Raub, 2002; Sherman et al., 2005; Garfinkel et al., 1994; Kolasinksi et al., 2005) and 
these findings, reported below, point to a possible mechanism by which yoga practices 
may improve sleep quality in individuals suffering from musculoskeletal pain. 
A review of the effect of yoga practice on musculoskeletal status identified ten 
relevant studies and reported improvement in isokinetic muscle strength and endurance, 
general flexibility, and body composition (Raub, 2002). 
A study of 101 adults with chronic low back pain compared three interventions: 
guided yoga classes, versus conventional therapeutic exercise classes versus home-work 
using a self-care book. Back-related function in the yoga group was significantly 
superior to the book and exercise groups at 12 weeks with the benefits persisting for 
several months as least (Sherman et al., 2005).  
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An eight week, one-class per-week, study of a yoga intervention for osteoarthritis 
of the hands found significant improvements in pain during activity, tenderness and 
finger range of motion in the intervention group compared to the control group 
(Garfinkel et al., 1994). A similar study of an Iyengar yoga intervention for 
osteoarthritis of the knee revealed significant improvements in pain level and physical 
function (Kolasinksi et al., 2005). 
Yoga may also improve non-musculoskeletal physical pain. A three months study 
(n=72) of yoga intervention versus self care intervention for migraine headaches 
(without aura) found significant improvement in the yoga group compared to self care 
group in various measures related to headache intensity, pain rating index, affective pain 
rating index, total pain rating index, anxiety and depression scores, and use of 
symptomatic medication (John et al., 2007).  
1.7.13.2.5 Yoga and common risk factors for chronic diseases 
Yoga has been shown to reduce a range of common risk factors for chronic 
disease, including blood pressure (BP), elevated levels of cholesterol, triglycerides, 
oxidative stress, glucose and coagulation factors (Yang, 2007; Innes et al., 2005; Innes 
& Vincent, 2007). 
A systematic review of yoga for common risk factors for chronic diseases found 
32 relevant studies (between1980 and 2007). Reviewers report that overall yoga 
interventions appear to be effective in reducing body weight, blood pressure, glucose 
level and high cholesterol but that not enough data is available regarding long-term 
adherence and long term effects (Yang, 2007).  
A systematic review by Innes et al. on yoga‟s effect on cardiovascular disease 
(CVD) and insulin resistance disorder (IRD) concludes that yoga may reduce various 
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IRD-related risk factors for CVD including glucose tolerance, insulin sensitivity, lipid 
profiles, anthropometric characteristics, blood pressure, oxidative stress, coagulation 
profiles, sympathetic activation, and cardio vagal function and suggests that yoga may 
improve clinical outcomes, and aid in the management of CVD and other IRD-related 
conditions. However, the poor quality of most studies prevented coming to more 
decisive conclusions (Innes et al., 2005). 
A systematic review on the influence of yoga-based programs on risk profiles in 
adults with type 2 diabetes mellitus (DM), found 25 relevant studies that overall suggest 
beneficial changes in several DM risk indices, including glucose tolerance and insulin 
sensitivity, lipid profiles, anthropometric characteristics, blood pressure, oxidative 
stress, coagulation profiles, sympathetic activation and pulmonary function, as well as 
improvement in specific clinical outcomes (Innes & Vincent, 2007).  
1.7.13.2.6 Yoga’s effect on cardiopulmonary function  
A review of yoga‟s effect on cardiopulmonary function identified 20 relevant 
studies. This review suggests that yoga interventions result in significant improvements 
in a range of parameters including lung function, cardiovascular endurance, 
improvement in work rate and reduction in oxygen consumption per work unit and 
improvement in exercise performance. Several of the reviewed studies also suggest that 
yoga practice may cause significant improvement in symptoms of chronic asthma and 
bronchitis (Raub, 2002). 
1.7.13.3 Specific effects of asana practice  
In general, the focus in asana practice is more on isometric strength training and 
stretching and less on aerobic cardiovascular training (Khalsa, 2004a) (see section 
1.7.4). However, there is a paucity of good quality evidence on the specific effects and 
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underlying mechanisms of specific asana practices. Significant research has been 
conducted on effects and benefits of non-yogic stretching (Thacker et al., 2004; Herbert 
& Gabriel, 2002; Andersen, 2005; Shrier, 2004) and some research has also been done 
on the effects of cycles of isometric effort and rest periods (Millar et al., 2007; Taylor et 
al., 2003; Peters et al., 2006). Arguably, due to the similarities between the non-yogic 
application of these exercise elements and its application in yogic asana practice, the 
results of these studies may help shed some light on possible underlying mechanisms of 
yogic asana practice 
There are currently few studies on the specific effects of the stretching component 
of yogic asana practice and few studies comparing the effects of yogic versus non-yogic 
stretching techniques. Furthermore, because yogic poses usually combine stretching and 
isometric effort (Khalsa, 2004a), both of these factors have to be taken into account in 
design of future studies on the effect of asana practice. Nevertheless, a number of 
studies have been conducted on the efficacy of stretching for improving sports 
performance and prevention of sports related injuries (Thacker et al., 2004; Herbert & 
Gabriel, 2002; Andersen, 2005; Shrier, 2004). Due to the similarities between the non-
yogic application of these exercise elements and its application in yogic asana practice, 
the results of these studies may be relevant to yogic asana practice. Overall, it seems 
that existing evidence indicates that pre- or post-exercise session stretching does not 
significantly decrease the likelihood of injury and it may only result in very small 
reductions in post-exercise muscle soreness or recovery time, although stretching may 
improve some performance parameters (Thacker et al., 2004; Herbert & Gabriel, 2002; 
Andersen, 2005; Shrier, 2004). On the other hand, cycles of isometric effort and rest 
periods have been shown to provide a range of significant health benefits including 
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reduction in blood pressure, reduction in oxidative stress and increased vagal 
modulation (Millar et al., 2007; Taylor et al., 2003; Peters et al., 2006). 
A comprehensive systematic review of 361 studies concluded that there is 
insufficient evidence to either support or oppose routine stretching before or after 
exercise to prevent injury in competitive or recreational sports (Thacker et al., 2004). 
Another systematic review concluded that stretching pre- or post-exercise session does
 
not give protection from muscle soreness and stretching before
 
exercising does not seem 
to reduce the risk of injury, and that findings are insufficient to determine
 
the effects of 
stretching on sports performance (Herbert & Gabriel, 2002). A third systematic review 
reported that on average, stretching results in a reduction in subjective soreness of less 
than 2% during the 72 hours after exercise and that stretching provides injury risk 
reduction of only 5%. Reviewers concluded that the stretching protocols used in the 
reviewed studies do not meaningfully reduce lower extremity injury risk in study 
population (Andersen, 2005). Another systematic and critical review on the effect of 
stretching on athletic performance concluded that regular stretching improves force, 
jump height, and speed; however there is no evidence that it also improves running 
economy. Furthermore, an acute bout of stretching was not seen to improve force or 
jump height (Shrier, 2004).  
Several studies have been conducted on the effects of isometric hand grip training 
(IHG) on various physiological parameters in hypertension patients. Intervention 
included IHG practice three days/week for eight weeks with each session consisting of 
several rounds of continuous isometric hand grip exercise at 30% of maximal voluntary 
contraction (MVC) for 2 minutes, separated by similar rest periods. Analysis of results 
amalgamated from three studies revealed significant decrease in both systolic and 
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diastolic blood pressure (BP) over time (5.7 and 3 mmHg reductions, respectively) with 
those participants with higher initial systolic pressure showing greater rates of BP 
decline (Millar et al., 2007). Other studies reveal similar results along with increased 
vagal modulation as demonstrated by a decrease in low frequency to high frequency 
area ratio of the power spectral analysis of heart rate variability (HRV) (Taylor et al., 
2003) and significant reduction in markers of oxidative stress demonstrated by a 
significant (266%) decrease in exercise-induced oxygen centred radicals and a 61% 
increase in the ratio between resting whole blood glutathione to oxidized glutathione 
(Peters et al., 2006).  
Interestingly, rounds of isometric effort followed by rest periods are commonly 
applied in several forms of yoga practice. One such example is Bikram Yoga in which 
each of the poses in the mat-based part of the basic protocol is followed by a complete 
relaxation in the „shavasana‟ (corpse pose) (Bikram, 2000, pp. 110-188). Another 
example is the yogic practice of Cyclic Meditation (CM which incorporates cycles of 
static yoga postures followed by relaxation period of several minutes (Telles et al., 
2000). Studies on the effects of CM are reported in detail above (see section 1.7.13.2.2). 
Both studies on the effects of CM and the effects of IHG revealed a shift in sympatho-
vagal balance in favour of parasympathetic dominance, yet further research is required 
to determine whether the principle of alternating isometric effort and complete rest 
periods is involved in the effects of CM and other yogic practices. This can be done by 
comparing CM practice to similar but continuous asana practices, which do not include 
resting periods. Additional research can then be conducted to determine the ideal 
durations and ratios of rest periods to asana periods. 
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In summary, additional high quality research is required in order to identify 
effects and benefits of asana practice. It seems that the reported benefits of asana 
practice cannot be attributed mainly to the stretching element involved. Isometric effort 
or a combination of isometric effort and rest periods may possibly play an important 
role in the overall effect of asana practice. Additional research is required to specifically 
isolate and examine various factors of asana practice including stretching, isometric 
effort, combinations of effort and rest periods, as well as other bio-mechanical aspects 
of asana practice. Future research may measure and compare the effects of specific 
asanas, asana combinations and various asana practice protocols. Furthermore, future 
research may examine if and how asana practice differs substantially from non-yogic 
stretching and isometric training practices. 
1.7.13.4 Specific effects of pranayama practice 
A relatively small number of studies have been published on the effect of 
pranayama breathing techniques performed on their own (i.e. not as part of a protocol 
which also includes yogic poses and/or meditation exercises). These studies, that are 
reported in detail below, have shown that pranayama exercises as well as device guided 
breathing which emulate some pranayama practices may bring various physical and 
mental health benefits including reduced anxiety, stress and depression, improved 
oxygen utilisation, oxidative status and immune system markers, reduced blood pressure 
and heart rate and modulation of sympathetic nervous system towards parasympathetic 
dominance. (Brown & Gerbarg ,2005a; Brown & Gerbarg, 2005b; Kjellgrenet al., 2007; 
Janakiramaiah et al., 2000; Sharma et al., 2008; Raju et al., 1994; Pramanik et al., 2009; 
Jain et al., 2005; Shannahoff-Khalsa, 1993; Grossman & Grossman, 2003; Grossman et 
al., 2001; Rosenthal et al., 2001; Schein et al., 2001; Meles et al., 2004). Currently, 
there is not enough evidence to enable any differentiation between the effects of various 
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pranayama practices. There is also a lack of evidence on the underlying physiological 
mechanisms of pranayama practice. Furthermore, although no adverse effects related to 
pranayama practice have been reported, more research is required regarding the safety 
of various types of pranayama practice at the beginner‟s level (see section 1.7.5). 
A growing body of evidence exists on the effects of a contemporary yogic 
breathing method named Sudarshan Kriya Yoga (SKY) that incorporates a sequence of 
specific yogic breathing techniques, including „ujai pranayama‟, „bastrika pranayama‟ 
(see glossary), and a special SKY breathing sequence (Brown & Gerbarg ,2005a; Brown 
& Gerbarg, 2005b). A review on SKY research concluded that it has been shown to 
alleviate anxiety, depression, everyday stress, post-traumatic stress, and stress-related 
medical illnesses with the reviewers concluding that there is sufficient evidence to 
consider SKY as a beneficial, low-risk, low-cost addition to current treatment strategies 
for stress, anxiety, post-traumatic stress disorder (PTSD), depression, stress-related 
medical illnesses, substance abuse, and rehabilitation of criminal offenders. (Brown & 
Gerbarg, 2005a; Brown & Gerbarg, 2005b). 
A six week controlled trial (n=103) examining the effect of 30 minutes of SKY 
practice daily versus an active control that included relaxing in an arm chair for the 
same period of time found reduced anxiety, depression and stress, and increased 
optimism in the SKY but not the control group as revealed by self reported 
questionnaires. Furthermore, the dropout rate was low and no adverse events were 
reported implying this intervention may be reasonably safe (Kjellgrenet al., 2007). A 
three week study (n=45,) compared SKY to electroconvulsive therapy (ECT) and 
Imipramine (IMN) treatment for melancholic depression and found significant 
improvement in all three groups although SKY and IMN were inferior to ECT 
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(Janakiramaiah et al., 2000). A one year pilot study (n=84), which compared SKY 
practice to non practicing controls found improved antioxidant status both at the enzyme 
activity level and RNA level in the SKY group which also had improved stress 
regulation and better immune status manifested by prolonged lymphocytes life span. 
These finding imply SKY practice may have a positive effect on immunity, aging, cell 
death, and stress regulation through transcriptional regulation (Sharma et al., 2008).  
A two year study on the effect of pranayama on athletic performance showed that 
pranayama practice helps athletes achieve higher work rates with reduced oxygen 
consumption and without an increase in blood lactate levels along with significantly 
reduced resting blood lactate levels (Raju et al., 1994). 
A relatively small number of studies have examined the effects of specific 
pranayama techniques. Most have shown breathing exercises may modulate breath rate, 
heart rate and other cardiovascular parameters. A small study (n = 39, age = 25-40 
years) has shown that a single slow pace (respiratory rate of six breaths per minute) 
Bhastrika pranayama (see glossary) technique for five minutes reduces systolic and 
diastolic blood pressure significantly and heart rate slightly. (Pramanik et al., 2009). A 
small (n=20) eight week study on the effect of left and right single nostril breathing has 
also shown both acute and chronic decreases in respiratory rate (RR), heart rate (HR), 
systolic blood pressure (SBP) and diastolic blood pressure (DBF) (Jain et al., 2005). 
Three similar earlier studies of forced unilateral nostril breathing (UFNS) (at rates of six 
breaths per minute or rates of 2-3 breaths per second) all showed that breathing via the 
right nostril increased HR compared to breathing via the left nostril (Shannahoff-
Khalsa, 1993). 
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„Device guided breathing‟ is a breathing technique that uses a bio-feedback device 
to help regulate breath rate. This resembles some pranayama practices, which use 
internal counting to regulate breath rate and the duration of the four phases of the breath 
cycle (i.e. inhalation, post inhalation breath retention, exhalation and post exhalation 
breath retention). The device first measures the patient‟s current breath rate to establish 
a baseline and then uses two different tones prompting the patient to breathe in and out 
more slowly than the baseline with the exhalation longer than the inhalation. Although 
this method uses modern technology for regulating the breath, the results of these 
studies may shed some light on possible effects and benefits of similar pranayama 
exercises. Recent studies with hypertensive patients (n=268) have shown that device- 
guided breathing interventions used for 15 minutes daily for eight weeks results in 
reduction in systolic and diastolic blood pressure (BP) of 12.1 and 6.1 mmHg 
respectively, as compared to reduction of 7.6 and 3.4 mmHg respectively in an active 
control group that listened to relaxing music for the same duration. The BP reduction in 
the device group was significantly greater than a predetermined clinically meaningful 
threshold of 10.0, 5.0 and 6.7 mmHg (for systolic BP, diastolic BP and Mean arterial 
pressure respectively). The study authors concluded that the intervention proved 
effective, for reducing BP with no reported adverse effects, for hypertensives and mild 
hypertensives, in office and home settings (Grossman & Grossman, 2003; Grossman et 
al., 2001; Rosenthal et al., 2001; Schein et al., 2001; Meles et al., 2004).  
1.7.13.5 Effects of yogic meditation and relaxation practices 
A relatively small number of studies have been published on the effects of yogic 
meditation and relaxation techniques on their own (i.e. not as part of a protocol which 
also includes yogic breathing and/or yoga postures). Conversely, a substantial number 
of studies have been published on the effects of non-yogic meditation techniques. 
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Arguably, the broad definition of yogic meditation in Patanjali‟s ”Yoga Sutra” may 
apply to non-yogic meditation methods if they share common principles and techniques. 
This section focuses on evidence on the effects of yogic meditation techniques, and the 
next section focuses on evidence on the effects of several similar non-yogic meditation 
techniques that may be of relevance to similar but less researched yogic practices. 
Yoga nidra has played a major role in studies on yogic meditation techniques 
which have shown that yoga nidra meditation is associated with improvement in a range 
of psychological and physiological measures including self reported stress (Pritchard et 
al., 2010), anxiety, and well-being (Kamakhya, 2004), increased release of endogenous 
neurotransmitter and changes in brain EEG spectra. (Lou et al., 1999; Kjaer et.al, 2002) 
and improvement in symptoms of diabetes (Amita et al., 2009), while the practice of 
other yogic guided meditation and relaxation techniques has been shown to be 
associated with decreases in heart rate, breath rate, oxygen consumption, and a 
regulatory effect on the autonomic nervous system (ANS) (Vempati & Telles, 2002; 
Amita et al.,2009). These findings are reported in detail below. 
Yoga nidra appears to assist in improving various subjective measures. A small 
study of yoga nidra practice consisting of daily half hour sessions for six months 
reported significant positive changes in practitioners‟ subjective measures of anxiety 
and well-being (Kamakhya, 2004 as reported by Jadhav & Havalappanavar, 2009) while 
another small study (n=22) found significant reductions in perceived stress in cancer 
patients and multiple sclerosis (MS) patients following six weeks of a yogic meditation 
program that incorporated a weekly 90 minute yoga nidra class with daily home-based 
practice using two audio CDs with two different meditation exercises that incorporated 
various meditative components including body scan; breath work; exploration of 
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sensations, emotions and thought patterns, moving back and forth between feeling and 
witnessing; and sitting in awareness (Pritchard et al., 2010).  
A Positron Emission Tomography (PET) and EEG study comparing brain activity 
of experienced yoga teachers during yoga nidra meditation to resting states of normal 
consciousness found differential activity in parts of the brain responsible for imagery 
tasks during yoga nidra versus differential activity in parts of the brain responsible for 
executive attentional network during normal consciousness (Lou et al., 1999). Another 
PET study demonstrated a 65% increase in endogenous dopamine release in the ventral 
striatum and a concomitant increase in EEG theta activity during yoga nidra meditation 
with all participants reporting a decreased desire for action during yoga nidra, along 
with heightened sensory imagery, suggesting that yoga nidra meditation causes a 
suppression of cortico-striatal glutamatergic transmission (Kjaer et.al, 2002). 
A three months study (n=41) of yoga nidra as an intervention for diabetes found 
that patients on yoga nidra plus oral hypoglycaemic regimen had better control of blood 
glucose levels and other symptoms associated with diabetes, compared to controls who 
were on a hypoglycaemic regimen alone (Amita et al., 2009). 
A study of the ANS responses of 35 male subjects aged 20 – 46 to yoga based 
guided relaxation compared to yogic rest in the supine rest position found that both 
techniques were associated with similar decrease in heart rate and skin conductance 
with the guided relaxation techniques also being associated with significant increases in 
breath volume and decreases in oxygen consumption. Heart rate variability (HRV) 
spectral analysis further indicated a reduction in sympathetic activation during guided 
relaxation in subjects with hyper-activation at baseline but not in others, implying a 
regulatory effect of guided yogic relaxation practice on ANS (Vempati & Telles, 2002). 
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1.7.13.6 Effects of non-yogic meditation methods 
A rapidly growing body of evidence exists on the effects of non-yogic meditation 
techniques, many of which are similar to various yogic meditation techniques. For the 
sake of brevity only the results of several major systematic reviews and meta-analyses 
are discussed as well as several studies on meditation intervention for insomnia. 
Overall, meta-analyses suggest that meditation practice may help reduce blood pressure, 
stress, anxiety, alcohol abuse and relapse of depression (Chiesa & Serretti, 2009; 
Chiesa, 2009; Chiesa, 2010). Studies have also, shown that meditation practice may 
affect changes in EEG spectra and brain physiology (Chiesa, 2010; Chiesa & Serretti, 
2010). Similar findings have been reported above with regards to the effects of yogic 
meditation practices - yoga nidra in particular (see section 1.7.13.5). This further 
demonstrates the great affinity between yogic and non-yogic meditation techniques. 
Most of the meditation techniques included in the reviews are shown to provide some 
benefits, although to varying degrees. Most reviews do not make a clear distinction 
between meditation techniques, breathing techniques and other mind-body cultivation 
techniques, and often use general terms such as yoga and chi-kung. Thus it is not clear if 
references are made to yoga and Qi Gong practices in general or specifically to the 
meditative components within these vast and diverse practice systems. 
A recent comprehensive systematic review of the effect meditation on health 
reviewed 813 predominantly poor-quality studies. A subset meta-analyses of 65 low-
quality studies on the effects of meditation on hypertension patients showed that 
Transcendental Meditation (TM), Qi Gong and Zen Buddhist meditation (see glossary) 
significantly reduce blood pressure and that Yoga helps reduce stress but is no better 
than Mindfulness Based Stress Reduction (MBSR) in reducing anxiety in patients with 
cardiovascular diseases. A subset meta-analysis of 55 poor quality studies on the 
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physiological and neuropsychological effects of meditation practices indicates that some 
meditation practices produce significant changes in healthy participants. Reviewers state 
however, that solid conclusions cannot be drawn based on available evidence and better 
quality evidence is required (Ospina et al., 2007). Similarly, a recent Cochrane review 
of meditation therapy as an intervention for anxiety disorders found only a small 
number of adequate quality studies and could not draw conclusions on the efficacy of 
the intervention (Krisanaprakornkit et al., 2006).  
A few studies indicate that TM is comparable to other kinds of relaxation 
therapies in reducing anxiety and that Kundalini Yoga (KY) does not demonstrate 
significant effectiveness in treating obsessive-compulsive disorders (OCD) compared to 
other relaxation and meditation methods. Furthermore, dropout rates in general 
appeared to be high (Krisanaprakornkit et al., 2006). 
Several studies have found a significant increase in alpha and theta brain wave 
activity during meditation with neuroimaging studies showing that Mindfulness 
Meditation (MM) practice, including Zen meditation, Vipassana meditation and MBSR, 
is associated with activation of the prefrontal cortex (PFC) and the anterior cingulate 
cortex (ACC) and that long-term MM practice is associated with an enhancement of 
cerebral areas related to attention (Chiesa, 2010; Chiesa & Serretti, 2010). MBSR has 
also been found to be comparable to standard relaxation in stress reduction and reduced 
stress and anxiety in comparison to an inactive control (Chiesa & Serretti, 2009). Zen 
meditation is also associated with stress reduction and blood pressure reduction and 
increased antioxidant activity (Chiesa, 2009; Chiesa & Serretti, 2010) while Vipassana 
meditation has been found to reduce alcohol and substance abuse in prison populations 
(Chiesa & Serretti, 2010).  
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Several studies have found mindfulness based practices to be effective for treating 
primary insomnia. A single eight week study (n=30) compared mindfulness based stress 
reduction (MBSR) to pharmacotherapy (PCT) intervention for primary insomnia  and 
found comparable large significant improvements in a range of subjective sleep quality 
measures and a significant objective improvement in SOL (Gross et al., 2011). Another 
study (n=21) of a combination of mindfulness meditation with cognitive behavioural 
therapy as an intervention for insomnia (CBT-I) revealed both acute and long term (12 
months) improvements in a range of subjective sleep quality measures (Ong et al., 
2009). 
In summary, yoga nidra incorporates several meditative techniques, which are 
similar to the non-yogic meditation techniques reviewed above (also see section 
1.7.13.5). Therefore, future research on yoga nidra and other yogic meditation 
techniques is required to examine whether they can also provide similar benefits.  
1.7.14 Yoga practice for older adults 
There is a growing awareness of the need to adapt yoga practice for the special 
needs and limitations of the elderly (Krucoff et al., 2010). A typical group of seniors is 
likely to have a wider range of physical abilities and health conditions than any other 
age group and various health conditions become more prevalent with age and need to be 
taken into consideration to ensure participants safety and well-being (Krucoff et al., 
2010). For example, hearing difficulties become prevalent with age and yoga teachers 
need to take this into account when instructing elderly students. Symptoms of dizziness 
also become more prevalent with age affecting up to 38% of older adults (CDC, 2007) 
and this may lead to falls and injuries especially with poses requiring good balance 
(Krucoff et al., 2010). Osteoporosis and associated risk of fractures also becomes 
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prevalent with age especially amongst post menopausal women and this may require 
avoiding or modifying various yoga poses. The National Osteoporosis Foundation has 
recommended avoiding exercises such as sit-ups, stomach crunches and toe-touches and 
also avoiding twisting the spine to the point of strain and bending forward from the hip 
(National Osteoporosis Foundation [NOF], 2010). It has therefore been suggested that 
yoga teachers who work with the elderly should be vigilant and that emergency medical 
assistance should be sought if elderly yoga students suddenly becomes uncomfortable, 
dizzy, develop nausea, chest pain or shortness of breath (Krucoff et al., 2010). These 
aspects were all taken into consideration in design of yoga protocol for the present study 
(see section 3.3). 
Increasingly special yoga programs are being developed for elderly populations. 
For example, a “Therapeutic Yoga for seniors” teachers training program was launched 
in 2007 by Duke University as part of integrative medicine facility. This program 
combines evidence based western medicine and traditional yogic teaching and includes 
yoga movement and meditation, health conditions common to the elderly and safety 
issues (Krocoff et al., 2010). Another example is Silver Age Yoga (SAY), a non- profit 
organization offering yoga classes and teachers training courses and promoting a system 
of hatha yoga developed for the elderly (SAY, 2010).  
Three studies have been conducted in Taiwan measuring the effect of a six months 
intervention of hatha yoga adapted for the needs of the elderly (“Silver Yoga”). Subjects 
for these studies include community dwelling elderly (two studies) and elderly living in 
assisted living facilities (a single study). The interventions included gentle yoga 
postures, relaxation exercises and guided imagery. Results reveal significant 
improvements in various subjective mental health and sleep quality measures along with 
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objective physical fitness measures including body composition, cardiovascular-
respiratory function, physical function and range of motion with improvements in 
fitness levels being associated with physical yoga exercises but not with meditative 
exercises (Chen et al., 2008; Chen et al., 2009; Chen et al., 2010a). Another six month 
Indian study (reported above), which examined subjective sleep quality outcomes of 
yoga versus „Ayurveda‟ medicine in normal older adults, revealed significant 
improvements in various subjective sleep quality measures including sleep latency, total 
sleep time and feeling refreshed in the morning in the yoga group, but not the control 
group (Manjunath & Telles, 2005) (see section 1.7.13.2.2). In view of the encouraging 
results reported in these studies, additional research is required to examine how yoga 
can be adapted for the special needs and limitations of older adults in general and in 
western cultural settings in particular and the present study has aimed at filling this gap 
in the existing evidence. 
1.7.15 ‘Western’ exercise versus yoga  
A recent review of 81 studies on yoga interventions, found ten studies that 
compared yoga outcomes to non-yogic (‟western‟) exercise intervention outcomes in 
both healthy and unhealthy populations. Reviewers concluded that yoga interventions 
appeared to be equivalent or superior to exercise interventions in almost every health-
related outcome measured except for those related to physical fitness (Ross & Thomas, 
2010). A small (n = 34) twelve week study comparing Iyengar yoga practice to walking 
(mentioned above) found greater improvement in psychological factors in the yoga 
group compared to the walking group. Furthermore, positive correlations were reported 
between changes in mood scales and increase in GABA levels pointing to a possible 
mood modulating mechanism which is affected to a greater extent by yoga than by 
walking (Streeter et al., 2010). Additional research is required however, to compare 
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various types of yogic exercise protocols to various types of non-yogic exercise 
protocols.  
1.7.16 Compliance in yoga and related practices 
Relatively few studies have examined adherence in yoga practice and the „dose 
response‟ relationship between yoga practice and the rate of change in physiological and 
psychological measures. More studies have examined adherence in non-yogic 
meditation practices. However, in most cases, it is not clear what the definition of 
„good‟ adherence and compliance level is based on, especially in the case of home-
based practice. Overall it seems that home-based practice compliance is somewhat 
lower than class compliance and that outcomes may be related to practice compliance 
levels (Flegal et al., 2007; Carmody & Baer, 2008) 
Several studies indicate a good level of adherence to yoga interventions as well as 
non-yogic meditation based interventions both for class and home-based practice 
(Flegal et al., 2007; Carmody & Baer, 2008). Only a few studies have examined long-
term adherence to yoga practice (Yang, 2007). A six month, three-armed study of a 
Iyengar yoga intervention versus exercise versus waiting list control of 135 generally 
healthy older adults (aged 65-85) found good adherence in both yoga and exercise 
interventions. Overall drop-out rate was 13% with class attendance scores being higher 
than home compliance scores in both groups and scores being higher in the yoga group 
than in the exercise group. For the yoga intervention group class attendance was 77% 
and home practice compliance was 64%, whereas for the exercise intervention, group 
class attendance was 69% and home practice compliance was 54% (Flegal et al., 2007). 
A four year study of a non-yogic meditation based intervention reported a high degree 
of adherence with the meditation technique, maintenance of improved status over time, 
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and a high degree of importance attributed to the training program (Kabat-Zinn et al., 
1986). A further study on the effect of a mixed intervention incorporating body scan, 
yoga, and mindfulness sitting meditation found that the amount of time spent in home-
based practice was significantly related to the extent of improvement in most aspects of 
mindfulness and some measures of physical symptoms and well-being (Carmody & 
Baer, 2008). 
1.8 Implications for present and future research 
The literature review above raises several points that are of special relevance to 
the present study: 
1. It seems that relatively few studies have been published on yoga for the 
elderly population or on yoga as an intervention for insomnia. Even fewer 
studies have been published specifically on yoga intervention for improving 
sleep quality in a geriatric population. As discussed in section 1.7.13, two 
studies were conducted recently in Taiwan (Chen et al., 2009; Chen et al., 
2010) and one in India (Manjunath &Telles, 2005). These studies did not 
specifically select participants with a history or present complaints of sleep 
disturbances. Furthermore, none of these studies used objective sleep quality 
measures, and were not conducted in a western cultural setting. Therefore, 
the present study was initiated in March 2007 with the aim of filling the gap 
in existing evidence, by studying the effects of yoga practice on insomnia 
and well being, of older adults in a western cultural setting, while 
incorporating both objective and subjective measures. 
2. This review discussed various risk factors for insomnia including cognitive 
and physiological hyper arousal, stress, anxiety, depression and chronic pain 
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and a range of yogic practices have been shown to reduce these risk factors. 
Arguably, practices that affect these psychological factors may also 
indirectly help improve sleep quality and the present study aimed at 
examining these relationships more closely by comprehensively measuring 
both sleep quality and psychological outcomes.  
3. Pranayama practice has been shown to provide various physiological and 
psychological benefits but ancient and some contemporary core texts 
recommend practicing pranayama only after a sufficient foundation of asana 
practice has been established. As a conservative precautionary measure the 
present study incorporated practices which include breath awareness but 
excluded practices which include breath regulation (i.e. pranayama practice)  
4. There is evidence on the benefits of practices which incorporate cycles of 
isometric effort and relaxation, both in yogic and non-yogic context. The 
present study applied this evidence by incorporating a short period or 
relaxation following each of the yoga poses performed during yoga classes  
5. Ancient texts point out that different yogic practice elements may be more 
suitable for different people. Yoga Nidra, is a yogic meditation which 
combines diverse meditative and relaxation elements, including somatic 
relaxation, breath awareness and breath counting, mindfulness of internal 
body sensations, objectless mindfulness, visualisations and positive 
suggestions. The diversity of meditative elements was one of the factors 
which weighed in favour of incorporating yoga nidra in the present study‟s 
protocol. Furthermore, the protocol also incorporated a yogic somatic 
relaxation practice and yogic breath counting/awareness practices separately 
to accommodate individual differences and to allow individuals to build 
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essential yogic practice elements to support the more complex yoga nidra 
practice  
6. There is some evidence that rate of improvement is related to practice 
compliance level and that home-based practice compliance may be lower 
than class attendance. The present study took this evidence into consideration 
by recording the home based practice exercises on an audio CD in order to 
facilitate easier application and higher compliance. 
In an analysis of meditation research Shapiro etc. al (2003) suggested specific 
recommendations, for future research on meditation including: 
1. Differentiation between types of meditation to identify general, overlapping 
and specific effects of different types of meditation.  
2. Recording frequency and duration of meditation to establish „dose effect 
relationship‟ between meditation and its effects. 
3. Long and short term follow-up assessment.  
4. Research on long-term as well as short term meditators. 
5. Comparing meditation to alternative attentional practices (e.g. playing a 
musical instrument). 
6. Component analysis of meditation including factors such as belief and 
expectancy, postural, somatic, attentional, cognitive etc. with the aim of 
differentiating the effects and interactions of various factors.  
7.  Examination of interaction effects between meditation and a variety of 
relevant psychological, spiritual and clinical factors. 
8. Development of subjective and objective mediating variables to determine 
those that account for the most variance in predicting change. 
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9. Collecting qualitative data on the subtlety, depth and overall experience of 
the meditation experiences as well as the interplay between subjective and 
objective factors. 
10.  Expanding meditation research from effects on symptoms reduction of 
mental and physiological conditions to effect on problem prevention and 
health enhancement and the transpersonal. 
11.  Research effect of meditation on traditional goals of meditation, such as 
the development of exceptional maturity, love and compassion, and 
lifestyles of service and generosity. 
In the last seven years some of Shapiro et al.‟s suggestions have been applied. 
Several studies and reviews have compared the effect of different meditation and 
relaxation techniques. Several studies have compared the effect of meditation to other 
alternative attentional activities such as listening to music for the same period.  
In a more recent comprehensive review of meditation practices for health Ospina et al. 
(2007) suggest the following regarding future research on meditation: 
1. Develop a consensus on a working definition of meditation applicable to a 
heterogeneous group of practices. 
2. Systematically compare the effects of different meditation practices that research 
has shown to have promise.  
3. Pay special attention to the appropriate selection of controls  
4. Conduct more research on the “dose response” of meditation practices to determine 
appropriate study durations and to help standardize courses of therapeutic 
meditation. 
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5. Employ designs and analytic strategies that optimise the ability to make causal 
inferences (even if in some cases it requires the use of uncontrolled pre and post 
intervention designs).  
6. Aim at using larger samples and concurrent controlled designs 
7. Use disease-specific measures. 
8. Provide clear descriptions of intervention components. 
9.  Better quality reporting by a wider dissemination and stricter enforcement of the 
CONSORT (Consolidated Standards of Reporting Trials) guidelines within the 
complementary and alternative medicine (CAM) community. 
 
Although the recommendations above were given specifically in the context of 
meditation research, they may arguably apply to yoga research as well. The present 
study addresses some of the points mentioned above by: 
1. Incorporating a daily practice log in order to establish a „dose - response‟ 
relationship between duration and frequency of practice and the effects. 
2. Supporting home-based practice with an audio CD as well as repeating the 
instructions and revising during class practice. 
3. Using comprehensive objective and subjective measures specific to sleep 
disorders in general and insomnia in particular. 
4. Incorporating various psychological, physiological, social, and quality of life 
measures in addition to specific sleep quality/disturbances measures. 
5. Providing a very detailed description of all aspects of the intervention. 
6. Striving to achieve the largest sample with available limited budget and 
human resources.  
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7. Selecting a suitable intervention for older adults that also represents a range 
of yoga practices practiced widely in western cultural settings. 
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Chapter 2. Study aims  
2.1 Study aims 
1. To examine the effectiveness of an integrated yoga intervention for improving 
quality of sleep in elderly people presenting with complaints of insomnia.  
2. To examine the effectiveness of an integrated yoga intervention for enhancing 
mood and quality of life in elderly people presenting with complaints of 
insomnia.  
3. To determine the suitability and acceptance of an integrated yoga intervention for 
elderly people living in a westernised culture. 
2.2. Hypotheses to be tested 
The following hypotheses were proposed and tested in the present study: 
1. Integrated yoga intervention will significantly improve subjective and objective 
measures of sleep quality in elderly presenting with complaints of insomnia. 
2. Integrated yoga intervention will significantly improve measures of both mood and 
quality of life in the elderly people presenting with complaints of insomnia. 
3.  That an integrated yoga intervention will be safe and acceptable for elderly people 
with complaints of insomnia living in a westernised cultural setting. 
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Chapter 3. Materials and methods 
3.1 Study design considerations 
3.1.1 Introduction 
The present study utilised a mixed study design that developed during the course of 
the research which was constrained by the limited available resources (Please refer to study 
flowchart - Figure 4.1). Organisations and individuals made generous contributions by 
donating precious expertise and time and/or by allocating equipment and space (see 
acknowledgments). Nevertheless, it was still necessary to find the right balance between an 
ideal design, described below, and between a feasible design dictated by available 
resources. As the study progressed, through divine providence, generosity and good will of 
individuals and organisations, additional resources were made available. These enabled 
reassessing and modifying the original study design. However, additional resources only 
became available incrementally while the study was already in progress. These enabled the 
study design to be modified to a stronger design, but nevertheless not the ideal design that 
would have been possible had all resources been available or committed at the outset. 
Overall, resource limitations affected the total number of sleep studies that could be 
conducted, the number of participants that could be recruited and measured, the number of 
groups that could be compared, the total duration of the intervention period, the choice of 
control and randomisation as described in detail below.  
3.1.2 Required resources 
A great number of resources were required for successful implementation of the 
present study including: 
 Certified yoga teachers to conduct yoga classes. 
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 Appropriate yoga practice venues.  
 Physician(s) for conducting medical interviews and examinations of 
candidates/participants. 
 Medical staff to assist with setting up, removing and collecting portable sleep 
monitoring equipment. 
 Sleep scientists for analysing sleep studies. 
  Administrative staff to assist with required paperwork at the medical centre 
 Hospital rooms and facilities for screening and examining applicants and 
participants. 
 Sleep monitoring equipment and related consumables for conducting sleep studies. 
 Computer hardware and software for interfacing with portable sleep monitoring 
equipment, downloading, analysing and storing acquired data.  
 Office supplies and equipment. 
 Human resources and equipment for creating, recording, editing and duplicating 
audio CDs with meditative yoga exercises for the home self practice intervention 
component. 
 Securing resources for advertising the study in local media, bulletin boards, 
community centres and medical centres throughout the Jerusalem metropolitan 
area. 
 Securing resources for communicating with applicants, participants, physicians, 
hospital staff, yoga teachers, practice venue administrators etc. 
 Means of transportation required for travel to various venues carrying necessary 
equipment. 
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3.1.3 Initial resources availability  
The author was awarded a research fellowship from the Australia Israel Scientific 
Exchange Foundation (AISEF) to the total sum of 5000 AUD, and a travel grant from 
RMIT University to the total sum of 1000 AUD, to cover transport, insurance and 
accommodation expenses associated with a return trip from Melbourne, Australia to 
Jerusalem, Israel. Two mobile sleep labs were assignd for two continuous two to three 
weeks periods. This enabled conducting objective pre- and post-intervention objective 
measures with participants admitted to the study but did not allow screening the much 
larger overall number of applicants (see section 4.2.2) for SRBD and OSA in particular. 
Furthermore, since availability of traditional PSG facilities at the medical centre was 
extremely limited it was decided that it would be used only if diagnosis based on portable 
monitoring was not possible. Overall, the number of sleep studies that could be conducted 
at each milestone was limited to around 30. Furthermore, the number of milestones for 
taking objective measures was limited to two, namely, pre- and post-intervention measures. 
Availability of sleep physicians, sleep technicians and sleep scientists was also limited to 
specific days and hours. Initially, only two yoga teachers were available for a duration of 
12 weeks, each able to teach one weekly class only. Also, only one practice hall was 
available for two weekly sessions for duration of 12 weeks. 
3.1.4 Additional resources made available 
Several positive though unforeseen developments occurred during the course of the 
study that led to reassessment and expansion of the original study design. Hundreds of 
phone enquiries continued to be received from potential participants well past the original 
application deadline. Applicants kept contacting the study‟s office weeks after the original 
participant quota for the study had already been reached, participants inducted and baseline 
measures taken. Also, four additional certified yoga teachers, affiliated with the Israeli 
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Yoga Teacher‟s Association, contacted the study office offering their help at no cost. An 
additional suitable yoga practice venue was offered at no cost for two weekly classes over 
a period of 12 weeks, and a third venue was later offered at a discount. Through the 
kindness of Dr. Cahan and Dr. Baharav two additional brand new portable sleep 
monitoring units were also made available. Dr. Cahan and Dr. Baharav kindly agreed to 
screen, process, analyse and diagnose additional applicants and participants. However, the 
rate at which it was possible to screen, process and induct additional applicants was slower 
due to other commitments of physicians, sleep scientists and technical staff and due to 
work load related to monitoring, acquiring, and processing data of the first group already in 
progress.  
3.1.5 Ideal versus feasible design  
The ideal strongest experimental design is a double blinded, randomised placebo 
controlled trial where subjects are assigned at random to treatment and placebo groups and 
both subjects and researchers are unaware of which treatment was given until the study has 
been completed (Sibbald & Roland, 1998). Furthermore, due to the nature of the 
intervention in the present study, it would arguably have been advantageous to incorporate 
at least four groups including a yoga intervention group, another active intervention (e.g. 
exercise or walking) group, a sham intervention group (discussed in more detail below) 
and a control group. That would have allowed better control for possible extraneous factors 
associated with participating in an intervention group (e.g., encountering fellow 
participants, being in contact with teachers, changes to daily and weekly routines, getting 
out of the house to go to practice sessions, etc.) as well as comparing effectiveness of the 
yoga intervention to another active intervention. All applicants would ideally be screened 
using both portable monitoring and standard clinical assessment. All participants would 
ideally be measured at pre-intervention, post –intervention and also at several pre-
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determined, equally spaced milestones during the intervention phase in order to examine 
not only the final effect of the intervention, but also the rate of change for each of the 
measures over the course of the intervention period. A long intervention period would 
ideally be incorporated to reduce extraneous factors such as the rate at which individuals 
are able to acquire and assimilate new skills.  
After consulting a substantial number of yoga masters and teachers (see 
acknowledgments), and taking safety considerations and available venues into account, a 
common consensus was reached that maximum class size should be around 30 participants, 
but ideally around 20 participants. Furthermore, a majority opinion among yoga masters 
and teachers consulted (see acknowledgments) was that a minimum of two weekly classes 
over 12 weeks was necessary in order to achieve tangible results, although several yoga 
teachers recommended periods of between 18 and 24 weeks.  
The present study‟s budget constraints and resource availability timeline also 
affected the control design. A control is essential in studies with an evaluation of a 
treatment‟s effect on behaviour, performance or mood compared to baseline levels 
(Goodwin, 2010, p. 173; Goodwin, 2010, p. 267). There are several varieties of possible 
control designs including no-treatment, placebo control, waiting list control (WLC) and 
yoked control (Goodwin, 2010, pp. 267-275).  
A no-treatment control is a typical and most straightforward type of control design 
for many types of studies while in drug trials a placebo control is often used (Goodwin, 
2010, p. 267). However, in studies designed to evaluate a therapy aimed at alleviating a 
physical or mental health problem, these types of control design may give rise to ethical 
issues. For example, if the therapy is later found to have been effective at alleviating a 
health problem, some may argue that withholding therapy from the subjects in the 
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control group is unethical (Goodwin, 2010, pp. 269-270). This ethical problem may be 
avoided by using a WLC design, often used in studies intended for assessing the 
efficacy of various therapies or programs (Goodwin, 2010, p. 267). The WLC group is a 
no-treatment group of subjects suffering from the same problem as the subjects in the 
active intervention group. The WLC group subjects are given an opportunity to receive 
an equivalent treatment after having completed the control phase (Goodwin, 2010, p. 
267). In the present study due to ethical considerations it was decided to incorporate the 
WLC principle in the design.  
A „placebo‟, typically used in drug intervention research, usually refers to an 
inactive pharmacological substance given to participants in the „placebo‟ control group 
while an active pharmacological substance is given to subjects in the treatment group. 
The participants in the „placebo‟ control do not know that they are receiving an inactive 
substance to prevent them from being subtly influenced by the knowledge that they are 
taking an inactive substance (Goodwin, 2010, p. 267). A placebo control design may 
sometimes be applied in procedure intervention research by using a „sham‟ procedure or 
treatment (Sutherland, 2007) defined as “An inactive treatment or procedure that is 
intended to mimic as closely as possible a therapy in a clinical trial. Also called 
placebo therapy” (National Cancer Institute, 2010). Obviously a sham intervention 
must be one that had previously been shown to have no effect on research outcomes of 
interest. In the present study, a „sham‟ intervention had been considered but rejected for 
the following reasons: 
1. The yoga intervention used in the present study incorporated a combination of 
yogic relaxation, meditation and physical exercises. A suitable „sham‟ protocol 
would have to be a comparable composite protocol that had already been validated 
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as having no effect on physical health, mental health and sleep quality. No such 
suitable „sham‟ protocol has been identified. 
2. A set of „non yogic‟ stretches as a „sham‟ physical yoga component was also 
considered. However, the known range of yoga stretches is vast and most „western 
style‟ stretching techniques have commonalities with subsets of yogic stretches.  
3. A „sham‟ meditative audio CD, was also considered (e.g. classical music, new age 
music or natural sounds such as waves or waterfall sounds), however, listening to 
music while sitting can in itself be considered a form of meditative technique, that 
uses music or sounds as objects of meditation (see section 1.7.10) that may 
contribute to the reduction of „the fluctuations of the mind‟ and therefore be related 
to the broad definition of the purpose of yoga and may possibly induce a meditative 
state in some participants (see section 1.7.3). A study (n=63) compared mental and 
physical  states of a subjects that listened to Mozart music, subjects that listened to 
new age music and subjects that spent the same amount of time reading recrational 
magazines. The study reported that listening to Mozart's music induced more 
psychological relaxation and less stress than listening to New Age music or reading 
recreational magazines. Those who had listened to Mozart music also reported 
significantly higher levels of mental quiet, awe, wonder, and mystery, while those 
who had listened to New Age music reported slightly higher levels of feeling at 
ease/peace and feeling rested/refreshed (Smith & Joyce, 2004).  People from 
different ethnic, cultural and educational backgrounds may arguably be affected 
differently by various types of music, and this in turn may affect their nervous 
systems differently. This could possibly have introduced an undesirable 
confounding factor to the study. 
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4. The efficacy of an intervention with a daily home-based practice component is 
affected significantly by the level of compliance (see sections 1.7.15 and 3.5.3). 
Using a „sham‟ protocol, with a „sham‟ audio CD, (e.g., with music) may possibly 
result in a different compliance profile (in frequency and/or duration of practice) 
compared to the intervention. This could have possibly introduced an additional 
confounding factor to the study. 
Under ideal study conditions, randomisation is incorporated in study design. This is 
done in an attempt to equalise the composition of the control group and intervention group, 
in a way that would make them as similar as possible in all relevant characteristics, 
including possible confounding factors (Chatburn, 2011, p. 328). Each subject is allocated 
to either control or intervention group using the laws of statistical probability. This can be 
done by flipping a coin, drawing a subject identification number from a hat (Chatburn, 
2011, p. 328) or by using random number generating software (Haahr, 2011). In the 
present study initial budget and resources limitations enabled recruiting only 31 
participants. A randomised controlled approach would have resulted in two groups 
(intervention and control) of 15 to 16 participants each, and consequently resulting in 
reduced statistical power, defined as the “probability of rejecting a false null hypothesis” 
(Christensen et al., 2011, p. 267), or in simple terms the probability of correctly stating that 
the intervention produced an effect (Christensen et al., 2011, p. 267). A greater number of 
participants increases statistical power and vice versa (Christensen et al., 2011, p. 267). 
The risk of a substantial number of dropouts from an already small (n=15) intervention 
group was of special concern, as it would have reduced power and would have had a 
detrimental effect on quality of randomisation (Lachin, 2000).  
Restricted resources also excluded the possibility of applying a „crossover design‟ 
where „group A‟ would undergo yoga intervention for 12 weeks followed by no-treatment 
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for 12 weeks and group „group B‟ would undergo no-treatment for 12 weeks followed by 
yoga intervention for 12 weeks (Chatburn, 2011, p. 323), as that would have required to 
double the number of „yoga teacher hours‟ and „venue  hours‟. Furthermore, since the yoga 
intervention involved participants acquiring meditative and relaxation skills, there was a 
strong possibility of a „carry over‟ effect, defined as “conditions from one experiment 
affecting subsequent experiment” (Chatburn, 2011, p. 323) occurring in the group that 
would start with yoga intervention for 12 weeks and then cross over to no-intervention for 
12 weeks („group A‟). This carry over effect could happen in two ways: The yoga 
intervention could theoretically affect long term or even permanent psychological and/or 
physiological changes that would affect participants well into the no-treatment period that 
would follow the treatment period (in „group A‟). Some crossover studies incorporate a 
„washout period‟ between the two periods of intervention and no-intervention, intended to 
allow the effect of the first intervention to wear out (Chatburn, 2011, p. 323). This may 
arguably be more suited to a drug intervention then for a yoga intervention because in a 
drug intervention, traces of the drug are gradually cleared out of the body after patients 
stop taking them but in a yoga intervention, changes may theoretically be long lasting, and 
acquired yogic practice skills may persist well into the future. Another confounding factor 
could occur if some of „group A‟ participants did not stop practicing yoga techniques 
during the 12 weeks of no-treatment following the crossover, despite being instructed to 
stop as would be required by study protocol. These participants might nevertheless 
continue practicing at home if they felt that the intervention had resulted in positive 
outcomes and worried that stopping to practice may result in deterioration in the progress 
they had made with regards to sleep quality or quality of life. It would be very difficult to 
monitor and detect such non-adherence to protocol. 
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Blinding is a method whereby the researchers do not know during the study the 
nature of the treatment (or no-treatment) a participant is receiving (Christensen et al., 2011, 
p. 497) and double blinding is a method whereby both researchers and participants do not 
know during the study the nature of the treatment (or no-treatment) a participant is 
receiving (Christensen et al., 2011, p. 500). In the present study each participant received a 
code number that was used to identify his/her subjective and objective data. In this way 
sleep physicians, scientists and technicians handling the data were blinded to the nature of 
treatment a participant had received. However, double blinding was not possible since no 
„sham‟ intervention /placebo was used. 
A follow-up of participants at a one year interval after the completion of the study 
had been considered. The purpose of the follow-up would have been to examine 
participants‟ sleep quality and quality of life a year later; to examine whether any 
significant changes in measures or trends had occurred and to compare these changes to 
changes that had occurred over the course of the study. Furthermore, a follow-up could 
have helped examine the percentage of participants that had continued to practice 
meditative yoga at home using the audio CD provided for the study and at what practice 
frequency level compared to the level that had been achieved during the study. Such 
findings could have helped shed more light on the long term effect of short duration yoga 
programs and may have helped formulate better protocols for such programs. 
Unfortunately and regrettably, due to limited funding and its affect on available resources 
and study timeline, no follow-up was possible. 
After taking all the above into consideration, it was decided at the outset that the 
optimal strategy would be to assign all those admitted to the study to WLC group followed 
by active yoga intervention. The control phase would consist of 12 weeks of no-
intervention. Pre- and post-WLC phase measures would be taken. After completing post 
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control phase measures all control phase completers would be contacted and given an 
opportunity to undertake a 12 week yoga intervention phase. Those who would accept the 
offer would be assignd to a 12 weeks yoga intervention phase after which post- yoga 
intervention measures would be taken. Using this method would enable using a smaller 
number of participants without losing statistical power. Obviously, this method does not 
allow random assignment of participants to treatment and control groups. The most 
effective control for the WLC study design was „control by matching‟ (Christensen et al., 
2011, p. 207). Matching can be an effective control method provided all the data required 
for matching participants is available (Christensen et al., 2011, p. 207). There are several 
matching techniques. Due to the initial small number of participants and the large number 
of variables, it was decided the best matching method would be matching by equating 
participants (Christensen et al., 2011, p. 211). There are various methods to equate 
participants. In the present study it was decided to use the most obvious method and equate 
each participant in the WLC phase to himself/herself in the subsequent yoga intervention 
phase. This matching technique can be very effective provided no major changes had 
occurred (Christensen et al., 2011, pp. 207 -208) within the participant or in the general 
environment from WLC baseline to the yoga intervention baseline. Possible changes may 
include significant changes in personal circumstances, physical health, mental health and 
general environmental conditions etc. 
As mentioned above, at the initial study design stage, the likelihood of additional 
resources becoming available was seen as extremely low. Nevertheless, additional 
resources became available incrementally during the course of the study and additional 
applicants responded for weeks after the original application closing deadline (see section 
3.1). Resource availability timeline and intermittent applicant inflow did not allow 
applying a randomised control design or a WLC design to additional participant intake 
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admitted to the study (n=43).It was therefore decided to assign all additional participants 
(n=43) to 12 weeks yoga intervention in the two separate venues that had become available 
and utilise the four additional yoga teachers that had become available. It was decide to use 
the existing WLC group as a control for all active yoga participants, as well as for itself, as 
originally intended (see section 3.1 &3.5.1). This resulted in a mixed experimental design 
combining, the original WLC experimental design (i.e., WLC completers versus 
themselves as subsequent yoga intervention participants) and an additional expanded 
experimental design (WLC versus all yoga intervention participants). The WLC design had 
a stronger control design and the expanded design involved a larger number of participants 
and therefore had greater statistical power. Arguably, combining the two designs provided 
a better design within the external constraints and limitations that had been described 
above. 
In the present study a much higher proportion of women applied to join the study and 
consequently the study included 81 percent woman. An ideal study would have had an 
equal number of men and women but this would have required processing a much larger 
number of applicants which the study‟s limited resources and timeline did not allow. 
3.2 Participants 
3.2.1 Recruitment 
Participants were recruited via an advertising campaign targeting elderly community-
dwelling and independent retirement-dwelling men and women with complaints of 
insomnia. Advertisement campaign used a range of means and media in order to target as 
wide as possible population base throughout the Jerusalem metropolitan area (see section 
3.2). Applicants were processed non-preferentially on a „first come first serve‟ basis. The 
following advertisement methods were used (see appendix 12): 
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1. Advertisements in local community newsletters and papers. 
2. Posters on bulletin boards in local community centres, retirement housing 
complexes (for independent dwelling), shopping centres, medical centres and 
outpatient clinics at main hospitals. 
3. Leaflets were left in offices of local community centres and retirement housing 
complexes (for independent dwelling). 
4. Phone calls were made to medical centres throughout metropolitan area, targeting 
general practitioners and asking for referrals of suitable candidates.  
5. Introductory lectures were given jointly by sleep physicians and yoga teachers at 
community and retirement housing complexes. The lectures covered geriatric 
insomnia, yoga, the intervention used in the study, subjective and objective 
measures used in the study and general inclusion and exclusion criteria. 
6. Word of mouth – many enquiries came from individuals who heard about the 
study from friends (or friends of friends) and relatives who had seen the 
advertisement. 
The response to the modest low budget advertisement campaign was substantial. 
Many enquiries from prospective candidates or their relatives were received well after 
having completed the initial recruiting process of 31 participants. 
3.2.2 Screening participants 
The study was designed to be ecologically valid in that it included typical older 
people presenting with insomnia symptoms. Accordingly, the screening process followed 
current clinical diagnostic guidelines regarding patients presenting with sleep complaints, 
whereby insomnia is primarily diagnosed by a clinical evaluation based on a systematic 
medical, psychiatric, substance use and sleep history acquired by interviewing patients, 
reviewing their medical records and administering medical/psychiatric questionnaires, 
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sleepiness assessment tool(s), sleep logs, measures of subjective sleep quality, 
psychological assessment scales, daytime function, and quality of life scales (AASM, 
2010; Schutte-Rodin et al., 2008; Mai & Buysse, 2008; Littner et al., 2003) (See sections 
1.5.6 and 3.2.2). As discussed in section 1.5.6, according to the 2003 AASM practice 
parameters, PSG is not indicated for the routine evaluation of insomnia unless a breathing 
disorder or limb movement disorder (PLMD) is suspected (Schutte-Rodin et al., 2008; 
Littner et al., 2003).  
On the other hand, as reported above a survey of 461 randomly selected elderly aged 
over 65 in the US has found 24 percent had Apnea index (AI) ≥ 5 and 62 percent had 
Respiratory Disturbance Index (RDI) ≥ 10 (Ancoli-Israel et al., 1991) (see section 1.6.4.4) 
and several studies have estimated the frequency of insomnia in OSA patients to be 
between 24.2 percent and 54.9 percent (Smith et al., 2004; Krakow et al., 2001; Chung, 
2005; Krell & Kapur, 2005) (see section 1.6.4.7). Furthermore, one study reported a high 
prevalence of undiagnosed sleep apnea in elderly insomniacs that had previously 
undergone an interview to screen for sleep apnoea with an AHI >5 in 43 percent and an 
AHI >15 in 29 percent of the study population and suggested using PSG as a screening tool 
when recruiting older adults for research on insomnia (Lichstein et al., 1999). The 
screening process of the present study was intended to minimise OSA diagnosis false 
negatives by combining a systematic clinical examination by a sleep and respiratory 
physician in conjunction with psychological and sleep quality questionnaires including the 
Multivariate Apnoea Prediction index (MAP) that had been reported as useful for 
discriminating between patients with and patients without sleep apnoea in non sleep centre 
populations (Maislin et al., 1996; Maislin et al., 1995). Also, if any previously undiagnosed 
psychiatric or medical disorder, including OSA, or PLMD, was suspected, the patient was 
referred to further medical investigation, including a sleep study if necessary, and was 
133 
 
excluded from the study unless all additional medical investigations were completed and 
yielded negative results. The assumption that this screening process would be adequate to 
minimise OSA diagnosis false negatives was later disproven as reported in section 4.6 and 
this is discussed further in section 5.3. 
The multi-stage screening process utilised in the present study included the following 
stages: 
1. An initial phone interview 
2. Mail-out of study information statement (see appendix 4.4) and medical forms (see 
appendixes 3.2-3.3) to potential participants and their personal physicians 
3. Review of letters from personal physicians including patient‟s full medical history 
and the physician signed approval for patient‟s participation in yoga activity.  
4. The completion of additional medical forms and subjective sleep quality (including 
MAP, PSQI, ESS and KSS) and psychological questionnaires at the medical centre 
5. A structured interview by a sleep and respiratory physician at the medical centre 
6. Signing of a consent form at the medical centre 
3.2.3 Inclusion and exclusion criteria 
3.2.3.1 Inclusion criteria  
The following inclusion criteria were applied in participants for the present study: 
1. Individuals – both male and female, 60 years of age and above. 
2. Presenting with insomnia complaints, occurring at least three times a week, for at 
least one month (see section 3.5.3). 
3. Willing to accept assignment procedure. 
4. Able and willing to comply with all study protocols including: Regular attendance 
of intervention yoga classes; not engaging in any other mind-body activities during 
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the study and not starting any new exercise or recreational activities for the 
duration of the study. Continuation of well established regular activities (e.g. 
walking, swimming, playing bridge and other hobbies) was allowed. 
5. Able to reach yoga practice venue independently or via public transport. 
6. Able and willing to read, understand and fill out all forms and questionnaires 
7. Able and willing to provide informed consent 
3.2.3.2 Exclusion criteria 
The following exclusion criteria were applied in screening participants for the present 
study: 
1. Evidence of other primary sleep disorders by history and/or previous sleep study -
such as untreated obstructive sleep apnea (OSA), NREM Parasomnias (e.g., restless 
leg syndrome [RLS], periodic leg movement [PLMD], confusional arousals, 
sleepwalking [somnambulism], sleep terrors, bruxism [teeth grinding] etc.) REM 
Parasomnias (e.g., REM sleep behaviour disorder, Catathrenia [breath holding and 
groaning] etc.) 
2. Any medical condition known to affect sleep and/or mental state.  
3. Chronic medical conditions which may affect sleep if uncontrolled, unstable or 
severe (e.g., diabetes, hypertension, ischemic heart disease, renal disease, urinary 
incontinence, prostate disease, etc.) 
4. Recent major medical procedures (e.g., major surgery) 
5. Severe chronic pain, caused by a primary health condition (e.g., musculoskeletal 
condition, cancer, fibromyalgia, arthritis, irritable bowel syndrome etc.) or by a 
primary pain disorder.  
6. Malignant arrhythmia by ECG (e.g., ventricular tachycardia, heart block, atrial 
flutter, paroxysmal atrial tachycardia, etc. not controlled by medications) 
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7. Any major mental illness, dementia, major depression (by DSM-IV criteria) (APA, 
2000). 
8. Currently receiving psychiatric or psychological care  
9. Reported current alcohol intake greater than two standard drinks daily (≥20 grams) 
10. Reported current drug abuse (prescription and/or „recreational‟) 
11. Any health condition or mental condition which precludes gentle physical exercise 
or meditation exercise in judgment of study physician and/or personal physician 
12.  Planned life stressors (e.g., moving house, divorce, overseas travel etc.). 
13. Engaged in similar mind-body activities over the last three months, or past history 
of similar mind-body activities (at least once per week for three months). 
14.  Note: use of sedative-hypnotics and/or relaxants was allowed if participant had 
been on a regular consumption pattern for at least 6 weeks. The present study 
examined changes in the consumption of these medications via the PSQI sleep 
medication subscale and via the daily sleep logs (see sections 3.4.2.3 and 3.4.2.8). 
3.3 Intervention  
3.3.1 General protocol design questions  
The yoga intervention protocol was designed after reviewing ancient and 
contemporary yogic texts and commentaries (see section 1.7). Discussions were held 
with several yoga masters who generously gave of their time and knowledge (please 
refer to the acknowledgments). To facilitate optimal protocol design the following 
questions were asked at the outset: 
1. Should the protocol be based on a specific yoga method/school or should it be a 
customised protocol which incorporates selected practices/components? 
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2. Should the protocol be based on class practice, home-based self practice or a 
combination of both? And if so what should the ideal ratio be? 
3. What is the optimal number of weekly practice sessions? 
4. What should the home self-practice component include and preclude? 
5. What specific modifications are needed to adapt yogic practices to an elderly 
population in a western cultural setting? 
6. What can be done to ensure the quantity and quality of home-based self-practice? 
3.3.2 Protocol design guidelines 
Yoga protocol requirements and priorities based on research aims and ethical 
guidelines:  
1. Safe and suitable for the general elderly population. 
2. Easy to understand, and apply by the elderly. 
3. Suitable for western living conditions and life style. 
4. Focuses on improving sleep quality and quality of life of elderly people presenting 
with complaints of insomnia. 
5. Easy to apply by yoga teachers and participants 
6. Designed to promote uniform and consistent practice by participants. 
3.3.3 Protocol design considerations 
1. The aging process is associated with physical decline and various common health 
conditions such as osteoporosis, hypertension, hearing loss, impaired vision, etc. 
Furthermore, the aging process may affect balance, coordination, muscular strength 
and response time (See section 1.2). These factors needed to be taken into account 
in the design of the yoga intervention protocol. 
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2. The present study had a limited budget. The yoga teachers were volunteers 
affiliated with the Israel Yoga Teacher‟s association and experienced in teaching 
general hatha yoga and not affiliated with any specific school or brand of yoga. 
Therefore, an intervention protocol that was unaffiliated with a specific yoga 
lineage was developed.  
3. A customised protocol tailored specifically for the study aims would better 
represent yoga‟s potential future benefits for the population under study.  
4. Two weekly classes were considered by the yoga masters consulted to be an 
optimal compromise: One weekly class was deemed insufficient to maintain 
continuity and to adequately support home practice, and three weekly classes might 
have been considered by many elderly people as an inconvenience or burden and 
may have resulted in lower attendance rates. 
5. On the other hand, all yoga masters consulted were of the opinion that to achieve 
significant results within a 12 week period, two weekly classes may not be 
adequate and adding a home self practice component was believed to be necessary. 
6. Of the eight „limbs‟ of classical Yoga described in the ancient seminal text “Yoga 
Sutra” of Patanjali (Iyengar, 1996; Feurstein, 1990) (See sections 1.7.4 -1.7.9), the 
following limbs were found of relevance to present study: „Asana‟(postures), 
„Pranayama‟ (breath control), „Pratyahara‟ (withdrawal of sensory stimuli, direction 
of attention inwards), „Dharana‟ (concentration on an object, controlling the mind 
not to be distracted by thoughts) and „Dhyana‟ (meditation, uninterrupted flow of 
awareness). However, a key ancient text and a contemporary master are of the 
opinion that practice of „Pranayama‟ (breath control), although an important tool 
for improving health, preventing and curing diseases, facilitating concentration and 
calming the mind, requires adequate preparation, including a good foundation in 
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asana practice. Furthermore, these sources believe that premature or improper 
practice of pranayama may harm the practitioner‟s health – specifically 
predisposing him/her to hypertension, respiratory disorders, and cardiovascular 
disorders (Svatmarama, 2002, pp. 36-37; Iyengar, 2010, pp. 53-54; Iyengar 2006, p. 
33) (See section 1.7.5). Taking these opinions into consideration, it was concluded 
that for an elderly population with no experience of yoga practice, due caution 
should be taken and pranayama breathing exercises should be excluded from the 
study‟s yoga protocol. Nevertheless, the breath did play an important part in the 
protocol as two of the three meditative yoga exercises, incorporated some form of 
breath awareness, by using the breath as an object of concentration. Furthermore, in 
the physical yoga practice, while standing in tadasana („mountain‟ pose), 
participants were asked to raise the arms while breathing in and lower them while 
breathing out, thus teaching basic breath – movement coordination.  
7. Safety considerations also precluded unsupervised home practice of yoga poses. 
Therefore, it was decided that the home self practice component would include 
meditation and relaxation exercises only. Thus, 30 - 50 percent of net class time 
was assignd to meditation and relaxation exercises in order to support home 
practice and ensure its correct execution. The remaining 50 – 70 percent of net 
class time was assignd to physical asana practice. 
8. Compliance and correct execution were considered the main challenges for home –
based self-practice. To facilitate home practice an audio CD was designed and 
produced, which included instructions and three guided meditation/relaxation 
exercises. The CD was designed to facilitate uniform execution of exercises and 
also make self discipline easier. 
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9. Taking all above considerations into account, a protocol which was based mostly 
on meditative aspects of yogic practice seemed the most applicable.  
3.3.4 Aims of physical yoga component  
General aims for the physical yoga component were to improve the following 
mind-body aspects: 
1. The ability to relax and concentrate 
2. Mind-body awareness 
3. Balance 
4. Core strength 
5. Posture and poise 
6. Spinal mobility, flexibility and strength 
7. Joint mobility and flexibility 
8. Coordination 
9. Blood circulation. 
3.3.5 Aims of meditative yoga component  
General aims for the meditative yoga component were to develop core skills of 
relaxation, concentration and awareness and more specifically to: 
1. Develop an ability to consciously relax. 
2. Develop an ability to consciously concentrate.  
3. Develop some awareness of the mind‟s habitual thinking patterns. 
4. Develop some ability to control/slow down the thinking process. 
5. Develop awareness of physical sensations and physical tension. 
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3.3.6 Yoga practice duration, frequency and timing 
The present study‟s yoga protocol was based on a combination of yoga classes 
and home-based self-practice. Practice time was assignd as follows: 
1. Intervention period: 12 weeks 
2. Practice frequency: Two yoga classes per week and home-based practice - 
recommended seven days a week (see item no. 5) 
3. ‘Practice unit’: a yoga class was considered as one „practice unit‟. For home-based 
practice – one guided meditative exercise (using an audio CD) plus time required to 
get ready for practice and then conclude the practice was considered one practice 
unit (net practice time was between 25 and 35 minutes). 
4. Yoga class duration: Total class duration was one hour which included net 
practice time as well as giving instructions, questions and answers, taking 
attendance, collecting forms and logs. Actual net practice time was between 25 and 
35 minutes (one „practice unit‟) 
5. Recommended daily practice: The recommended total daily practice was three 
„practice units‟, seven days per week (a total of 21 practice units per week). Since 
each supervised class was considered one practice unit, on days that yoga classes 
were held, recommended home practice was two practice units (roughly 40 -50 
minutes) and on other days, recommended home practice was three practice units 
(roughly 60 -75 minutes). Recommending participants practice seven days a week 
was intended to reinforce the general intention and suggestion of making yoga 
practice an integral part of the daily routine. Applying this recommendation was 
possible for all participants including orthodox Jews that observe the holy day of 
the Sabbath, as according to the Jewish tradition the Sabbath religious rituals and 
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customary restrictions end at nightfall (Israel Ministry of Tourism, 2010; Chabad, 
2010).  
3.3.7 General precautions during class 
The following precautions were taken during yoga classes: 
1. Participants were placed at a safe distance from other participants. 
2. Unobstructed access and line of sight from yoga teacher to each participant was 
maintained 
3. A first aid kit, telephone and water were available at all yoga venues. 
4. Comfortable ambient temperature was maintained.  
5. The classrooms were close to the toilets 
3.3.8 Yoga class structure 
Each of the yoga classes had the following general structure: 
1. General welcoming of students by the teacher 
2. The completion of an attendance log.  
3. Physical yoga exercises 
4. Meditative yoga exercises 
5. General question and answer time 
6. Discussion of any administrative issues 
3.3.9 Physical yoga component  
3.3.9.1 Introduction  
The physical practice component included a sequence of yoga poses (asana) and 
movements. Standing, sitting, horizontal prone and supine poses were incorporated.  
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3.3.9.2 Cautions 
The following cautions were given every class: 
1. Participants were asked to make sure they understood the instructions before 
performing a pose and if not to raise their hand and ask the teacher for assistance. 
2. Participants were asked not to do anything which they felt might compromise their 
health and safety. 
3. Participants with a (controlled) blood pressure condition were asked not to raise 
their hands above their shoulders and not to bend their head below the chest (heart) 
level. 
4. Participants with osteoporosis were asked to avoid postures that involve bending 
forward from the waist and avoid twisting to the point of strain.  
5. Participants were asked to perform every exercise gently and gradually, and avoid 
straining. 
6. Participants were asked to stop any exercise immediately and notify the teacher if 
they felt dizzy, short of breath, tired, with a chest pain, with nausea, generally 
unwell or injured. 
7. Participants were asked not to leave class without teacher‟s permission. 
8. Participants were asked to alert the teacher immediately if they did not feel well. 
9. Teachers were instructed to have the entire class in their field of vision.  
10. In case of any adverse effects teachers were instructed to stop class activity, ask 
other participants to rest, and attend to the participant with the problem 
immediately. 
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3.3.9.3 Alternative poses 
An important protocol design issue was whether or not to provide 
alternative/modified poses for participants who could not, or were reluctant, to perform 
any particular pose. In community based yoga classes, alternative poses are offered 
regularly due to prevalence of physical limitations among individuals in the elderly 
population (see section 1.2.). Under ideal conditions, all participants would be able to 
perform all poses. However, the prevalence of musculoskeletal complaints, poor 
balance and individual discomfort, make this an unrealistic expectation in elderly 
cohorts. Two possible solutions were suggested: The first was to offer constrained 
participants alternative poses. The second solution was to ask participants who thought 
that they could not perform a particular pose, to rest until the next pose was called out. 
Both methods resulted in reduced uniformity of practice. However, it was considered 
that the former option offered higher a level of uniformity because the 
alternative/modified poses were designed to preserve the basic physiological principle 
(e.g.,  spinal twist, forward stretch etc.) and core benefits (e.g., flexibility, mobility,  
core strength, balance etc.) of the original pose. 
The yoga teachers and masters who were consulted reported many elderly 
participants are reluctant to perform mat based poses because of difficulty or hesitation 
in getting down to the mat and getting up from the mat. There can be various reasons for 
this, including, leg and knee weakness, knee pains, poor balance etc. Thus most of the 
alternative poses were chair-based substitutes for mat-based poses. Chairs were also 
used for those who required support in standing poses.  
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3.3.9.4 Protocol 
The total duration and number of poses in the physical yoga component of a class 
varied in accordance with the time assignd to explanations, questions and answers, and to 
the meditative component etc. Total duration of the physical yoga component normally 
ranged from 35 to 20 minutes. Number of repetitions for most exercises was one or two, 
but in some cases up to nine depending on the exercise and available time. Total duration 
in most poses was from 20 seconds up to 60 seconds depending on the pose. Each of the 
chair and mat based poses was followed by a relaxation period of approximately 20 
seconds. The general sequence of the physical component was: 
1. standing poses 
2. chair based poses 
3. Mat based poses (or chair based alternate poses). 
The general sequence of mat based poses was: 
1. a short relaxation in shavasana (corpse pose)  
2. supine poses 
3. prone poses 
4.  sitting poses 
5. a short relaxation in Savasana (corpse pose)  
Table 3.1 includes a detailed full sequence of the physical yoga component. The 
table lists the poses as well as alternative/modified poses. Appendix no. 9 provides 
photographs of all poses. 
Please continue to the next page  
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Table 3.1 
Yoga poses sequence used in the protocol 
No. Sanskrit  name English name type base Rep Modification comment 
1 Tadasana Mountain pose STA  1   
1-ALT Tadasana Mountain pose STA  1 MOD # 1  
2 Tadasana Mountain pose STA  1 - 2 MOD # 1A  
3 Tadasana Mountain pose STA  1 - 2 MOD # 1B  
4 Virabhadrasana II Hero pose II STA  1 - 2  RS, LS 
4-ALT Virabhadrasana II Hero pose II STA  1 - 2 MOD # 1 RS, LS 
5 Bikram style Ardha-
Chandrasana 
Bikram style 
 half moon pose 
STA  1 - 2 MOD # 2 RS, LS 
5-ALT Ardha-Chandrasana modified 
 half moon pose 
STA  1 - 2 MOD # 2A  
6 Adho Mukha 
Svanasana 
downward  facing 
dog pose 
STA  1 - 2   
6-ALT Adho Mukha 
Svanasana 
downward  facing 
dog pose 
STA CHR 1 - 2 MOD # 3  
7 Manibandha Chakra Wrist rotations SIT CHR 3 -9  CW, CCW 
8 Goolf Chakra Ankle rotations SIT CHR 3 -9  CW, CCW 
9 Skandh Chakra shoulder rotations SIT CHR 3 -9  CW, CCW 
10 Garurasana Eagle pose SIT CHR 1 - 2 MOD # 4 RS, LS 
11 Savasana Corpse pose SUP MAT 1   
11-ALT  seated relax SIT CHR 1 MOD #11  
12 Ardha Pavana 
muktasana 
Half Wind removing 
pose 
SUP MAT 1 - 2  RS, LS 
12-ALT Ardha Pavana 
muktasana 
Half Wind removing 
pose 
SUP CHR 1 - 2 MOD # 5 RS, LS 
13 Bhujangasana (easy 
version) 
“Baby” Cobra Pose PRN MAT 1 - 2 MOD # 6  
13-ALT  standing baby cobra SIT WAL 1 - 2 MOD # 7  
14 Ardha shalbhasana  
 
Half Locust Pose PRN MAT 1 - 2   
14-ALT  standing half Locust STA WAL 1 - 2 MOD # 7  
15 Marjaryasana cat pose  MAT 2-4   
15-ALT Marjaryasana cat pose  CHR 2-4 MOD # 3  
16 Bitilasana Cow pose  MAT 2-4   
16-ALT Bitilasana Cow pose  CHR 2-4 MOD # 3  
17 Marichyasana (easy 
version) 
Spinal twist SIT MAT 1 - 2  RS, LS 
17-ALT Chair twist Spinal twist SIT CHR 1 - 2 MOD # 8 RS, LS 
18 Ardha-Kurmasana Half Tortoise Pose SIT MAT 1 - 2 MOD # 9  
18-ALT Ardha-Kurmasana chair - Tortoise STA CHR 1 - 2 MOD # 10  
19 Balasana Child‟s pose SIT MAT 1 - 2 MOD # 9  
19-ALT  Chair child pose STA CHR 1 - 2 MOD # 10  
20 Paschimottanasana Seated forward bend SIT MAT 1 - 2 MOD # 12  
20-ALT  Chair –forward bend SIT CHR 1 - 2 MOD # 12  
21 Savasana Corpse pose SUP MAT 1   
21-ALT  Chair – relax 1 SIT CHR 1 MOD #11  
21-ALT  Chair – relax 2 SIT CHR 1 MOD #11a  
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Notes for Table 3.1: 
1. The following abbreviations are used in table above: 
 RS – right side, LS- left side, CW – clockwise, CCW – counter clockwise, 
STA- standing pose. SIT – sitting pose, PRN – prone pose, SUP- supine 
pose, MAT – mat based pose, CHR – chair based pose, WAL –using wall 
for support, MOD –modified pose, ALT – alternative 
2. The following modifications have been applied or offered optionally: 
MOD # 1 - Holding onto back of chair for balance 
MOD # 1A –shifting weight to right, left, front, back while engaging abdominal 
muscles gently  
COM #1B – raising hands while breathing in. Lowering hands while breathing 
out  
MOD # 2 – when bending to right – right hand on hip and left hand over head 
and vice versa 
MOD # 2A – same as MOD # 2 but with right hand on back of chair for support 
MOD # 3 – holding seat of chair or top of back of chair and bending forward 
MOD # 4 – in chair sitting position arms interlaced with left elbow below right 
and the legs – right knee over left knee and vice versa on the other side 
MOD # 5 – in chair sitting position raise knee towards trunk and hug over or 
below knee 
MOD # 6 – gentle upper back raise with neck in line with the spine, facing 
down, palms on floor next to armpits facing down 
MOD # 7 – facing wall, hands on wall, weight forward slightly, back arched 
looking up 
MOD # 7A – facing wall, hands on wall, weight forward slightly, back arched 
looking up. One leg extended back, off the floor 
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MOD # 8 when twisting to the right – left hand over right tight grabbing chair 
seat and right hand grabbing back of chair and vice versa 
MOD # 9 – in case of knee restriction pose is executed with increased angle 
between calf and thigh (up to 90 degrees if needed) 
MOD # 10 –standing and bending forward placing forehead and palms of hands 
on chair‟s seat. 
MOD # 11 – sitting upright back to chair‟s back support, palms resting on 
thighs, feet flat on ground, close eyes and relax 
MOD # 11a – sitting upright back to chair‟s back support, palms resting on 
thighs, legs extended forward on another chair, close eyes and relax 
MOD # 12 – bending forward with palms resting on thighs for support. Legs 
together 
MOD # 12a – bending forward sitting on a chair with legs extended on another 
chair 
MOD # 13 – sitting while leaning forward with palms and head resting on back 
of another chair for support. Folded towel may be used under forehead 
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3.3.9.5 Poses and effects 
Ancient and contemporary yogic texts asanas list various claimed physiological 
effects and benefits of yoga poses. Table 3.2 below lists claimed effects and benefits of 
selected poses in line with defined aims of the physical yoga component of the protocol. 
Table 3.2 
Yoga poses used in protocol - claimed effect and benefits 
Pose 
No. 
Sanskrit  name English name Claimed benefits/ protocol aim 
1 Tadasana  Mountain pose Improve posture, strengthen legs  
2 Tadasana  Mountain pose 
variation 
Improve balance and core strength 
3 Tadasana  Mountain pose 
variation 
Develop Fuller breathing 
4 Virabhadrasana II Hero pose II strengthen and stretch legs, ankles improves stamina 
5 Bikram style Ardha-
Chandrasana 
Bikram style 
 half moon pose 
Improve Lateral spinal mobility, flexibility and strength, stretch 
shoulders 
6 Adho Mukha Svanasana downward  
facing dog pose 
Improve circulation to brain, calms the mind, Strengthen arms 
and legs, Stretch the shoulders, hamstrings, calves, arches, and 
hands 
7 Manibandha Chakra Wrist rotations Improve wrist mobility and flexibility  
7 Goolf Chakra Ankle rotations Improve Ankle mobility and flexibility 
8 Skandh Chakra shoulder 
rotations 
Improve shoulder mobility and flexibility 
9 Garurasana Eagle pose Strengthen & stretch ankles, hips, shoulders, elbows and upper 
back 
10 Savasana Corpse pose Relax whole body, resting pose 
11 Ardha Pavana 
muktasana 
Half Wind 
removing pose 
Massage abdomen and remove wind, improve hip joint 
flexibility 
12 Bhujangasana (easy 
version) 
“Baby” Cobra 
Pose 
Strengthen spinal muscles, stretch chest, shoulders, , buttocks, 
massage  abdomen 
13 Ardha shalbhasana  
 
Half Locust Pose Strengthen spinal muscles & buttocks, stretch chest, shoulders, 
buttocks, and backs of the arms and legs  
chest, abdomen, and thighs, massage abdomen 
14 Marjaryasana Cat pose Counter Stretches the back torso and neck 
15 Bitilasana Cow  pose Stretches the back torso and neck gently 
16 Marichyasana (easy 
version) 
Spinal twist Improve spinal and hip flexibility , mobility and circulation, 
Massage abdomen 
18 Ardha-Kurmasana Half Tortoise 
Pose 
Relaxation pose. Calms the mind. Increases circulation to the 
brain and upper lungs, improve flexibility of hip joints, ankles 
and shoulder girdle  
18 Balasana Child‟s pose Relaxation pose. Calms the mind. Increases circulation to the 
brain improve flexibility of hip joints, ankles , relieves back  
tension 
19 Paschimottanasana Seated forward 
bend 
Stretches the spine, shoulders, hamstrings 
20 Savasana Corpse pose Relaxes whole body, resting pose 
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Note for table 3.2: 
The following references were used: Yoga Journal website Asana section (Yoga 
Journal, 2010), Asana Pranayama Mudra Banda (Swami Satyananda Saraswati, 1996), 
Light on Yoga (Iyengar, 2001); Yoga Wisdom and Practice (Iyengar, 2009), Bikram‟s 
Beginning Yoga Class (Bikram, 2000).  
3.3.9.6 Uniformity of practice and quality control 
Yoga teachers were certified by the Israel Yoga Teachers Association. Several 
pre-intervention meetings were held with the teachers to discuss the intervention class 
structure, pose sequences, modified poses, safety regulations, cautions and precautions, 
in order to ensure correct and uniform practice and participants‟ health and safety. Also, 
to ensure uniformity of practice, sheets containing pose sequences and photographs of 
all poses and modified poses were distributed to the yoga teachers. An investigator 
monitored all classes to ensure uniformity and adherence to protocol. 
3.3.10 Meditative and relaxation yoga component 
3.3.10.1 Overview 
The Meditation/Relaxation protocol consisted of three basic meditative exercises 
designed to facilitate the development of basic mind-body meditative skills including 
relaxation, concentration, breath awareness and sensory awareness. These are intended 
to facilitate a state of mind which combines alertness, concentration, relaxation and 
mind-body awareness. Three basic mediation exercises were taught during yoga classes 
and were also included in the audio CD for home-practice:  
1. Breath counting meditation  
2. Muscular relaxation 
3. Yoga Nidra  
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3.3.10.2 Audio CD for at-home self-practice 
A pre- recorded audio CD containing all necessary instructions and three guided 
meditation sequences was provided to all participants. The recorded instructions 
allowed participants to review, revise, and refresh their memory whenever necessary. 
The recorded guided meditations facilitated uniformity in execution and were designed 
to facilitate better concentration and relaxation during practice by allowing participants 
to simply follow instructions rather than having to remember the sequence, decide what 
to do next or for how long to do each exercise. Furthermore, the voice of an experienced 
teacher, although from a recording and not in person, provided some simulation of class 
atmosphere and a feeling of being supervised and guided. The participants provided a 
lot of feedback on the content and form of the CD via space provided on their daily 
sleep and practice logs (DSPL).The majority of participants‟ comments were positive, 
indicating the CD fulfilled its intended objectives. There were some critical remarks but 
these tended to focus on the vocabulary and grammatical style used in the CD.  
The audio CD for home self practice contained these five tracks: 
1. Track 1 – instructions on how to use the audio CD 
2. Track 2 – general instructions on yoga practice in the study 
3. Track 3 –Breath counting meditation – 20 minute guided meditation sequence 
4. Track 4 – Muscle relaxation practice - 20 minute guided meditation sequence 
5. Track 5 –Yoga Nidra meditation- 20 minute guided meditation sequence’ 
3.3.10.3 ‘Breath counting meditation’ exercise 
The first meditative exercise incorporated in the audio CD was a natural breath 
counting meditation. It is similar to one of essential components incorporated in a 
typical yoga nidra  sequence (Satyananda, 1976, p. 69).The aim of this exercise was to 
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prepare participants for full yoga nidra practice, by improving concentration and 
developing awareness of the natural breath cycle and also of the mind‟s tendency to get 
distracted by random thoughts. Because the ability to concentrate the mind leads to and 
is essential for success in any meditative technique (Yogendra, 2003, pp. 40-41; 
Feuerstein, 2000, p. 85) (see section 1.7.7), participants were taught the „breath counting 
meditation‟ during the first week of the intervention and it was also the first of three 
meditative techniques included in the audio CD (see appendix 10.1 for a full CD 
sequence transcript.) It was recommended to conduct this exercise while sitting or lying 
down with the eyes closed. The practitioners were asked to simply direct their attention 
to the natural breath without altering it in any way. In order to facilitate breath 
awareness, the practitioners were instructed to observe the rising and falling of the 
abdomen, or as an alternative, observe the sideways expansion and contraction of the rib 
cage, or observe the flow of air via the nostrils. The practitioners were instructed to 
count each complete breath cycle as follows: The practitioner observes the inhalation 
phase followed by the exhalation phase. Towards the end of the exhalation phase the 
practitioner counts the current breath cycle number. The practitioner continues to count 
up (1, 2, 3 etc.) until the end of the exercise on the CD is reached. In case of losing 
concentration or forgetting to count, the practitioner was instructed to start counting up 
again from one. On the CD track for this exercise, instructions were given at the 
beginning of the exercise and then every few minutes a short repetition of the 
instructions was given and finally the end of the session was announced (See Appendix 
10.1 for CD transcript). 
3.3.10.4 Muscle relaxation exercise 
As discussed above muscle relaxation techniques aim at training the practitioner 
to voluntarily relax muscular tension and affect physiological relaxation in order to 
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induce psychological relaxation utilising the linkage between body and mind (see 
section 1.5.12.3.9). Yoga also incorporates various muscle relaxation techniques which 
are also one of the components in most „Yoga Nidra‟ protocols (see section 1.7.12). In 
current study a separate muscular relaxation exercise was incorporated to induce 
somatic relaxation and also as preparation for the full „Yoga Nidra‟ practice. 
Participants were taught the muscle relaxation sequence, as recorded on the audio CD, 
during the second week of the intervention. In the muscle relaxation exercise used in the 
present study, practitioners were asked to assume a comfortable position, ideally the 
supine shavasana (corpse pose). The practitioner were then asked to direct his/her 
attention sequentially to muscle groups throughout the body starting from the feet, then 
calves, thighs, lower back, middle back, upper back, lower abdomen, chest, shoulders, 
upper arms, lower arms, palms and fingers, scalp, temples, back of the head, neck, 
forehead, eyebrows, cheeks, nose, mouth, chin, throat. Once awareness was focused on 
a particular body part, the practitioner was asked to quietly tell that body part “relax”. 
Uttering the word “relax” by whispering or by silently moving the lips rather than by 
inward silent mental repetition. The word “relax” is used in this meditation as a Mantra 
(see section 1.7.10) with the intention of facilitating concentration and mind-body 
integration. This is repeated several times for each muscle group. If the practitioner 
finds it difficult to relax a particular muscle group, he/she is instructed to consciously 
contract that muscle group while breathing in and then consciously relax it while 
breathing out (See Appendix 10.2 for CD transcript.). 
3.3.10.5 Yoga nidra exercise  
There are various variants of „Yoga Nidra‟ sequences. In the present study the 
yoga nidra protocol incorporated main components of yoga nidra transcripts as taught 
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by Swami Satyananda Swaraswati of the Bihar school of yoga (Satyananda, 1976, pp. 
81- 150) as follows: 
1. Preparation – the practitioner is instructed to lie down comfortably on a mat in 
the supine position, feet apart and palms facing upwards, cover the body with a 
blanket if necessary to keep warm and once comfortable stay still till the end of 
the practice. If the supine position is not comfortable other horizontal or sitting 
positions are permissible. 
2. Relaxation - the practitioner is instructed to feel the tension in the muscles 
dissolving and relax the whole body (part by part or all at once) 
3. Resolve - the practitioner is instructed to make a wish for any positive change 
in life, health, relationship etc.  
4. Rotation of consciousness – Body parts are mentioned sequentially in a rapid 
succession from top to bottom and from right to left. The practitioner directs 
his/her awareness to the body part called out by the teacher (or audio recording) 
and tries to sense it and visualise it as vividly and clearly as possible. The 
sequence used in this protocol starts on the right side of the body: first finger, 
second finger, third finger, fourth finger, fifth finger, palm of the hand, back of 
the hand, wrist, forearm, inside of the elbow, back of the elbow, upper arm, 
shoulder, armpit, torso, hip, buttock, thigh, front of the knee, back of the knee, 
calf, shin, top of the foot, heel, sole, first toe, second, toe, third toe, fourth toe, 
fifth toe. The awareness is then directed to the left side of the body and a mirror 
image sequence is repeated. Awareness is then directed to the stomach, chest, 
lower back, middle back, upper back, back of the neck, scalp, forehead, 
eyebrows, eyes, cheeks, nose, nostrils, lips, inside the mouth, teeth, chin, and 
throat. Awareness is then directed to the entire lower part of the body from the 
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waist down. Then to upper part of the body from the waist up. Then to the 
entire right side of the body. Then to the entire left side of the body. Then to the 
entire back side. Then to the entire front of the body. Finally to the entire body. 
5. Breath awareness – the practitioner directs awareness to the breath as it 
manifests in the movement of the abdomen, ribs, chest, throat, nostrils. In each 
of these body parts, the practitioner maintains focus and counts down from a 
certain number to zero (or vice versa). This component is similar to the breath 
counting meditation mentioned above. 
6. Awareness of sensations – The practitioner senses opposite sensations in the 
body: Heat and then cold, lightness and then heaviness, painful sensations and 
then pleasant sensations etc. 
7. Focusing on the inner space – The practitioner observes whatever appears in 
the inner space between the eyebrows (with the eyes closed). 
8. Visualisations – The practitioner is instructed to visualise a sequence of 
objects, scenery, animals etc. which the practitioner tries to visualise as vividly 
as possible as they are called out in a rapid succession. 
9. Repeating the Resolve – The practitioner is instructed to repeat the initial 
resolve three times (a wish for any positive change in your life, health, 
relationship etc.). 
10. Completion – The practitioner is instructed to become aware of the body, the 
room, the surroundings, stretch gently, move the limbs gently, blink the eyes a 
few times and then get up slowly 
Notes:  
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1. The full standard „Yoga Nidra‟ protocol above may take between 40 to 45 
minutes. In the home practice audio CD a shorter version was used which 
omitted steps 6 – 8, thus taking  25 minutes in total duration. 
2. In some classes the full „Yoga Nidra‟ protocol was used and in others - 
shorter versions, depending on time assignd for other exercises etc.  
(See Appendix 10.3 for CD transcript.) 
3.4 Outcome measures 
3.4.1 Introduction 
Both subjective and objective instruments were used to measure the study 
outcomes. Measures were taken during the ten day period pre-intervention and again 
during the ten day period post-intervention. Pre-intervention subjective measures were 
administered at the SZMC medical centre and post-intervention subjective measures 
were administered at the training locations (for the intervention group) or SZMC 
medical centre (for the control group). Subjective measures were derived from a range 
of reliable and valid self-reported questionnaires, eliciting information on sleep quality 
and disturbances, daytime sleepiness and function, psychological wellbeing, physical 
wellbeing, daily and social functioning. These measures included the Profile of Mood 
States –short form (POMS-SF), the Depression Anxiety Stress Scale –long form 
(DASS-42), the Pittsburgh Sleep Quality Index (PSQI), the Karolinska Sleepiness Scale 
(KSS), the Epworth Sleepiness Scale (ESS), the  Multivariable Apnea Prediction Index 
(MAP), the Health Survey (SF36) and daily sleep and practice logs (DSPL). There were 
several overlaps in measures amongst these questionnaires, but the selected combination 
was deemed to provide a comprehensive set of measures. Where measures overlapped, 
the most specific and detailed measures were relied on. Furthermore, some redundancy 
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was incorporated intentionally by using two similar questionnaires for mood states, 
namely the POMS and the DASS. This was done primarily because the POMS 
incorporates six mood state scales (Tension-Anxiety, Depression-Dejection, Anger-
Hostility, Vigour-Activity, Fatigue-Inertia and Confusion-Bewilderment) whereas the 
DASS has only three scales (depression, anxiety and stress). However, the DASS is 
more detailed and specific in itemising possible symptoms of depression, anxiety and 
stress. It has separate scales for anxiety and stress, whereas the POMS has a single 
combined scale for tension-anxiety. In addition the DASS gives a detailed situational 
description for each of the items (e.g., “I found myself in situations that made me so 
anxious I was most relieved when they ended”) whereas, each of the POMS items 
consists of a single adjective (e.g., “tense”, “anxious”, etc.) and is therefore more prone 
to variation in respondents‟ interpretation of the precise meaning. Indeed, most queries 
from respondents while filling out the questionnaires were related to the POMS. 
However, the POMS does have the useful scales of fatigue and vigour which are not 
included in the DASS. 
Daily Sleep and Practice logs (DSPL) were used during the study to provide daily 
information on sleep and dietary patterns, consumption of medications, including 
hypnotics and relaxants and home practice patterns. In addition, demographic (age, 
gender, marital status, weight, height) and medical questionnaires were used during pre-
study recruitment stage to elicit medical and demographic information including 
medical history and diagnoses of any medical or psychiatric conditions, and also 
prescriptions of any medications (including hypnotics and relaxants).  
Several studies have been conducted to validate Hebrew versions of the SF-36 
(Lewin-Epstein et al., 1998), the PSQI (Shochat et al., 2007) and the POMS (Netz et al., 
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2005). The Hebrew versions have been found appropriate for the intended purpose. 
There is a need to conduct validation studies for the Hebrew versions of  the DASS, 
MAPS, KSS and ESS for diverse Hebrew speaking populations as the validity of the 
translated version cannot be automatically assumed. In the present study it was decided 
to use the Hebrew versions of KSS, ESS and MAPS due to the simple language and 
concepts used in these questionnaires. The significant overlap between DASS and 
POMS (see above) enabled comparing the results of overlapping subscales and they 
were found to be similar. 
Objective measures were derived from an analysis conducted by a sleep scientist 
based on data recordings acquired during overnight sleep studies at participants‟ homes 
using portable monitoring equipment in conjunction with the Hypnocore sleep analysis 
system. Sleep studies were conducted on “regular” nights with respect to participants‟ 
sleep-wake schedules (i.e. not on nights during which special activities had been 
scheduled or anticipated) and sleep time was „ad libitum‟. Each participant was given a 
detailed explanation of the procedure on the day of the study. A brief explanation was 
also included in the consent forms (see appendix 4). 
3.4.2 Subjective instruments used 
3.4.2.1 The Karolinska Sleepiness Scale (KSS)  
The Karolinska Sleepiness Scale (KSS) (see appendix 5.1) is a very simple 
frequently used self-rated questionnaire for evaluating subjective sleepiness. It asks the 
respondent to rate “How sleepy are your right now?” on a scale of 1 to 9 which ranges 
from (1) “not sleepy at all” to (9) “extremely sleepy-fighting sleep”. The advantage of 
KSS is in its simplicity and the short time required to complete it. The main 
disadvantages are that it measures transient sleepiness rather than a usual or average 
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state and its lack of detail. Consequently, the scores may fluctuate according to quality 
or quantity of the last sleep period, time of day, and transient circumstances - making 
test conditions difficult to duplicate and thus possibly affecting measure stability. 
Furthermore, transient sleepiness may be affected by the act of responding to a 
questionnaire. A study that investigated whether verbal rating of sleepiness can itself 
affect sleepiness and performance revealed that the act of rating affects both subjective 
and EEG measures of sleepiness perhaps via the modest stimulation involved in this act 
(Kaida et al., 2007). However, the validity and reliability of the KSS have been 
established in several studies. A study revealed that the KSS score was closely related to 
EEG and behavioural variables, indicating a high validity in measuring sleepiness and 
concluded that the KSS ratings may be a useful proxy for EEG or behavioural indicators 
of sleepiness (Kaida, 2006). Another study of sleep deprived subjects found scores on 
the KSS showed high correlations with performance tasks (Gillberg, et al., 1994). In 
summary, the KSS is a useful and convenient tool for measuring transient sleepiness  
3.4.2.2 The Epworth Sleepiness Scale (ESS) 
The Epworth Sleepiness Scale (ESS) (see appendix 5.2) is a short self-rated 
questionnaire shown to provide a general level of daytime sleepiness. It asks the 
respondent to rate the likelihood of falling asleep in eight different common daily life 
situations on a scale of 0 to 3 as follows: 0 = would never doze, 1= slight chance of 
dozing, 2 = moderate chance of dozing, 3 = high chance of dozing. If respondents have 
not encountered a particular situation in daily life, they are asked to estimate the 
likelihood of falling asleep in that situation. The scores of all eight items are then 
summed to yield the total score. A total score between 0 and 9 is considered normal. A 
total score between 10 and 24 is considered to indicate excessive daytime sleepiness 
(EDS) that may require additional medical investigation (Johns, 1991). 
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In a study with 180 participants (30 normal and 150 patients with a range of sleep 
disorders) ESS scores were significantly correlated with sleep latency measured in the 
multiple sleep latency test (MSLT) and overnight polysomnography (Johns, 1991). In 
patients with obstructive sleep apnea (OSA), ESS scores were significantly correlated 
with the respiratory disturbance index (RDI) and minimum blood oxygen saturation 
(SaO2) whereas the ESS scores of normal snorers did not differ from controls (Johns, 
1991). The ESS was also able to easily discriminate between normal subjects and 
patients suffering from various sleep disorders such as OSA , narcolepsy and idiopathic 
hypersomnia, demonstrating concurrent validity (Johns, 1991). A study analysing 
results from several previous studies of narcoleptic patients suffering EDS clearly 
showed that the ESS is more discriminating than the maintenance of wakefulness test 
(MWT) and the multiple sleep latency test (MSLT), which had previously been 
considered as the gold standard. The ESS was shown to have both a high specificity 
(100%) and sensitivity (93.5%) (Johns, 2000). In a one year study with more than 600 
participants, the ESS was completed two times at a 12 months interval and was shown 
to be a stable measure of sleepiness over time in middle-aged adults (Knutson, 2006). A 
Spanish version of the Epworth Sleepiness Scale (ESS-Sp) was tested and validated in 
345 patients with OSA and shown to be sensitive to post-treatment changes and level of 
severity and correlated with polysomnography variables (Chiner et al., 1999). 
3.4.2.3 The Pittsburgh Sleep Quality Index (PSQI) 
The Pittsburgh Sleep Quality Index (PSQI) (see appendix 5.3) is a self-rated 
questionnaire designed specifically to measure sleep quality and sleep disturbances in 
clinical populations. The PSQI asks subjects to rate sleep quality and disturbances over 
the month preceding test administration. The PSQI questionnaire consists of 19 items 
eliciting information on usual sleep habits, nature of sleep disturbances, suspected 
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causes for sleep disturbances, use of sleep medication, overall sleep quality, daytime 
sleepiness, and vitality, and also includes an additional five items eliciting information 
from a bed-partner or roommate. The responses to the latter five questions are not used 
in the calculation of PSQI global and subscale-scores. They serve only to provide 
additional information which may be useful in a clinical setting (Buysse et al., 1989). 
The first 19 items are used to yield seven separate subscale scores (each ranging from 0 
to 3), each calculated from related questionnaire items using simple algorithms. The 
seven subscale scores are then summed to yield a global PSQI score (ranging from 0 to 
21). The seven subscales are: subjective sleep quality, sleep latency, sleeps duration, 
habitual sleep efficiency, sleep disturbances, use of sleeping medications and daytime 
dysfunction. (Buysse et al., 1989).  
In a study of more than 600 participants the PSQI was administered twice, 
approximately one year apart and was found to be a stable measure of sleep quality in 
early middle-aged adults. A PSQI global score greater than 5 was classified as poor 
quality sleep (Knutson, 2006). Clinical and clinometric properties of the PSQI were 
assessed over an 18-month period comparing “good” sleepers and “poor” sleepers 
suffering various disorders. Acceptable measures of internal homogeneity and validity 
were obtained. A global PSQI score > 5 yielded a diagnostic sensitivity of 89.6% and 
specificity of 86.5% (Kappa =.75, p ≤.001) in distinguishing between good and poor 
sleepers, demonstrating concurrent validity and indicating the PSQI is a useful tool for 
psychiatric clinical practice and research (Buysse et al., 1989). A study reported 
reliability, validity, sensitivity and specificity of PSQI seven subscales/components as 
follows: Overall reliability coefficient for the seven PSQI components -0.83. Largest 
component-total correlation coefficient was found in habitual sleep efficiency and 
subjective sleep quality components (0.76 each). Lowest component-total correlation 
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coefficient  was found in sleep disturbances component (0.35), possibly due to the large 
number of items in this component that may also be more susceptible to variation. Test-
retest reliabilities for PSQI components ranged from 0.84 to 0.65. Global score test-
retest reliability was 0.85 (Buysse et al., 1989). Polysomnography findings did not 
correlate well with all PSQI component scores. The discrepancy may be related to the 
fact that PSQI elicits self estimate of usual sleep quality over a one-month period, thus 
decreasing its sensitivity to daily variations (Buysse et al., 1989).   
A Hebrew version of the PSQI (PSQI-H) has been administered to 450 patients 
from two sleep clinics and to 61 health subjects. The results showed that the PSQI-H 
had adequate reliability, good validity and is suitable for use as a standardised tool for 
the assessment of subjective sleep quality in clinical research with a Hebrew language 
speaking population (Shochat et al., 2007). 
3.4.2.4 The Multivariable Apnea Prediction index (MAP).  
The MAP is a self-rated questionnaire designed mainly to predict probability/risk 
of sleep apnea, based on self-assessed frequency of occurrence of various symptoms 
during the month preceding test administration. The questionnaire includes 13 questions 
on frequency of snorting, gasping, snoring, breathing cessations, frequent awakenings, 
movement during sleep, cataplexy upon awakening, difficulty falling asleep, jumpy or 
jerky legs, falling asleep during daily activities, and excessive daytime sleepiness. 
Respondents are asked to rate the frequency of each symptom on a scale of zero to four 
as follows: Never – 0; rarely/ less than once a week – 1; 1-2 times a week – 2; 3-4 times 
a week – 3; 5-7 times a week – 4; don‟t know/not sure – 0 (see appendix 5.4). The 13 
items can be grouped into four separate component scores, by averaging the scores of 
items related to sleep-disordered breathing (items 1, 2 and 3), difficulty sleeping (items 
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4, 5, 6, 7,8) excessive daytime sleepiness (items 9, 10 and 11) and catatonia (items 12 
and 13). The responses to items 1-3 are used in conjunction with data on body mass 
index (BMI), gender and age to predict apnea probability/risk using a logistic regression 
procedure. 
MAP was assessed as a screening tool for sleep apnoea using questionnaire data 
from 928 patients presenting at three sleep disorders centres. Multiple logistic 
regressions using survey responses, age, gender and BMI were then used to estimate a 
multivariable apnea risk index. The survey was shown to be reliable in a subset of 
patients from one of the three sites with a test-retest correlation of 0.92. Survey data 
were then compared to RDI obtained from polysomnography studies. Receiver 
Operating Characteristic (ROC) curves was then used to assess the predictive ability of 
the MAP predictive procedure. Using all above risk factors resulted in an area of 0.79 
under the ROC curve (p <.0001); using only the BMI risk factor resulted in an area of 
0.73 and using only self-reported frequency of apnea symptoms resulted in an area of 
0.70. Maislin et al. concluded that the MAP may be useful in clinical settings for 
discriminating between patients with and without sleep apnea (Maislin et al., 1995).  
A validity study of the MAP in an elderly population compared MAP scores of 
relatively healthy older adults with (n=50 cases) and without (n=58) excessive daytime 
sleepiness (EDS) MAP values were compared to stratified polysomnography derived 
RDI values (RDI<10, 10≤ RDI<20, RDI≥20). ROC curves were utilised for quantitative 
analysis of the predictive utility of MAP. As an example, for a MAP cut point of 0.40 
the sensitivity and specificity (95% C.I.) for RDI>=20 for EDS subjects were 0.61 and 
0.72 respectively and for controls 0.56 and 0.80 respectively. Maislin et al. concluded 
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that the MAP may be useful in clinical settings for discriminating between patients with 
and patients without sleep apnoea in non sleep centre populations (Maislin et al., 1996). 
In contrast to the above findings, a recent comprehensive meta-analysis of clinical 
screening tests for obstructive sleep apnoea (OSA) compared a range of tests and 
clinical procedures, including the MAP index, Berlin questionnaire, Kushida index and 
several others and found poor reproducibility and significant variability in accuracy in 
repeated validation studies of the same screening test and suggested this may result 
from an underlying heterogeneity in either the clinical presentation of OSA or in the 
tests‟ measured clinical elements (Ramachandran & Josephs, 2009). The study 
concluded that due to the significant rates of false-negatives, there is a high probability 
that most of the clinical screening tests will miss a significant percentage of patients 
with OSA and although it is possible to predict severe OSA with a high degree of 
accuracy by clinical methods, no single prediction tool functions as an ideal test 
(Ramachandran & Josephs, 2009).  
3.4.2.5 The Depression Anxiety Stress Scale (DASS) 
The DASS (see appendix 5.6) is a self-report questionnaire designed for both 
research and clinical applications. It consists of three separate scales that measure 
negative emotional states, including depression, anxiety and stress. These three 
components can also be summed to yield a global DASS score. The depression scale 
assesses dysphoria (i.e., unpleasant or uncomfortable mood), hopelessness, devaluation 
of life, self-deprecation, lack of interest/involvement, anhedonia (i.e., inability to 
experience pleasurable emotions from normally pleasurable life events), and inertia. The 
anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, 
and subjective experience of anxiety. The stress scale assesses levels of chronic non-
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specific arousal manifested by difficulty relaxing, nervous arousal, and being easily 
upset/agitated, irritable/over-reactive and impatient. There are two versions of DASS, 
namely the DASS42 with 42 items (and 14 items per scale), and the shorter version 
DASS21 with 21items (and 7 items per scale). Respondents are asked to rate the extent 
to which they have experienced each state over the past week using 4-point 
severity/frequency scale. Scores for depression, anxiety and stress scales are calculated 
by summing the scores of the items belonging to each subscale (Lovibond & Lovibond, 
1995a).  
All three DASS subscales (depression, anxiety and stress) have been shown to 
have high internal consistency and to provide meaningful discriminations in a variety of 
settings (Lovibond & Lovibond, 1995a). The psychometric properties of the DASS have 
been evaluated and compared to Beck Depression inventory (BDI) and the Beck 
Anxiety Inventory (BAI) using a normal population of 717 respondents. The DASS 
psychometric properties were found to be satisfactory and the factor structure was 
substantiated by both exploratory and confirmatory factor analysis. The DASS scales 
showed greater separation in factor loadings than the BDI and BAI. The DASS anxiety 
scale correlated 0.81 with the BAI. DASS depression scale correlated 0.74 with the 
BDI. Factor analyses implied that the main difference between BDI and the DASS 
depression scale is that the BDI includes various items such as weight loss, insomnia, 
somatic preoccupation and irritability, which do not discriminate between depression 
and other emotional states (Lovibond & Lovibond, 1995b). The psychometric properties 
of the DASS were evaluated in two large studies. In the first study (N = 437), the DASS 
subscales were shown to have excellent internal consistency and temporal stability. An 
exploratory factor analysis found high consistency with the factor structure previously 
found in nonclinical samples. Between-groups comparisons found DASS predictably 
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distinguished various anxiety and mood disorder groups (Brown et al., 1997). In the 
second study (N = 241), the conceptual and empirical latent structure of the DASS was 
corroborated by factor analysis. In addition, convergent and discriminate validity of the 
subscales was demonstrated by correlations between the DASS and other questionnaires 
and clinical rating measures of anxiety, depression, and stress (Brown et al., 1997). 
There is some overlap between DASS and POMS (described next). They both 
include a depression subscale. However, DASS specifically focuses on three factors that 
are thought to play a major role in insomnia, namely, depression, anxiety and stress (see 
section 1.5.7), where as The POMS does not have specific stress and anxiety subscales 
but rather a more general tension subscale. 
3.4.2.6 The Profile of Mood States (POMS) 
The POMS is a psychological test designed to measure a person's transitory 
mood/emotional states. POMS has been used in more than 5000 studies in a wide range 
of research domains, demonstrating wide user acceptance (McNair et al, 2003as cited in 
Bourgeois et al., 2010). Each POMS item includes an adjective used to describe a 
positive or negative mood state. Respondents are requested to rate each item using a 
five-point scale ranging from 0 (not at all) to 4 (extremely) according to the degree that 
they have experienced that mood state or emotion in the week preceding test 
administration. The items are then grouped into six subscales. Subscale scores are 
obtained by summing the numeric responses of the items comprising each subscale. The 
higher the score, the higher the level of disturbance for the particular subscale, except 
for the vigour subscale where the opposite applies. The six subscales are: Tension-
Anxiety, Depression-Dejection, Anger-Hostility, Vigour-Activity, Fatigue-Inertia and 
Confusion-Bewilderment. The six subscales are then summed to yield a global mood 
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disturbance score. When summing the subscale scores, the Vigour-Activity score is 
negatively weighted (i.e., subtracted from the sum of the other subscales) and all others 
positively weighted (McNair et al., 1981). 
A study (n=479) examined the reliability and validity of the POMS with a 
population of older adults and concluded that older adults adopted the same underlying 
mood constructs as younger adults when responding to the POMS (Gibson, 1997). The 
POMS was able to distinguish between normal subjects and those suffering mood 
disturbances with an excellent internal consistency and a very good test retest reliability 
for the POMS subscales. The study found strong support for the POMS subscales 
concurrent validity and concluded that the POMS is a reliable and valid measure of 
mood states in older adults, although a considerable shift of normative values for POMS 
across the age spectrum had been noted (Gibson,1997). 
The original long form POMS consisted of 65 items. A short version SV-POMS, 
(sometimes also referred to as POMS-SF) with the same six subscales but only 37 items 
was later introduced (Shacham, 1983). Other abbreviated POMS versions have been 
introduced more recently, including a 30-item abbreviated version (EPOMS) introduced 
in1991 by the Educational and Industrial Testing Service (EDITS) and several others 
(Bourgeois et al., 2010). A recent study evaluated several abbreviated versions of 
POMS, including the EPOMS and SV-POMS and others in relation to the full-scale 
POMS by analysing combined data from six studies conducted over four years that had 
used the full-scale POMS (N = 915, 439 men and 476 women, age range 17 to 34 
years). Results showed that the abbreviated versions of POMS have comparable, and in 
some cases superior reliability, compared to the full-scale POMS and that the 
abbreviated versions of POMS are valid and applicable where the full-scale POMS has 
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been proven valid and applicable. Furthermore, because shorter forms substantially 
reduce administration time and are comparable to the full-scale POMS, their use is 
recommended (Bourgeois et al., 2010). A study (n=83) found correlation coefficients 
between the POMS-SF and the original POMS scales were all above .95, indicating the 
POMS-SF was suitable for estimating the original mood scale scores in the study‟s 
population of cancer patients (Shacham, 1983). Another larger study (n= 600) using 
data of both clinical and healthy samples revealed that internal consistency estimates for 
the POMS–SF subscales were very similar to those for the original long form POMS. In 
addition, correlation values between the global score and subscale scores on the POMS–
SF and those on the original long form POMS were all greater than .95 (Curran et al., 
1995). A more recent study examined the internal consistency, validity, and factor 
structure of the POMS-SF with a sample of 428 cancer patients. It reported Cronbach's 
alphas ranging from 0.78 to 0.91 for each of the six POMS subscales and for the global 
score. This study also incorporated correlational analyses with other questionnaires 
including the CES-D, the self-rated Karnofsky, the MOS SF-20 physical functioning, 
and the Bradburn positive and negative affect scales, which have shown the convergent 
and discriminant validity of the POMS-SF. Confirmatory factor analysis further 
supported the mood factor interpretation of the POMS items in the POMS-SF (Baker et 
al., 2002). Based on these findings it was decided to use POMS-SF in the present study 
(see appendix 5.6). 
A study of a Hebrew version of a 28 item POMS showed valid psychometric 
properties but concluded that further studies in various populations were needed (Netz, 
2005). 
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There is some overlap between POMS and DASS as they both include a 
depression subscale. However, POMS also has additional useful subscales including 
anger, confusion, vigour and fatigue which DASS does not have. Therefore, the present 
study incorporated both POMS-SF and DASS.  
3.4.2.7 The SF -36 health survey 
The SF-36 (see appendix 5.7) is a multi-purpose, short-form self-reported health 
survey. A second version -SF36 Ver. 2.0 has been developed later (Ware, 2010). The 
SF-36 has become the tool of choice for measuring health status (Dexter et al., 1996). It 
is a generic measure that can be used across age, disease, or treatment group and has 
been proven useful in a wide range of general and specific populations, in comparing 
the relative burden of diseases, and differentiating health benefits from a wide range of 
interventions (Ware, 2010; Ware & Gandek, 1998; McHorney et al., 1994). Experience 
using SF-36 has been documented extensively in close to 1500 articles and reports 
including reports of close to 200 randomised controlled trials (Ware et al., p. 6, 2002). 
The SF36 consists of 36 items, the responses to which are summed to yield eight 
subscale-scores of functional health and wellbeing (physical functioning, role 
limitations due to physical problems, role limitations due to emotional problems, 
general mental health, general health perceptions, bodily pain, and vitality). These eight 
health-related concepts were selected from 40 concepts incorporated in the survey used 
in the Medical Outcomes Study (MOS) and thus enabled far fewer questions (Ware et 
al., 2000). The eight SF36 scales represent the most frequently measured concepts in 
commonly used health surveys and those most affected by disease and intervention 
(Ware et al., p. 6, 2002; Ware et al., 1995). Condition specific symptoms are not 
included in the SF-36 due to the fact that it is a generic measure (Ware, 2010). The eight 
scales‟ scores may also be grouped into two main categories; physical health and mental 
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health and summed accordingly to yield two category summary scores, physical health 
summary (PCS) and mental health summary (MCS) respectively. All subscale scores 
can be also be summed to yield a SF36 global health score (Ware, 2010). The present 
study relied mainly on the detailed POMS and DASS questionnaires for psychological 
measures and the SF36 was intended mainly to measure general health and well-being, 
physical function, physical role,  and social function. 
The SF-36 has undergone rigorous psychometric analysis both in the US and 
elsewhere to establish scale reliability, precision, and validity (Hays and Stewart 1990; 
McHorney et al., 1994; Ware & Gandek, 1998). With rare exceptions all SF-36 items 
have been found to correlate substantially with their respective hypothesized scales 
(Ware & Gandek, 1998). In the vast majority of published reliability estimates, SF-36 
measures exceeded the minimum standard of 0.70 recommended for measures that are 
used in group comparisons. A summary of 15 studies showed that most measures 
exceeded 0.80 (Ware & Gandek, 1998). Reliability estimates for physical and mental 
summary scores exceed 0.90 in most studies. These trends in reliability for the SF-36 
scales and summary measures have also been replicated across 24 patient groups of 
diverse socio-demographic characteristics and conditions (Ware & Gandek, 1998). The 
content validity of the SF-36 has been found comparable to that of other widely used 
generic health surveys. The eight SF-36 subscales were found to address the most 
frequently measured health concepts thus demonstrating content validity in both 
physical health and mental health measures (Ware & Gandek, 1998). Relative to the 
much longer MOS measures, that the SF-36 was designed to reproduce, the SF-36 
scales have been found to have roughly 80–90% empirical validity for physical and 
mental health concepts. On the other hand, some of the long-form measures, that the 
SF-36 had been compared to, require five to ten times longer time to complete, implying 
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that the SF-36 provides a practical alternative to much longer measures for measuring 
physical or mental health status in group level comparisons (Ware & Gandek, 1998). 
A validation study of a Hebrew version of the SF36 concluded that it provided an 
appropriate measure of general health status and that the translation into the Hebrew 
language did not diminish its qualities (Lewin-Epstein et al., 1998). 
3.4.2.8 Daily Sleep and Practice Logs (DSPL) 
A sleep log is a 24 hour recording of a person‟s sleep-wake pattern (Pollak et al., 
2010, p. 221). Participants were asked to complete a daily sleep and practice log 
(DSPL) (see appendix 5.8). The DSPL was designed to collect self reported information 
about daily sleep and wake patterns, eating patterns, yoga practice patterns and usage of 
hypnotics and relaxants. The DSPL data was used in conjunction with class attendance 
records to calculate participants‟ global compliance to treatment. The DSPL allows 
collecting detailed daily information. However, it was observed that many participants 
considered it a significant inconvenience, which may have affected compliance and 
accuracy in filling it out. Furthermore, some participants commented that they couldn‟t 
remember exact sleep onset time and/or number and duration of awakenings. Others 
mentioned that trying to remember and note these details increased their stress levels 
and affected their sleep quality. In order to prevent DSPL data entry becoming a 
distracting and confounding factor, participants were asked to do the best they could and 
not to worry whether they would remember all the details in the morning. In order to 
avoid these confounding factors more emphasis was given in sleep quality analysis on 
pre- and post-intervention PSQI measures while the DSPL was used mainly for 
corroborating the PSQI data, monitoring and calculating practice compliance and 
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receiving timely feedback from participants about various issues relevant to 
management of the intervention.  
3.4.2.9 Summary of subjective measures  
Following is a summary of subjective measures obtained from above subjective 
instruments in the present study:  
1. KSS – sleepiness (now) score 
2. ESS – sleepiness (in various situations) score 
3. PSQI – global score 
4. PSQI – subjective sleep quality subscale score 
5. PSQI – sleep latency subscale score  
6. PSQI – sleep duration subscale score 
7. PSQI – sleep efficiency subscale score 
8. PSQI – sleep disturbances subscale score 
9. PSQI – sleep medication subscale score 
10. PSQI – daily dysfunction subscale score 
11. MAP – derived apnea prediction score 
12. DASS – global score 
13. DASS – depression subscale score 
14. DASS – anxiety subscale score 
15. DASS – stress subscale score 
16. POMS – global score 
17. POMS – tension subscale score 
18. POMS – depression subscale score 
19. POMS – anger subscale score 
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20. POMS – fatigue subscale score 
21. POMS – confusion subscale score 
22. POMS – vigour subscale score 
23. SF36 – global score 
24. SF36 –physical function subscale score (PF) 
25. SF36 – limitation in physical role subscale score (RP) 
26. SF36 – body pain subscale score (BP) 
27. SF36 – general health subscale score (GH) 
28. SF36 – vitality subscale score (VT) 
29. SF36 – social functioning subscale score (SF) 
30. SF36 – limitation in emotional role subscale score (RE) 
31. SF36 – mental health subscale score (MH) 
3.4.3 Objective outcome measures 
3.4.3.1 Introduction 
In the present study portable sleep monitoring was used in conjunction with a 
computerised sleep diagnostic system. Portable monitoring allowed sleep studies to be 
conducted in participants‟ natural home environment and facilitated conducting pre- and 
post-intervention measures in a short period of time, because there was no reliance on 
the availability of sleep clinic laboratory facilities. By using four mobile sleep labs 
concurrently it was possible to conduct 20 to 24 sleep studies per week. Using a 
computerised sleep diagnostic system operated by a sleep scientist to analyse the data 
allowed consistent and timely derivation of all polysomnography variables required to 
examine pre- to post-intervention change in main sleep measures. With regards to OSA, 
diagnosis of existence and severity level of OSA was done by a sleep physician, after 
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reviewing sleep study analysis results and medical data and then interviewing the 
participant and conducting a physical examination. 
3.4.3.2 The Embletta portable monitoring system 
The present study used the Embletta mobile sleep recording system, produced by 
Embla systems, Denver CO, USA (Embla Systems, 2010). The Embletta is fully 
compliant with US Centres for Medicare & Medicaid Services (CMS) and the American 
Academy of Sleep Medicine (AASM) recommendations for portable monitoring (Embla 
Systems, 2010). It has been used in over half million sleep studies worldwide, and has 
been chosen by the American Sleep Medicine Foundation (ASMF) for use in their study 
on portable monitoring in the diagnosis and management of OSA (Embla Systems, 
2010). The Embletta is battery powered with an internal memory that is able to store the 
amount of data generated during a full sleep study. It is easy to use, light weight and 
compact, and attaches to a belt system with the wiring connecting the sensors to the 
Embletta directly, allowing participants to independently get out of bed during the night, 
and go to the toilet, if required, without having to disconnect any of the wires or sensors 
(Embla Systems, 2010). In the present study the Embletta was used to record ECG, 
pulse oximetry and body position/actigraphy data. The data was downloaded in the 
morning to a central computer system for analysis and diagnosis by a sleep scientist and 
a sleep physician. 
3.4.3.3 The HC1000P sleep diagnosis system  
In the present study the HC1000P sleep analysis system, produced by Hypnocore, 
Yehud, Israel (Hypnocore, 2010) was used to assist in analysing the data recorded by 
the Embletta (see above). The HC1000P provides full analysis of sleep architecture, 
movements, body position changes, respiratory disturbances, and oxygen saturation as 
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well as information on Autonomic Nervous System (ANS) function and balance, thus 
providing all information related to insomnia and OSA. The HC1000P performs these 
tasks by analysing continuous ECG and pulse oxygen saturation data, acquired using 
traditional PSG or portable monitoring, from a sleeping patient (Hypnocore, 2010), thus 
simplifying sleep diagnostic process by eliminating the need to record multiple 
physiological variables (Hypnocore, 2010). The HC1000P performs Heart Rate 
Variability (HRV) analysis by time-dependant spectral analysis of instantaneous Inter 
Beat Interval (IBI) of the ECG signal using various algorithms based on numerous 
scientific studies (Moody et al., 1985; Keselbrener et al., 1996; Ehrhart et al., 2000; 
Shinar et al., 2000; Shinar et al., 2001; Shinar et al., 2003; Shinar et al., 2006; Shinar et 
al., 2003; Shinar et al., 1999; Baharav et al., 1995; Baharav et al., 2001; Baharav et al., 
2004; Baharav et al., 2009; Dorfman-Furman, 2005) (see section 1.3.3). The ECG is 
considered the best and most robust signal for deriving the HRV data (Chatlapalli, 2004; 
Piotrowski, & Rozanowski, 2010; Hypnocore, 2010). This presents a substantial 
advantage when conducting unmonitored sleep studies in the home environment as the 
occurrence of poor quality ECG or pulse oximetry signals is relatively low compared to 
other signals, such as EEG. The interpretation of the results provided by the HC1000P 
is performed by a sleep scientist and supplemented with clinical information obtained 
from the patient by a qualified sleep physician. Analysis and diagnosis is labour and 
time efficient compared to traditional PSG (Hypnocore, 2010). This allows a faster, 
cost-effective, reliable and consistent diagnosis with multiple patients within a short 
time period thus providing significant advantage in research settings such as the present 
study where a substantial number of sleep studies needed to be performed within a short 
period of time and then analysed reliably and consistently. Furthermore, this technology 
was capable of providing all the necessary data for the present study where main 
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emphasis was on the pre- to post-intervention changes in main sleep features and main 
insomnia and OSA measures. 
The HC1000P system has been validated extensively and approved by both the 
Federal Drug Administration (FDA) and the Conformité Européene (CE) approval 
processes for medical technologies (CE, 1993; FDA, 2008a; FDA, 2008b). Its output 
was found essentially equivalent to traditional PSG results. This was statistically 
confirmed via retrospective analysis of a large number of cases from a clinical study 
(FDA, 2008; Hypnocore, 2010). A multicentre retrospective validation study used 
randomly selected, standard PSG recordings from a cohort Chronic Fatigue Syndrome 
study at the CDC and from consecutive patients referred for PSG at Share Zedek 
Medical Center in Jerusalem (Cahan et al., 2008). The PSG data had been manually 
scored according to Rechtschaffen & Kales and AASM criteria. The ECG and pulse 
oximetry signals of this PSG data were separately and blindly analysed by the HC1000P 
system. No significant differences were found between sleep architecture and RDI 
derived using manual PSG analysis and the HC1000P analysis. Specifically no 
significant differences were found between ECG and PSG derived values of TST 
(391.5+62.8 vs. 387.7 ± 31.6 minutes), SE (84.6% ± 10.4% vs. 82.7% ± 4.5%), wake 
(54.3 ± 39.5 vs. 58.5 ± 19 minutes), NREM (322.1 ± 52.5 vs. 319.0 ± 29.8 minutes), 
and REM sleep (72.9 ± 33.8 vs. 68.7 ± 25.2 minutes). There was also a strong 
correlation (correlation coefficient of R=0.92) between RDI values derived using the 
HC1000P and using standard manual analysis with a 98.0% match-up. Cohen's Kappa 
was 0.96, and both specificity and sensitivity were 0.98 (Cahan et al., 2008). 
The HC1000P system has the following limitations: 
1. It is not suitable for measuring patients with arrhythmia and pacemakers.  
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2. Diagnostic capabilities are limited to the two most common sleep disorders; 
insomnia and OSA. 
3. HC1000P uses direct measurement of ECG and pulse oximetry and indirect 
measurement of all other traditional channels, by extracting the data 
mathematically from the ECG. In traditional PSG all signals (ECG, EEG, EMG, 
EOG, oral and nasal airflow) are measured directly (Hypnocore, 2010).  
As discussed above these limitations were not considered to be significant in the 
present study, which focused on examining pre- to post-intervention changes in main 
sleep features, and was mainly interested in changes in measures related to insomnia 
and co-morbid OSA. 
3.4.3.4 Sleep data recording quality control 
Since portable monitoring was conducted unsupervised in participants‟ homes, great 
care was taken while setting up the equipment and connecting the leads and sensors in 
order to prevent potential technical faults and subsequent loss of data. Recording signal 
quality was verified using special software when downloading the data to the central 
computer the following morning. Only good quality recordings were accepted. If a 
technical fault had occurred during the night (e.g. loose leads, detached sensors etc.) or a 
poor signal quality insufficient for performing a reliable sleep analysis was detected, the 
recording was conducted again on one of the following nights. Due to limited resources, 
only one additional measurement was allowed per person per milestone. If the second 
measurement also failed to yielded good quality signal, the data was excluded from the 
analysis. In some cases data quality allowed reliable derivation of most but not all 
measures. In such cases only measures that could be derived reliably were included. 
177 
 
3.4.3.5 Summary of objective variables  
Sleep was measured using the Embletta device and the subsequent analysis of the 
sleep data was done using the HC1000P system. This process resulted in an output of a 
large number of variables. However, for the purpose of the current study only the 
variables listed below were considered essential and subsequently included in the 
statistical analyses. The variables derived and scored using the HC1000P program were 
also further validated by a sleep technician who was independent from the study and 
later review by a sleep physician. 
The following variables were used as objective measures in statistical analysis: 
1. Sleep onset latency (SOL) - time period measured from bedtime to the beginning 
of first stage of sleep, either REM or non-REM sleep (Pollak et al., 2010, p. 221). 
2. Total sleep time (TST) - The total amount of actual sleep time in a sleep period 
equalling to the total sleep period minus the wake time period. Total sleep time 
consists of the total of all REMs and non-REMs in a sleep period (Pollak et al., 
2010, p. 251). 
3. Total time in bed (TTB) – total period spent in bed including wake and sleep 
periods 
4. Wake after sleep onset (WASO) - total time that is scored as a wakefulness state 
in a PSG recording occurring between sleep onset time and the final wake-up time 
(Pollak et al., 2010, p. 261). 
5. Light sleep duration – total durations of all non SWS NREM. Equivalent to the 
total of stage one and stage two NREM sleep. 
6. SWS duration – total durations of all SWS stage. Typically comprises sleep stages 
NREM 3 and NREM 4 combined together (Pollak et al., 2010, p. 235).  
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7. REM sleep duration– total durations of REM sleep stage. 
8.  Slow Wave Sleep (SWS) latency - time period measured from sleep onset to the 
first appearance of SWS.  
9. REM latency - time period measured from sleep onset to the first appearance of 
stage REM sleep (Pollak et al., 2010, p. 192).  
10. Oxygen saturation (SPO2) –indirect measurement using infrared sensor reflecting 
oxygen saturation level in the blood (Pollak et al., 2010, p. 166). 
11. Respiratory Disturbance Index (RDI) – mean number of respiratory events that 
disturb sleep per hour (Pollak et al., 2010, p. 193).  
12. Oxygen Desaturation Index (ODI3) – mean number of blood oxygen 
desaturations >3% per hour 
13. Sleep efficiency (SE) – is the ratio of the amount of actual sleep to amount of time 
available for sleep during the sleep episode (Pollak et al., 2010, p. 217) calculated 
by dividing the total sleep time (TST) by total time in bed (TTB)  
3.5 Data analysis 
3.5.1 Comparators 
As discussed in section 3.1 the study design was constrained by the limited resources 
available. This resulted in a mixed experimental design combining, an initial WLC design 
component with a better quality control, and a subsequent expanded design component 
involving a larger number of participants and therefore with a greater statistical power and 
arguably, combining the two designs, with WLC participants serving as control in both 
designs, provided an optimal design within the context of the external constraints and 
limitations described above. Regular contacts were made with WLC participant by phone 
on a fortnightly basis. 
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In the course of the WLC phase 5 of 31 participants had dropped out. At the end of 
the WLC phase, 26 participants were available for post-WLC-phase measures. After taking 
the post-WLC -phase measures all WLC completers were contacted and offered to 
participate in a yoga group (YI). 16 participants accepted the offer and joined a subsequent 
YI and 10 participants declined the offer.  
The wait list control group (WLC) served a dual purpose. First, WLC served as a 
control group for all participants in yoga intervention (YI) (see section 3.1.5). In addition, 
the 16 WLC completers that accepted the offer to join a subsequent YI phase were found to 
be a good matching control to themselves and were used in an additional analysis (see 
sections 3.1.5 & 3.5.2).  
All applicants wishing to participate in the study were told in advance they would be 
assigned to either a control group or an intervention group. This information was also 
stated in the consent form, which they were requested to sign when joining the study. The 
„waiting list control‟ period was 12 weeks which was identical to the 12 week intervention 
period. The measures for the control and intervention groups were identical. These 
included subjective measures (self reported questionnaires) and objective measures (sleep 
studies ) taken at baseline – pre-control/intervention phase and at post- control/intervention 
phase and daily sleep logs. 
Both intervention and control groups were asked to continue their daily routine 
normally. For example, if a participant had a habit of walking his/her dog twice a day, 
going swimming  twice a week, going to a concert once a week, playing bridge once a 
week, going to social functions etc. then he/she was asked to continue doing so. However 
all participants, both intervention and control, were asked not to start any new activity 
whether physical, mental, spiritual or social during the study period. The rationale behind 
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these guidelines was that any change in a person‟s routine, either by adding a new regular 
activity or by suspending a regular activity would be a confounding factor.  
3.5.2 Statistical strategies and methods 
This section describes statistical strategies and methods that were used to analyse the 
data derived from subjective and objective measures. The most common strategy for 
analysing treatment efficacy in similar studies is the „intention to treat‟ (ITT) analysis (also 
called “intent to treat”). ITT is based on initial treatment intent. It yields information 
regarding potential effects of an intervention using data from all participants assignd to a 
particular group, whether or not they actually completed or even received the treatment. 
The ITT strategy is intended to avoid bias, which may be caused by confounding artifacts 
such as compliance (Chatburn, 2011, p. 325). For example, participants with a more 
serious health disorder tend to drop out at a higher rate, and therefore using only 
completers‟ data may distort the overall effect of the intervention. Furthermore, using only 
completers‟ data may degrade randomisation (Lachin, 2000). However, ITT strategy may 
be applied most effectively only if there is complete outcome data for all randomised 
participants including dropouts (Chene, 1993; Lachin, 2000) as dropping subjects with 
missing outcomes and ignoring compliance information can be biased for the intention-to-
treat effect (Frangakis et al., 1999). A contrasting form of analysis is the „per-protocol (PP) 
analysis‟ also called „on treatment‟ (OT) analysis‟. It is based on treatment actually 
administered and the potential effects of a specific intervention under specific conditions. 
In some cases it is used to avoid the dilution of the treatment effect (Chene, 1993; Lachin, 
2000). In „Efficacy subset analysis‟ a subset (or subsets) of the patients who received the 
treatment of interest regardless of initial randomisation, is selected; some subjects and 
observable subject data may be excluded from the analysis based on information obtained 
post-randomisation. However, this may introduce a potential bias, such as the inflation in 
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Type I Error, even when the null hypothesis is true (Lachin, 2000). Subset analyses is often 
associated with problems of multiplicity and limitations in numbers of patients studied 
(Simon, 1982). 
In the present study both ITT and OT approaches were used in order to reduce 
bias and confounding artefacts on one hand, and on the other hand obtain a fair 
representation of the intervention‟s effect on study outcomes by avoiding dilution of the 
treatment effect that may result from significant variability in compliance. For both 
analyses strategies, mixed analysis of variance (ANOVA) and multivariate analysis of 
variance (MANOVA) methods were used. The between subjects factor was group and 
the within subjects factor was time (Pre-intervention versus post-intervention). In ITT 
analyses the groups were Intervention (YI) versus control. In OT analyses the groups 
were high compliance intervention participants (YHC) versus low compliance 
intervention participants (YLC) versus control participants. 
A third supplementary analysis strategy was used to support the findings of the 
two main analyses above. The third method involved using a matching technique which 
can be an effective technique to equate groups where randomisation is not possible, 
provided adequate information is available to enable good matching (Christensen et al., 
2011, p. 207) (see section 3.1.5). In this case high quality matching was obtained by 
matching a group of subjects to themselves with the 16 WLC phase completers that 
joined subsequent YI phase being matched to themselves. The ensuing control and 
intervention groups in this third analysis were smaller (n=16) resulting in reduced 
power. However the quality of the control was higher than in the two main analyses. A 
paired samples t test was used to compare the mean measure values of pre- and post 
WLC phase measures to the post YI measure values. 
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Correlational analyses were also used to examine the relationship between the 
degree of co-morbid OSA and pre- to post-intervention changes in the dependent 
variables. This was done in order to identify measures that may have been affected by 
the presence of co-morbid OSA component and to determine the direction and extent of 
the potentially confounding co-morbid OSA component. 
In the majority of participants a high degree of conformity was found between the 
DSPL and responses to PSQI items. As described above more emphasis was given in 
sleep quality analysis to pre- to post-intervention change in PSQI measures while the 
DSPL was used mainly for corroborating PSQI data, deriving practice compliance 
scores,  and receiving timely feedback from participants about various issues relevant to 
management of the intervention. Therefore, the PSQI scores were used for statistical 
analysis of changes in sleep quality. 
3.5.3 The compliance factor 
Defining and measuring compliance is more complex with a yoga intervention 
than in a typical medical intervention that requires taking medication or undergoing a 
medical procedure. In both yoga and medical interventions participants may be required 
to remember to follow a set of instructions, take certain actions, attend intervention 
sessions when required etc. However, in the present study the yoga intervention 
included a substantial unsupervised home self-practice component that required 
comprehension of instructions, concentration, patience, perseverance and mental 
acceptance of the process and its challenges. These factors may vary significantly from 
individual to individual, are difficult to measure, and yet may have a significant impact 
on timing, frequency, duration and quality of practice. Furthermore, home environments 
may also vary and affect these variables. To reduce variability all participants were 
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provided with a pre-recorded audio CD, containing all necessary instructions and guided 
meditation sequences. The CD was designed to increase uniformity in duration and 
quality of practice by simulating a teacher-led guided meditative yoga session. 
However, the audio CD on its own may not have a significant effect on choice of timing 
and frequency of practice. Recommendations were made regarding optimal and minimal 
level of practice but participants‟ personal choice determined to what extent to comply 
with these recommendations. Also, since there were three guided meditation exercises 
on the CD, a participant may have chosen to perform one, two, three or more exercises 
per session, which would result in practice duration varying further. Duration may also 
have been affected, if for some reason, a participant while practicing at home decided to 
stop practicing before reaching the end of a particular exercise. 
In the present study analysis of class attendance records and self-reported daily 
sleep and practice logs (DSPL), revealed considerable variability in both home-based 
practice compliance and to a lesser extent in class attendance (see results section 4.3). 
Variability in compliance implies that participants are getting the intervention in 
varying „dosages‟. In randomised control trials (RCTs) poor participant compliance may 
result in the reporting of „false negative‟ results and erroneous conclusions (Kehoe et 
al., 2008). These implications underscore the importance of taking compliance into 
account in the analyses. 
Measuring compliance was affected by the limitations described above. It was 
decided to rely only on the number of „practice units‟ performed and to differentiate 
between two levels of compliance only (low and high). Due to the relatively small 
overall participant number, using three levels of compliance (i.e., - low, medium, high) 
or more, would have resulted in reduced group size and reduced statistical power. The 
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number of practice units was derived from self-reported daily sleep and practice logs 
(DSPL) in conjunction with class attendance records kept for all yoga classes as 
follows: 
1. Two levels of compliance were defined (low and high).  
2. A single home-based meditative exercise was scored as one practice unit (an 
average duration of 25 to 30 minutes of preparation plus practice time. 
3. A single yoga class was also scored as one practice unit (actual practice duration 
equivalent to total class time minus time taken for introductions, explanations, 
instructions, questions and answers, conclusions, administrative issues etc. – 
roughly 25 to 35 minutes. (See section 3.3). 
4. Daily score was calculated by summing up scores for all home and class practice 
units performed on that day 
5. Global personal compliance score was calculated by summing up all daily scores 
and dividing by the number of intervention days. 
6. Participants below median compliance score were classified as „low compliance‟ 
participants (YLC). Participants equal to or above the median were classified „high 
compliance‟ participants (YHC). This delineation resulted in three groups:YLC 
(N=29), YHC (N=30) and wait list control - WLC (N=31) of similar size for most 
measures (as group size may vary from measure to measure due to omissions in 
completing subjective measures by some participants or due to poor/variable signal 
quality in individual overnight sleep studies).  
There is a question whether high and low compliance participants may have 
different psychological characteristics that may affect subjective perception of 
intervention outcomes. The term “demand characteristics" which was originated by 
Orne (1959  refers to the totality of cues and mutual role expectations inherent in a 
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psychological experiment or therapy that influence behaviour and/or self-reported 
outcomes. According to Orne (Orne, 1959, pp. 469-470), the behavioural impact of 
“demand characteristics” will vary with the extent to which they are perceived, and also 
with the motivation and ability of the participant to comply. Applying this theory to a 
yoga intervention (or any other „self help‟ method) one may argue that the same 
psychological characteristics contributing to higher yoga practice compliance may also 
lead to a different perception of yoga intervention outcomes. However, this theory is yet 
to be studied specifically for yoga or similar interventions. Furthermore, variability in 
compliance may also be affected by other factors, such as individual, family, social and 
environmental circumstances. In other words, personal traits are only one of various 
factors which contribute to participant‟s compliance level. As an example, two female 
participants had noticeable fluctuations in their compliance levels during the present 
study With both noting in their DSPL that their respective husbands‟ deteriorating 
health and hospitalisation was the cause for their decrease in home practice compliance. 
Another example was that some participants used private transportation to get to classes 
while others used public transportation. Public transportation users‟ class attendance 
was affected more frequently by bad weather. 
3.5.4 The OSA factor 
A multi stage screening process designed to include participants presenting with 
complaints of insomnia and exclude various medical and/or psychiatric conditions 
which may affect sleep was used. Nevertheless, despite this process, 69% of participants 
were diagnosed post study, as having some level of co-morbid obstructive sleep apnea 
(OSA) (see section 4.6). Presence of co-morbid OSA is a potential confounding factor 
in the present study, since both OSA and insomnia have both been shown to be 
associated with reduced sleep quality and diminished mental health, physical health and 
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quality of life in general., In order to determine whether and to what extent the presence 
of OSA may have had a confounding effect, further analysis was conducted as follows: 
1. The changes pre- to post-intervention in measures‟ scores were calculated and 
defined as new variables.  
2. Pearson‟s correlational analyses were used to determine whether there was an 
association between co-morbid OSA presence or degree and these new 
variables (see section 4.6).  
3. Pearson‟s Chi Square tests were used to determine whether there was an 
association between co-morbid OSA presence or degree and compliance level 
(see section 4.6). 
4. In order to find out why MAP apnea prediction score had not been effective in 
predicting OSA in the study population, Pearson‟s Chi Square tests were used 
to determine whether there was an association between co-morbid OSA 
presence or degree and between MAP derived apnea predictions score (see 
section 4.6) 
3.5.5 Handling missing data 
All dropouts were contacted but regrettably declined to make themselves available 
for post intervention (or post control measures) and were excluded from the analysis. 
In some cases, objective measures could not be derived reliably from recording 
data due to poor signal quality and a second data recording was conducted within the 
next few days. Limited resources allowed conducting only one additional recording per 
subject per milestone (see section 3.4.3.5). In several other cases data quality allowed 
deriving most but not all objective measures. OSA diagnosis was only made based on 
adequate and reliable data. 
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Great care was taken to ensure complete filling out of self reported questionnaires. 
Nevertheless, in some cases, it was later revealed that a subject had failed to respond to 
a certain questionnaire item. As described in section 3.4.2 subjective measures are 
calculated based on questionnaire items and consequently missing reposes to 
questionnaire items may have prevented calculating scores for specific subjective 
measures in some cases. 
For ANOVA analyses, cases with missing measure scores were excluded from 
any specific single design in which the missing value had occurred while correlations 
were computed using pair wise deletion of missing data based on the number of pairs 
with non-missing data (UCLA Statistics Consulting Group, 2011). 
As described in section 4.2, a total of 74 subjects were included in the study. 31 
were assigned to WLC with five dropping out and 26 remaining (31-5=26). 16 WLC 
completers agreed to participate a in subsequent YI with all 16 completing the YI. The 
additional 43 subjects recruited to the study were assigned directly to YI with two 
dropping out and 57 remaining (16+43-2=57). For every single measure without any 
data losses there could be a maximum of 83 data „cases‟ (26+57=83). Due to reasons 
explained above, the actual number of „cases‟ fluctuated with the mean number of 
„cases‟ per subjective measure being 73 (88%) and per objective measure being 70 
(84%).  
3.5.6 Testing for assumptions underlying parametric testing 
The subjective and objective dependent variables measured pre- and post-
intervention were subjected to the tests of the assumptions underlying ANOVA and 
MANOVA. To test the assumptions of normality all data were subjected to visual 
inspections of frequency distributions and also Kolmogorov-Smirnov and Shapiro-
188 
 
Wilks tests of normality. Given the sample size, emphasis was placed on visual 
inspection of the stem and leaf plot and histograms over the inferential tests of the 
assumption. Although several of the variables exhibited some degree of skew, none of 
these deviations was considered large enough to warrant transformation. Homogeneity 
of variance was tested using Levene‟s test. Where violation of homogeneity of variance 
assumption was identified, the suggested power transformation was applied to pre- and 
post-interventions measures of the variable. The transformed variables were again tested 
for homogeneity. Where the recommended transformation did not result in acceptable 
homogeneity, another transformation was carried out. Table 3.3 lists the variables that 
showed a violation of homogeneity of variance and with the recommended power figure 
for transformation or other successful transformation: 
Table 3.3 
Variables which violated homogeneity of variance and suggested power transformation  
Variable Recommended/ suitable power transformation  var. type 
KSS score None found subjective 
PSQI medication subscale score None found subjective 
POMS global score None found  subjective 
POMS depression score (-2) power transfor. of (POMS depression +100) subjective 
SF36 social function score None found subjective 
SF36 emotional role score None found subjective 
Number of position changes (-.36) power transformation objective 
Number of awakenings (-1) power transformation objective 
RDI (-1.939) power transformation objective 
SWS latency (-1) power transformation of  (SWS latency +1) objective 
SWS percentage None found objective 
Light sleep  percentage None found objective 
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3.6 Procedure and study milestones 
1. Research proposal was submitted and approved at RMIT University. 
2. Ethics committee approval at RMIT University. 
3. Ethics („Helsinki‟) committee approval at Shaare Zedek Medical Centre. 
4. Advertisement campaign in community papers, bulletin boards, medical centres etc. 
5. Initial screening phase: telephone interviews. 
6. Mail-out of detailed information about the study and medical forms and 
questionnaires to candidates and their personal physicians. 
7. Second screening phase: detailed review of medical forms and history/records 
received from applicants‟ personal physicians.  
8. Candidates fill out detailed questionnaires and medical forms at the medical centre. 
9. Third screening phase: review of detailed questionnaires and medical forms.  
10. Fourth screening phase: Structured examination by a sleep & respiratory physician 
at the medical centre.  
11. Taking pre-intervention measures of  the WLC group. 
12. Start of WLC phase – 12 weeks. 
13. Additional participants screened and assigned over several months in line with 
resources availability.  
14. Pre intervention measures taken – for all additional participants. 
15. All additional participants assigned to yoga intervention (YI).  
16. Post intervention measures taken from WLC complete after12 weeks. 
17. All WLC completers offered to enrol in (YI)..  
18. WLC completers assigned to a 12 week (YI).. 
19. Post intervention measures taken from (YI) participants upon completion of 12 
week YI phase. 
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20. Completion of analysis of all sleep studies.  
21. All participants invited to attend post study medical appointments at the medical 
centre.  
22. Post study medical reports sent to participants‟ personal physicians . 
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Chapter 4. Results 
4.1 Introduction 
The present study hypothesised that an integrated yoga intervention would 
significantly improve sleep quality and quality of life (QoL) in elderly people presenting 
with complaints of insomnia. It also hypothesised that an integrated yoga intervention 
would be safe and acceptable for elderly people in a western cultural setting. This chapter 
contains a summary of the results including study demographic data; results related to 
acceptance and compliance, QoL, sleep quality; findings on prevalence and severity of 
OSA among participants and the impact OSA had on measures in present study. The 
significance and implications of the results are discussed in depth in the discussion chapter. 
Most of the results are reported in concise tabular format. Appendix 11 contains a more 
detailed reporting format. Please refer to it if needed. 
4.2 Study demographics 
4.2.1 Introduction 
This section includes the present study‟s demographic data from the recruitment phase, 
through screening, pre- and post- intervention measures and data analysis phases. It also 
reports on dropouts and the reasons given for dropping out. 
4.2.2 Study flow demographics   
1. First screening phase: 458 phone interviews were conducted with people who 
responded to the advertisement campaign.  
2. Based on phone interviews results, 247 letters were sent out to applicants who 
passed initial screening and agreed to have the forms mailed to them. Mail out 
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included detailed information about the study, a medical form and an approval form 
to be filled out and signed by applicant‟s personal physician. 
3. Second screening phase: Of the 247 forms mailed out -126 were received back 
and reviewed. 21 applicants were excluded based on review of the medical forms. 
Invitation letters to attend a third screening phase at the medical centre were sent to 
105 responders who passed second screening phase. 
4. Third screening phase: 105 people filled out detailed questionnaires and were 
interviewed at the medical centre. After reviewing the questionnaires, 10 people 
were excluded and 95 who fit inclusion/exclusion criteria were given an 
appointment with a sleep physician at the Shaare Zedek medical centre 
5. Fourth screening phase: 95 people attended an appointment with a sleep 
physician at the Shaare Zedek medical centre. 16 were excluded based on 
exclusion/inclusion criteria and five declined to sign the consent forms and thus 
could not be admitted to the study. In total - 74 participants were included in the 
study. 
6. The first 31 participants to be admitted to the study were assigned to a waiting list 
control (WLC). 
7. 26 participants completed the WLC phase 
8. 16 WLC completers accepted an offer to continue to a subsequent yoga 
intervention (YI) phase while 10 WLC completers declined the offer. 
9.  Additional participants admitted over the following months (n= 43) were all 
assigned to YI  
10. In total 458 applicants were processed, 232 did not meet inclusion criteria, 152 
decline to join, 74 joined the study and 67 completed the study.  
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The study flowchart in Figure 4.1 below illustrates study progression, including, 
number of applicants, participants, dropouts and completers in control and intervention 
during all phases of the study. 
Please go to next page 
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Included stage I  
Waiting List Control (WLC) (n=31) 
Excluded (n=384)  
 Not meeting inclusion criteria (n=232)  
 Declined to participate (n=152) 
 Other reasons (n=0) 
Assigned to yoga intervention (n=43) 
Received assigned intervention (n=41) 
Did not receive intervention (n= 2) 
Reasons: dropped out due to:  
Family related overseas trip (n=1) 
Medical (n=1) 
Assigned to no-treatment (n=31) 
Received assigned intervention (n=26) 
Did not receive assigned intervention (n=5)  
Reasons: dropped out due to: 
loss of patience (n=3), changes of personal 
circumstance (n=1), medical (n=1) 
Treatment assignment (Not randomised) 
Analysis 
No follow-up due to budget constraints 
Enrolment 
Figure 4.1 Study flowchart 
 
Included stage II  
Yoga intervention (YI) (n=43) 
 
Assigned to yoga intervention (n=16) 
Received allocated intervention (n=16) 
Analysed (n=16)  
Excluded from analysis (n=0) 
Analysed (n=41)  
Excluded from analysis (n=2) 
Analysed (n=26)  
Excluded from analysis (n=5) 
In total: Analysed – control (n=26), intervention (n= 57 cases) 
        Excluded from analysis – control (n=5), intervention (n=2) 
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4.2.3 Demographics characteristics of participants 
 
1. Age - participants‟ ages ranged from 60 to 87, (M = 74.4, SD = 7.1) 
2. Gender - 81% of participants were women and 19% men 
3. Marital status - 45% of participants were married, 55% widowed, divorced or 
single.  
4. Housing status - 60% living within the general community, 40% living in 
independent retirement housing 
5. Ethnic and religious background – for ethical and privacy reasons, information 
regarding ethnicity, religion, culture, political views or political affiliations was not 
collected, however, observations made during the interview process revealed that 
participants were from a wide range of ethnic backgrounds (including Jewish 
„Ashkenazi‟ and „Sephardic‟, European and middle eastern) and  religious 
backgrounds (secular, traditional, conservative, and modern orthodox), country of 
birth (Israeli born, and immigrants from Middle Eastern countries, Eastern Europe, 
Russia, Western Europe, North America and South America). At least three 
participants were holocaust survivors. 
6.  Locality - Approximately 70% of participants lived within 7 Km radius of the 
medical centre and 30% in other locations throughout the greater Jerusalem 
metropolitan area. Practice venues and medical centre were easily accessible by 
public and private transport with ample parking facilities available. However, venue 
location may have influenced some candidates‟ final decision whether to participate 
or not.  
Table 4.1 below demonstrates a high degree of similarity of demographics 
characteristics between the control and intervention groups. 
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Table 4.1 
Demographic characteristics of control and intervention groups 
 group control intervention 
Age  M=71.26 , SD=6.77 M=74.66 , SD=7.39 
Gender male 84% 81% 
female 16% 19% 
Marital status married 52% 45% 
single / widowed 48% 55% 
Number  N=31 N=74 
 
4.2.4 Participants, completers and dropouts 
Table 4.2 below includes numbers of participants, dropouts, and completers in the 
waiting list control (WLC) group, intervention (YI) group, and in total. „Total 
participants‟ refers to all applicants who passed the screening process and were assigned 
to a group (WLC or YI). „Completers‟ refers to those who did not drop out and 
underwent both pre- and post- intervention or control phase measures. 
Table 4.2 
Participants, dropouts, and completers 
Category Started completed  Dropouts Dropout rate 
Total Yoga intervention (YI) 59 57 2 3.4 % 
Waiting list control (WLC) 31 26 5 16.1 % 
Control completers assigned to intervention. 16 16 0 0% 
Total participants  74 67 7 9.5 % 
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4.2.5 Dropouts and reasons given 
As shown in table 4.2 above there were a total of seven mid phase dropouts; five 
were from the WLC group and two from the YI group.  
The reasons for dropping out of the intervention group were: (1) Medical reasons: 
One subject complained of dizziness and vertigo at home (not during yoga practice) and 
was removed from the study and referred to detailed medical examinations that revealed 
BP fluctuations and irregular consumption of related medication. (2) Family reasons: 
One subject was forced to travel overseas due to unforeseen family circumstances. 
The reasons for dropping out of WLC were: (1) Medical reasons: One subject dropped 
out due to self reported deterioration in health status („not feeling well‟) (2) Personal 
reasons: Three subjects dropped out due to „running out of patience‟ or „losing interest 
in the study‟ (3) Family reasons: One subject dropped out due to change of personal 
circumstances related to a close family member. None of the dropouts were able and/or 
willing to attend post- phase measures. Numbers of dropouts are summarised in table 
4.3 below. 
Table 4.3 
Numbers of dropouts and reasons given 
Reason given Total  WLC YI 
Medical  2 1 1 
Personal 3 3  
Family related issue  2 1 1 
Total 7 5 2 
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4.2.6 A note on WLC subsequent assignment to YI  
As described and illustrated above, 31 participants were assigned to the WLC 
group. Of these - 5 (16%) dropped out during the WLC phase. The remaining 26 (84%) 
completed their „post control‟ measures and were then contacted and offered to 
participate in a yoga intervention (YI) group. 16 of the 26 WLC completers (62%) 
accepted the offer and were assigned to YI. The remaining 10 who completed the 
control phase (38%) declined the offer. The reasons given for declining to continue to 
YI were: (1) inconvenient timing of yoga intervention classes (five participants), (2) 
changing personal /family circumstances (three participants), (3) and loss of patience or 
interest (two participants).  
4.3 Safety and acceptance of yoga practice  
Hypothesis three, which stated that “an integrated yoga intervention will be safe and 
acceptable for elderly people with complaints of insomnia living in a westernised cultural 
setting”, was tested using the present study‟s demographics, compliance and adverse 
reports data. Yoga as an intervention for geriatric insomnia generated much interest within 
the target community. As reported above, the response to a low budget and very modest 
advertisement campaign was substantial as 458 enquiries were received within several 
months.. The control group had a much higher dropout rate (16.1%) than the intervention 
group (3.4%) (See tables 4.1 and 4.2). Participants were encouraged to practice a total of 
three practice units per day (equivalent of 60 – 75 minutes net practice including class net 
practice and/or self practice), for seven days a week, but in case this was not possible, then 
they were advised to complete a minimum of one practice unit per day (see section 3.3.6 ). 
Class attendance, expressed in percent of classes attended, was: Mdn=72.0 %, M=63.7%, 
SD=30.6% and global compliance score (incorporating class and home practice), expressed 
in practice units per day was: Mdn=.96, M=1.34, SD=1.54. In other words, median 
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compliance was close to the requested minimum of one practice unit per day but only 10% 
of participants practice compliance level was equal to or greater than the recommended 
three practice units per day. 
Overall, adherence to instructions during yoga classes was good with the graded 
yoga poses variations enabling most participants to follow instructions and complete the 
full sequence in most classes.  A small number of reported events where participants 
decided to abstain from a particular exercise occurred mostly during the first two weeks of 
the intervention period. 
As reported above there were two dropouts from the intervention group both 
unrelated to the yoga intervention. One participant dropped out due to spells of dizziness 
and vertigo (not during yoga classes) and further medical examinations revealed BP 
fluctuations and irregular use of related medications. The other participant dropped out due 
to unforeseen personal/family circumstances. No other adverse effects were reported 
throughout the study by participants, yoga teachers, personal physicians or study 
physicians.  (See tables 4.1 and 4.2)  
Overall, the study‟s adverse event data, demographic data and compliance data 
reported above shows that yoga intervention as applied in present study is a safe, well 
accepted and applicable intervention for elderly people with complaints of insomnia 
living in a westernised cultural setting. However, data also shows that compliance in 
general and home practice compliance in particular was considerably lower than what 
had been recommended to participants. In other words despite good acceptance of yoga, 
most participants found compliance with self-practice at home - challenging.  
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4.4 Quality of life results 
4.4.1 Quality of life results – overview 
Hypothesis two, which stated that: “an integrated yoga intervention will significantly 
improve measures of both mood and quality of life (QoL) in elderly people presenting with 
complaints of insomnia” was tested using the POMS DASS and SF36 instruments. 
Overall, significant improvements (p<.05) were found in many QoL measures with 
ITT ANOVA analysis in the yoga intervention (YI) group but not in the control group, and 
with OT ANOVA analysis in the YHC but not in YLC group or control. Specifically, 
significant improvements (p<.05) were found in the YI group but not in control group in 
the global scores of the DASS (p=.010), POMS (p=.09) and SF36 (p=.008), and also in the 
following mental and physical health subscales: depression (p=.019), stress (p=.020), 
fatigue (p=.010), emotional role function (p=.043), physical role function (p=.035), vitality 
(p=.053) and also in social function (p=.030). Furthermore, significant improvements 
(p<.05) were found in the YHC group but not in YLC group in the global scores of the 
DASS (p=.002), POMS (p=.09) and SF36 (p=.008), and also in the following mental and 
physical health subscales: depression (p=.003), stress (p=.008), anxiety (p=.011), tension 
(p=.044), anger (p=.005) and also in social function (p=.001). Significant deterioration was 
seen in the control only in emotional role limitation (p=.035). 
In summary the results show that yoga intervention resulted in improvement in many 
aspects of QoL. Improvement was strongly related to practice compliance level as 
evidenced by the significant improvement in YHC compared to YLC and control in most 
measures where improvement had been seen.  
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4.4.2 Depression Anxiety Stress Scale (DASS)  
Scores on the DASS were analysed using „intention to treat‟ (ITT) and „on 
treatment‟ (OT) analyses. For the former, a 2 x 2 mixed analysis of variance (ANOVA) 
was used. The between-subjects factor was group (YI, control). The within-subjects 
factor was time (pre- versus post-intervention). For the latter, a 2 x 3 mixed analysis of 
variance (ANOVA) was used. The between-subjects factor was group - low compliance 
yoga participants (YLC), high compliance yoga participants (YHC) and control. The 
within-subjects factor was time (pre- versus post-intervention). Means and standard 
deviations and ANOVA results of the two analyses are shown in tables 4.4 and 4.5. ITT 
analyses revealed a significant (p≤.05) improvement in the YI group but not in the 
control group in the depression, and stress subscale scores and also in the global DASS 
score. In addition, OT analyses revealed a significant (p≤.05) improvement in the YHC 
group but not in the YLC and control groups, in the anxiety, depression and stress 
subscale scores and also in the global DASS score, indicating that high compliance to 
yoga practice was vital to improvement in these psychological measures. 
Table 4.4 
Pre- and post-intervention means and standard deviations and 2 x 2 mixed ANOVA pre to post intervention 
change by group (control, YI) results for Depression Anxiety Stress Scale (DASS)  
Variable group N M (SD) - pre M (SD) - post F df p η2 
DASS control 21 23.48 (23.30) 19.86 (16.28) 1.61 1,71 .21 .022 
Global YI  52 21.87 (17.32) 17.06 (14.03) 7.03 1,71 .010 .090 
DASS control 21 6.00 (6.86) 5.38 (5.43) .34 1,72 .56 .005 
Depression YI 53 5.34 (6.23) 3.74 (4.75) 5.77 1,72 .019 .074 
DASS control 22 7.00 (6.60) 6.68 (5.80) .12 1,76 .73 .002 
Anxiety YI 56 7.07 (5.72) 5.96 (4.96) 3.66 1,76 .060 .046 
DASS control 22 10.50 (11.08) 8.91 (7.65) 1.35 1,73 .25 .018 
Stress YI 53 9.53 (7.90) 7.43 (7.27) 5.64 1,73 .020 .072 
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Table 4.5 
Pre- and post-intervention means and standard deviations and 2 x 3 mixed ANOVA pre to 
post intervention change by group (YLC, YHC, control) results for Depression Anxiety 
Stress Scale (DASS)  
Variable group N M (SD) - pre M (SD) - post F df p η2 
DASS YLC  23 20.04 (19.21) 19.04 (13.08) .14 1,70 .71 .002 
Global YHC 29 23.31 (15.86) 15.48 (14.77) 10.78 1,70 .002 .13 
score control 21 23.48 (23.30) 19.86 (16.28) 1.67 1,70 .20 .023 
DASS YLC 24 5.08 (7.41) 4.88 (5.91) .05 1,71 .83 .001 
Depression YHC 29 5.55 (5.18) 2.79 (3.34) 9.69 1,71 .003 .12 
subscale control 21 6.00 (6.86) 5.38 (5.43) .35 1,71 .55 .005 
DASS YLC 26 6.19 (5.64) 6.15 (4.10) .002 1,75 .96 <.001 
Anxiety YHC 30 7.83 (5.78) 5.80 (5.67) 6.79 1,75 .011 .083 
subscale control 22 7.00 (6.60) 6.68 (5.80) .12 1,75 .73 .002 
DASS YLC 24 8.71 (7.86) 8.00 (7.13) .30 1,72 .59 .004 
Stress YHC 29 10.21 (8.01) 6.97 (7.48) 7.50 1,72 .008 .094 
subscale control 22 10.50 (11.08) 8.91 (7.65) 1.36 1,72 .24 .019 
 
4.4.3 Profile of Mood States (POMS) 
Scores on the POMS were analysed using „intention to treat‟ (ITT) and „on 
treatment‟ (OT) analyses. For the former, a 2 x 2 mixed analysis of variance (ANOVA) 
was used. The between-subjects factor was group (YI, control). The within-subjects 
factor was time (pre- versus post-intervention). For the latter, a 2 x 3 mixed analysis of 
variance (ANOVA) was used. The between-subjects factor was group - low compliance 
yoga participants (YLC), high compliance yoga participants (YHC) and control. The 
within-subjects factor was time (pre- versus post-intervention). Means and standard 
deviations and ANOVA results of the two analyses are shown in tables 4.6 and 4.7 
below. ITT analyses revealed a significant (p≤.05) improvement in the YI group but not 
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in the control group in the depression, and fatigue subscale scores and also in the global 
POMS score. OT analyses revealed a significant (p≤.05) improvement in the YHC 
group but not in the YLC and control groups, in the tension and anger subscale scores 
and also in the global POMS score. 
Table 4.6 
Pre- and post-intervention means and standard deviations and 2 x 2 mixed ANOVA pre to 
post intervention change by group (control, YI) results for POMS  
Variable group N M (SD)-pre M (SD)-post F df p η2 
POMS control 19 16.16 (25.65) 11.21 (20.86) 1.81 1,64 .18 .028 
Global * YI  47 11.96 (19.10) 5.68 (13.58) 7.21 1,64 .009 .10 
Depression control 21 4.67 (6.37) 4.10 (4.71) .50 1,68 .48 .007 
** YI 49 3.47 (4.11) 2.35(3.24) 4.54 1,68 .037 .063 
Depression control 21   .30 1,68 .59 .004 
(transformed) YI 49   5.14 1,68 .027 .070 
Tension control 22 6.14 (7.03) 5.41 (4.50) .58 1,69 .45 .008 
 YI 49 5.29 (4.86) 4.24 (4.09) 2.61 1,69 .11 .036 
Anger control 20 4.70 (4.93) 5.15 (4.16) .41 1,67 .52 .006 
 YI 49 4.33 (4.20) 3.24 (3.00) 3.31 1,67 .073 .047 
Fatigue control 22 4.59 (3.71) 4.73 (2.80) .04 1,72 .84 .001 
 YI 52 4.96 (3.06) 3.79 (2.62) 7.08 1,72 .010 .089 
Confusion control 22 2.95 (3.00) 3.45 (2.63) .69 1,70 .41 .010 
 YI 50 3.45 (3.24) 2.82 (2.47) 2.72 1,70 .10 .037 
Vigour control 21 8.33 (3.84) 10.52(8.86) 2.20 1,69 .14 .031 
 YI 50 9.94 (7.24) 10.00 (5.20) .007 1,69 .93 <.001 
Notes: * Homogeneity assumption not satisfied for this variable. No suitable transformation found 
** Homogeneity assumption not satisfied for this variable.  Homogeneity corrected using power transformation and 
ANOVA performed on transformed variable   
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Table 4.7 
Pre- and post-intervention means and standard deviations and 2 x 3 mixed ANOVA pre to 
post intervention change by group (YLC, YHC, control) results for POMS  
Variable group N M (SD)-pre M (SD)-post F df p η2 
POMS YLC 21 10.05(17.27) 5.90 (12.46) 1.40 1,63 .24 .022 
Global  YHC 26 13.50 (20.67) 5.50 (14.65) 6.45 1,63 .014 .093 
Score * control 19 24.89 (24.45) 11.21 (20.85) 1.80 1,63 .18 .028 
Depression YLC 22 3.18 (4.33) 2.18 (3.98) 1.60 1,67 .21 .023 
subscale YHC 27 3.70 (4.00) 2.48 (2.56) 2.92 1,67 .09 .042 
** control 21 4.67 (6.37) 4.10 (4.71) .50 1,67 .48 .007 
POMS YLC 22   1.96 1,67 .17 .028 
Depression YHC 27   3.12 1,67 .082 .044 
(transformed) control 21   .29 1,67 .59 .004 
POMS YLC 23 4.52 (4.73) 4.35 (3.20) .034 1,68 .85 .001 
Tension YHC 26 5.96 (4.97) 4.15 (4.81) 4.21 1,68 .044 .058 
subscale control 22 6.14 (7.03) 5.41 (4.50) .58 1,68 .45 .008 
POMS YLC 23 3.48 (3.62) 3.17 (2.62) .22 1,66 .64 .003 
Anger YHC 26 5.08 (4.59) 3.31 (3.35) 8.28 1,66 .005 .11 
subscale control 20 4.70 (4.93) 5.15 (4.16) .41 1,66 .52 .006 
POMS YLC 25 4.60 (3.19) 3.40 (2.36) 3.51 1,71 .065 .047 
Fatigue YHC 27 5.30 (2.96) 4.15 (2.84) 3.47 1,71 .067 .047 
subscale control 22 4.59 (3.71) 4.73 (2.80) .04 1,71 .84 .001 
POMS YLC 24 3.29 (3.33) 3.04 (2.20) .19 1,69 .67 .003 
Confusion YHC 26 3.65 (3.20) 2.62 (2.73) 3.50 1,69 .066 .048 
subscale control 22 2.95 (3.00) 3.45 (2.63) .69 1,69 .41 .010 
POMS YLC 24 8.04 (5.19) 8.96 (5.85) .44 1,68 .51 .006 
Vigour YHC 26 11.69 (8.45) 10.96 (4.40) .30 1,68 .58 .004 
subscale control 21 8.33 (3.84) 10.52(8.86) 2.20 1,68 .14 .031 
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Notes: 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found 
** Homogeneity assumption not satisfied for this variable.  Homogeneity corrected using power transformation and 
ANOVA performed on transformed variable  
4.4.4 Health Survey short form (SF36) 
Scores on the SF36 were analysed using „intention to treat‟ (ITT) and „on 
treatment‟ (OT) analyses. For the former, a 2 x 2 mixed analysis of variance (ANOVA) 
was used. The between-subjects factor was group (YI, control). The within-subjects 
factor was time (pre- versus post-intervention). For the latter, a 2 x 3 mixed analysis of 
variance (ANOVA) was used. The between-subjects factor was group - low compliance 
yoga participants (YLC), high compliance yoga participants (YHC) and control. The 
within-subjects factor was time (pre- versus post-intervention). Means and standard 
deviations and ANOVA results of the two analyses are shown in tables 4.8 and 4.9. ITT 
analyses revealed a significant (p≤.05) improvement in the YI group but not in the 
control group in the SF36 global score, role limitation due to physical factors, role 
limitations due to emotional factors, vitality and social functioning. OT analyses 
revealed a significant (p≤.05) improvement in the YHC subset group but not in the YLC 
subset group and control group in the global SF36 score and social functioning subscale 
score. In addition, significant deterioration was seen in the control group only in the role 
limitations due to emotional factors subscale score. 
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Table 4.8 
Pre- and post-intervention means and standard deviations and 2 x 2 mixed ANOVA pre to 
post intervention change by group (control, YI) results for SF36  
Variable group N M (SD) - pre M(SD) - post F df p η2 
SF36 control 19 68.16 (11.25) 67.82 (11.69) .03 1,61 .87 <.001 
Global YI  44 66.21 (11.87) 69.90 (12.73) 7.54 1,61 .008 .11 
PF *† control 24 81.81 (11.22) 79.79 (14.41) .63 1,77 .43 .008 
 YI 55 75.05 (19.40) 76.64 (20.40) .91 1,77 .34 .012 
RP † control 23 65.22 (37.49) 57.61 (39.48) 1.26 1,71 .26 .08 
 YI 50 54.33 (37.95) 64.17 (35.60) 4.64 1,71 .035 .061 
BP † control 23 65.78 (22.77) 64.96 (25.23) .033 1,76 .86 <.001 
 YI 55 67.25 (23.46) 67.04 (22.05) .006 1,76 .94 <.001 
GH † control 20 59.99 (19.45) 59.80 (14.05) .005 1,71 .94 <.001 
 YI 53 61.41 (16.85) 62.57 (17.70) .51 1,71 .47 .007 
VT † control 20 58.25 (17.50) 61.50 (18.36) .83 1,70 .37 .012 
 YI 52 59.33 (17.35) 63.65 (17.84) 3 86 1,70 .053 .052 
RE *† control 22 86.36 (26.54) 68.18 (39.14) 4.61 1,68 .035 .064 
 YI 48 61.11 (40.29) 72.92 (35.57) 4.25 1,68 .043 .059 
SF *† control 23 81.52 (21.93) 75.00 (22.61) 2.36 1,77 .13 .03 
 YI 56 77.45 (21.93) 83.70 (21.57) 4.91 1,77 .030 .060 
MH † control 20 67.00 (17.60) 69.65 (15.75) .42 1,70 .52 .006 
 YI 52 70.92 (15.92) 71.65 (17.22) .35 1,70 .56 .005 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found., PF – physical function, 
RP – physical role limitation, BP – physical pain, GH – general physical health, VT – vitality, RE – emotional role 
limitation, SF – social function, MH- mental health,  
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Table 4.9 
Pre- and post-intervention means and standard deviations and 2 x 3 mixed ANOVA pre to 
post intervention change by group (YLC, YHC, control) results for SF36  
Variable group N M (SD) - pre M (SD) - post F df p η2 
SF36 YLC 19 61.68 (9.67) 64.81 (11.88) 2.33 1,60 .13 .04 
Global YHC 25 69.65 (12.39) 73.73 (12.19) 5.23 1,60 .030 .08 
score control 19 68.16 (11.25) 67.82 (11.69) .03 1,60 .87 <.001 
SF36 YLC 25 75.31 (19.71) 76.82 (21.52) .37 1,76 .55 .005 
PF *† YHC 30 74.83 (19.40) 76.50 (19.79) .54 1,76 .47 .007 
 control 24 81.81 (11.22) 79.79 (14.41) .63 1,76 .43 .008 
SF36 YLC 21 50.00 (38.73) 61.11 (38.04) 2.45 1,70 .12 .034 
RP † YHC 29 57.47 (37.75) 66.38 (34.25) 2.18 1,70 .14 .030 
 control 23 65.22 (37.49) 57.61 (39.48) 1.26 1,70 .26 .08 
SF36 YLC 25 62.88 (25.23) 63.44 (21.76) .017 1,75 .90 <.001 
BP † YHC 30 70.90 (21.63) 70.03 (22.21) .048 1,75 .83 .001 
 control 23 65.78 (22.77) 64.96 (25.23) .033 1,75 .86 <.001 
SF36 YLC 25 56.94 (17.11) 57.58 (17.17) .072 1,70 .79 .001 
GH † YHC 28 65.39 (15.86) 67.02 (17.24) .53 1,70 .47 .007 
 control 30 59.99 (19.45) 59.80 (14.05) .005 1,70 .94 <.001 
SF36 YLC 24 55.21 (14.78) 58.40 (15.51) .96 1,69 .33 .014 
VT † YHC 28 62.86 (18.89) 68.15 (18.73) 3.08 1,69 .083 .043 
 control 20 58.25 (17.50) 61.50 (18.36) .83 1,69 .37 .012 
SF36 YLC 19 47.37 (38.99) 63.16 (41.41) 2.92 1,67 .09 .04 
RE *† YHC 29 70.11 (39.18) 79.31(27.33) 1.54 1,67 .22 .02 
 control 22 86.36 (26.54) 68.18 (39.14) 4.57 1,67 .035 .06 
SF36 YLC 26 77.40 (19.69) 75.96 (26.20) .13 1,76 .72 .002 
SF *† YHC 30 77.50 (20.86) 90.42 (13.80) 12.09 1,76 .001 .13 
 control 23 81.52 (21.93) 75.00 (22.61) 2.36 1,76 .13 .03 
SF36 YLC 24 67.17 (14.67) 66.12 (16.41) .08 1,69 .78 .001 
MH † YHC 28 74.14 (16.49) 77.82 (17.50) 1.12 1,69 .29 .016 
 control 20 67.00 (17.60) 69.65 (15.75) .42 1,69 .52 .006 
 
Notes:  * Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
†, PF – physical function, RP – physical role limitation, BP – physical pain, GH – general physical health, VT – 
vitality, RE – emotional role limitation, SF – social function, MH- mental health,  
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4.4.5 Comparing QoL of WLC matched to themselves as YI  
Results of quality of life measures revealed statistically significant pre- to post-
intervention improvements in most psychological measures including stress (p=.001), 
anxiety (p=.018), depression (p=.005), tension (p=.028), anger (p=.014), fatigue (p=.004) 
and confusion (p=.023). A significant pre- to post-intervention improvement was also seen 
in the SF36 social function subscale score (p=.002). Results also revealed a trend of pre- to 
post-intervention improvement in all SF36 physical health measures although, none were 
statistically significant. Arguably, the reduced power due to the small sample size (n=16) 
may have resulted in fewer significant results than those seen in ANOVA analyses that 
compared the entire control group (n=26) to the entire intervention group (n=59) as 
reported above. Nevertheless, these results support the results of ANOVA analyses above 
in demonstrating that yoga intervention improved various sleep quality and quality of life 
measures. The results are shown in table 4.10 below. 
Table 4.10  
QoL scores of WLC subset– matched to themselves as YI subset. Paired samples t test.  
Measure N M (SD) - pre M (SD) - post t df p 
DASS global score 15 32.37 (21.30) 15.47 (8.85) 3.95 14 .001 
DASS stress  15 14.10 (8.93) 7.13 (4.82) 4.09 14 .001 
DASS anxiety  16 8.87 (5.12) 7.56 (3.44) 2.66 15 .018 
DASS depression  16 8.59 (6.82) 3.94 (3.11) 3.28 15 .005 
POMS global score 14 27.07 (18.80) 13.50 (10.34) 2.18 13 .048 
POMS tension  15 17.036 (21.79) 5.28 (10.22) 2.45 14 .028 
POMS depression  14 5.32 (5.67) 2.21 (2.66) 2.075 13 .058 
POMS anger  15 5.13 (3.86) 3.07 (2.58) 2.79 14 .014 
POMS fatigue  15 4.90 (2.89) 2.80 (2.18) 3.41 14 .004 
POMS confusion  15 3.40 (2.53) 2.07 (1.79) 2.55 14 .023 
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POMS vigour  14 8.96 (3.34) 9.79 (4.06) -.75 13 .47 
SF36 physical function  15 81.26 (15.11) 85.11 (16.77) -1.73 14 .10 
SF36 physical role  16 64.06 (36.76) 70.31(40.02) -1.52 15 .15 
SF36 physical pain  16 65.87 (22.20) 71.50 (20.67) -1.51 15 .15 
SF36 general health  15 63.22 (13.60) 67.03 (15.24) -1.41 14 .18 
SF36 vitality  16 61.41 (16.10) 67.19 (17.41) -1.17 15 .26 
SF36 social function  16 76.17 (20.57) 90.62 (14.79) -3.79 15  .002 
SF36 emotional role  16 72.92 (29.11) 85.42 (24.25) -1.69 15 .11 
SF36 mental health  16 66.53 (12.16) 69.25 (22.89) -.54 15 .60 
SF36 global score  15 68.69 (10.00) 73.37 (10.37) -1.74 14 .10 
4.5 Sleep quality results 
4.5.1 Overview 
Hypothesis one, which stated that: “an integrated yoga intervention will significantly 
improve measures of sleep quality in elderly presenting with complaints of insomnia” was 
tested using the results of the subjective and objective sleep quality measures reported in 
detail below. Overall, significant improvements (p<.05) were found in most subjective 
measures corresponding to the insomnia diagnostic criteria discussed above (see section 
1.5.2) with ITT ANOVA analysis in the yoga intervention (YI) group but not in the control 
group, and with OT ANOVA analysis in the high compliance yoga participants subset 
group (YHC) but not in the low compliance yoga participants subset group (YLC). 
Specifically, significant improvements (p<.05) were found in the intervention group but 
not in the control group in the subjective measures of sleep efficiency (p=.045), sleep 
duration (p=.042) and self assessment of sleep quality (p=.002). Significant improvements 
were seen in subjective measures of sleep latency measures for both control (p=.004) and 
intervention (p=.012) groups. Significant improvements (p<.05) were found in the YHC 
subset group but not in YLC subset group in subjective sleep efficiency (p=.012), sleep 
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duration (p<.001), and self assessment of sleep quality (p=.012). Analyses revealed 
significant (p≤.05) deterioration in the control group but not in the YI group in KSS 
sleepiness score (p=.01). No significant (p<.05) change was seen in any of the 
corresponding direct objective measures for insomnia (namely, SOL, TST, WASO and SE) 
in any of the analyses. However, ITT multivariate analysis (MANOVA) revealed a 
significant change (p=.024) in the insomnia multivariate which comprised of these four 
measures (i.e., SOL, WASO, TST and SE) in the YI group, but not in the control group. A 
significant decrease was seen in total time in bed (TTB) in the YLC only (p=.045). No 
significant changes were seen in other insomnia related objective measures. No significant 
change was seen in any of the groups with consumption of sleep related medications. A 
significant (p=.042) increase of 11.5% in SWS duration, and a significant change (p=.022) 
in the SWS multivariate (comprised of SWS duration and latency) was revealed in the 
YHC subset group only. The results did not reveal a significant change in other objective 
measures including OSA related measures. 
In summary the results show that yoga intervention resulted in improvement in most 
aspects of subjective sleep quality and also in the duration of SWS phase and in the 
objective insomnia related multivariate. Improvement was strongly related to practice 
compliance level as evidenced by the significant improvement in YHC and lack of change 
in YLC in the majority of the measures mentioned above. The discrepancies between 
subjective and objective measures related to insomnia are discussed in detail in the 
discussion section (see section 5.5). The results did not reveal a significant change in OSA 
related measures.  
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4.5.2 Subjective sleep quality measures 
4.5.2.1 Pittsburgh Sleep Quality Index (PSQI) 
Scores on the PSQI were analysed using „intention to treat‟ (ITT) and „on 
treatment‟ (OT) analyses. For the former, a 2 x 2 mixed analysis of variance (ANOVA) 
was used. The between-subjects factor was group (YI, control). The within-subjects 
factor was time (pre- versus post-intervention). For the latter, a 2 x 3 mixed analysis of 
variance (ANOVA) was used. The between-subjects factor was group - low compliance 
yoga participants (YLC), high compliance yoga participants (YHC) and control. The 
within-subjects factor was time (pre- versus post-intervention). Means and standard 
deviations and ANOVA results of the two analyses are shown in tables 4.11 and 4.12 
below. ITT analyses revealed a significant (p≤.05) improvement in the yoga group but 
not in the control group in the global sleep quality score and also in subjective sleep 
quality assessment, sleep duration and sleep efficiency subscale scores. The only 
exception was found in the sleep latency subscale score, where both yoga and control 
groups improved significantly. In addition, OT analyses revealed a significant (p≤.05) 
improvement in the YHC group but not in the YLC group in the in the global sleep 
quality score and also in the subjective sleep quality assessment, sleep latency, sleep 
duration and sleep efficiency subscale scores, indicating that high compliance with yoga 
practice was vital to improvement in sleep quality seen in the yoga intervention group. 
Please continue to the next page  
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Table 4.11 
Pre- and post-intervention means and standard deviations and 2 x 2 mixed ANOVA pre to 
post intervention change by group (control, YI) results for PSQI 
Variable group N M(SD)- pre M(SD)-post F df p η2 
PSQI control 21 10.14 (3.21) 10.00 (3.08) .057 1,64 .81 .001 
Global  YI  45 9.82 (3.49) 8.67 (3.62) 6.84 1,64 .011 .097 
Sleep control 25 1.84 (.62) 1.72 (.54) .59 1,78 .44 .008 
Quality YI 55 1.60 (.65) 1.27 (.52) 9.83 1,78 .002 .11 
Sleep control 22 2.45 (.67) 2.00 (.93) 6.70 1,62 .012 . 099 
Latency YI 42 1.86 (.98) 1.48 (1.02) 8.72 1,62 .004 .12 
Sleep control 23 2.04 (.82) 2.26 (.75) 1.87 1,73 .17 .025 
Duration YI 52 2.00 (.99) 1.77 (.85) 4.29 1,73 .042 .055 
Sleep control 14 1.50 (1.29) 1.86 (1.10) 1.41 1,53 .24 .026 
Efficiency YI 41 1.41 (1.22) 1.05 (1.09) 4.23 1,53 .045 .074 
Sleep control 22 1.27 (.46) 1.27 (.63) .00 1,70 1.00 <.001 
Disturbance YI 50 1.34 (.56) 1.26 (.49) .87 1,70 .35 .012 
Sleep * control 26 1.77 (1.18) 1.73 (1.15) .050 1,79 .82 .001 
Medication YI 55 1.38 (1.41) 1.33 (1.41) .22 1,79 .64 .003 
Sleep control 24 .92 (.58) .88 (.68) .06 1,72 .80 .001 
Dysfunction YI 50 .80 (.76) .74 (.63) .28 1,72 .60 .004 
 
Note:   * Homogeneity assumption not satisfied for this variable. No suitable transformation found  
Please continue to the next page  
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Table 4.12 
Pre- and post-intervention means and standard deviations and 2 x 3 mixed ANOVA pre to 
post-intervention change by group (YLC, YHC, control) results for PSQI 
Variable group N M(SD)- pre M(SD)-post F df p η2 
PSQI YLC 18 9.17 (3.94) 9.72 (4.03) .74 1,63 .39 .012 
Global YHC 27 10.26 (3.14) 7.96 (3.22) 18.90 1,63 <.001 .23 
score control 21 10.14 (3.21) 10.00 (3.08) .057 1,63 .81 .001 
Sleep YLC 25 1.56 (.71) 1.28 (.46) 3.23 1,77 .076 .04 
Quality YHC 30 1.63 (.61) 1.27 (.58) 6.66 1,77 .012 .08 
subscale control 25 1.84 (.62) 1.72 (.54) .59 1,77 .44 .008 
Sleep YLC 17 1.94 (1.03) 1.82 (1.07) .35 1,61 .56 .006 
Latency YHC 25 1.80 (.96) 1.24 (.93) 11.56 1,61 .001 .166 
subscale control 22 2.45 (.67) 2.00 (93) 6.70 1,61 .012 . 099 
Sleep YLC 23 1.74 (1.10) 1.87 (.87) .67 1,72 .41 .009 
Duration YHC 29 2.21(.86) 1.69 (.85) 13.38 1,72 <.001 .16 
subscale control 23 2.04 (.82) 2.26 (.75) 1.87 1,72 .17 .025 
Sleep YLC 18 1.28 (1.23) 1.22 (1.00) .044 1,52 .83 .001 
Efficiency YHC 23 1.52 (1.24) .91 (1.16) 6.75 1,52 .012 .11 
subscale control 14 1.50 (1.29) 1.86 (1.10) 1.41 1,52 .24 .026 
Sleep YLC 21 1.24 (.54) 1.33 (.48) 5.3 1,69 .47 .008 
Disturbance YHC 29 1.41 (.57) 1.21 (.49) 3.49 1,69 .066 .048 
subscale control 22 1.27 (.46) 1.27 (.63) .00 1,69 1.00 <.001 
Sleep * YLC 25 1.44 (1.39) 1.40 (1.41) .052 1,78 .82 .001 
Medication YHC 30 1.33 (1.45) 1.27 (1.48) .174 1,78 .68 .002 
subscale control 26 1.77 (1.18) .73 (1.15) .050 1,78 .82 .001 
Sleep YLC 22 .91 (.81) .95 (.65) .71 1,71 .79 .001 
Dysfunction YHC 28 .71 (.71) .57 (.57) .89 1,71 .35 .012 
subscale control 24 .92 (.58) .88 (.68) .06 1,71 .80 .001 
Note: * Homogeneity assumption not satisfied for this variable. No suitable transformation found.   
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4.5.2.2 Karolinska Sleepiness Scale (KSS) 
Scores on the KSS were analysed using „intention to treat‟ (ITT) and „on 
treatment‟ (OT) analyses. For the former, a 2 x 2 mixed analysis of variance (ANOVA) 
was used. The between-subjects factor was group (intervention, control). The within-
subjects factor was time (pre- versus post-intervention). For the latter, a 2 x 3 mixed 
analysis of variance (ANOVA) was used. The between-subjects factor was group - low 
compliance yoga participants (YLC), high compliance yoga participants (YHC) and 
control. The within-subjects factor was time (pre- versus post-intervention). Means and 
standard deviations and ANOVA results of the two analyses are shown in table 4.13 and 
table 4.14. Analyses revealed significant (p≤.05) deterioration in the control group but 
not in the yoga intervention group or any of its subsets, 
Table 4.13 
Pre- and post-intervention means and standard deviations and 2 x 2 mixed ANOVA pre to 
post intervention change by group (control, YI) results for KSS * 
Variable group N M (SD) - pre M (SD) - post F df p η2 
KSS control 24 2.79 (1.35) 4.00 (1.93) 7.04 1,76 .01 .083 
 YI 54 3.02 (1.51) 2.96 (1.53) .033 1,76 .86 <.001 
Note: * Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
Table 4.14 
Pre- and post-intervention means and standard deviations and 2 x 3 mixed ANOVA pre to 
post intervention change by group (YLC, YHC, control) results for KSS * 
Variable group N M (SD) - pre M (SD) - post F df p η2 
KSS * YLC 24 2.96 (1.46) 3.46 (1.93) 1.20 1,75 .28 .016 
 YHC 30 3.07 (1.57) 2.57 (.97) 1.51 1,75 .22 .020 
 control 24 2.79 (1.35) 4.00 (1.93) 7.04 1,75 .01 .086 
 
Note: * Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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4.5.2.3 Epworth Sleepiness Scale (ESS) 
Scores on the ESS were analysed using „intention to treat‟ (ITT) and „on 
treatment‟ (OT) analyses. For the former, a 2 x 2 mixed analysis of variance (ANOVA) 
was used. The between-subjects factor was group (YI, control). The within-subjects 
factor was time (pre- versus post-intervention). For the latter, a 2 x 3 mixed analysis of 
variance (ANOVA) was used. The between-subjects factor was group - low compliance 
yoga participants (YLC), high compliance yoga participants (YHC) and control. The 
within-subjects factor was time (pre- versus post-intervention). Means and standard 
deviations and ANOVA results of the two analyses are shown in table 4.15 and table 
4.16. No significant change was seen in any of the groups.  
Table 4.15 
Pre- and post-intervention means and standard deviations and 2 x 2 mixed ANOVA pre to 
post intervention change by group (control, YI) results for ESS  
Variable group N M (SD) - pre M (SD) - post F df p η2 
ESS control 26 7.00 (3.67) 7.85 (3.47) 1.97 1,80 .16 .024 
 YI  56 6.80 (3.88) 7.49 (3.83) 1.61 1,80 .21 .020 
 
Table 4.16 
Pre- and post-intervention means and standard deviations and 2 x 3 mixed ANOVA pre to 
post intervention change by group (YLC, YHC, control) results for ESS  
Variable group N M (SD) - 
pre 
M (SD) - post F df p η2 
ESS YLC 26 6.08 (4.23) 6.69 (4.42) 1.04 1,79 .31 .013 
 YHC 30 7.43 (3.49) 7.78 (3.58) .60 1,79 .44 .008 
 control 26 7.00 (3.67) 7.85 (3.47) 1.97 1,79 .16 .024 
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4.5.2.4 Consumption of hypnotics and relaxants 
Sleep related medication consumption did not change significantly pre to post 
intervention in any of the groups. No significant pre to post change was seen in PSQI 
(sleep related) medication subscale score in ITT analysis or OT subsets analysis in any 
of the groups (see above). Analysis of sleep related medication consumption revealed 
that 50.9 percent of participants self reported using these medications pre-intervention 
and 47.4 percent self reported using them post-intervention. Analysis of daily logs and 
medical questionnaires revealed that among sleep medication users 68 percent used 
sedative-hypnotics, 12 percent used relaxants and 20 percent used both.  
In summary: Yoga practice did not affect sleep medication consumption  
4.5.2.5 Comparing WLC matched to themselves as YI  
As discussed in section 4.2, the first 31 participants recruited to the study were 
assignd to a WLC. Five participants dropped out during the control phase and the 
remaining 26 participants completed the 12 weeks control phase. Subjective and objective 
measures were taken pre- and post- control phase. The 26 WLC completers were then 
offered to participate in a 12 week yoga intervention (YI). Of these, 16 accepted the offer 
and 10 declined. An additional analysis was conducted using paired samples t tests to 
comparing the mean WLC measure scores to the post- YI phase measure scores in these 16 
participants who served as a well matched control to themselves.  
Results of subjective sleep quality measures revealed a trend of pre- to post- 
improvement in all measures (with the exception of the apnoea probability score). 
However significant improvement was seen only in the PSQI global score (p=.037), sleep 
latency subscale score (p=.003) and sleep duration subscale score (p=.037). The results are 
shown in table 4.17. 
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Table 4.17  
WLC subset group – matched to themselves as YI subset group. Paired samples t test. 
Subjective Sleep quality measures scores. 
Measure N M (SD) - pre M (SD) - post t df p 
KSS 16 3.44 (.96) 2.94 (1.00) 1.62 15 .13 
ESS 16 7.78 (2.83) 7.31 (3.38) .61 15 .55 
PSQI Global score 15 9.80 (2.53) 8.07 (3.77) 2.31 14 .037 
PSQI subjective sleep quality 16 1.53 (.34) 1.37 (.62) 1.00 15 .33 
PSQI sleep latency 14 2.00 (.71) 1.36 (.93) 3.63 13 .003 
PSQI sleep duration 15 2.17 (.70) 1.73 (.88) 2.69 14 .017 
PSQI sleep efficiency 14 1.18 (1.12) 1.07 (1.33) .27 13 .79 
PSQI sleep disturbances 16 1.34 (.51) 1.19 (.40) 1.32 15 .21 
PSQI medication 16 .78 (1.12) .75 (1.24) 1.74 15 .86 
PSQI daytime dysfunction 16 1.03 (.72) .69 (.70) 1.70 15 .11 
MAP – apnoea probability 15 .35 (.26) .44 (.34) -1.09 14 .29 
 
4.5.3 Objective sleep quality measures 
4.5.3.1 Objective sleep quality measures - ANOVA analyses 
Scores of the objective sleep study variables were analysed using „intention to 
treat‟ (ITT) and „on treatment‟ (OT) analyses. For the former, a 2 x 2 mixed analysis of 
variance (ANOVA) was used. The between-subjects factor was group (YI, control). The 
within-subjects factor was time (pre- versus post-intervention). For the latter, a 2 x 3 
mixed analysis of variance (ANOVA) was used. The between-subjects factor was group 
- low compliance yoga participants (YLC), high compliance yoga participants (YHC) 
and control. The within-subjects factor was time (pre- versus post-intervention). Means 
and standard deviations and ANOVA results of the two analyses are shown in table 4.18 
and table 4.19 below. OT analysis revealed a significant (p=.042) increase in the 
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duration of the Slow wave sleep (SWS) phase in YHC subset group but not in other 
groups  with the mean total SWS duration in YHC increasing by 13.9 minutes per night 
( 13 percent increase). In addition, OT analysis also revealed a significant (p=.045) 
reduction in the total time spent in bed (TTB) in the YLC subset group but not in other 
groups. The mean total TTB in YLC decreased by 38.4 minutes per night (8.9 percent 
decrease). No other significant changes were seen in any of the measures.  
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Table 4.18 
Pre- and post-intervention means and standard deviations and 2 x 2 mixed ANOVA pre to 
post intervention change by group (control, YI) results for objective sleep study variables. 
Variable group N M (SD) - pre M (SD) - post F df p η2 
TTB † control 23 402.3 (91.43) 416.30 (73.98) .50 1,69 .48 .008 
(minutes) YI  49 424.85 (70.33) 414.04 (78.31) .61 1,69 .44 .009 
TST † control 23 355.91 (80.92) 363.78 (62.06) .20 1,68 .65 .003 
(minutes) YI 47 375.32 (57.24) 367.74 (74.57) .38 1,68 .54 .006 
SOL * † control 23 9.11 (10.36) 8.39 (8.33) .027 1,69 .87 <.001 
(minutes) YI 49 9.46 (14.97) 14.07 (18.13) 2.33 1,69 .13 .033 
WASO† control 22 50.73 (18.14) 57.14 (19.79) 1.46 1,66 .23 .022 
(minutes) YI 46 59.80 (22.12) 53.74 (15.72) 2.76 1,66 .10 .040 
sleep control 22 .87 (.040) .87 (.030) 1.04 1,66 .31 .016 
Efficiency (%) YI 46 .86 (.004) .87 (.037) 1.48 1,66 .23 .022 
light sleep  control 23 176.83 (55.30) 184.69 (47.48) .44 1,68 .51 .007 
duration (min) YI 47 192.59 (45.39) 183.82 (43.42) 1.13 1,68 .29 .016 
SWS † control 23 106.74 (24.80) 107.44 (20.70) .009 1,68 .92 <.001 
Duration (min) YI 47 106.49 (28.00) 112.34 (30.92) 1.28 1,68 .26 .019 
SWS † ** control 23 18.61 (20.40) 15.39 (16.27) .19 1,68 .66 .003 
Latency (min) YI 47 20.92 (34.46) 24.44 (30.34) . 47 1,68 .50 .007 
SWS latency. control 23   .45 1,68 .50 .007 
(transformed) YI 47   2.13 1,68 .15 .030 
REM † control 23 70.43 (28.12) 69.39 (28.53) .023 1,68 .88 <.001 
Duration (min) YI 47 71.04 (25.74) 66.72 (34.80) . 80 1,68 .37 .012 
REM † control 23 98.30 (44.25) 113.70 (48.49) 2.16 1,67 .15 .032 
Latency (min) YI 46 104.61 (47.80) 99.72 (45.66) .44 1,67 .51 .007 
SPO2 † (%) control 23 97.13 (4.20) 96.87 (4.21) .057 1,69 .81 .001 
 YI 48 97.12 (4.82) 96.71 (2.95) .31 1,69 .58 .004 
RDI † ** control 23 10.90 (6.45) 10.24 (5.55) .25 1,68 .62 .004 
Events/hour YI 47 14.92 (10.99) 15.32 (12.96) .19 1,68 .66 .003 
RDI † control 23   .06 1,68 .81 .001 
(transformed) YI 47   2.11 1,68 .15 .030 
ODI † control 23 7.83 (6.70) 7.74 (5.94) .005 1,69 .94 <.001 
Events/hour YI 48 11.34 (10.45) 11.70 (11.30) .19 1,69 .66 .003 
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Notes: 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found 
** Homogeneity assumption not satisfied for this variable.  Homogeneity corrected using power transformation and 
ANOVA performed on transformed variable  
† TST – total sleep time, TTB – total time in bed, SOL – sleep onset latency, WASO – wake after sleep onset, SWS – 
slow wave sleep stage, REM – rapid eye movement stage, SE – sleep efficiency, SPO2 – blood oxygen level, RDI – 
respiratory disturbance index, ODI –oxygen desaturation index  
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Table 4.19  
Pre- and post-intervention means and standard deviations and 2 x 3 mixed ANOVA pre to 
post intervention change by group (YLC, YHC, control) results for objective sleep study 
variables 
Variable group N M (SD) - pre M (SD) - post F df p η2 
TTB † YLC 20 431.70 (71.09) 393.30 (77.36) 3.27 1,68 .045 .046 
(minutes) YHC 28 419.96 (70.68) 428.86 (76.93) .25 1,68 .62 .004 
 control 23 402.3 (91.43) 416.30 (73.98) .51 1,68 .48 .008 
TST † YLC 20 375.70 (68.72) 347.40 (72.75) 2.30 1,67 .13 .033 
(minutes) YHC 27 375.04 (48.46) 382.81 (73.59) .23 1,67 .63 .003 
 control 23 355.91 (80.92) 363.78 (62.06) .20 1,67 .65 .003 
SOL†  * YLC 20 7.10 (9.78) 12.80 (16.70) 1.46 1,68 .23 .02 
(minutes) YHC 28 11.14 (17.77) 14.98 (19.33) .93 1,68 .34 .01 
 control 23 9.11 (10.36) 8.39 (8.33) .027 1,68 .87 <.001 
WASO† YLC 19 63.37 (23.91) 53.63 (16.03) 2.60 1,65 .092 .043 
(minutes) YHC 27 57.30 (20.86) 53.81 (15.68) .69 1,65 .47 .008 
 control 22 50.73 (18.14) 57.14 (19.79) 1.46 1,65 .23 .022 
sleep YLC 19 .85 (.05) .87 (.04) 1.69 1,65 .20 .025 
efficiency YHC 27 .87 (.04) .87 (.05) .25 1,65 .62 .004 
(%) control 22 .87 (.04) .87 (.03) 1.04 1,65 .31 .016 
light sleep YLC 20 189.70 (41.57) 176.45 (41.44) .93 1,67 .39 .014 
duration YHC 27 195.44 (48.03) 189.30 (45.43) .32 1,67 .57 .005 
(minutes) control 23 176.83 (55.30) 184.69 (47.48) .44 1,67 .51 .007 
SWS † YLC 20 106.25 (24.59) 101.25 (23.64) .80 1,67 .52 .006 
duration YHC 27 106.67 (30.75) 120.56 (33.45) 4.30 1,67 .042 .060 
(minutes) control 23 106.74 (24.80) 107.44 (20.70) .009 1,67 .92 <.001 
SWS †,** YLC 20 24.05(46.89) 31.27 (39.12) .52 1,67 .43 .009 
latency YHC 27 18.61 (21.92) 20.11 (21.56) .049 1,67 .83 .001 
(minutes) control 23 18.61 (20.40) 15.39 (16.27) .19 1,67 .66 .003 
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Table 4.19  continued from previous  Page:    
Variable group N M (SD) - pre M (SD) - post F df p η2 
SWS. YLC 20   2.31 1,67 .13 .033 
latency YHC 27   .37 1,67 .54 .006 
(transf.) control 23   .45 1,67 .50 .007 
REM † YLC 20 73.40 (31.35) 64.75 (34.66) 2.31 1,67 .13 .03 
duration YHC 27 69.29 (21.17) 68.18 (35.49) .008 1,67 .93 <.001 
(minutes) control 23 70.43 (28.12) 69.39 (28.53) .023 1,67 .88 <.001 
REM YLC 20 99.32 (44.89) 88.39 (42.47) .90 1,66 .35 .019 
latency YHC 27 108.33 (50.22) 107.68 (46.90) .004 1,66 .95 <.001 
 (minutes) † control 23 98.30 (44.25) 113.70 (48.49) 2.16 1,66 .15 .032 
SPO2 † YLC 20 96.55(5.07) 96.95 (2.52) .12 1,68 .73 .002 
(%) YHC 28 97.53 (4.69) 96.54 (3.25) 1.02 1,68 .31 .015 
 control 23 97.13 (4.20) 96.87 (4.21) .057 1,68 .81 .001 
RDI  † ** YLC 20 15.53 (11.32) 17.22 (14.97) 1.41 1,67 .24 .021 
Events/hour YHC 27 14.47 (10.93) 13.92 (11.33) .20 1,67 .66 .003 
 control 23 10.90 (6.45) 10.24 (5.55) .25 1,67 .62 .004 
RDI † YLC 20   .29 1,67 .62 .004 
(transf.) YHC 27   2.20 1,67 .14 .032 
 control 23   .06 1,67 .81 .001 
ODI † YLC 20 13.17 (12.05) 13.28 (12.84) .007 1,68 .93 <.001 
Events/hour YHC 28 10.03 (9.15) 10.58 (10.22) .25 1,68 .62 .004 
 control 23 7.82 (6.70) 7.74 (5.94) .005 1,68 .94 <.001 
Notes: 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found 
** Homogeneity assumption not satisfied for this variable.  Homogeneity corrected using power transformation and 
ANOVA performed on transformed variable  
† TST – total sleep time, TTB – total time in bed, SOL – sleep onset latency, WASO – wake after sleep onset, SWS – 
slow wave sleep stage, REM – rapid eye movement stage, SE – sleep efficiency, SPO2 – blood oxygen level, RDI – 
respiratory disturbance index, ODI –oxygen desaturation index   
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4.5.3.2 Objective sleep quality measures -MANOVA analyses 
Four different multivariates were examined. The Insomnia multivariate dependent 
variable was made up of SOL, WASO, TST and sleep efficiency (SE). The SWS 
multivariate dependent variable was made up of SWS duration and SWS latency 
(transformed) measures. The REM multivariate dependent variable was made up of 
REM duration and REM latency measures. The OSA multivariate dependent variable 
was made up of RDI (transformed), ODI, and SPO2 measures The data for these 
multivariates were analysed using „intention to treat‟ (ITT) and „on treatment‟ (OT) 
analyses. For the former, a 2 x 2 multivariate analysis of variance (MANOVA) was 
used. The between-subjects factor was group (YI, control). The within-subjects factor 
was time (pre- versus post-intervention). For the latter, a 2 x 3 multivariate analysis of 
variance (MANOVA) was used. The between-subjects factor was group - low 
compliance yoga participants (YLC), high compliance yoga participants (YHC) and 
control. The within-subjects factor was time (pre- versus post-intervention). ITT 
analyses of the insomnia multivariate simple main effects for time within group 
revealed a significant pre - to post-intervention change for the intervention group only. 
OT analyses of the SWS multivariate simple main effects for time within group 
revealed a significant pre - to post-intervention changes for the YHC subset group only. 
MANOVA results summary are shown in table 4.20 and table 4.21 below followed by 
detailed results of the analyses in which significant changes were noted. 
  
224 
 
Table 4.20 
Pre- to post-intervention change by group (control, YI) results for 2X2 mixed MANOVAs 
of objective sleep study variables 
Multivariate group N Ʌ F df p η2 
Insomnia control 22 .97 .40 4,63 .81 .025 
multivariate YI  46 .84 3.02 4,63 .024 .16 
OSA control 23 1.00 .077 3,66 .97 .004 
multivariate YI 47 .93 1.63 3,66 .19 .069 
SWS control 23 .99 .23 2,66 .80 .007 
multivariate YI 46 .94 1.99 2,66 .14 .057 
REM control 23 .97 1.06 2,65 .35 .032 
multivariate YI 45 .99 .25 2,65 .78 .008 
 
Table 4.21 
Pre- to post-intervention change by group (YLC, YHC, control) results for 2 X 3 mixed 
MANOVAs based on sleep study variables 
Multivariate group N Ʌ F df p η2 
Insomnia YLC 19 .92 1.29 4,62 .28 .077 
multivariate YHC 27 .89 1.99 4,62 .11 .11 
 control 22 .97 .39 4,62 .81 .025 
OSA YLC 20 .094 .094 3,65 .96 .004 
multivariate YHC 27 .91 2.16 3,65 .10 .091 
 control 23 1.00 .078 3,65 .97 .004 
SWS YLC 20 .96 1.50 2,65 .23 .044 
multivariate YHC 26 .89 4.05 2,65 .022 .11 
 control 23 .99 .23 2,65 .80 .007 
REM YLC 19 .98 .67 2,64 .51 .021 
multivariate YHC 26 1.00 .012 2,64 .99 <.001 
 control 23 .97 1.05 2,64 .35 .032 
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4.5.3.3 Comparing WLC matched to themselves as YI  
As discussed in section 4.2, the first 31 participants recruited to the study were 
assignd to WLC. Five participants dropped and the remaining 26 completed 12 weeks 
control phase. Subjective and objective measures were taken pre- and post- control phase. 
The 26 WLC completers were then offered to participate in a 12 week yoga intervention 
(YI) with 16 accepting and 10 declining. This WLC subset group although relatively small 
served as a well matched control, to themselves as YI subset group (see section 3.5.1). 
Since no significant pre- to post- control changes were seen in this group, the pre-
intervention values were taken as the mean of the pre- and post- control phase scores. 
Paired samples t tests were then conducted comparing the mean WLC measure scores to 
the post- YI phase measure scores. No significant changes were seen in any of the 
objective sleep quality measures with this analysis. The Results are shown in table 4.22. 
Table 4.22 
Objective sleep quality measures scores of WLC subset group – matched to themselves as 
YI subset group. Paired samples t test.  
Measure N M (SD) - pre M (SD) - post t df p 
Total time in bed (TTB) (min) 14 421.36 (65.25) 449.14 (84.16) -1.40 13 .18 
Total sleep time (TST) (min) 13 377.88 (51.00) 398.08 (89.67) -.99 12 .34 
SOL (min) 14 7.59 (6.17) 12.86 (12.88) -1.24 13 .24 
WASO (min) 13 53.86 (16.00) 54.14 (19.88) -.067 12 .95 
Sleep efficiency (%) 13 .88 (.069) .87 (.047) .65 12 .53 
light sleep duration (min) 13 188.077 (40.24) 202.077 (47.74) -.96 12 .36 
SWS duration (min) 13 113.23 (17.30) 126.85 (32.64) -1.51 12 .16 
SWS latency (min) 14 17.54 (17.43) 20.07 (19.70) -.30 13 .77 
REM sleep duration (min) 13 74.19 (23.99) 66.46 (39.26) .65 12 .52 
REM sleep latency (min) 14 117.30 (29.22) 102.54 (54.48) 1.08 13 .30 
blood oxygen saturation(%) 14 93.29 (1.85) 93.11 (1.28) .38 13 .71 
RDI (events/hr) 13 9.47 (5.73) 9.99 (5.73) -.49 12 .63 
ODI (events/hr) 14 6.47 (3.93) 6.92 (3.20) -.50 13 .63 
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4.6 Presence of OSA and its effect on study measures 
As mentioned above, the present study incorporated a multi stage screening process 
designed to include participants presenting with complaints of insomnia and exclude 
conditions such as OSA or other medical and/or psychiatric conditions which may affect 
sleep (see section 3.2.2). The screening process followed current diagnostic 
recommendations for patients presenting with insomnia complaints, which do not include 
an overnight sleep study (see section 1.5.6). Nevertheless, a significant proportion of 
participants were diagnosed post sleep studies, as having some level of co-morbid 
obstructive sleep apnea (OSA). OSA diagnosis results reported below were made based on 
all available data, including a detailed post intervention medical examination by a sleep 
physician and data from pre- and post-intervention sleep studies. Table 4.23 below shows 
apnea frequency in study population, with 69% of participants diagnosed with some level 
OSA (very light to severe) that had not been detected by the pre-study multistage screening 
procedure.  
Table 4.23 
Apnea severity levels frequency in study population, diagnosed post study 
 total  control  yoga  Follow-up required? 
OSA diagnosis number percent number percent number percent  
No OSA 14 18.9% 4 12.9% 13 22.0% no 
Very light or Light  18 24.3% 11 35.5% 16 27.1% no 
moderate OSA 23 31% 6 19.4% 21 35.6% yes 
Severe OSA 10 13.5% 2 6.5% 8 13.6% yes 
Insufficient data  9 12% 8 25.8% 1 1.7% no 
total 74 100% 31 100% 59 100%  
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The MAP apnea probability scores were calculated by means of the MAP 
algorithm using MAP items in conjunction with BMI, age and gender data (see section 
3.4.2.4). Pearson’s Chi Square tests revealed no statistically significant relationship 
between diagnosed OSA degree, (none, mild, moderate, severe) as reported above, and 
the MAP pre intervention apnea probability scores, 22 (192, N = 65) = 195.0, p= .43 
and also no statistically significant relationship was seen between diagnosed OSA 
degree and the post-intervention MAP apnea probability score, 22 (183, N = 62) = 
186.0, p = .42. These analyses demonstrate that the MAP apnea probability score was 
not useful at predicting OSA in the study population.  
MAP apnea probability scores were further analysed using „intention to treat‟ 
(ITT) and „on treatment‟ (OT) analyses. For the former, a 2 x 2 mixed analysis of 
variance (ANOVA) was used. The between-subjects factor was group (YI, control). The 
within-subjects factor was time (pre- versus post-intervention). For the latter, a 2 x 3 
mixed analysis of variance (ANOVA) was used. The between-subjects factor was group 
- low compliance yoga participants subset group (YLC), high compliance yoga 
participants subset group (YHC) and control. The within-subjects factor was time (pre- 
versus post-intervention). Means and standard deviations and ANOVA results of the 
two analyses are shown in table 4.24 and table 4.25 below. No significant pre- to post- 
intervention change in MAP apnoea probability scores was seen in any of the groups. 
However, since Pearson’s Chi Square tests analysis reported above revealed this 
measure had not been reliable in predicting OSA in the present study‟s population, the 
results in tables 4.24 and 4.25 below are probably of limited value. 
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Table 4.24 
Pre- and post-intervention means and standard deviations and 2 x 2 mixed ANOVA pre to 
post intervention change by group (control, yoga) results for MAP apnea probability score  
Variable group N M (SD)- pre M (SD)- 
post 
F df p η2 
Apnea  control 22 .37 (.29) .36 (.29) .06 1,66 .80 .001 
Probability 
score (%) 
yoga  46 .42 (.31) .42 (.33) .32 1,66 .91 .005 
 
Table 4.25 
Pre- and post-intervention means and standard deviations and 2 x 3 mixed ANOVA pre to 
post intervention change by group (YLC, YHC, control) results for MAP apnea probability 
score  
Variable group N M (SD)- pre M (SD)- 
post 
F df p η2 
Apnea  YLC 20 .42 (.31) .37 (.29) .44 1,65 .51 .007 
probability YHC 26 .42 (.32) .46 (.35) .32 1,65 .57 .005 
Score (%) control 22 .37 (.29) .36 (.29) .06 1,65 .80 .001 
 
In order to examine whether the presence of co-morbid OSA had been a 
confounding factor with the measures used in the present study, Pearson‟s correlation 
tests were conducted to determine the relationship between OSA degree (none, mild, 
moderate, severe), and between the change pre- to post-intervention in measure scores 
in both the control and intervention groups. Detailed results of the analyses are shown in 
tables 4.26 to 4.31. For the intervention group a statistically significant positive 
correlation was found between OSA degree and pre to post change in the PSQI global 
score (r=.34, p=.023, N=45), PSQI sleep efficiency subscale score (r=.52, p=.001, 
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N=41) and POMS tension subscale score (r=.29, p=.043, N=49). A statistically 
significant negative correlation was found between OSA degree and pre to post change 
in the SF36 global score (r= -.33, p=.032, N=42), SF36 role limitation due to physical 
factors subscale score (r= -.38, p=.007, N=50), SF36 role limitation due to emotional 
factors subscale score (r= -.46, p=.001, N=48) and SF36 social function subscale score 
(r= -.29, p=.030, N=56). For the control group a statistically significant positive 
correlation was found between OSA degree and pre to post change in the MAP apnea 
probability score (r=.43, p=.052, N=21) and objective sleep latency score (r=.48, 
p=.028, N=21). Other measures were not affected by the presence or degree of OSA. 
With PSQI and POMS scales a higher post-intervention mean score indicates a 
deterioration, while with SF36 scales a higher post-intervention mean score indicates an 
improvement. Therefore a positive correlation between OSA and PSQI and POMS 
subscale scores and a negative correlation between OSA and SF36 subscale scores 
indicates that in all of these measures OSA had a negative impact on improvement. 
Nevertheless, in these measures, pre- to post-intervention improvement had been seen in 
the YI group but not in the control group despite the presence of co-morbid OSA. These 
findings indicate that yoga can improve QoL and sleep quality even in the presence of a 
co-morbid OSA component. This is discussed in more detail in the discussion chapter.  
Since compliance levels proved to have a significant effect on pre- to post-
intervention changes in many measures, and since the presence of OSA was detected in a 
significant proportion of study participants, Pearson‟s Chi Square test was conducted to 
examine the relationship between presence or degree of OSA and between compliance 
levels. Pearson‟s Chi Square test revealed no statistically significant relationship between 
OSA degree, (none, mild, moderate, severe) and between compliance level, 
2(3,N=58)=1.94. This finding indicates that OSA did not affect practice compliance level 
230 
 
and therefore the presence or degree of OSA did not have a fundamentally confounding 
affect on OT analysis   
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Table 4.26 
Results of Pearson‟s correlation test between OSA degree (none, mild, moderate, severe) 
and pre- to post- change in subjective sleep quality measure scores in the yoga (YI) 
group 
Pre to Post change  r p  N Note 
KSS score change .15 .28 54  
ESS score change .13 .35 56  
MAP score change .16 .27 46  
MAP apnea probability score change .22 .093 58  
PSQI global score change .34 .023 45 #1 
PSQI subjective subscale score change .037 .79 55  
PSQI latency subscale score change .16 .30 42  
PSQI duration subscale score change .31 .026 52  
PSQI efficiency subscale score change .52 .001 41 #1 
PSQI disturbance subscale score change .006 .97 50  
PSQI medication subscale score change .089 .52 55  
PSQI dysfunction subscale score change .009 .95 50  
Notes: 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed)  
#1  Significant correlation found  and ANOVA test revealed  significant pre to post change in this 
measure 
#2  Significant correlation found  however  ANOVA test revealed no significant pre to post change in this 
measure 
Please continue to the next page   
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Table 4.27 
Results of Pearson‟s correlation test between OSA degree (none, mild, moderate, severe) 
and pre- to post change in objective sleep quality measure scores in the yoga (YI) group  
Pre to Post change  r p  N Note 
 Mean blood oxygen saturation level (SPO2) -.22 .13 47  
 Respiratory disturbance index (RDI) -.22 .13 46  
Oxygen desaturation index (ODI) .018 .90 47  
Sleep onset latency (SOL) -.172 .25 47  
REM latency .019 .90 46  
SWS latency -.062 .68 47  
Total time in bed (TTB) .092 .54 47  
Total sleep time (TST) .093 .54 46  
Total wake time after sleep onset (WASO) .17 .26 45  
Total light sleep  duration -.040 .79 46  
Total REM duration  .00 1.00 46  
Total SWS duration .19 .19 46  
Sleep efficiency (SE) -.14 .33 47  
Notes: 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
#1  Significant correlation found  and ANOVA test revealed  significant pre to post change in this 
measure 
#2  Significant correlation found  however  ANOVA test revealed no significant pre to post change in this 
measure  
Please continue to the next page   
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Table 4.28 
Results of Pearson‟s correlation test between OSA degree (none, mild, moderate, severe) 
and between change pre to post in subjective sleep quality measure scores in the control  
Pre to Post change  r p  N Note 
KSS score change .18 .44 20  
ESS score change .06 .81 21  
MAP score change -.01 .96 19  
MAP apnea probability score change .43 .052 21 #2 
PSQI global score change -.25 .33 17  
PSQI subjective subscale score change -.28 .23 20  
PSQI latency subscale score change .05 .83 18  
PSQI duration subscale score change -.14 .59 18  
PSQI efficiency subscale score change -.50 .11 11  
PSQI disturbance subscale score change .25 .31 19  
PSQI medication subscale score change -.25 .27 21  
PSQI dysfunction subscale score change .28 .23 20  
Notes: 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
#1  Significant correlation found  and ANOVA test revealed  significant pre to post change in this 
measure 
#2  Significant correlation found  however  ANOVA test revealed no significant pre to post change in this 
measures 
Please continue to the next page   
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Table 4.29 
Results of Pearson‟s correlation test between OSA degree (none, mild, moderate, severe) 
and change pre to post in objective sleep quality measure scores in the control group. 
Pre to Post change  r p  N Note 
 Mean blood oxygen saturation level  -.037 .87 21  
 Respiratory disturbance index (RDI) -.26 .26 21  
Oxygen Desaturation index (ODI) .024 .92 21  
Total de-saturations -.01 .96 21  
Sleep latency .48 .028 21 #2   
REM latency .053 .82 20  
SWS latency .028 .91 20  
Total time in bed -.18 .44 21  
Total net sleep time -.09 .70 21  
Total wake time after sleep onset -.28 .21 21  
Total light sleep  duration .18 .42 21  
Total REM duration  -.33 .15 21  
Total SWS duration -.31 .18 21  
Sleep efficiency (SE) -.27 .23 21  
Notes: 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
#1  Significant correlation found  and ANOVA test revealed  significant pre to post change in this 
measure 
#2  Significant correlation found  however  ANOVA test revealed no significant pre to post change in this 
measures 
Please continue to the next page   
235 
 
Table 4.30 
Results of Pearson‟s correlation test between OSA degree (none, mild, moderate, severe) 
and between change pre quality of life measure scores in the yoga (YI) group  
Pre to Post change  r p  N Note 
DASS global score change .14 .31 52  
DASS stress subscale score change .10 .46 53  
DASS anxiety subscale score change .16 .23 56  
DASS depression subscale score change .13 .35 53  
POMS global score change .012 .94 49  
POMS tension subscale score change .29 .043 49 #2 
POMS depression subscale score change .24 .10 49  
POMS anger subscale score change .19 .19 49  
POMS fatigue subscale score change .24 .088 52  
POMS confusion subscale score change .23 .10 50  
POMS vigour subscale score change .16 .26 50  
SF36 physical function subscale score change -.009 .95 55  
SF36 physical role limitations score change -.38 .007 50 #1 
SF36 body pain  subscale score change .17 .22 55  
SF36 general health subscale score change -.21 .13 53  
SF36 vitality subscale score change -.026 .86 52  
SF36 social function subscale score change -.29 .03 56 #1 
SF36 emotional role limitation score change -.46 .001 48 #1 
SF36 mental health subscale score change -.19 .18 52  
SF36 global score change -.33 .032 42 #1 
Notes: 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
#1  Significant correlation found  and ANOVA test revealed  significant pre to post change in this 
measure 
#2  Significant correlation found  however  ANOVA revealed no significant pre to post change in 
measure  
Please continue to the next page  
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Table 4.31 
Results of Pearson‟s correlation test between OSA degree (none, mild, moderate, 
severe) and pre to post change in subjective quality of life measure scores in the 
control group  
Pre to Post change  r p  N Note 
DASS global score change .07 .80 17  
DASS stress subscale score change -.05 .84 18  
DASS anxiety subscale score change .10 .69 18  
DASS depression subscale score change .12 .63 17  
POMS global score change -.30 .22 18  
POMS tension subscale score change -.003 .99 18  
POMS depression subscale score change -.07 .79 17  
POMS anger subscale score change -.09 .75 16  
POMS fatigue subscale score change -.06 .80 18  
POMS confusion subscale score change .03 .91 18  
POMS vigour subscale score change -.22 .39 17  
SF36  physical function subscale score change .18 .45 19  
SF36  role limitations (physical) score change -.09 .70 19  
SF36  body pain  subscale score change -.40 .09 19  
SF36  general health subscale score change -.13 .64 16  
SF36  vitality subscale score change .05 .85 16  
SF36  social function subscale score change -.03 .91 19  
SF36  role limitation (emotional) subscale score change -.18 .46 18  
SF36  mental health subscale score change -.008 .98 16  
SF36  global score change -.43 .11 15  
Note:  N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
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Chapter 5. Discussion 
5.1 Overview 
The present study was a pragmatic study that examined a typical geriatric population, 
presenting with insomnia symptoms. The screening process incorporated a standard 
diagnostic procedure which was based on prevailing clinical diagnostic guidelines that 
currently do not recommend prescribing sleep studies for patients presenting with insomnia 
symptoms (see section 1.5.6). In other words, a „real life‟ situation was investigated and 
the results are therefore widely applicable to this population. The yoga protocol used in 
this study is widely applicable throughout the western world as it is non-sectarian and not 
specific to a particular yoga method or school while still being representative of 
mainstream yoga practices.  
The present study both supports and expands on findings of other studies on yoga for 
improving geriatric sleep quality and QoL. A single study conducted in India (Manjunath 
& Telles, 2005) and two studies conducted in Taiwan (Chen et al., 2008; Chen et al., 2009; 
Chen et al., 2010) have shown yoga practice resulted in significant improvements in some 
subjective sleep quality and quality of life measures (QoL) in older people. These studies 
have been conducted in non-western cultural settings (Manjunath & Telles, 2005; Chen et 
al., 2008; Chen et al., 2009; Chen et al., 2010) and the intervention periods were twice as 
long in comparison to the present study (six months versus 12 weeks). The yoga 
interventions in these studies relied on three (Chen et al., 2008; Chen et al., 2009; Chen et 
al., 2010) or six (Manjunath & Telles, 2005) yoga classes each week, while the present 
study incorporated two yoga classes per week in conjunction with daily home-based self-
practice of yogic meditation and relaxation techniques using an audio CD. The shorter 
overall intervention period, the fewer number of weekly classes and the addition of home-
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based self-practice were deemed more suitable for a western cultural setting, although a 
longer intervention period may have possibly resulted in more significant changes in 
additional measures. As the present study incorporated a significant home-based self-
practice component, it was decided to also examine practice compliance and its impact on 
the efficacy of yoga intervention. The present study‟s results on practice compliance may 
help improve future home-based self-practice yoga programs as discussed in detail below.  
In comparison to other studies on yoga for geriatric QoL and sleep quality 
(Manjunath & Telles, 2005; Chen et al., 2008; Chen et al., 2009; Chen et al., 2010), the 
present study has examined a wider range of sleep quality and QoL measures in order to 
get a more comprehensive view of changes in psychological and sleep status. In contrast to 
previous studies, the present study has also examined a range of objective sleep quality 
measures. These were conducted in the natural home environment and not in a clinic, 
making the measurement conditions closer to a „real life‟ situation. Using objective 
measures was considered essential in view of previous findings of significant discrepancies 
between subjective and objective sleep quality results (Haimov, 2005) discussed in detail 
below. The results of the objective measures both support and expand on findings of 
previous studies on the effect of yoga on the deep sleep stage  (Patra &. Telles, 2010; Patra 
& Telles, 2009; Telles et al., 2000) as discussed in detail below. The results of the 
objective measures used in the present study have also helped show how yoga affects sleep 
quality and QoL of older people with co-morbid insomnia and OSA as discussed in detail 
below.  
5.2 Study limitations 
The present study‟s modest budget put limitations on available resources and 
timelines which impacted on the experimental design and overall sample size. Total 
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available resource dictated a mixed experimental design that lacked double-blinding and 
randomisation (see section 3.1). These weaknesses were mitigated to some extent by the 
recruitment process method, the use of a supplementary analysis for WLC, and the use of 
single blinding as follows: 
1. The study‟s advertisement campaign targeted a wide population base 
throughout the Jerusalem metropolitan area and applicants were processed on a 
„first come first serve basis‟ (see section 3.2). The wide target population base 
and the non-preferential „first come first serve‟ process introduced an element 
of quasi randomness into the recruitment and treatment assignment process 
with the first 31 accepted to the study being assignd to WLC and all subsequent 
subjects admitted to the study assignd to YI. Nevertheless, applicants‟ response 
time to the advertisement campaign, which determined their processing 
placement, may have possibly been influenced to some extent by various 
extraneous and potentially confounding psychological and socio-economical 
factors. 
2.  All WLC completers were contacted post control phase and offered 
assignment to YI and 16 accepted the offer (see section 4.2). A supplementary 
statistical analysis was conducted, with 16 WLC subjects matched to 
themselves as YI. This analysis had a stronger control design, than in the main 
analyses which used WLC as control for the entire YI group. This 
supplementary analysis supported the findings of the main analyses by 
revealing similar trends and some similar results (see sections 3.51, and 3.5.2.).  
3. Participant identity code numbers were used to blind administrative staff and 
sleep scientists to participants‟ identity and treatment assignment (see section 
5.2). 
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Nevertheless, since the mixed study design utilised in the present study lacked double-
blinding and randomisation (see section 3.1), all significant findings on both 
subjective and objective measures should be confirmed by a future larger scale 
randomised controlled trial.  
The subjective instruments used in the present study have been translated from 
English into the Hebrew Language. Studies had been conducted to validate Hebrew 
versions of the SF-36 (Lewin-Epstein et al., 1998), the PSQI (Shochat et al., 2007) and 
the POMS (Netz et al., 2005) but there is still a need for validation studies of the 
Hebrew versions of DASS, MAPS, KSS and ESS for diverse Hebrew speaking 
populations as the validity of the translated versions cannot be automatically assumed 
and this may present a limitation in interpreting the results of these instruments. 
Nevertheless, in the present study it was decided to use the Hebrew versions of KSS, 
ESS and MAPS due to the simple language and concepts used in these questionnaires. 
The significant overlap between DASS and POMS (see above) enabled comparing the 
results of overlapping subscales. 
5.3 The OSA factor 
The present study employed a screening process intended to exclude any disorders 
and conditions which may affect sleep, including OSA (see section 3.2.2). The 
screening process followed current medical guidelines for patients presenting with 
insomnia complaints and included a systematic medical examination and review of 
medical and psychiatric history and if OSA was suspected, the patient was referred to 
further medical investigation, including PSG and not accepted to the study unless 
negative findings were reported (see section 3.2.2 – 3.2.3). However, limited resources 
did not allow using objective sleep studies to screen applicants for OSA during the 
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recruitment phase of the study (see section 3.2.2). A second systematic medical 
examination and review of all data obtained during the study, including results of all 
sleep studies, was conducted post-intervention. This resulted in close to 69 percent of 
study participants being diagnosed with some level OSA, with 24.3 percent -very light 
or light OSA, 31 percent moderate OSA and 13.5 percent severe OSA (see section 4.6).  
Several studies have shown a high prevalence of insomnia complaints in patients 
with OSA (Krakow et al., 2001; Smith et al., 2004; Krell & Kapur, 2005; Chung, 2005) 
and one study has shown a high prevalence of undiagnosed OSA (29 %  with AHI>15 
and 43 % with AHI>5) amongst elderly with insomnia complaints (Lichstein et al., 
1999), yet, until recently  the association between OSA and insomnia has received 
relatively little attention in both research and clinical practice (Beneto et al., 2009). 
Nevertheless, in view of the systematic screening procedure used in the present study, 
although without the use of sleep studies for screening for OSA (see section 3.2.2), the 
prevalence of undiagnosed co-morbid OSA in study participants was higher than 
expected. These findings raised the following questions: 
1. Why was such a high percentage of OSA/morbid OSA cases not detected by 
study‟s multi stage screening process? 
2. Was co-morbid OSA a confounding factor and to what extent? What are the 
implications for data analysis and interpretation of the results? 
3. Was co-morbid OSA affected by the intervention? 
4. What are the implications of these findings on diagnostic and treatment guidelines 
for older adults presenting with insomnia symptoms? 
Previous studies have shown a higher prevalence of OSA in geriatric populations 
than in the general population (Ancoli-Israel et al., 1991; Delbarton et al., 1996; Wolkove 
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et al., 2007) (see section 1.6.4). Ancoli-Israel et al. (1991) reported that in a survey of 
sleep-disordered breathing of 427 randomly selected older American adults, aged 65 years 
and over, 24 percent were found with AI≥5 and 62 percent with RDI≥10. The findings 
reported by Ancoli-Israel et al. (1991) are similar to those revealed in the present study. 
However, in the former study, participants were selected randomly, where as in the present 
study an elaborate screening process described above was utilised. Therefore, such a high 
prevalence of previously undetected OSA suggests that the screening procedures used were 
inadequate. 
In the present study the apnea probability score, which is derived from several 
MAPS questionnaire items in conjunction with body mass index (BMI), age and gender, 
using a special algorithm, was unreliable at predicting OSA. Furthermore, no statistically 
significant relationship was found between OSA degree (none, mild, moderate, severe), as 
diagnosed post intervention, based on all available data collected during the study, and 
between both pre- and post-intervention apnea probability scores derived from the MAPS 
(see section 4.6).The MAPS has previously been reported in several studies to be a useful 
tool for discriminating between patients with and patients without sleep apnoea in both 
general and older populations (Maislin et al., 1995; Maislin et al., 1996) (see section 
3.4.2.4), yet the results of the present study strongly support the findings of a more recent 
meta-analysis of clinical screening tests for OSA (Ramachandran & Josephs, 2009) that 
suggest that both the MAP and systematic clinical reviews may yield a significant 
proportion of false negative predictions for OSA. 
In the present study the significant proportion of OSA prediction false negatives may 
be related to the fact that the MAP apnea prediction algorithm uses several MAP items 
including frequency of snoring, snorting and gasping for air in conjunction with BMI, age, 
and gender. In the present study, many respondents ticked the option “I do not know” 
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(scored zero – same as for the option “never”) in response to the first three items. This may 
be related to the fact that 55 percent of the study population reported living on their own 
(see table 4.1) and therefore lacked external feedback on their sleep disturbances. Several 
participants who were living with a partner also responded “I do not know” to these items. 
When queried later about it they explained that their insomnia symptoms (e.g. having 
difficulty falling asleep or waking up frequently during the night) had a disruptive 
influence on their partner‟s sleep and that forced them to sleep in separate rooms. 
Consequently their partner could not give them reliable feedback on their sleep disruptions.  
Failure of the MAP to predict apnea in the study population, demonstrates the 
difficulty of excluding apnea in a geriatric population presenting with complaints of 
insomnia, as the standard medical examination process also relies on questions similar in 
content to MAP items. The physician also conducts a physical examination and reviews 
detailed medical history/records. But if a patient presents with insomnia complaints and the 
examination and questioning yield negative findings, current medical diagnosis would 
most likely be „insomnia‟ and treatment regimen prescribed accordingly. In their large 
scale (n=5615) study on the predictors of sleep-disordered breathing (SDB) in community-
dwelling adults (aged 40 to 98) Young et al. (2002b) found that as age increased, the 
magnitude of associations between SDB and snoring, breathing pauses and physical 
attributes such as body mass index and neck girth, decreased. They concluded that 
breathing pauses and obesity may be particularly insensitive indicators for identifying SDB 
in older adults. They also concluded that there is a need to attain a better understanding of 
predictive factors for SDB, particularly in older people. The results of the present study 
support Young et al.‟s conclusions and suggest one possible reason why self reported 
snoring and breathing pauses are unreliable for prediction of SDB in older adults. Overall, 
it seems that diagnosis based on physical examination, medical history and instruments 
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such as MAP are not reliable in detecting OSA in an elderly population presenting with 
insomnia complaints, while in- home sleep studies using portable monitoring in 
conjunction with a computerised diagnosis system used in the present study, has helped 
detect and diagnose previously undiagnosed OSA in an elderly population at similar rates 
to those reported by previous large scale studies that had utilised PSG (Ancoli-Israel et al., 
1991; Young et al., 2002b).  
The findings of the present study support previous studies‟ findings on the high 
prevalence of undiagnosed OSA in the elderly (Lichstein et al., 1999; Ancoli-Israel et al., 
1991) and suggest the possible benefit of prescribing objective sleep studies for all elderly 
presenting with complaints of insomnia, despite of the relatively high costs involved, 
before prescribing pharmacotherapy for their insomnia symptoms. The present study‟s 
findings also support Lichstein et al.‟s (1999) conclusions on the need to use objective 
sleep studies when screening participants for research on geriatric insomnia. 
Although portable monitoring is still not recommended for screening of OSA in 
asymptomatic populations (Collop et al., 2007) (see section 1.3.3), it may however, be a 
useful tool for initial OSA screening of elderly patients presenting with insomnia 
symptoms prior to prescribing sedative-hypnotics, in particular benzodiazepines, due to 
their respiratory depressant effects that may worsen sleep-related breathing disorders 
(SRDB) that may even cause complete obstructive sleep apnea in heavy snorers with long 
term use (Guilleminault, 1990; Wagner et al., 1998) (see section 1.5.12.2). When used 
chronically benzodiazepines may also lead to physiologic and psychologic depence (Longo 
& Johnson, 2000). The respiratory depressant effects in conjunction with the potentially 
addictive characteristics of benzodiazepines may cause a vicious circle in case of failure to 
diagnose the presence of SRDB, or a co-morbid SRDB, as the symptoms may persist or 
even deteriorate, which in turn may lead to chronic use and forming of an addiction, which 
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may lead to further aggravation of the SRDB and its symptoms, including excessive 
daytime sleepiness (EDS). This vicious circle may be avoided by detecting SRDB earlier. 
This vicious circle may have also occurred in a proportion of the participants in the present 
study. 
The high proportion of co-morbid OSA diagnosed post-intervention in the present 
study was a possible confounding factor since both OSA and insomnia are associated with 
reduced sleep quality, physical health, mental health and quality of life in general (Young 
et al., 2002a; Neubauer, 2001; Pepperell, et al. 2002; Bédard et al., 1991). While co-morbid 
OSA appeared to be a factor working against improvement in overall subjective sleep 
quality and sleep efficiency measures, a significant (p<.05) improvement was nonetheless 
found in these measures, as well as in most other subjective sleep quality measures in the 
intervention group but not in control group suggesting that yoga improved sleep quality 
despite the presence of comorbid OSA. Furthermore, the results of pre- to post-intervention 
changes in OSA measures suggest that yoga does not result in significant change in OSA 
status. 
In an ideal geriatric insomnia study, all participants would be totally free of OSA, as 
well as other conditions which may affect sleep quality, such as physical pain. However, it 
seems that the present study‟s population better reflects the „real life‟ situation of older 
adults presenting with insomnia complaints with a high proportion also having 
undiagnosed co-morbid OSA, and perhaps other undiagnosed health conditions. The 
significant improvements seen in the intervention but not in the control group in many 
quality of life health measures and subjective sleep quality measures indicate that yoga 
significantly improved subjective sleep quality, physical, mental and social quality of life 
in the study population despite the influence of co-morbid OSA working to reduce these 
improvements.  
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Future studies on yoga intervention for improving QoL and sleep quality of the 
elderly, may take advantage of the findings of the present study and apply a modified 
experimental design as follows: 
1. A substantially larger budget would be assignd to enable recruiting a much 
larger number of subjects with a randomised controlled design and screening of 
all applicants using portable sleep monitoring. 
2. A precise OSA diagnosis would be made pre-study and both intervention and 
control groups would be stratified according to participants‟ OSA status as 
follows: no OSA, light OSA, moderate OSA and severe OSA.  
3. A much larger number of participants would be assignd to both control and 
yoga intervention groups to ensure that each stratified subset would be 
adequately powered.  
4. In the present study a much higher proportion of women applied to join the 
study and consequently the study included 81 percent woman. An ideal study 
would include an equal number of men and women. This may require 
screening a larger number of applicants still and significantly extending the 
recruitment phase 
5. The statistical analysis should examine closely the relationships between levels 
of OSA and pre- to post-intervention changes in measures, in each stratified 
subset group as well as for the entire intervention and control groups.  
5.4 Slow wave sleep (SWS)  
A significant pre- to post-intervention improvement was seen in the YHC subset 
group but not in other groups in the deep sleep (SWS) duration which increased 
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significantly but no pre to post changes were seen with other sleep stages (i.e. light sleep 
and REM) in any of the groups. Previous short studies have shown that Cyclic Meditation 
(CM) yogic practice was associated with increased proportion of SWS duration and 
decreased proportion of REM sleep on the night that followed practice (Patra &. Telles, 
2010; Patra & Telles, 2009; Telles et al., 2000) (see section 1.7.13.2.2). The SWS is 
believed to contribute to the restorative physiological processes that occur during sleep. An 
association has been found between SWS and secretion of Growth Hormone and increased 
insulin sensitivity (in humans) (Van Cauter et al., 1998; Van Cauter et al., 1997; Gronfier 
et al., 1996; Holl, 1991) and higher rates of brain protein synthesis (in rats) (Ramm & 
Smith, 1990) (see section 1.3.2). Arguably, the significant improvement in subjective 
measures of sleep quality, fatigue and vitality in the YHC intervention subset group only, 
may also be related to the relation between SWS and restorative physiological processes 
which result in participants feeling more refreshed in the morning. Further research is 
required to determine the underlying mechanisms by which yoga affects sleep staging and 
how yoga intervention may be used to achieve better sleep architecture. 
5.5 Discrepancy between subjective and objective measures. 
The results reveal a marked discrepancy between subjective and objective 
insomnia related measures. Several previous studies have also reported similar 
discrepancies and have suggested that subjective perception of sleep may be 
significantly affected by psychological factors. Haimov (2005) reports a substantial 
discrepancy between subjective and objective sleep quality measures of 98 healthy 
elderly subjects with the subjective sleep quality measures significantly associated with 
self esteem and a sense of coherence while Klein et al. (2003) report lower perception of 
sleep quality among patients with post traumatic stress disorder (PTSD) caused by 
motor vehicle crash (MVC) compared to MVC survivors with no PTSD or other non 
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PTSD patients while no significant differences were found amongst the three groups on 
objective actigraphy measures. Edinger et al. (2000) have shown that psychological 
factors may mediate subjective self reported sleep satisfaction but at the same time may 
also predict objective sleep difficulties. The discrepancy between objective and 
subjective sleep measures may also result from a „Sleep State Misperception‟ disorder 
defined by the ICSD as a sleep disorder „in which a complaint of insomnia or excessive 
sleepiness occurs without objective evidence of sleep disturbance’ (AASM, 2010, pp. 
32-33). This disorder may appear as a convincing and genuine sleep complaint by 
patients with no psychological disorders and has been suggested to result from 
excessive mentation during sleep which causes a perception of being awake or from 
actual changes in sleep physiology that are too subtle to be detected by PSG (AASM, 
2010, p.33). It has also been suggested that this disorder may be a sleep equivalent of 
hypochondriasis (AASM, 2010, p.33). Furthermore, a previous study has shown that 
polysomnography findings did not correlate well with all PSQI component scores and 
suggested that the discrepancy may be related to the fact that PSQI elicits self estimate 
of usual sleep quality over a one-month period, thus decreasing its‟ sensitivity to daily 
variations (Buysse et al., 1989).  
Similar factors may have been involved in the discrepancy seen in the present study 
between subjective and objective measures. The present study has shown that the yoga 
intervention significantly improved a range of psychological factors (see section 4.4) 
which may have improved subjective sleep satisfaction and not objective sleep quality. On 
the other hand, the significant improvement (p=.024) seen in the yoga group but not in the 
control group with the insomnia objective measures multivariate (made up of SOL, 
WASO, TST and SE), while no change was seen with any of these variables 
independently, may indicate an objective subtle change which had taken place in sleep 
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physiology that was only detected by multivariate analysis. A longer intervention period 
(e.g. six months) may possibly have resulted in significant changes in several independent 
insomnia related variables. Also, the subjective feeling of having slept better may also be 
related to the significant (p=.042) objective increase of 11.5% in the duration of SWS 
(deep sleep) stage seen in the YHC group discussed above. In other words, the sleep had 
become significantly „deeper‟ and therefore more refreshing despite the fact that there was 
no significant change in other objective insomnia related measures (i.e. SOL, WASO, TST 
and SE).  
It can also be speculated that being connected to the portable sleep monitoring 
equipment may have had some effect on participants‟ sleep patterns. For example, the 
discomfort associated with walking around connected to the equipment may have resulted 
in some participants retiring to bed earlier than they would normally do. It may have also 
been a factor affecting participants to remain in bed or spend shorter time out of bed in 
case of an awakening during the night. This in turn may have resulted in a more rapid sleep 
onset, an overall shorter WASO and higher sleep efficiency. 
Since diminished subjective sleep quality is one of the most frequent health 
complaints in the elderly (Prinz, 1995), the significant improvement in most aspects of 
subjective sleep status in the yoga group is an important finding despite the discrepancy 
seen between the subjective and corresponding objective sleep quality measures. 
5.6 Use of sedatives/hypnotics and relaxants. 
Despite significant improvements (p<.05) in subjective sleep quality measures in the 
YI group in general and in the YHC subset group in particular, there was no corresponding 
reduction in use of sedatives/hypnotics and relaxants, with close to half of participants still 
reporting regular usage (see section 4.5.2.5). This may be partially explained by the 
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potentially addictive characteristics of these medications (Longo & Johnson, 2000). 
Perhaps a longer intervention period may be needed to reduce dependency on these 
medications.  
Daytime impairment was measured directly by KSS and ESS sleepiness scores and 
the PSQI daytime dysfunction subscale score and indirectly by the POMS fatigue and the 
SF36 vitality subscales scores. No significant change was seen in ESS sleepiness scores or 
in PSQI daytime dysfunction subscale scores with any group. However, a significant 
(p=.010) deterioration was seen in the control group in the KSS sleepiness score, a 
significant (p=.010) improvement in the POMS fatigue subscale score and a significant 
(p=.053) improvement in the SF36 vitality subscale score were seen in the intervention 
group and not in the control group. The lack of significant change in sleepiness and 
daytime dysfunction measures may possibly be related to persistent consumption of 
sedatives/hypnotics and relaxants, as regular use of these medications has been shown to 
be associated with daytime drowsiness (Nowell et al., 1997) (see section 1.5.12.2). The 
lack of significant change in sleepiness and daytime dysfunction measures may also be 
related to the high prevalence of co-morbid OSA among participants see section 4.6) as 
OSA has also been shown to be associated with daytime drowsiness, sleepiness and 
dysfunction (Young et al., 2002b; Berg, 2008) (see section 1.6.4) and no significant change 
was seen in direct OSA related measures in any of the groups (see results section 4.6)  
5.7 Association between quality of life factors and insomnia  
As discussed above, insomnia is often associated with anxiety, stress and depression 
(Schneider, 2002; Buysse et al., 2005; NIH, 2003; Lichstein et al., 2001) and geriatric 
insomnia specifically has been strongly associated with anxiety, neuroticism and 
depression (Beullens, 1999). The present study has demonstrated that yoga results in 
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significant improvements (p<.05) in many subjective measures for insomnia and also for 
anxiety, stress and depression. Additional studies are required to further examine the 
psycho-physiological mechanisms involved in the strong association between anxiety, 
stress, depression and insomnia and how yoga affects those mechanisms. This will enable 
developing more effective yoga interventions for these conditions. Overall, the present 
study‟s findings support prescribing yoga to older adults presenting with primary insomnia 
symptoms. Furthermore, the study‟s findings support prescribing yoga to older adults 
presenting with co-morbid insomnia and OSA symptoms but do not support prescribing 
yoga intervention for primary OSA without a significant co-morbid insomnia component. 
5.8 Safety, acceptance and compliance of yoga intervention 
It appears that the yoga intervention used in this study was well accepted and safe 
with compliance levels being variable. The acceptability of yoga is evidenced by the rapid 
and wide-ranging response to the recruitment advertising campaign and the low dropout 
rate, while the safety is indicated by the lack of adverse events. However, compliance in 
general and home practice compliance in particular was below recommended level. 
Overall, only 10 percent of participants achieved a practice compliance level equal or 
above the recommended level of three daily practice units. The median compliance level 
was close to the requested minimum of one daily practice unit (20 – 25 minutes per day) 
(see section 4.3). On treatment (OT) subset analysis revealed that the high compliance 
yoga participants subset group (YHC) (with compliance equal or above median) improved 
significantly in a wide range of sleep quality and QoL measures compared to the low 
compliance subset group (YLC) (below median practice level) and control (see section 4.4 
– 4.5), thus demonstrating the importance of achieving high practice compliance level for 
improving sleep quality and quality of life.  
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Compliance with any therapy is always an important consideration. The results of the 
daily logs revealed that for the present study compliance level did not vary much over the 
12 weeks intervention period with most participants maintaining a constant individual 
compliance level and changes in compliance being related to transient events (i.e., catching 
a cold, social/ family engagements etc.). 
Overall, study findings revealed that achieving an adequate practice compliance level 
was essential for effective application of the yoga protocol, especially for improving 
insomnia status. It seems that at least 25 minutes of daily practice is required to achieve 
these benefits. This is significantly less than the level of practice used in previous studies 
(Manjunath and Telles, 2005) and roughly 50 percent of the intervention group was able to 
sustain this level of practice compliance indicating that present study‟s yoga protocol may 
be suitable for urban geriatric population in western settings. The use an audio CD 
incorporated in the present study may have been a factor in keeping compliance at 
reasonable levels and use of audio visual aids should be considered in future studies.  
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Chapter 6. Conclusions  
1. Yoga practice, as applied in the present study, appears to be a safe, easy to 
implement, and well accepted non-drug intervention for the elderly in a western 
urban cultural setting. 
2. In a geriatric population with primary insomnia, or insomnia with comorbid 
obstructive sleep apnea (OSA), practicing yoga for at least 25 minutes a day for 
twelve weeks improved most aspects of subjective sleep status. Specifically, 
improvements were seen in subjective measures of sleep latency, sleep duration, 
self assessed sleep quality, fatigue and vitality. Improvements were also found in 
duration of the deep sleep (SWS) stage.  
3. In a geriatric population with primary insomnia or insomnia with comorbid 
obstructive sleep apnea (OSA), practicing yoga for at least 25 minutes a day 
(roughly one „practice unit‟ as discussed in sections 3.3.6, 3.5.3 and 4.3) for twelve 
weeks also improved many aspects of psychological and emotional well being. 
Specifically, improvements were seen in levels of depression, anxiety, stress, 
tension and anger. Improvements were also seen in vitality and daily function in 
physical, emotional and social roles.  
4. Twelve weeks of regular yoga practice did not affect use of sedative-hypnotic 
medications in study‟s population. 
5. Twelve weeks of regular yoga practice did not improve OSA status in the study‟s 
population. While the presence of OSA partially reduced the efficacy of yoga 
intervention in improving overall sleep quality and sleep efficiency and in 
improving some aspects of life quality, specifically carrying out daily roles and 
social function, the presence of OSA did not reduce the efficacy of yoga practice in 
improving other aspects of sleep quality including subjective measures of self 
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assessed sleep quality, sleep latency and sleep duration, as well as the duration of 
the deep sleep stage (SWS). Furthermore, the presence of OSA did not reduce the 
efficacy of yoga in improving most aspects of psychological well being. 
6. While yoga was readily accepted by an elderly population, maintaining practice 
levels at a minimum of 25 minutes per day appears to be crucial for improving 
sleep quality and quality of life in this population. Factors that may increase 
participation include providing materials to support home practice, maintaining a 
yoga class component with one or two weekly classes to introduce, revise and 
reinforce the exercises prescribed for home practice, as well as providing a choice 
of exercises that can be graded according to different abilities. 
7. Obstructive sleep apnea (OSA) appears to be present to varying degrees in the 
majority of elderly people presenting with insomnia symptoms. The MAP 
questionnaire, detailed doctor examination and full medical history appear 
inadequate to diagnose OSA reliably in this population. Although portable 
monitoring is not recommended for screening of OSA in asymptomatic 
populations, it may however, be a useful tool for initial OSA screening of elderly 
patients presenting with insomnia symptoms prior to prescribing sedative-hypnotics 
and for screening for OSA in research settings.  
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Chapter 7. Implications for future research 
Due to the high prevalence of co-morbid insomnia and OSA in the geriatric 
population, inclusion/exclusion criteria and screening procedures for similar future studies 
should enable screening all applicants for OSA and stratification of subjects according to 
their OSA status (no OSA, light OSA, moderate OSA and severe OSA) in order to 
examine the precise relationship between OSA level and changes in all measures. 
The present study has shown that yoga can be applied effectively to improve sleep 
and life quality in elderly presenting with complaints of insomnia. However, this study has 
also revealed factors that reduce intervention efficacy, including low compliance and 
presence of undetected and untreated co-morbid obstructive sleep apnea (OSA).  
Further research is now needed to: 
1. Examine if short and medium duration yoga programs can result in long term 
persistence of self home-based practice  
2.  Identify yoga protocols that yield better compliance levels. 
3. Develop recommendations for optimal treatment strategies for co-morbid insomnia 
and OSA including treatment priorities and sequence. For example, at what stage of 
treatment should yoga be introduced to treat the co-morbid insomnia component in 
co-morbid insomnia & OSA disorder? 
4. Examine long term effects of short and medium duration yoga programs on sleep 
quality and quality of life 
Yoga encompasses a diversity of practices and techniques. Additional research is also 
needed to: 
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1. Examine various physical and meditative yoga techniques to determine most 
effective for improving sleep quality.  
2. Establish optimal ratio between home and class practice. 
3.  Establish optimal ratio between physical and meditative practices 
4. Establish optimal dose – effect ratios 
An Audio CD was used successfully in the present study to support home based self 
practice of meditative exercises. Future studies may benefit from making use of additional 
audio-visual aids such as video recordings of yoga sessions as well as software for personal 
computers with a menu system and links to detailed instructions, supporting material, 
detailed daily sleep and practice logs and questionnaires. Future studies may also benefit 
from making use of the internet to allow study participants to communicate with their yoga 
teachers and participate in online yoga classes. This would allow future studies to increase 
the number of classes and offer daily classes at convenient times. Applying such measures, 
may allow increasing the sample size and improving home practice compliance level. 
Introduction of online research systems may also be used for long term observation and 
follow up of practice outcomes and compliance levels. 
Using portable monitoring, in conjunction with a computer assisted FDA and CE 
approved sleep diagnostic system has been used successfully in present study. Future 
research in the area of geriatric insomnia would benefit from making use of such tools both 
as screening and diagnostic tools. The robustness of the ECG and pulse oximetry signals in 
conjunction with the reduced number of required channels may enable conducting diverse 
large scale studies on the effect of mind-body interventions on sleep, autonomic nervous 
system balance, the relaxation response etc. The measures could easily be taken in 
participants‟ home environments, during meditation and relaxation sessions and even 
during gentle exercise.  
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Appendix 1. Ethics committee approval 
Phone:  9925 2251 
Fax:  9925 2387 
peter.burke@rmit.edu.au 
24 April 2008 
Dear Jonathan, 
Project No 36/07: A randomised clinical trial of integrated yoga style practice 
intervention for improving sleep and quality of life in the elderly 
I am pleased to advise that this project is now approved by the Human Research Ethics 
Committee for the period specified in the application, that is, until 31 March 2009. The project 
has been classified as level 3 as it involves higher risks to the participants than discomfort or 
inconvenience. 
Responsibilities of primary investigator  
It is important to emphasise that primary investigators are responsible for ensuring that the 
project proceeds according to the proposal approved by the Human Research Ethics 
Committee. The Committee’s approval of the project is not absolute. New and unforeseen 
ethical issues may arise. A researcher should continue to consider the ethical dimensions of the 
research as the project progresses. 
Adverse events or unexpected outcomes 
As the primary investigator you have a significant responsibility to monitor the research and to 
take prompt steps to deal with any unexpected outcomes. You must notify the Committee 
immediately of any serious or unexpected adverse effects on participants, or unforeseen events, 
which may affect the ethical acceptability of your project. Any complaints about the project 
received by the researcher must be referred immediately to the Ethics Executive Officer.  
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Reporting 
Approval to continue a project is conditional on the submission of annual reports (see attached 
sample form). A final report should also be provided at the conclusion of the project. If your 
work is completed within twelve months a final report only is required. Report forms are 
available from the Human Research Ethics Committee web site: 
(http://www.rmit.edu.au/rd/hrec_apply).  
Please note that failure to submit reports will mean that a project is no longer approved, and/or 
that approval will be withheld from future projects. 
Conditions of approval 
The Human Research Ethics Committee may apply additional conditions of approval beyond 
the submission of annual/final reports.   
Conflicts of interest 
When reporting the research, the researcher should again disclose any actual or potential 
conflicts of interest, including any financial or other interest or affiliation that bears on the 
research. Conflicts of interest can arise after a project has been approved, and where they do 
they must be reported as soon as possible.   
Amendments 
If, as you proceed with your investigation you find reason to amend your research method, you 
should advise the Human Research Ethics Committee and seek approval for the proposed 
changes. If you decide to discontinue your research before its planned completion you must also 
advise the Committee of this and of the circumstances. Depending on the type of amendment 
— whether it is minor or major — will determine how long the review process for an 
amendment will take.  
Storage of Data 
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All data should normally be stored on University Network systems. These systems provide high 
levels of manageable security and data integrity, can provide secure remote access, are backed on 
a regular basis and can provide Disaster Recover processes should a large scale incident occur. 
The use of portable devices such as CDs and memory sticks is valid for archiving, data transport 
where necessary and some works in progress. The authoritative copy of all current data should 
reside on appropriate network systems; and the principal investigator is responsible for the 
retention and storage of the original data pertaining to the project for a minimum period of five 
years. 
If you anticipate any problems in meeting this requirement please contact me to discuss an 
alternative secure data storage arrangement. 
All reports or communication regarding this project is to be forwarded to the Ethics Executive 
Officer. 
National Ethics Application Form (NEAF) 
As you may be aware during 2008 RMIT University is introducing a number of reforms to 
human research ethics arrangements including the format of applications. Currently RMIT 
accepts applications on a variety of forms. However, it is intended that by the middle of the year 
all RMIT applications would be lodged on the online-based National Ethics Application Form. 
Therefore you are requested to use this format when you next make an application. For further 
information and to access NEAF see: 
https://www.neaf.gov.au/ 
 On behalf of the Human Research Ethics Committee I wish you well with your research. 
Yours sincerely, 
 Peter Burke 
Ethic Executive Officer -RMIT Human Research Ethics Committee 
cc:   Prof Marc Cohen 
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Appendix 2. Clinical trial registration 
 
 
 
 
Protocol Registration Preview  
 
 
A Study of Yoga for Treating Geriatric Insomnia  
This study has been completed.  
 
Sponsor: Shaare Zedek Medical Center 
Collaborators: 
Royal Melbourne Institute of Technology University 
The Australia-Israel Scientific Exchange Foundation 
(AISEF) 
Israel Yoga Teachers Association 
Information provided by: Shaare Zedek Medical Center 
ClinicalTrials.gov 
Identifier: 
NCT00661843   
 
Purpose  
Insomnia is common in the elderly population and is associated with increased health 
problems, reduced quality of life and greater use of sleep inducing drugs. This research 
aims to examine the effectiveness of Yoga practice to treat insomnia in elderly people, 
determine the ability to enhance their quality of life and determine if it is suitable to 
western culture and conditions. 
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Condition Intervention Phase 
Primary Geriatric Insomnia 
Sleep Initiation and Maintenance 
Disorders 
Integrated Yoga style 
practice 
N/A  
 
Study Type: Interventional  
Study Design: Supportive Care, Parallel Assignment, Open Label, Non-Randomized, 
Safety/Efficacy Study  
 
Official Title: A Mixed Design, With Wait List Control Crossover to Intervention, Clinical 
Trial of Integrated Yoga Style Practice Intervention for Improving Sleep and Quality of 
Life in the Elderly Population  
 
Further study details as provided by Shaare Zedek Medical Centre:  
Primary Outcome Measure:  
 Subjective sleep and life quality assessment using standard questionnaires and sleep 
logs  
All measures taken at baseline and post intervention for all participants participant 
who crossed over measured pre and post control phase and post intervention phase 
 Objective home based sleep studies using  Embletta mobile sleep recording system 
in conjunction with the HPC1000 sleep analysis system. 
All measures taken pre and post intervention. Participants who crossed over 
measured pre control, post control and post intervention phases 
Enrolment: 74  
Study Start Date: May 2008  
Study Completion Date: February 2009  
Primary Completion Date: January 2009  
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Introduction: Geriatric insomnia is prevalent, reducing life quality, diminishing cognition 
and increasing risk of accidents and mortality. Treatment with sedative-hypnotic drugs has 
limited effectiveness and further increases the risk of accidents and falls. Yoga has been 
shown to increase well-being in the elderly. 
Hypotheses 
1. Integrated yoga style practice can improve sleep quality/quantity 
2. Integrated yoga style practice can improve quality of life. 
Objectives: 
1. Examine effectiveness of yoga for insomnia and reduction in use of 
hypnotics/relaxants in the elderly; 
 
Arms Assigned Interventions 
Experimental: 1  
Intervention group: Intervention 
constitutes of 2 supervised yoga classes 
per week incorporating gentle Yoga 
postures, relaxation and meditation 
sequences In addition: daily home 
based sessions of yogic relaxation and 
meditation using a pre-recorded audio 
CD 
Integrated Yoga style practice  
Intervention constitutes of 2 supervised yoga 
style classes per week incorporating gentle 
postures, relaxation and meditation 
sequences. In addition daily home based 
sessions of yogic relaxation, and meditation 
a an audio CD 
No Intervention: 2  
Wait List Control to be crossed over 
after control phase completed. 
Participants of this group studied using 
same objective and subjective outcome 
measures. 
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2. Determine whether yoga enhances quality of life in the elderly; and 3. Determine 
whether yoga is suitable for elderly in western culture(s). 
Methods: 
A mixed design crossover controlled trial (n =74, age range 60-87, M = 74.4, SD = 7.1) 
with 2 weekly classes incorporating physical and meditative yoga, and daily home practice 
of meditative yoga for 12 weeks. Measures included self-reported assessment of sleep 
quality (Sleep Logs, KSS, ESS, PSQI, and MAP), mood states (DASS, POMS), general 
health (SF-36) and mobile objective home sleep studies. 
Eligibility  
Ages Eligible for Study: 60 Years and older  
Genders Eligible for Study: Both  
Inclusion Criteria: 
 Age 60 years or older 
 Independent, self mobile 
 Suffering from light to severe primary insomnia 
Exclusion Criteria: 
 Age less than 60 years 
 Currently or in the past engaged in regular yoga practice 
 Suffering from any physical or mental health condition or disability which may 
affect sleep, or for which Yoga practice is counter indicated or may lead to health 
risks or complications. 
 Suffering from co-morbid insomnia in conjunction with another condition clearly 
salient to sleep disturbance. 
Contacts and Locations  
Locations  
Israel, Israel 
     Shaare Zedek Medical Center, Sleep Lab      
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         Jerusalem, Israel, Israel, 91031   
Investigators  
Study Chair:     Anda Baharav, MD     Shaare Zedek Medical Center 
Study Chair:     Jonathan Halpern, 
M.Sc. 
    Royal Melbourne Institute of 
Technology University 
Principal Investigator:     Clement Cahan, 
MD 
    Shaare Zedek Medical Center 
More Information  
Responsible 
Party:    
Shaare Zedek Medical Center (Dr. Clement Cahan, head of the 
Sleep Lab, Shaare Zedek Medical Center)  
Study ID 
Numbers:    
SZMCSL0001 
Health 
Authority:    
Israel: Ministry of Health 
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Appendix 3.   Medical questionnaires and interview formats  
Appendix 3.1   Initial Telephone Screening Interview Format (English Version) 
Hello. My name is [interviewer‟s name].  I am part of a research team at 
the Shaare Zedek Medical Centre, Jerusalem, and conducting research on the 
effect of Yoga practice on Insomnia in the elderly aged 60 years and over. It is a 
joint effort of Shaare Zedek medical Centre and R.M.I.T. University.   I am 
working with Dr. Clement Cahan Director of the sleep lab at Shaare Zedek 
Medical centre. The information we collect will help us develop better methods 
to help elderly people suffering from insomnia. 
First, let me give you some general information about this study and what it 
will require from you as a participant: The study will be conducted over 12 
weeks. Participants may be assigned to a Yoga practice group or to a waiting 
group. The assignment may be random so there is no way of knowing in advance 
which group you will be assigned to. A condition for joining the study is to agree 
to join whatever group you are assigned to. The waiting group will wait for 3 to 4 
months before being assigned to a Yoga practice group. 
 Participants in a yoga group will be required to attend two gentle yoga 
classes per week and also practice special relaxation and meditation exercises at 
home.  The yoga classes have been designed to suit elderly people. Each class 
will be 1 hour in duration. You will need to be able to come to classes by private 
or public transport. Classes and will be held at a convenient venue close to the 
Shaare Zedek medical centre, with lots of parking space and convenient access to 
public transport. The practice rooms will be clean and well ventilated. We will 
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provide chairs and yoga mats. Participants will need to come in comfortable 
loose cloths. The yoga teachers are all experienced, qualified and certified by the 
Yoga Teachers Association.  
The daily home practice includes relaxation and meditation exercises which 
are done while lying in bed or sitting in a chair following pre-recorded 
instructions on an audio CD. You need an audio CD player in order to listen to 
the CD. We can provide audio cassettes to people who only have a cassette 
player. If you have an MP3 player, we can provide an internet website link where 
you can download the entire audio CD in MP3 format. 
Scientific research requires collecting information. Your privacy will be 
respected. We will only collect information about your sleep, health and well 
being. All data we collect will be kept strictly confidential. No personal 
information will be disclosed to anyone outside the research team and will never 
be published anywhere. In order to be a candidate to join the study, you will need 
to provide us with a letter from your doctor, including full medical information 
and any other information relating to your sleep disturbances.  For the purpose of 
collecting data you will also be invited to the medical centre several times for 
approximately one hour to fill questionnaires and attend medical interviews by 
doctors of our team. You will have an opportunity to discuss any concerns you 
may have related to your health and sleep with our medical team. 
We will also monitor your sleep overnight two or three times. This will be 
done using a mobile sleep lab which will enable you to sleep at home in your 
own bed. The mobile sleep lab consists of a small recording unit you wear with a 
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strap around your waist. The recorder has several wires which are connected to 
sensors that are applied with stickers to your finger and several places on your 
body. These sensors are external - non invasive and harmless.  During the 12 
weeks of yoga program you will be asked to fill daily logs with information 
related your sleep patterns and daily routine. 
Do you think you may be interested in joining the study? If so, I would like 
to ask you a few questions, just to make sure you fit the joining criteria of this 
particular study. 
1) This research studies people aged 60 and over. Is your age 60 or over? 
2) All forms and questionaries are in Hebrew (or English if you prefer) do 
you think you will be able to understand and reply to these questionnaires? 
3) Are you currently suffering from any serious medical condition?  
4) Are you currently suffering from any psychiatric condition? 
5) Do you currently have any other serious personal problem at present? If so:  
1. How does it affect you life and sleep? 
2. Are you currently seeking professional help for this? 
6) Are you currently getting professional help for any condition or problem? 
7) Have you ever attended a sleep lab? Seen a sleep specialist? If so- can you 
remember the diagnosis? 
 
If candidate fits criteria so far: 
Thank you. I think you may be a suitable candidate. In order to continue to 
the next screening stage we need some information from your doctor. I will mail 
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you a special form for your doctor. Please mail back the forms and attach the 
information that your doctor provides. The form has our address and phone 
number. You or your doctor can contact us if you have further questions.  
Can you please give me your full name, mailing address and phone number? 
 
If candidate does not fit criteria:  
I am sorry but from the information you have provided it seems that you 
would not be able to attend this particular study.  
 
Thank you very much for your time,  
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  רפואי אישור טופס
  ,ןהמעוניי לכל
  ,.נ.ג.א
  בזהת /מאשרמ "הח אני
 
  ___________________________  מר/ ' כי גב 
  ).המבוגר לגיל מותאמים התרגילים(ה לפעילות גופנית במסגרת סדנת יוגה /כשיר
  :ל"הנ של דם ולחץ דופק נתוני
  ____________________: דופק
  ____________________: דם לחץ
 
  רב בכבוד
  __________________________  ר"ד
  ______________________: הסמכה מס
  _________________________: טלפון
  ________________________: תאריך
 
 נא לצרף תדפיס רפואי
 
 נא להחזיר את הטופס בהקדם ל
  הלפריןת מעבדת שינה עבור מחקר שינה שערי צדק  
  22269  ירושלים, צדק שערי רפואי מרכז
  9136666-20 
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Appendix 3.3  Approval of patient’s participation in study by personal physician 
(English version) 
 
Medical approval formי 
To whomever it may concern, 
I hereby confirm that 
Mr./Mrs./Ms.___________________________ 
Is physically fit to participate in gentle yoga training  
I have checked heart rate and blood pressure and they are: 
Heart rate:  ____________________  
Blood pressure_________/___________ 
___________________ 
(Physician signature and stamp) 
 
Regards, 
Dr.__________________________ 
Licence no.  :______________________  
Phone no.  :_________________________  
Date:  ________________________  
 
Please attach full medical transcript to this form 
Please return the form to 
 J. Halpern, Sleep lab, Shaare Zedek Medical centre, Jerusalem    02-6666319  
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  טופס רפואי כללי – נדודי שינהליוגה  מחקר
  ___________:תאריך
  __________________________ :שם המשתתף
  ___________:גובה__________:משקל__________:גיל
  :מצב בריאות כללי
 מחלות רקע:
  __________________________ :יתר לחץ דם__________________________ :לב
  __________________________ :כליות__________________________ :סכרת
  __________________________ :אלרגיות__________________________  :נשימה
  __________________________ :כאבים__________________________ :סרטן
  :אחר
  _______\חרדה\מתח: נפשיות בעיות
  שינה נדודי\שינה הפרעות של משפחתי סיפור
 רשימת תרופות :
  ___________________.3___________________.2__________________.1
  __________________.6__________________.5___________________.4
  ___________________:הרגעה  תרופות__________________ :שינה תרופות
  :שאלות
  :תלונות
 
 למילוי על ידי הצוות הרפואי שערי צדק:
  :הערות
  :המלצות
  :בודק רופא
  :חתימה
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Appendix 3.5  General Demographic and Medical form (English version) 
 
Yoga for geriatric insomnia – general medical form 
Date: :___________  
Participant name (first/middle/last) : __________________________  
Age__________weight__________height :___________  
General health 
Physiological Medical history 
cardio_________________________hypertension__________________________ 
Diabetes__________________________kidneys  __________________________  
Breathing : ______________________ allergies__________________________ 
Cancer  __________________________ pains : __________________________  
Mental conditions, stress/anxiety/depression__________________________ 
Family history of sleep disorders__________________________ 
Current medications 
1.__________________2.___________________3.___________________  
4.___________________5.__________________6.__________________  
Hypnotics __________________relaxants  :___________________  
Questions: 
Complaints: 
Fields below to be filled by the medical staff at SZMC 
Comments: 
Recommendation: 
Physician’s name: 
Signature: 
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Appendix 4. Consent and invitation forms  
Appendix 4.1   Prescribed Consent Form for Persons Participating In Research 
Projects Involving Tests and/or Medical Procedures (RMIT English versions) 
 
Portfolio  Science, Engineering & Technology 
School of Health Sciences 
Name of participant:  
Project Title: A clinical trial to assess the effectiveness of Yoga style 
practice for improving sleep and quality of life in an 
elderly population 
Name(s) of investigators:   
 
  (1) Jonathan Halpern (RMIT) Phone 03 9925 7440 
(2) Prof. Marc Cohen (RMIT) Phone 03 9925 7440 
(3) Dr. Gerard Kennedy (Victoria Uni.) Phone 03 991 92481 
1. I have received a statement explaining the tests/procedures and 
interview/questionnaire involved in this project. 
2. I consent to participate in the above project, the particulars of which - including 
details of tests or procedures or interviews or questionnaires - have been 
explained to me. 
3. I authorise the investigator or his or her assistant to use with me the tests or 
procedures or to interview me or administer a questionnaire referred to in 1 above. 
4. I acknowledge that: 
(a) The possible effects of the tests or procedures have been explained to me to 
my satisfaction. 
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(b) I have been informed that I am free to withdraw from the project at any time 
and to withdraw any unprocessed data previously supplied (unless follow-up 
is needed for safety). 
(c) The project is for the purpose of research and/or teaching.  It may not be of 
direct benefit to me. 
(d) (d) The privacy of the personal information I provide will be 
safeguarded and only disclosed where I have consented to the disclosure or 
as required by law.  
(e) (e) The security of the research data is assured during and after 
completion of the study.  The data collected during the study may be 
published, and a report of the project outcomes will be provided to all 
participants and scientific publications. Any information which will identify 
me will not be used. 
Participnt’s Consent 
Participant  Date:  
(Signature) 
Witness:  Date:  
(Signature) 
Participants should be given a photocopy of this consent form after it has been signed. 
Any complaints about your participation in this project may be directed to the Executive Officer, RMIT Human Research 
Ethics Committee, Research & Innovation, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 2251.   
Details of the complaints procedure are available from the above address.  
Prescribed Consent  statement Version no. 1, 10 Nov. 07 
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Appendix .4.2  Prescribed consent form for persons participating in research 
projects involving tests and/or medical procedures (SZMC English version) 
 
Hospital  Shaare Zedek Medical Centre 
Department Sleep research centre 
Name of participant:  
Project Title: A clinical trial to assess the effectiveness of Yoga style 
practice for improving sleep and quality of life in an 
elderly population 
Name(s) of 
investigators:   
   
  (1) Dr. Clement Cahan (SZMC) Phone: 02 666 9136 
(2) Jonathan Halpern (at SZMC) Phone: 02 666 9136 
5. I have received a statement explaining the tests/procedures and 
interview/questionnaire involved in this project. 
6. I consent to participate in the above project, the particulars of which - including 
details of tests or procedures or interviews or questionnaires - have been 
explained to me. 
7. I authorise the investigator or his or her assistant to use with me the tests or 
procedures or to interview me or administer a questionnaire referred to in 1 
above. 
8. I acknowledge that: 
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(f) The possible effects of the tests or procedures have been explained to me to 
my satisfaction. 
(g) I have been informed that I am free to withdraw from the project at any 
time and to withdraw any unprocessed data previously supplied (unless 
follow-up is needed for safety). 
(h) The project is for the purpose of research and/or teaching.  It may not be of 
direct benefit to me. 
(d) The privacy of the personal information I provide will be safeguarded and 
only disclosed where I have consented to the disclosure or as required by 
law.  
(e) The security of the research data is assured during and after completion of 
the study.  The data collected during the study may be published, and a 
report of the project outcomes will be provided to all participants and 
scientific publications. Any information which will identify me will not be 
used. 
Participnt’s Consent 
Participant:  Date:  
(Signature) 
Witness:  Date:  
(Signature) 
Participants should be given a photocopy of this consent form after it has been signed. 
Any complaints about your participation in this project may be directed to the Executive Officer, 
Shaare Zedek Research Ethics Committee, Shaare Zedek Medical Centre, P. O. Box  3235   Jerusalem 
91031 Israel 
Plain language statement Version no. 1, 10 Nov. 07 
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-eettimmoc ’iknisleH‘ – htlaeh fo yrtsinim learsI - mrof tnesnoC  3.4 xidneppA
 )noisrev werbeH(
   ): הוועדה מזכירות ידי-על למילוי(הבקשה בוועדת הלסינקי  מספר
 אני החתום מטה:
  :פרטי ומשפחה  שם
 
 
  :מספר תעודת זהות
 
 
  :כתובת
 
  :מיקוד
 
 
רפואי במחקרה להשתתף /ה בזה כי אני מסכים/מצהיר )א
1
 .זה במסמך כמפורט, 
 
משתתף לא/משתתף אניכי , ה בזה/מצהיר )ב
2
 במשך כל רבניסוי רפואי אח, בזמן חתימת מסמך זה 
 .זה מחקרתקופת 
 
 :ידי-ה בזה כי הוסבר לי על/מצהיר )ג
 
  :חוקר המשנה המסביר/שם החוקר
 
 
המוסד  ממנהלקיבל    כהאן קלמנט ר"ד ): הרופא  שם (  כי החוקר הראשי .1
בתקנות בריאות  כמשמעותו, אדם-הרפואי בבני המחקראישור לביצוע , הניסוי ייערך בו, הרפואי
 ). הניסוי הרפואי  להלן( 0891-א"תשמ  ) אדם-ניסויים רפואיים בבני(העם 
 .3המחקרזיקה ליוזם  1אין/כי לחוקר הראשי ולחוקרי המשנה יש .2
  .3
 לשיפור אינטגרטיבית יוגה בסגנון תרגול: הרפואי נערך בנושא המחקרכי : פרט  –אם יש 
  המזדקנת האוכלוסיה של החיים ואיכות השינה איכות
בכל עת את  קה להפסי/וכי אני חופשי, הרפואי במחקרה לבחור שלא להשתתף /כי אני חופשי .4
 .המקובל הטיפול את לקבל בזכותיכל זאת מבלי לפגוע , במחקרהשתתפותי 
 .מהן חלק על או שבשאלון השאלות כל על לענות שלא ת/אני רשאי –במקרה של מילוי שאלון  כי .5
 תפורסם ולא במחקר והמעורבים העוסקים כל ידי-על סודית תשמר האישית שזהותי לי מובטח כי .6
 .מדעיים בפרסומים כולל, פרסום בכל
                                                 
1
 .פרט למחקר גנטי', מחקר בדגימות רקמה וכו, מחקר אפידמיולוגי, שאלונים, לקיחת דמים: כולל, מחקר רפואי 
2
 מחק את המיותר 
3
 .יש לציין זאת במפורש, גם יוזם המחקר אם החוקר הראשי הוא  
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 הרפואי והצוות הרופאים, החוקרים שלהולם  יביטוח כיסויכי המוסד הרפואי פעל להסדרת  .7
' ג צד תביעות או/ו הקליני בניסוי משתתפים י"ע שיוגשו תביעות מפני הקליני בניסוי העוסקים
 לפגוע כדי באמור אין. לאחריו ובין הניסוי ביצוע בתקופת בין הקליני הניסוי עם הקשורות
 .דין כל פי על בזכויותיי
לדוגמא ( ידי וכן האפשרות להיוועץ בגורם נוסף-כי מובטחת לי נכונות לענות לשאלות שיועלו על .8
או להמשיך /הרפואי ו  להשתתף בניסוי הבאשר לקבלת החלט, )'בני משפחה וכו, משפחה-רופא
 .בו
 __________________ר"ד/'כי בכל בעיה הקשורה לניסוי הרפואי אוכל לפנות לפרופ .9
  .היממה שעות בכל,  __________________________ :משיבון/מספר טלפון
  : להלן המפורטים הנושאים פי על, הרפואי המחקרה לי מידע מפורט על /ה כי נמסר/הנני מצהיר 
 ;המחקר מטרות .1
  ;במחקר המשתתפים של בקירוב והמספר במחקר ההשתתפות למשך הצפויה התקופה .2
 לבין המחקריים ההליכים בין ברורה הבחנה תוך, המחקר תקופת במשך השונים ההליכים תיאור .3
 ;ברפואה המקובלים ההליכים
 ;מהמחקרכתוצאה , לאחרים אוהיתרונות הצפויים למשתתף  .4
 ;הנוחות שניתן לחזותם למשתתף במחקר-או אי/ו הידועיםהסיכונים  .5
 :אחר רלוונטי מידע .6
 ,כן-כמו. לעיל רל נתתי מרצוני החופשי וכי הבנתי את כל האמו"כי את הסכמתי הנ ,ה בזה/הנני מצהיר )ד
 . נושא תאריך וחתום כדין, זהקיבלתי עותק של טופס הסכמה מדעת 
 לגוף, לוועדת הלסינקי המוסדית, הרפואי המחקרהנני מתיר ליוזם , ם חתימתי על טופס הסכמה זהע )ה
לשם אימות שיטות המחקר , ולמשרד הבריאות גישה ישירה לתיקי הרפואי הרפואי במוסד המבקר
לחוקים  בהתאם, תוך שמירת סודיות  גישה זו למידע הרפואי שלי תבוצע. הרפואי והנתונים הקליניים
 .ולנהלים של שמירת סודיות
ת /חתימת המשתתף  הרפואי במחקר ת/שם המשתתף
 במחקר
 תאריך
   
במקרה הצורך
 4
שם העד הבלתי 
 תלוי
 תאריך חתימת העד מספר תעודת זהות
    
 הצהרת החוקר/חוקר המשנה:
ת בניסוי הרפואי כל האמור לעיל וכן /וזאת לאחר שהסברתי למשתתף, ידי-על  נתקבלה  ל"ההסכמה הנ
 .ידה/ידו-הובנו על יהסבריוידאתי שכל 
 תאריך חתימתו  חוקר המשנה המסביר/שם החוקר
   
                                                 
4
 .תאריך החתימה 
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Appendix 4.4  Invitation to participate in a research project (English version)  
PROJECT INFORMATION STATEMENT 
 
Project Title: 
 Integrated yoga style practice for improving sleep and quality of life in the elderly population  
Investigators: 
1. Dr. Clement Cahan, Director  of Sleep Lab at Shaare Zedek Medical Centre 
2. Dr. Anda Baharav, Sleep specialist,  Sleep Lab at Shaare Zedek Medical Centre 
3. Mr Jonathan Halpern (PhD degree student, School of Health Sciences, RMIT University, 
jonthan.halpern@student.rmit.edu.au, 02-6666319) 
4. Prof. Marc Cohen (Senior Supervisor, School of Health Sciences, RMIT University, 
marc.cohen@rmit.edu.au, 03- 99257440) 
5. Dr. Gerard Kennedy (Supervisor: Victoria University, School of Psychology, 
Gerard.kennedy@vu.edu.au, 03- 9919 2481) 
 
Dear Sir / Madam, 
You are invited to participate in a research project being conducted by Shaare Zedek Medical 
Centre and RMIT University in the Jerusalem area. This information sheet describes the project 
in straightforward language, or „plain English‟. Please read this sheet carefully and be confident 
that you understand its contents before deciding whether to participate.  If you have any 
questions about the project, please ask one of the investigators.   
Who is involved in this research project? Why is it being conducted? 
My name is Jonathan Halpern. I am a PhD student at RMIT school of Health Sciences. My 
supervisors are Dr. Clement Cahan, Director of Sleep Lab at Shaare Zedek Medical Centre 
(SZMC), Dr. Anda Baharav, Sleep specialist,  Sleep Lab at SZMC, Professor Marc Cohen PhD 
MBBS from RMIT School of Health Sciences, currently President of the Australasian 
Integrative Medicine Association and Dr. Gerard Kennedy, Victoria University – Dept. of 
Psychology, a medical psychologist and sleep and insomnia expert. This study is conducted as 
part of my research towards a PhD degree. It has been approved by the Human Research Ethics 
Committees at RMIT and at SZMC.  
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Why have you been approached? 
You have been approached at random because you may fit the criteria (healthy adult, 60 years 
or older, suffering from disturbed sleep). If you fit these criteria then you may apply to 
participate in the trial. 
What is the project about? What are the questions being addressed? 
Insomnia is common in the elderly population and is associated with increased health problems, 
reduced quality of life and greater use of sleep drugs. This research aims to examine the 
effectiveness of Integrated Yoga style practice for treating insomnia in elderly people, and 
enhancing their quality of life. We hope to find out whether: 
1. Integrated yoga style practice can improve sleep quality/quantity 
2. Integrated yoga style practice can improve quality of life. 
We expect to have at least two groups. One group will undergo yoga training. The other group 
will serve as Wait List Control group and will join a yoga group later. 
If I agree to participate, what will I be required to do? 
  Participants in a Yoga group will be required to attend - free of charge - Yoga style training, 
two times per week for three months. Each session will be one hour long.  Yoga training will 
include gentle Yoga poses, relaxation and meditation exercises. Our Yoga teachers are 
experienced and certified.  Yoga group participants will also be required to perform relaxation, 
and meditation exercises daily using an audio CD supplied free of charge. Participants will be 
required to fill out sleep logs daily and various forms and questionnaires before and after the 
study including, sleep quality and life quality questionnaires. Participants will also be required 
to spend up to 3 nights connected to a mobile sleep measurement device (at home) to monitor 
the quality and quantity of their sleep. These measurements are very safe and non invasive and 
measure electrical activity of the heart, movement, position, oxygen saturation etc.  
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We extend an invitation to anyone interested in participating to come to our office, view the 
questionnaire forms and view a folder which contains additional information about the 
intervention  
What are the risks or disadvantages associated with participation? 
The risk of injury or adverse physical or emotional response resulting from gentle yoga or 
relaxation practice during the trial is low. However, as in any kind of physical exercise there is 
always a risk of discomfort, pain, or unexpected injury. The staff will do their utmost to 
minimise these risks. Any complaint or concern you report will be dealt with promptly. 
Participation in this research is voluntary and you may withdraw at anytime. If you are unduly 
concerned about your responses to any of the questionnaire items or if you find participation in 
the project emotionally or physically distressing or difficult in any way, you should contact us 
to discuss your concerns with confidentiality and suggest appropriate follow-up, if necessary. 
If any of the medical or sleep examinations, during the trial, reveal any data which is in your 
interest to know, such as any serious health risk, you may be contacted and referred to someone 
who can be of assistance. 
What are the benefits associated with participation? 
All Participants in the study will undergo free sleep assessment as well as some other free non 
invasive medical examinations.  If any of these reveal any data which is in your interest to 
know, you may be contacted and referred to someone who can be of assistance. Participants in 
the Yoga group (s) will also gain the benefit of undergoing free yoga and relaxation training for 
three months. Similar trials in the past have reported some improvement in various aspects of 
participants‟ physical and emotional well being, and sleep quality as well. Participants will gain 
basic knowledge of yoga practice, meditation and relaxation techniques, which they may choose 
to continue applying in their lives beyond the scope of this trial. 
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What will happen to the information I provide? 
Any information that you provide can be disclosed only if (1) to protect you or others from 
harm, or (2) a court order is produced, or (3) you provide the researchers with written 
permission. 
Participants need to be identified in the research records only, for health and safety reasons, i.e. 
to enable us to contact a participant if necessary in case any of the medical or sleep data, during 
the trial, reveal anything which is in your interest to know, such as any serious health risk. The 
data collected will be analysed by me, my supervisors, and by sleep lab staff. Data will be used 
for research and the results may be disseminated in reports, scientific papers, academic 
conferences etc. The results will be aggregated and reported in a manner, which maintains 
participant‟s total anonymity. The research data will be kept securely at SZMC for a period of 5 
years before being destroyed.  
What are my rights as a participant? 
Participants’ rights, include: 
1. The right to withdraw their participation at any time, without prejudice. 
2. The right to have any unprocessed data withdrawn and destroyed, provided it can be reliably 
identified, and provided that so doing does not increase the risk for the participant. 
3. The right to have any questions answered at any time. 
4. The right not to perform any exercise which they feel may be harmful or stressful to them in 
any way. 
 
Whom should I contact if I have any questions? 
 Please contact the following people, if you have any further questions: 
1. Prof. Marc Cohen, School of Health Sciences, RMIT University, marc.cohen@rmit.edu.au, 
03- 99257440 
2. Dr. Gerard Kennedy (Victoria University, School of Psychology, 
Gerard.kennedy@vu.edu.au, 03- 9919 2481 
3. Dr. Clement Cahan, Director  of Sleep Lab at Shaare Zedek Medical Centre , Jerusalem, 
02-6666319 
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What other issues should I be aware of before deciding whether to participate? 
We require that you provide us with accurate and full information before during and after the 
trial in the questionnaires and others examinations. This is essential to help us ensure your 
health and safety. Also, please report any problem immediately to your Yoga instructor or to the 
investigators. We also require that participants fully accept in advance the selection and 
assignment process. We also require that all participants attend all scheduled examinations, fill 
out fully and submit all questionnaires on time, attend all yoga practice sessions and perform the 
relaxation exercises as prescribed at home (for those in the yoga group). The success of the trial 
as well as your well being depends on your full cooperation. We ask that you join only if you 
are fully committed to comply with the requirements and believe that you will be able to do so. 
Yours sincerely 
Name: Jonathan Halpern   15 Nov. 07 
(Signature of Principal Investigator) 
Mr Jonathan Halpern (PhD degree student, School of Health Sciences, RMIT University) 
Name:   15 Nov. 07 
(Signature of senior supervisor if applicable) 
Prof. Marc Cohen (PhD, MBBS, Senior Supervisor, School of Health Sciences, RMIT 
University) 
Name:   15 Nov. 07 
(Signature of Investigator) 
Dr. Gerard Kennedy (PhD, Medical Psychologist, Senior lecturer Victoria University, School 
of Psychology) 
Any complaints about your participation in this project may be directed to the Executive Officer, RMIT Human Research 
Ethics Committee, Research & Innovation, RMIT, GPO Box 2476V, Melbourne, 3001.    
Details of the complaints procedure are available at:  http://www.rmit.edu.au/rd/hrec_complaints  
Plain language statement Version no. 1, 10 Nov. 07 
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Appendix 5.  Subjective measures questionnaires (English versions) 
Appendix 5.1 Karolinska Sleepiness Scale (KSS) 
The following is a nine point scale to describe your sleepiness level. Tick the box next 
to the point that describes how SLEEPY you feel RIGHT NOW.  
1.  extremely alert 
2.   
3.  alert 
4.   
5.  neither alert nor sleepy 
6.   
7.  sleepy-but no difficulty remaining awake 
8.   
9.  extremely sleepy-fighting sleep 
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Appendix 5.2  Epworth Sleepiness Scale (ESS) 
The following questions refer to sleepiness or the tendency to doze off when 
relaxed. How likely are you to doze off or fall asleep in the following situations, 
in contrast to just feeling tired? This refers to your usual way of life in recent 
times. Even if you haven‟t done some of these things recently, try to work out 
how they would have affected you. Choose the most appropriate number for each 
situation by putting an X in one box for each question. 
 0 1 2 3 
Situation  never slight 
chance 
Moderate 
chance 
High 
chance 
1) Sitting and reading     
2) Watching TV     
3) Sitting, inactive in a public place  (e.g. 
theatre or a meeting) 
    
4) As a passenger in a car for an hour 
without a break 
    
5) Lying down to rest in the afternoon 
when circumstances permit 
    
6) Sitting and talking to someone     
 7) Sitting quietly after a lunch without 
alcohol 
    
8) In a car, while stopped for a few 
minutes in traffic 
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Appendix 5.3 Pittsburgh Sleep Quality Questionnaire (PSQI) 
The following questions relate to your usual sleep habits during the past month only. 
Your answers should indicate the most accurate reply for the majority of days and nights 
in the past month.   
(1) During the past month, what time have you usually gone to bed at night? 
BED TIME: __________________ 
(2) During the past month, how long (in minutes) has it usually taken you to fall 
asleep each night?  
NUMBER OF MINUTES: _______________ 
(3) During the past month, what time have you usually gotten up in the morning?  
GETTING UP TIME: ______________ 
(4) During the past month, how many hours of actual sleep did you get at night? 
(This may be different than the number of hours you spent in bed) 
HOURS OF SLEEP PER NIGHT: _____________ 
(5) For each of the following questions, tick X in the box [ ] of the one response that 
best describes your sleeping patterns. Please answer all questions. 
During the past month, how often have you had trouble sleeping because you: 
 
Not 
during 
the 
past 
month 
Less 
than 
once a 
week 
Once or 
twice a 
week 
Three 
or more 
times a 
week 
a. Cannot get to sleep within 30  
minutes     [    ]  [    ]  [    ]  [    ] 
b. Wake up in the middle of the 
night or early morning  [    ]  [    ]  [    ]  [    ] 
c. Have to get up to use the 
bathroom    [    ]  [    ]  [    ]  [    ] 
d. Cannot breath comfortably [    ]  [    ]  [    ]  [    ] 
e. Cough or snore loudly  [    ]  [    ]  [    ]  [    ] 
f. Feel too cold   [    ]  [    ]  [    ]  [    ] 
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g. Feel too hot   [    ]  [    ]  [    ]  [    ] 
h. Had bad dreams   [    ]  [    ]  [    ]  [    ] 
i. Have pain   [    ]  [    ]  [    ]  [    ] 
j. Other reason(s), please describe:  
k. How often during the past have you had trouble sleeping because of the above 
reasons 
Not 
during 
the 
past 
month 
Less 
than 
once a 
week 
Once or 
twice a 
week 
Three 
or more 
times a 
week 
     [    ]  [    ]  [    ]  [     ] 
 (6) During the past month, how would you rate your sleep quality overall? 
 
 Very good    [    ] 
 Fairly good   [    ] 
 Fairly bad    [    ] 
 Very bad    [    ] 
 
(7) During the past month, how often have you taken medicine to help you sleep 
(Prescribed or "over the counter")? 
 Not during the past month [    ] 
 Less than once a week  [    ] 
 Once or twice a week  [    ] 
 Three or more times a week [    ] 
 
(8) During the past month, how often have you had trouble staying awake while 
driving, eating meals, or engaging in social activity?  
 Not during the past month [    ] 
 Less than once a week  [    ] 
 Once or twice a week  [    ] 
 Three or more times a week [    ] 
 
(9) During the past month, how much of a problem has it been for you to keep up 
enough enthusiasm to get things done? 
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 No problem at all   [    ] 
 Only a very slight problem [    ] 
 Somewhat of a problem  [    ] 
 A very big problem   [    ] 
 
(10) Do you have a bed partner or roommate?  
 No bed partner or roommate   [    ] 
 Partner/roommate in other room   [    ]  
 Partner in same room, but not same bed  [    ]  
 Partner in same bed    [    ] 
 
(11) If you have a roommate or bed partner, ask him/her how often in the past month 
you have had: 
Not 
during 
the 
past 
month 
Less 
than 
once a 
week 
Once or 
twice a 
week 
Three 
or more 
times a 
week 
a. Loud snoring   [    ]  [    ]  [    ]  [    ] 
b. Loud pauses between breaths  
while asleep   [    ]  [    ]  [    ]  [    ] 
c. Legs twitching or jerking while 
you sleep    [    ]  [    ]  [    ]  [    ] 
d. Episode of disorientation or 
confusion during sleep  [    ]  [    ]  [    ]  [    ] 
e. Other restlessness while you sleep; please describe: 
______________________________________________________________________
______________________________________________________________________ 
f. How often during the past have you had trouble sleeping because of the above reason? 
Not 
during 
the 
past 
month 
Less 
than 
once a 
week 
Once or 
twice a 
week 
Three 
or more 
times a 
week 
     [    ]  [    ]  [    ]  [    ] 
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Appendix 5.4 Multivariate Apnea Prediction index (MAP) questionnaire 
The following questions are about your sleep 
During the last month, have you had, or have you been told about the following symptoms: 
(show the frequency by putting a cross in one box) 
During the last month, have you had, or have you been told about the following symptoms: 
(show the frequency by putting a cross in one box) 
 
 0 1 2 3 4 0 
Frequency   
Symptoms  
 never rarely 1-2 
times 
p/week 
3-4 
times 
p/week 
5-7 
times 
p/week 
Don‟t 
know 
1. snorting or gasping         
2. loud snoring         
3. breathing stops, choke or 
struggle for breath  
       
4. frequent awakenings        
5. tossing, turning or thrashing         
6. difficulty falling asleep         
7. legs feel jumpy or jerky         
8. morning headaches         
9. falling asleep when at work or 
school 
       
10. falling asleep when driving         
11. excessive sleepiness during 
the day  
       
12. awaken feeling paralysed, 
unable to move for short 
period‟s  
       
13. find yourself in a vivid 
dreamlike state when falling 
asleep or awakening even 
though you know you‟re 
awake  
       
 
Please continue to the next page  
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Appendix 5.5 Profile of Mood States- Short Form (POMS-SF) Questionnaire 
Below is a list of words that describe feelings people have. Please read each one carefully. 
Then, mark an X in the box that best describes how you have been feeling during the past 
week including today 
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1. Tense        20. Discouraged      
2. Angry        21. Resentful      
3. Worn out        22. Nervous      
4. Unhappy       23. Miserable      
5. Lively       24. Cheerful      
6. Confused       25. Bitter      
7. Peeved       26. Exhausted      
8. Sad       27. Anxious      
9. Active       28. Helpless      
10. On edge       29. Weary      
11. Grouchy       30. Bewildered      
12. Blue       31. Furious      
13. Energetic       32. Full of pep      
14. Hopeless       33. Worthless      
15. Uneasy       34. Forgetful      
16. Restless       35. Vigorous      
17. Unable to 
concentrate 
      36. Uncertain 
about things 
     
18. Fatigued       37. Bushed      
19. Annoyed       
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Appendix 5.6 Depression Anxiety Stress Scale (DAS S – 42) Questionnaire 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the statement 
applied to you over the past week.  There are no right or wrong answers.  Do not spend too much time on 
any statement. 
The rating scale is as follows: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
 
1 I found myself getting upset by quite trivial things 0      1      2      3 
2 I was aware of dryness of my mouth 0      1      2      3 
3 I couldn't seem to experience any positive feeling at all 0      1      2      3 
4 I experienced breathing difficulty (e.g., excessively rapid breathing, 
breathlessness in the absence of physical exertion) 
0      1      2      3 
5 I just couldn't seem to get going 0      1      2      3 
6 I tended to over-react to situations 0      1      2      3 
7 I had a feeling of shakiness (e.g., legs going to give way) 0      1      2      3 
8 I found it difficult to relax 0      1      2      3 
9 I found myself in situations that made me so anxious I was most relieved 
when they ended 
0      1      2      3 
10 I felt that I had nothing to look forward to 0      1      2      3 
11 I found myself getting upset rather easily 0      1      2      3 
12 I felt that I was using a lot of nervous energy 0      1      2      3 
13 I felt sad and depressed 0      1      2      3 
14 I found myself getting impatient when I was delayed in any way  (e.g., lifts, 
traffic lights, being kept waiting) 
0      1      2      3 
15 I had a feeling of faintness 0      1      2      3 
16 I felt that I had lost interest in just about everything 0      1      2      3 
17 I felt I wasn't worth much as a person 0      1      2      3 
18 I felt that I was rather touchy 0      1      2      3 
19 I perspired noticeably (e.g., hands sweaty) in the absence of high 
temperatures or physical exertion 
0      1      2      3 
20 I felt scared without any good reason 0      1      2      3 
21 I felt that life wasn't worthwhile 0      1      2      3 
 Please continue on next page   
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Reminder of rating scale: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
 
22 I found it hard to wind down 0      1      2      3 
23 I had difficulty in swallowing 0      1      2      3 
24 I couldn't seem to get any enjoyment out of the things I did 0      1      2      3 
25 I was aware of the action of my heart in the absence of physical 
exertion (e.g., sense of heart rate increase, heart missing a beat) 
0      1      2      3 
26 I felt down-hearted and blue 0      1      2      3 
27 I found that I was very irritable 0      1      2      3 
28 I felt I was close to panic 0      1      2      3 
29 I found it hard to calm down after something upset me 0      1      2      3 
30 I feared that I would be "thrown" by some trivial but 
unfamiliar task 
0      1      2      3 
31 I was unable to become enthusiastic about anything 0      1      2      3 
32 I found it difficult to tolerate interruptions to what I was doing 0      1      2      3 
33 I was in a state of nervous tension 0      1      2      3 
34 I felt I was pretty worthless 0      1      2      3 
35 I was intolerant of anything that kept me from getting on with 
what I was doing 
0      1      2      3 
36 I felt terrified 0      1      2      3 
37 I could see nothing in the future to be hopeful about 0      1      2      3 
38 I felt that life was meaningless 0      1      2      3 
39 I found myself getting agitated 0      1      2      3 
40 I was worried about situations in which I might panic and make 
a fool of myself 
0      1      2      3 
41 I experienced trembling (e.g., in the hands) 0      1      2      3 
42 I found it difficult to work up the initiative to do things 0      1      2      3 
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Appendix 5.7 Health Survey (SF36) questionnaire  
This questionnaire asks for your views about your general health, how you feel and how well you are 
able to do various activities. Please answer every question by checking one choice only for each. Thank 
you. 
 
1.  In general, would you say your health is? 
  1. Excellent   2. Very good   3. Good   4. Fair   5. Poor 
2.  Compared to one year ago, how would you rate your health in general now? 
  1. MUCH BETTER than one year ago. 
  2. Somewhat BETTER now than one year ago. 
  3. About the SAME as one year ago. 
  4. Somewhat WORSE now than one year ago. 
  5. MUCH WORSE now than one year ago. 
 
 
 
 
 
 
3.  The following items are about activities you might do during a typical day.  Does your health 
now limit you in these activities? If so, how much? 
Activities 1. Yes, 
limited a 
lot 
2.  Yes, 
limited  
a Little 
3. Not 
limited at 
all 
a) Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports? 
   
b) Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing 
golf? 
   
c) Lifting or carrying groceries?    
d) Climbing several flights of stairs?    
e) Climbing one flight of stairs?    
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f) Bending, kneeing or stooping?    
g) Walking more than a mile?    
h) Walking several blocks?    
i) Walking one block?    
j) Bathing or dressing yourself?    
 
4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular activities as a result of your physical health? 
 Yes No 
a) Cut down on the amount of time you spent on work or other 
activities? 
  
b) Accomplished less than you would like?   
c) Were limited in the kind of work or other activities?   
d) Had difficulty performing the work or other activities (for 
example it took extra effort)? 
  
 
5. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
 Yes No 
a) Cut down on the amount of time you spent on work or other 
activities? 
  
b) Accomplished less than you would like?   
c) Didn‟t do work or other activities as carefully as usual?   
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6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups? 
  1. Not at all   2. Slightly   3. Moderately       4. Quite a bit       5. Extremely 
7. How much bodily pain have you had during the past 4 weeks? 
  1. None        2. Very mild       3. Mild       4. Moderate      5. Severe       6. Very severe 
8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
work outside the home and housework)? 
  1. Not at all   2. A little bit   3. Moderately       4. Quite a bit       5. Extremely 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you have been 
feeling.  How much of the time during the past 4 week … 
 1. All 
of the 
time 
2. Most 
of the 
time 
3. A 
good 
bit of 
the 
time 
4. 
Some 
of 
the 
time 
5. A 
little 
of the 
time 
6. 
None 
of 
the 
time 
a) Did you feel full of 
pep? 
      
b) Have you been a very 
nervous person? 
      
c) Have you felt so 
down in the dumps that 
nothing could cheer you 
up?  
      
d) Have you felt calm 
and peaceful? 
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e) Did you have a lot of 
energy? 
      
f) Have you felt 
downhearted and blue? 
      
g) Do you feel worn 
out? 
      
h) Have you been a 
happy person? 
      
i) Did you feel tired?       
 
10. During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives, etc.)? 
  1. All of the time 
  2. Most of the time. 
  3. Some of the time 
  4. A little of the time. 
  5. None of the time. 
 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
 1. 
Definitel
y true 
2. 
Mostly 
true 
3.  
Don‟t 
know 
4. 
Mostly 
false 
5. 
Definitely 
false 
a) I seem to get sick a 
little easier than other 
people? 
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b) I am as healthy as 
anybody I know? 
     
c) I expect my health to 
get worse? 
     
d) My health is excellent?      
 
 
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Appendix 5.8–Daily Sleep and practice log (DSPL) English version 
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Comments: 
1. The method for filling out the table at the top of the sleep diary: 
2. A period of continuous sleep is indicated with a horizontal line 
3. Getting out of bed is indicated with an upward pointing arrow  
4. Getting into bed is indicated with a downward pointing arrow.  
The researcher is then able to determine the number and duration of mid sleep awakenings as well as early morning awakenings , bed time, 
sleep onset, and final arising.
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 )snoisreV werbeH( seriannoitseuq – serusaem evitcejbuS   .6 xidneppA
 noisrev werbeH – )SSK( elacS ssenipeelS aksniloraK 1.6 xidneppA
  מעבדת שינה –הרפואי שערי צדק  המרכז
 שאלונים בנושא איכות שינה , מצב רוח ובריאות
בסדרת השאלונים הבאה שאלות  כיצד את/ה  מרגיש/ה או מעריך/ה את מצבך. אין צורך להתלבט יותר מדי  
 כי מדובר בהרגשה / הערכה הסובייקטיבית של כל אדם לגבי עצמו כרגע . אין תשובות נכונות יותר או פחות. 
כל משתתף ימלא את שמו ואת התאריך . לאחר מכן אנו ניתן לכל שאלון קוד סודי והאינפורמציה תישמר 
 בעילום שם עם הקוד הסודי בלבד באופן שפרטיותכם תשמר לחלוטין.
  ______________________________ : משתתף  שם
  _____________________:תאריך_____________ :משתתף  קוד
הקף בעיגול את הספרה בשורה המתארת בצורה  נא  .להירדם הנטייה לדרוג סולם  להלן
 המדויקת ביותר כיצד אתה מרגיש ברגע זה. נא לבחור באפשרות אחת בלבד.  תודה.
 1  ערני מאד
 2  3 לאפשרות  1 אפשרות בין משהו
 3 ערני
 4  5 לאפשרות  3 אפשרות בין משהו
 5  רדום ולא ערני לא
 6  7 לאפשרות  5 אפשרות בין משהו
 7  בקלות ער להישאר מסוגל אך רדום
 8  9 לאפשרות  7 אפשרות בין משהו
 9  להירדם ולא ער להישאר כדי רב מאמץ נדרש. רדום מאד
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  noisrev werbeH – )SSE( ELACS SSENIPEELS HTROWPE   2.6 xidneppA
 
  ______________________________ : משתתף שם
  _____________________:תאריך_____________ :משתתף  קוד
 הרגשת לסתם בניגוד, הבאים במצבים ממש להירדם או תנומה לחטוף נטייה לך יש כמה עד
 אחת את עשית לא האחרון בזמן אם אפילו. שלך הנוכחיים יום-היום לחיי מתייחסת השאלה ?עייפות
 בדירוג השתמש. עליך משפיעים היו אלה כיצד לשער נסה, המפורטים במצבים שהית ולא הפעולות
  :פעולה/מצב לכל ביותר המתאים המספר את  לבחור מנת על) 3 עד 0 -מ( הבא
 נא בחר  מסולם האפשרויות הבא למתן תשובה:
  זה במצב מנמנם הייתי לא לעולם) 0(
  זה במצב מנמנם שהייתי נמוך סיכוי) 1(
  זה במצב מנמנם שהייתי בינוני סיכוי) 2(
  זה במצב מנמנם שהייתי גבוה סיכוי) 3(
  בכל בלבד אחת באפשרות בחר נא , בשורה ביותר המתאימה האפשרות של הספרה סביב עיגול סמן נא
 סיכוי
 גבוה
 שהייתי
 מנמנם
  זה במצב
 בינוני סיכוי
 שהייתי
 במצב מנמנם
 זה
 נמוך סיכוי
 שהייתי
 מנמנם
  זה במצב
 לא לעולם
 הייתי
 מנמנם
  זה במצב
 המצב
 קריאה בישיבה 0 1 2 3
  בטלוויזיה צפייה 0 1 2 3
 ציבורי במקום פסיבית ישיבה 0 1 2 3
  )קונצרט, סרט, תיאטרון(
) כנהג לא( במכונית כנוסע 0 1 2 3
  רצופה שעה במשך
 אחר בשעות למנוחה שכיבה 0 1 2 3
 הדבר כאשר, הצהריים
 מתאפשר
 שיחה עם מישהו בישיבה 0 1 2 3
 ארוחת לאחר רגועה ישיבה 0 1 2 3
 שתייה שתית לא שבה( צהריים
  )אלכוהולית
 בזמן, )כנהג( במכונית ישיבה 0 1 2 3
  )פקק, רמזור( עצירה קצרה
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 ______________________________: משתתף  שם
 _____________________:תאריך_______ :משתתף  קוד 
 צריכות התשובות. בלבד האחרון החודש במהלך שלך השינה בהרגלי עוסקות הבאות השאלות :הוראות
 . האחרון בחודש והלילות הימים מרבית את לשקף
 שאלה לאותה ביותר המתאימה לתשובה מתחת איקס סמן נא
 .שורה בכל בלבד אחת תשובה השאלות כל על לענות נא
 : האחרון החודש במהלך
 ______________  ? למיטה הלכת כלל בדרך מתי .1
 _____________  ? לילה בכל להירדם לך לקח) בדקות( זמן כמה .2
 _____________  ? בבוקר קמת כלל בדרך מתי .3
 __________  ?)במטה שעות לא – שינה שעות רק(? בלילה ישנת שעות כמה .4
  האחרון החודש במהלך מהן שסבלת  שינה בעיות תדירות בטבלא מלא נא .5
 
 באיזה האחרון החודש במהלך 
 בשינה מבעיות  סבלת תדירות
 :הבאות הסיבות עקב
 סבלתי לא
 בחודש
  האחרון
 פחות
 מפעם
 בשבוע
 או פעם
 פעמיים
 בשבוע
 שלוש
 פעמים
 או בשבוע
  יותר
 03 במשך להירדם ה/יכול לא  .א
 דקות
    
 או הלילה באמצע ת/מתעורר  .ב
 בבוקר מוקדם
    
     לשירותים בלילה לקום ת/חייב. ג
     בנוח לא ת/נושם. ד
     בחוזקה נוחרת או ת/משתעל. ה
     קר מאד ה/מרגיש. ו
     חם מאד ה/מרגיש. ז
     רעים חלומות לך יש. ח
     מכאבים ת/סובל. ט
 אותן י/תאר: אחרות סיבות. י
 :זו בשורה במילים
 
 סבלתי לא 
 בחודש
  האחרון
 פחות
 מפעם
 בשבוע
 או פעם
 פעמיים
 בשבוע
 שלוש
 פעמים
 או בשבוע
  יותר
 לך הפריעו תדירות באיזה. יא
 :לישון ל"הנ הסיבות
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 ? כ"בסה שנתך איכות את ה/מעריך ה/את כיצד, האחרון החודש במהלך. 6
 מאד רעה  רעה  טובה מאד טובה
    
 
 ?)מרשם ללא או במרשם( לשינה תרופה לקחת תדירות באיזה, האחרון החודש במהלך. 7
 .בלבד אחת בתשובה לבחור נא. ביותר המתאימה התשובה תחת איקס לסמן נא
 
 לקחתי  לא
 בחודש כלל
  האחרון
 מפעם פחות לקחתי
 בשבוע
 פעמיים או פעם לקחתי
 בשבוע
 פעמים שלוש לקחתי
  יותר או בשבוע
    
 
 בפגישות או, בארוחות, בנהיגה ערה להישאר בעיה לך הייתה תדירות באיזו, האחרון החודש במהלך. 8
 ?חברתיות
 
 לא  כלל  
 בחודש
  האחרון
 בשבוע פעמים שלוש בשבוע פעמיים או פעם בשבוע מפעם פחות
  יותר או
    
 
 ?דברים לעשות מנת על התלהבות על לשמור  בעיה לך הייתה כמה עד, האחרון החודש במהלך. 9
 
 לא  כלל  
 בעיה
 בחודש
  האחרון
 במידה בעיה 
 מועטה
 גדולה במידה בעיה בינונית במידה בעיה
    
 
 ? כ"בסה שנתך איכות את ה/מעריך ה/את כיצד, האחרון החודש במהלך. 01
 מאד רעה  רעה  טובה מאד טובה
    
 
 בזמן הבאות התופעות לך היו תדירות באיזו ה/אותו שאל נא למיטה  או/ו לחדר ה/שותף לך יש באם. 11
 .בלבד אחת בתשובה לבחור נא. ביותר המתאימה התשובה תחת איקס לסמן נא?  השינה
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  כלל   
 לא
 בחודש
  האחרון
 פחות
 מפעם
 בשבוע
 או פעם
 פעמיים
 בשבוע
 שלוש
 פעמים
 בשבוע
  יותר או
     קולניות נחירות. א
 ביו ארוכות הפסקות. ב
 נשימות
    
 וקפיצות תנועות. ג
  ברגליים
    
 איבוד,  בלבול תופעות  .ד
 כוון
    
 של אחרות תופעות. ה
 לתאר נא – שקט חוסר
 במילים
 
  כלל   
 לא
 בחודש
  האחרון
 פחות
 מפעם
 בשבוע
 או פעם
 פעמיים
 בשבוע
 שלוש
 פעמים
 או בשבוע
  יותר
 הפרעה תדירות באיזה. ו
 התופעות  ידי על שנתך
 ? זו בשאלה המתוארות
    
 
  הבא לדף לעבור נא
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_______ :משתתף  קוד_______________________ : משתתף  שם
  _____________________:תאריך
 האחרון החודש במהלך אם ציין נא. לאדם מאדם שונה בתדירות שונות תופעות להופיע עשויות השינה במהלך
נא בחר . האפשרות המתאימה ביותרנא סמן בטור של . לתופעות הבאות) אחריםי "ע לך נאמראו ( לב שמת
  .באפשרות אחת בלבד בכל שורה
לא  
 יודע
  5 – 7
 פעמים
 
 בשבוע
  3 – 4
 פעמים
 
 בשבוע
  
  1 – 2
  פעמים
 בשבוע
 
 פחות
 מפעם
 בשבוע
 לעולם
 לא
  תאור התופעה
 שאיפות או חרחורים      
 פתאומיות אוויר
 וחדות
 1
 2  חזקות נחירות      
, נשימה הפסקות      
 נשימה קשיי, מחנק
  מאומצת נשימה/ 
 3
 תכופות מתעורר      
 משינה
 4
 6  להירדם קשיים      
 או קופצות רגליים      
 בועטות
 7
 8  בבוקר ראש כאבי      
 או בעבודה נרדם      
 בלימודים
 9
1  נהיגה כדי תוך נרדם      
 0
 במשך יתר עייפות      
 היום
1
 1
 בהרגשה מתעורר      
/  משותק  שאתה
 תנועה יכולת חוסר
  קצר זמן לפרק
1
 2
 ההרדמות כדי תוך      
 ההתעוררות או
 עצמך מוצא משינה
 אך חלום כמו במצב
 לכך מודע זמנית בו
    ער שבעצם
1
 3
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_______ :משתתף  קוד______________________ : משתתף  שם
  _____________________:תאריך
 להרגשתך ההתאמה למידת בהתאם  3 או, 2, 1, 0 המספר סביב אחד  עגול וסמן סעיף ובכל קרא נא
 הנאמר של התאמה/  הנכונות מידת לדירוג הסולם להלן. בלבד אחת אפשרות לבחר נא. שחלף בשבוע
  :החולף בשבוע למצבך
  נכון לא לגמרי   0
  בלבד הזמן מן חלק נכון או מסוימת במידה נכון  1
  הזמן מן ניכר חלק נכון או רבה במידה נכון  2
  הזמן רב נכון או מאד רבה במידה נכון 3
 1  פעוטים דברים בגלל הנפש שלוות את אבדתי  3         2         1         0  
 2  בפה ליובש מודע הייתי  3         2         1         0  
 3  כלשהם חיוביים רגשות לחוות מסוגל הייתי לא  3         2         1         0  
 נשימה קוצר או מהירות נשימות לדוגמה( בנשימה קושי חשתי  3         2         1         0  
  )גופני מאמץ בעת שלא
 4
 5  דברים להתחיל/  לפעולה להיכנס התקשיתי  3         2         1         0  
 6  שונים במצבים מוגזמות לתגובות נטיתי  3         2         1         0  
 7  )ברגליים חולשה למשל(  יציבות חוסר הרגשתי  3         2         1         0  
 8  להירגע קשה לי היה  3         2         1         0  
 מרובה הקלה והרגשתי חרדה בי שעוררו במצבים עצמי מצאתי  3         2         1         0  
  כשחלפו
 9
 01  תקווה חוסר הרגשתי  3         2         1         0  
 11  בקלות הנפש שלוות את אבדתי  3         2         1         0  
 21  רבה עצבים אנרגית מוציא/ ' עצבים'  על חי שאני הרגשתי  3         2         1         0  
 31  ומדוכא עצוב הייתי  3         2         1         0  
 למשל( כלשהיא בדרך להתעכב כשנאלצתי סבלנותי את אבדתי  3         2         1         0  
  )בתור בהמתנה, ברמזור, במעלית
 41
 51  חולשה חשתי  3         2         1         0  
 61  שהוא דבר בכל עניין מאבד שאני הרגשתי  3          2          1          0  
 71  ערך חסר הרגשתי  3          2          1          0  
 81  )נפשית( יתר רגישות פתחתי  3          2          1          0  
 גופני מאמץ בהעדר) הידיים בכפות למשל( מוגברת בצורה הזעתי  3          2          1          0  
  חם היה שלא ולמרות
 91
 463
 
 02  הגיונית סיבה ללא פחד חשתי  3          2          1          0  
 12  לחיי ערך שאין הרגשתי  3          2          1          0  
 22  ולהירגע קצב להוריד  התקשיתי  3          2          1          0  
 32  בבליעה קשיים לי היו  3          2          1          0  
 42  שעשיתי ממה ליהנות התקשיתי  3          2          1          0  
 ללא) סדיר לא או מוגבר לב קצב( ליבי לפעימות  מודע הייתי  3          2          1          0  
  נלווה גופני מאמץ
 52
 62  ומדוכדך שפוף הרגשתי  3          2          1          0  
 72  בקלות התעצבנתי  3          2          1          0  
 82  פאניקה/  עשתונות אבדן למצב קרוב הייתי  3          2          1          0  
 92  משלוותי אותי הוציא שמשהוא לאחר להירגע קשה לי היה  3          2          1          0  
 03  חדשה אך פשוטה משימה עם להתמודד אצליח שלא חששתי  3          2          1          0  
 13  שהוא דבר מכל  להתלהב התקשיתי  3          2          1          0  
 23  במשהו עסוק כשהייתי לי כשהפריעו סבלנות לגלות התקשיתי  3          2          1          0  
 33  ועצבני מתוח הייתי  3          2          1          0  
 43  ערך חסר הרגשתי  3          2          1          0  
 פעילות במהלך אותי שעיכב מה כל  כלפי סובלנות חוסר גיליתי  3          2          1          0  
 כלשהיא
 53
 63  נורא פחד  חשתי  3          2          1          0  
 73  מוחלט תקווה חוסר חשתי  3          2          1          0  
 83  משמעות חסרי שהחיים הרגשתי  3          2          1          0  
 93  עצבני הייתי  3          2          1          0  
 04  אחרים בעיני מגוחך ואראה לפאניקה שאקלע חששתי  3          2          1          0  
 14  )בידיים למשל( רעידות/  רעד הרגשתי  3          2          1          0  
 24  דברים ולבצע יזמה לתפוש  התקשיתי  3          2          1          0  
  הבא לדף לעבור נא
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 noisrev werbeH – )SMOP( SETATS DOOM FO ELIFORP 6.6 xidneppA 
 את בחר נא שורה  / סעיף בכל  .בשאלון זה רשימת מילים המתארות מצבי רוח שונים שבני אדם עשויים לחוות
  . הנכונה לאפשרות המתאימה סמן נא.האחרון בשבוע רוחך למצב ביותר המתאימה האפשרות
 
 במידה  
    מאד רבה
 
 במידה 
  רבה
 
 במידה 
  בינונית
 
 במידה  
  מועטה
 
 בכלל 
 לא
  
 1 מתוח     
 2 כועס     
 3 שחוק     
 4  שמחה ללא     
 5  חיים מלא     
 6 מבולבל     
 7  סבלנות וחסר מעוצבן     
 8 עצוב     
 9 פעיל     
 עד מתוחים עצבים     
  גבולתיהיכולת הקצה
 01
 11  רע רוח במצב     
 21  שפוף/  מדוכא     
 31  אנרגיה מלא     
 41  תקווה חסר     
 51  נפשי שקט חסר     
 61  מנוחה חסר     
 71  להתרכז מסוגל לא     
 81 עייף     
 91 מעוצבן     
 02  אמונה/  תקווה חוסר     
 גרוע יחס על נרגן     
 שקיבלתי
 12
 22 עצבני     
 32 אומלל     
 42 עליז     
 52  מרירות חש     
 62  כוחות נטול     
 72 חרד     
 82  אונים/  תמיכה חסר     
 92 יגע     
 03  אבוד מרגיש     
 13 זועם     
 23 תוסס     
 33  ערך חסר     
 43 שכחן     
 53  וכוח עצמה מלא     
 דברים לגבי ודאות חוסר     
 שונים
 63
 73  לחלוטין תשוש     
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 noisrev werbeH – )63-FS( yevruS htlaeH 7.6 xidneppA
: משתתף קוד_______________________: משתתף  שם__________ : תאריך
 _____
  ? כללי  באופן שלך הבריאות מצב מה  דעתך את הביע  נא) 1(   
 אפשרות לבחור נא. (ביותר קרובה/המתאימה האפשרות מעל הספרה סביב עגול לסמן נא 
  .) בלבד אחת
 1 2 3 4 5
 מצוין  מאוד טוב טוב בינוני רע
 
 (2) בהשוואה לשנה אחת אחורה כיצד היית מדרג/ת את מצבך הבריאותי כפי שהוא עכשיו.
 נא לסמן עגול סביב הספרה מעל האפשרות המתאימה/קרובה ביותר. (נא לבחור אפשרות 
  .)בלבד אחת
 1 2 3 4 5
 הרבה
  גרוע יותר
 מאשר
  שנה לפני
  גרוע יותר
 לפני מאשר
 שנה
 כמו בערך
  שנה לפני
  טוב יותר
 לפני מאשר
 שנה
 יותר הרבה
 טוב
 לפני מאשר
 שנה
 
 מגביל הבריאותי מצבך האם ציין נא. רגיל ביום לפעילותך נוגעות הבאות השאלות) 3( 
. בלבד אחת אפשרות לבחור נא. מידה באיזו כן ואם הבאות הפעילויות את מלבצע אותך
 נא(  .ביותר קרובה/המתאימה האפשרות של  הספרה סביב עגול לסמן נא שורה בכל
  .)בלבד אחת אפשרות לבחור
 מוגבל לא
  )3( כלל
  מוגבל
  )2( חלקית
 מוגבל  
 מאד
  )1(
 
 הפעילות
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
 מוגבל   1 
  מאד
 הרמת, כריצה נמרצת פעילות) א(
 בפעילות  השתתפות, כבדים חפצים
  .מאומצת ספורטיבית
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  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
, שולחן כהזזת מתונות פעילויות) ב(  מאד מוגבל   1
  קלים משחקים  ,אבק שואב דחיפת
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
  מצרכים סל נשיאת) ג(  מאד מוגבל   1
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
  קומות מספר  - במדרגות עליה) ד(  מאד מוגבל   1
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
 אחת קומה  - במדרגות עליה) ה(  מאד מוגבל   1
 בלבד
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
  לכרוע, ברכיים לכופף, להתכופף) ו(  מאד מוגבל   1
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
  וחצי מקילומטר למעלה – הליכה) ז(  מאד מוגבל   1
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
  מטר 057 – הליכה) ח(  מאד מוגבל   1
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
  מטר 001– הליכה) ט(  מאד מוגבל   1
  לא    3
  כלל מוגבל
 מוגבל    2
 חלקית
  ולהתלבש להתרחץ) י(  מאד מוגבל   1
 
4)  בארבעת השבועות האחרונים האם מצבך הבריאותי או הגופני גרם לך לבעיות הבאות 
 האפשרות של הספרה סביב עגול לסמן נא שורה בכל. השגרתיות פעילויות או בעבודתך
  .)בלבד אחת אפשרות לבחור נא(? ביותר קרובה/המתאימה
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 לא
  )2(
   )1( כן
   2
  לא
  אחרות בפעילויות או בעבודה נמצא שאני הזמן כמות את לקצר נאלצתי) א(  כן   1
   2
  לא
  שרציתי ממה פחות לעשות הספקתי) ב(  כן   1
   2
  לא
  לעשות שיכולתי הפעילות או העבודה בסוג ת/מוגבל הייתי) ג(  כן   1
   2
  לא
  )יתר מאמץ נדרש – למשל( אחרת פעילות או עבודה בביצוע התקשיתי) ד(  כן   1
 
(5)  בארבעת השבועות האחרונים האם מצבים נפשיים (כגון חרדה או דיכאון)  גרמו לך 
  .)בלבד אחת אפשרות לבחור נא(? השגרתיות פעילויות או בעבודתך הבאות לבעיות
 לא
  )2(
   )1( כן
   2
  לא
  אחרות בפעילויות או בעבודה נמצא שאני הזמן כמות את לקצר נאלצתי) א(  כן   1
   2
  לא
  שרציתי ממה פחות לעשות הספקתי) ב(  כן   1
   2
  לא
  הרגילה הלב בתשומת אחרות פעילויות או העבודה  את בצעתי לא  )ג(  כן   1
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(6)  בארבעת השבועות האחרונים באיזו מידה השפיעו בעיות בריאות גופנית או בעיות  
, משפחה עם וקשריך השגרתיות החברתיות פעילויות על  )דיכאון או חרדה כגון( נפשיות
  .)בלבד אחת אפשרות לבחור נא( אחרות חברתיות קבוצות או שכנים, מכרים, חברים
 1 2 3 4 5
  לא כלל  מאד מעט  בינונית במידה הרבה  מאד הרבה
 
  (7)  בארבעת השבועות האחרונים מה הייתה מידה הכאב הגופני שחשת (אם בכלל)? 
 1 2 3 4 5 6
 כאב
 חזק
 מאד
 קל כאב  קל כאב  בינוני כאב  חזק כאב
 מאד
  כאב אף
 
(8)  בארבעת השבועות האחרונים באיזו מידה השפיעו הכאבים גופניים מהם סבלת על 
  .)בלבד אחת אפשרות לבחור נא(? )בית בעבודות וגם לבית מחוץ גם( לעבוד יכולתך
 1 2 3 4 5
  לא כלל  מאד מעט  בינונית במידה הרבה  מאד הרבה
 
 (9) השאלות הבאות הם לגבי הרגשתך ומצבך הכללי בארבעת השבועות האחרונים.
  )בלבד אחת אפשרות לבחור נא. ביותר הקרובה התשובה את י/בחר נא
  – האחרונים השבועות בארבעת הזמן מן חלק איזה
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 כלל
 לא
  )6(
 מעט
 מן
 הזמן
  )5(
 חלק
 מן
 הזמן
  )4(
 חלק
 ניכר
 מן
 הזמן
  )3( 
 רב
 הזמן
  )2(  
 כל
 הזמן
  )1( 
 
  ? חיים מלא הרגשת האם) א( 1 2 3 4 5 6
  ?עצבני מאד היית האם) ב( 1 2 3 4 5 6
 ת/מדוכדך כה הרגשת האם) ג( 1 2 3 4 5 6
 יכול לא כלשהוא שדבר עד
  ?אותך לשמח
  ? ושלוו רגוע הרגשת האם) ד( 1 2 3 4 5 6
 הרבה לך הייתה האם) ה( 1 2 3 4 5 6
  ?אנרגיה
 מדוכדך הרגשת האם) ו( 1 2 3 4 5 6
  ?ועצוב
  ?תשוש הרגשת האם) ז( 1 2 3 4 5 6
  ?שמח היית האם) ח( 1 2 3 4 5 6
  ?עייפות חשת האם  )ט( 1 2 3 4 5 6
  
(01)  בארבעת השבועות האחרונים באיזו מידה השפיעו בעיות בריאות גופנית או בעיות  
, משפחה אצל ביקור כגון( החברתיות פעילויות על  )דיכאון או חרדה כגון( נפשיות
  ?)חברים
 173
 
 1 2 3 4 5
  הזמן כל  הזמן רב  הזמן מן חלק  מהזמן מעט  לא בכלל
  ?)שלך במקרה( נכונות לא או נכונות הבאות הקביעות מידה באיזו) 11( 
  )5(
 בכלל
 לא
 נכון
  )4(
 בדרך
 כלל
 לא
 נכון
  )3(
 לא
 יודע
  ) 2(
 נכון
 בדרך
 כלל
) 1(
 נכון
 מאד
 
 מרב בקלות יותר לחלות נוטה אני) א( 1 2 3 4 5
 האנשים
 שאני מי כל כמו  לפחות בריא אני) ב( 1 2 3 4 5
 מכיר
 ותהיה תלך שבריאותי צופה אני) ג( 1 2 3 4 5
  יותר גרועה
  מצוין  בריאותי מצב) ד( 1 2 3 4 5
 נא הקדישו רגע לוודא שעניתם על כל הסעיפים. כלומר שבכל סעיף מוקף בעיגול  מספר אחד בלבד
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Appendix 6.8    Daily Sleep and Practice Log (DSPL) – Hebrew version 
 
  
373 
 
App.6.9    Daily Sleep and practice log - Hebrew version (DSPL) - Instructions and filling out example 
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Appendix 7. Embletta ® mobile sleep lab 
Appendix 7.1 Embletta ® data recording unit – technical specifications 
Table App.7.1 
Embletta ® data acquisition and recording unit – technical specifications 
Dimensions (H x W 
x D) 
0.8"x2.5"x49" / 2x65x12 mm 
Weight Embletta 0.24lb/110g, batteries: 0.1lb/46g 
Batteries 2 AA batteries (12 hours duration) 
Housing 
construction 
Injection moulded plastic, covered with aluminium shields. 
Number of channels 7 sensors, 14 derived signals 
Recording capacity Up to 12 hours (16MB memory) 
Maximum patient 
leakage current 
10µA, complying with EN6060-1 
Operating 
temperature 
40°F to 120°F (+5°C to +50°C) 
Storage temperature 0°F to 120°F (-20°C to +50°C) 
Humidity 90% non-condensing 
IEC 601-1 
Classifications 
Class IIa, Type BF 
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Appendix 7.2 Embletta ® recording unit features 
Table App.7.2 
Embletta ® available and used features 
Measure Available Feature  used 
ECG X30: x10 Proxy + (1) EKG  
EEG X50: x10 Proxy + (1) EEG  
combination X100: X10 Proxy + (4) ExG  
Flow/Pressure pressure transducer  
Nasal/Oral flow (thermistor)  
Snore by pressure transducer or by neck sensor  
Abdominal Movement respiratory effort sensor  
Chest Wall Movement respiratory effort sensor  
Oximetry SpO2 averaged and not averaged  
Pulse Rate oximeter  
Body Position built-in position/activity sensor  
Activity built-in position/activity sensor  
Flow Limitation  pressure transducer  
Event event button   
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Appendix 7.3 Embletta ® recording unit connection to sensors 
 
 
 
 
© Embla Systems 
Figure App.7.3 
Embletta®  unit connection scheme with 3 ECG sensors and an oximeter sensor  
 
* Curtesy of Embla systems 
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Appendix 7.4 Embletta ® recording unit image  
 
© Embla Systems 
Figure App.7.4 
Embletta®  mobile recording unit graphical image  
* Curtesy of Embla systems 
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Appendix 8.  HC1000P Sleep analysis system graphic displays 
 
 
Figure App.8.1 
HC1000P report summary screen shot 
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Figure App.8.2 
HC1000P graphic report screen shot 
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Appendix 9. Yoga poses used in practice protocol 
Appendix 9.1 Yoga poses images 
The following table includes images of the full Asana sequence including 
alternative postures (ALT) and modified poses (MOD). For example, pose No. 1 is the 
first pose in the sequence; pose no.1-ALT is an alternative pose to pose no. 1. Pose no. 2 
is the second pose in the sequence etc. MOD indicates a modified traditional pose  
Table App.9.1 
Yoga poses sequence used in the study 
No. Sanskrit  
name 
English name Modification. 
image 
1 Tadasana Mountain pose  
 
 
1 -
ALT 
Tadasana Mountain pose MOD # 1 
 
 
2 Tadasana Mountain pose MOD # 1A 
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3 Tadasana Mountain pose MOD # 1B 
 
 
4 Virabhadras
ana II 
Hero pose II  
 
 
4-
ALT 
Virabhadras
ana II 
Hero pose II MOD # 1 
 
 
5 Bikram 
style Ardha-
Chandrasan
a 
Bikram style 
 half moon pose 
 
 
 
5- 
ALT 
Ardha-
Chandrasan
a 
modified 
 half moon pose 
MOD # 2 
 
 
6 Adho 
Mukha 
Svanasana 
downward  
facing dog pose 
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6- 
ALT 
Adho 
Mukha 
Svanasana 
downward  
facing dog pose 
MOD # 3 
 
 
7 Manibandha 
Chakra 
Wrist rotations  
 
 
8 Goolf 
Chakra 
Ankle rotations  
 
 
9 Skandh 
Chakra 
shoulder 
rotations 
 
 
 
10 Garurasana Eagle pose MOD # 4 
 
 
11 Savasana Corpse pose  
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11-
ALT 
 seated relax MOD #11 
 
 
12 Ardha 
Pavana 
muktasana 
Half Wind 
removing pose 
 
 
 
12-
ALT 
Ardha 
Pavana 
muktasana 
Half Wind 
removing pose 
MOD # 5 
 
 
13 Bhujangasa
na (easy 
version) 
“Baby” Cobra 
Pose 
MOD # 6 
 
 
13-
ALT 
Bhujangasa
na (ALT) 
standing baby 
cobra 
MOD # 7 
 
 
14 Ardha 
shalbhasana  
 
Half Locust 
Pose 
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14-
ALT 
Ardha 
shalbhasana  
(ALT) 
 
standing half 
Locust 
MOD # 7A 
 
 
15 Marjaryasan
a 
cat pose  
 
 
15-
ALT 
Marjaryasan
a 
cat pose MOD # 3 
 
 
16 Bitilasana Cow  pose  
 
 
16-
ALT 
Bitilasana Cow  pose MOD # 3 
 
 
17 Marichyasa
na (easy 
version) 
Spinal twist  
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17-
ALT 
Chair twist Spinal twist MOD # 8 
 
 
18 Ardha-
Kurmasana 
Half Tortoise 
Pose 
MOD # 9 
 
18-
ALT 
 chair - Tortoise MOD # 10 
 
19 Balasana Child‟s pose  
 
 
19-
ALT 
Balasana Child‟s pose MOD # 13 
 
 
20 Paschimotta
nasana 
Seated forward 
bend 
MOD # 12 
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20-
ALT 
Paschimotta
nasana 
Chair –forward 
bend 
MOD # 12A 
 
 
21 Savasana Corpse pose  
 
 
21-
ALT 
 Chair - relax MOD #13 
 
 
21-
ALT 
 Chair - relax MOD #11 
 
 
Comment: [n-ALT ]=  alternative pose to pose number [#n] 
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Appendix 9.2 Yoga poses sequence details 
Table App.9.2 Details of yoga pose sequence 
No. Sanskrit  name English name type base Rep Modified Note 
1 Tadasana  Mountain pose STA  1   
1-ALT Tadasana  Mountain pose STA  1 MOD # 1  
2 Tadasana  Mountain pose STA  1 - 2 MOD # 1A  
3 Tadasana  Mountain pose STA  1 - 2 MOD # 1B  
4 Virabhadrasana II Hero pose II STA  1 - 2  RS, LS 
4-ALT Virabhadrasana II Hero pose II STA  1 - 2 MOD # 1 RS, LS 
5 Bikram style 
Ardha-
Chandrasana 
Bikram style 
 half moon pose 
STA  1 - 2 MOD # 2 RS, LS 
5-ALT Ardha-
Chandrasana 
modified 
 half moon pose 
STA  1 - 2 MOD # 2A  
6 Adho Mukha 
Svanasana 
downward  facing 
dog pose 
STA  1 - 2   
6-ALT Adho Mukha 
Svanasana 
downward  facing 
dog pose 
STA CHR 1 - 2 MOD # 3  
7 Manibandha 
Chakra 
Wrist rotations SIT CHR 3 -9  CW, CCW 
8 Goolf Chakra Ankle rotations SIT CHR 3 -9  CW, CCW 
9 Skandh Chakra shoulder rotations SIT CHR 3 -9  CW, CCW 
10 Garurasana Eagle pose SIT CHR 1 - 2 MOD # 4 RS, LS 
11 Savasana Corpse pose SUP MAT 1   
11-ALT  seated relax SIT CHR 1 MOD #11  
12 Ardha Pavana 
muktasana 
Half Wind 
removing pose 
SUP MAT 1 - 2  RS, LS 
12-ALT Ardha Pavana 
muktasana 
Half Wind 
removing pose 
SUP CHR 1 - 2 MOD # 5 RS, LS 
13 Bhujangasana 
(easy version) 
“Baby” Cobra 
Pose 
PRN MAT 1 - 2 MOD # 6  
13-ALT  standing baby 
cobra 
SIT WAL 1 - 2 MOD # 7  
14 Ardha 
shalbhasana  
 
Half Locust Pose PRN MAT 1 - 2   
14-ALT  standing half 
Locust  
STA WAL 1 - 2 MOD # 7  
15 Marjaryasana cat pose  MAT 2-4   
15-ALT Marjaryasana cat pose  CHR 2-4 MOD # 3  
16 Bitilasana Cow pose  MAT 2-4   
16-ALT Bitilasana Cow pose  CHR 2-4 MOD # 3  
17 Marichyasana 
(easy version) 
Spinal twist SIT MAT 1 - 2  RS, LS 
17-ALT Chair twist Spinal twist SIT CHR 1 - 2 MOD # 8 RS, LS 
18 Ardha-Kurmasana Half Tortoise 
Pose 
SIT MAT 1 - 2 MOD # 9  
18-ALT Ardha-Kurmasana chair - Tortoise  STA CHR 1 - 2 MOD # 10  
19 Balasana Child‟s pose SIT MAT 1 - 2 MOD # 9  
19-ALT  Chair child pose STA CHR 1 - 2 MOD # 10  
20 Paschimottanasan
a 
Seated forward 
bend 
SIT MAT 1 - 2 MOD # 12  
20-ALT  Chair –forward 
bend 
SIT CHR 1 - 2 MOD # 12  
21 Savasana Corpse pose SUP MAT 1   
21-ALT  Chair – relax 1 SIT CHR 1 MOD #11  
21-ALT  Chair – relax 2 SIT CHR 1 MOD #11a  
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Notes: 
Abbreviations used in table App.9.2 
The following abbreviations are used: RS – right side, LS- left side, CW – clockwise, 
CCW – counter clockwise, STA- standing pose. SIT – sitting pose, PRN – prone pose, 
SUP- supine pose, MAT – mat based pose, CHR – chair base pose, WAL – using wall, 
MOD –modified pose, ALT - alternative 
Modifications indicated in table App.9.2 
MOD # 1 - Holding onto back of chair for balance 
MOD # 1A –shifting weight to right, left, front, back while engaging abdominal muscles 
gently  
COM #1B – raising hands while breathing in. Lowering hands while breathing out  
MOD # 2 – when bending to right – right hand on hip and left hand over head and vice 
versa 
MOD # 2A – same as MOD # 2 but with right hand on back of chair for support 
MOD # 3 – holding seat of chair or top of back of chair and bending forward 
MOD # 4 – in chair sitting position arms interlaced with left elbow below right and legs 
– right knee over left knee and vice versa on the other side 
MOD # 5 – in chair sitting position raise knee towards trunk and interlace hands over or 
below knee 
MOD # 6 – gentle upper back raise with neck in line with the spine, facing down , palms 
on floor next to armpits facing down 
MOD # 7 – facing wall, hands on wall, weight forward slightly, back arched looking up 
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MOD # 7A – facing wall, hands on wall, weight forward slightly, back arched looking up. 
One leg extended back, off the floor 
MOD # 8 when twisting to the right – left hand over right tight grabbing chair sit and 
right hand grabbing back of chair and vice versa 
MOD # 9 – in case of knee restriction pose is executed with increased angle between 
calf and thigh (up to 90 degrees if needed) 
MOD # 10 –standing and bending forward placing forehead and palms of hands on 
chair‟s sit. 
MOD # 11 – sit upright back to chair‟s back support, palms resting on thighs, feet flat 
on ground, close eyes and relax 
MOD # 11a – sit upright back to chair‟s back support, palms resting on thighs, with legs 
extended on another chair, close eyes and relax 
MOD # 12 – bending forward with palms resting on thighs for support. Legs together 
MOD # 12a – bending forward sitting on a chair with legs extended on another chair 
MOD # 13 – sitting leaning forward with palms and head resting on back of another 
chair for support. Folded towel may be used under forehead 
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Appendix 10. Transcripts of meditation and relaxation exercises 
Appendix 10.1 Breath counting meditation – transcript 
Preparation: Please prepare yourself for the practice of breath counting 
meditation. Please sit on an arm chair, or in a reclining chair. Or a regular chair. Rest 
your hands on your lap. Relax them completely. You may also lie down in your bed if 
possible lie on your back with your feet slightly apart and the palms of your hands 
facing upwards. However, the sitting position is preferred for this exercise. If this is not 
possible please find a position which suits your physical condition. Gently close your 
eyes. Keep your lips touching lightly, relax your jaws. Take some time to make yourself 
even more comfortable. Try to breathe in deeply and then breathe out with a big sigh. 
As you sigh, try to feel you are letting go of stress and tension. Repeat it two more 
times. 
Instructions: In this exercise you will pay close attention to your breath. You 
may focus your attention on your lower abdomen. Watch what happens to the abdomen 
as you inhale and exhale. When you inhale, your lower abdomen goes out, and when 
you exhale it goes back in. You may also focus your attention on your ribcage Watch 
what happens to the ribcage as you inhale and exhale. When you inhale, your ribcage 
expands sideway and when you exhale it goes back.  Just choose one point of focus to 
observe the breath. The one that you can really feel is moving in and out when you 
inhale and exhale. Do not try to alter your breath. Do not try to control your breath in 
any way. Just observe the natural breath as it is.  Observe your breath carefully. It may 
be deep. Or it may be shallow. It may be long or it may be short. There may be a short 
pause following the inhalation. There may be a short pause following the exhalation. 
Whatever your breath is at the moment – just observe it. Do not change it. Just be aware 
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of it. You will now start counting the breaths silently.  Synchronize the count with the 
last part of the exhalation. As the air is being exhaled and you are getting close to the 
end of the exhalation count silently. You may count by whispering or just moving your 
lips silently. Start from one, two, three etc. If you forget the present count, start again 
from one. If a thought arises, do not fight it. It is natural for thoughts to arise in the 
mind. Just pay more attention to the counting. If you are very distracted by thoughts, 
utter the count a little louder till your mind becomes more concentrated on the counting.  
Keep counting till you I tell you to stop. 
A few minutes later: keep observing your breath very attentively. Observe the 
inhalation. Observe the exhalation. Towards the end of the exhalation count silently. If 
you lost the count, that is OK. Just start again from one. From day to day your 
concentration will improve and you will be able to count continuously without losing 
the count for a longer period of time. If thoughts come, let them come and let them pass 
away, just like clouds in the sky or bubbles in a glass of soda water. Just give more 
attention to the counting, and eventually fewer thoughts will come to distract you. 
At the end of twenty minutes: Conclusion: You may stop counting now. 
Become aware of your surroundings. Become aware of the sounds in the room. Become 
aware of sounds outside the room. Slowly open your eyes. Slowly stretch your arms and 
legs. Move your fingers. Move your toes. Breath counting practice has now come to its 
conclusion. Make sure you are completely awake and ready to return to daily activity. 
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Appendix 10.2 Muscle relaxation – transcript 
Preparation: Please prepare yourself for the practice of muscle relaxation. Please 
lie down on a mat, or a bed, or in a reclining chair.  If possible lie on your back with 
your feet slightly apart and the palms of your hands facing upwards. But if this is not 
possible please find a position which suits your physical condition. You may use a 
pillow or cushion or a folded blanket to keep your neck aligned with your spine. Cover 
yourself with a blanket to stay comfortably warm during the practice. Gently close your 
eyes. Keep your lips touching lightly, smile gently and relax your jaws as if you have 
experienced something pleasant, let the back of your neck relax. It is important that you 
be as comfortable as possible. So take some time to make yourself even more 
comfortable. Try to breathe in deeply and then breathe out with a big sigh. As you sigh, 
feel you are letting go of stress and tension. Repeat it two more times. It is important 
that you maintain this position without movement throughout the practice. Say to 
yourself in your mind: “I will not move throughout the practice. I will be aware of my 
body but I will not move”. In this muscle relaxation exercise you need to stay awake 
and alert. Do not fall asleep. All you have to do is to listen to the teacher‟s voice. Do not 
analyse the words you hear or intellectualize. Do not try to concentrate too hard. Simply 
listen to the instructions and let your mind follow. From time to time a thought may 
come. That is OK. Do not try to stop the thoughts forcefully but do not react to them. 
Simply stay calm and alert and pay more attention to the instructions being called out in 
the moment. 
Instructions: Throughout life we accumulate stress and tension. Some of the 
tension may manifest as muscular tension which may become chronic. Tense muscles 
may cause stiffness, reduced blood flow, musculoskeletal pains and poor posture.  In 
this exercise you will direct your attention sequentially to muscle groups throughout the 
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body from top to bottom starting from the feet, then calves, thighs, lower back, middle 
back, upper back, lower abdomen, chest, shoulders, upper arms, lower arms, palms and 
fingers, scalp, temples, back of the head, neck, forehead, eyebrows, cheeks, nose, 
mouth, chin, and throat. Whenever a muscle group or body part is called out, direct your 
awareness there. Once your awareness is focused on a particular body part, you will be 
asked to quietly tell that body part “relax”. This can be done by whispering or silently 
moving the lips. You can also try to breathe out, and visualise the breath flowing 
through that particular muscle group, helping it to relax more. This is repeated several 
times for each muscle group. If you find it very difficult to relax a particular muscle 
group, you can try to consciously contract that muscle group while inhaling fully and 
then consciously relax it while exhaling. But if you find it easy to relax a muscle just by 
focusing on it and telling it to relax, then there is no need to contract and release. 
Now let us begin. Direct your awareness to your feet. Throughout life tension may 
accumulate in the muscles of the feet. Inhale fully, and as you exhale tell the muscles in 
your feet: “relax!” Feel the tension in your feet dissolving away. You may do this by 
whispering or simply by moving your lips. You may also just breathe out and visualise 
that the breath is flowing through the feet caressing and relaxing them. Repeat this 
several times. With every repetition more and more tension dissolves, and the feet 
muscles are becoming softer and more relaxed. 
Now move your awareness to your calves. Throughout life tension may 
accumulate in the muscles of the calves. Inhale fully, and as you exhale tell the muscles 
in your calves: “relax!” Feel the tension in your calves dissolving away. You may do 
this by whispering or simply by moving your lips. You may also just breathe out and 
visualise that the breath is flowing through the calves caressing and relaxing them. 
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Repeat this several times. With every repetition more and more tension dissolves, and 
the calves‟ muscles are becoming softer and more relaxed. 
Direct your awareness to your thighs. Throughout life tension may accumulate in 
the muscles of the thighs. Inhale fully, and as you exhale tell the muscles in your thighs: 
“relax!” Feel the tension in your thighs dissolving away. You may do this by whispering 
or simply by moving your lips. You may also just breathe out and visualise that the 
breath is flowing through the thighs caressing and relaxing them. Repeat this several 
times. With every repetition more and more tension dissolves, and the thigh muscles are 
becoming softer and more relaxed. 
Direct your awareness to your buttocks. Throughout life tension may accumulate 
in the muscles of the buttocks. Inhale fully, and as you exhale tell the muscles in your 
buttocks: “relax!” Feel the tension in your buttocks dissolving away. You may do this 
by whispering or simply by moving your lips. You may also just breathe out and 
visualise that the breath is flowing through the buttocks caressing and relaxing them. 
Repeat this several times. With every repetition more and more tension dissolves, and 
the buttocks muscles are becoming softer and more relaxed. 
Direct your awareness to your lower back. Throughout life tension may 
accumulate in the muscles of the lower back. Inhale fully, and as you exhale tell the 
muscles in your lower back: “relax!” Feel the tension in your lower back dissolving 
away. You may do this by whispering or simply by moving your lips. You may also just 
breathe out and visualise that the breath is flowing through the lower back muscles 
caressing and relaxing them. Repeat this several times. With every repetition more and 
more tension dissolves, and the lower back muscles are becoming softer and more 
relaxed. 
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Direct your awareness to your lower abdomen. Throughout life tension may 
accumulate in the muscles of the lower abdomen. Inhale fully, and as you exhale tell the 
muscles in your lower abdomen: “relax!” Feel the tension in your lower abdomen 
dissolving away. You may do this by whispering or simply by moving your lips. You 
may also just breathe out and visualise that the breath is flowing through the lower 
abdomen caressing and relaxing it. Repeat this several times. With every repetition 
more and more tension dissolves, and the lower abdomen muscles are becoming softer 
and more relaxed. 
Direct your awareness to your upper back and scapula. Throughout life tension 
may accumulate in the muscles of the upper back and scapula. Inhale fully, and as you 
exhale tell the muscles in your upper back and scapula: “relax!” Feel the tension in your 
upper back and scapula dissolving away. You may do this by whispering or simply by 
moving your lips. You may also just breathe out and visualise that the breath is flowing 
through the upper back and scapula muscles caressing and relaxing them. Repeat this 
several times. With every repetition more and more tension dissolves, and the upper 
back and scapula muscles are becoming softer and more relaxed. 
Direct your awareness to your chest. Throughout life tension may accumulate in 
the muscles of the chest. Inhale fully, and as you exhale tell the muscles in your chest: 
“relax!” Feel the tension in your chest dissolving away. You may do this by whispering 
or simply by moving your lips. You may also just breathe out and visualise that the 
breath is flowing through the chest caressing and relaxing it. Repeat this several times. 
With every repetition more and more tension dissolves, and the chest muscles are 
becoming softer and more relaxed. 
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Direct your awareness to your shoulders. Throughout life tension may accumulate 
in the muscles of the shoulders. Inhale fully, and as you exhale tell the muscles in your 
shoulders: “relax!” Feel the tension in your shoulders dissolving away. You may do this 
by whispering or simply by moving your lips. You may also just breathe out and 
visualise that the breath is flowing through the shoulders caressing and relaxing it. 
Repeat this several times. With every repetition more and more tension dissolves, and 
the shoulders muscles are becoming softer and more relaxed. 
Direct your awareness to your upper arms. Throughout life tension may 
accumulate in the muscles of the upper arms. Inhale fully, and as you exhale tell the 
muscles in your upper arms: “relax!” Feel the tension in your upper arms dissolving 
away. You may do this by whispering or simply by moving your lips. You may also just 
breathe out and visualise that the breath is flowing through the upper arms caressing and 
relaxing it. Repeat this several times. With every repetition more and more tension 
dissolves, and the upper arms muscles are becoming softer and more relaxed. 
Direct your awareness to your lower arms. Throughout life tension may 
accumulate in the muscles of the lower arms. Inhale fully, and as you exhale tell the 
muscles in your lower arms: “relax!” Feel the tension in your lower arms dissolving 
away. You may do this by whispering or simply by moving your lips. You may also just 
breathe out and visualise that the breath is flowing through the lower arms caressing and 
relaxing it. Repeat this several times. With every repetition more and more tension 
dissolves, and the lower arms muscles are becoming softer and more relaxed. 
Direct your awareness to your hands and fingers. Throughout life tension may 
accumulate in the muscles of the hands and fingers. Inhale fully, and as you exhale tell 
the muscles in your hands and fingers: “relax!” Feel the tension in your hands and 
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fingers dissolving away. You may do this by whispering or simply by moving your lips. 
You may also just breathe out and visualise that the breath is flowing through the hands 
and fingers caressing and relaxing it. Repeat this several times. With every repetition 
more and more tension dissolves, and the hands and fingers are becoming softer and 
more relaxed 
Direct your awareness to your neck. Throughout life tension may accumulate in 
the muscles of the neck. Inhale fully, and as you exhale tell the muscles in your neck: 
“relax!” Feel the tension in your neck dissolving away. You may do this by whispering 
or simply by moving your lips. You may also just breathe out and visualise that the 
breath is flowing through the neck caressing and relaxing it. Repeat this several times. 
With every repetition more and more tension dissolves, and the neck muscles are 
becoming softer and more relaxed. 
Direct your awareness to your scalp. Throughout life tension may accumulate in 
the muscles of the scalp. Inhale fully, and as you exhale tell the muscles in your scalp: 
“relax!” Feel the tension in your scalp dissolving away. You may do this by whispering 
or simply by moving your lips. You may also just breathe out and visualise that the 
breath is flowing through the scalp caressing and relaxing it. Repeat this several times. 
With every repetition more and more tension dissolves, and the scalp muscles are 
becoming softer and more relaxed. 
Direct your awareness to your forehead. Throughout life tension may accumulate 
in the muscles of the forehead. Inhale fully, and as you exhale tell the muscles in your 
forehead: “relax!” Feel the tension in your forehead dissolving away. You may do this 
by whispering or simply by moving your lips. You may also just breathe out and 
visualise that the breath is flowing through the forehead caressing and relaxing it. 
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Repeat this several times. With every repetition more and more tension dissolves, and 
the forehead muscles are becoming softer and more relaxed. 
Direct your awareness to your temples. Throughout life tension may accumulate 
in the muscles of the temples. Inhale fully, and as you exhale tell the muscles in your 
temples: “relax!” Feel the tension in your temples dissolving away. You may do this by 
whispering or simply by moving your lips. You may also just breathe out and visualise 
that the breath is flowing through the temples caressing and relaxing it. Repeat this 
several times. With every repetition more and more tension dissolves, and the temples 
muscles are becoming softer and more relaxed. 
Direct your awareness to your cheeks. Throughout life tension may accumulate in 
the muscles of the cheeks. Inhale fully, and as you exhale tell the muscles in your 
cheeks: “relax!” Feel the tension in your cheeks dissolving away. You may do this by 
whispering or simply by moving your lips. You may also just breathe out and visualise 
that the breath is flowing through the cheeks caressing and relaxing it. Repeat this 
several times. With every repetition more and more tension dissolves, and the cheeks 
muscles are becoming softer and more relaxed. 
Direct your awareness to your eye sockets. Throughout life tension may 
accumulate in the muscles of the eye socket. Inhale fully, and as you exhale tell the 
muscles in your eye socket: “relax!” Feel the tension in your eye socket dissolving 
away. You may do this by whispering or simply by moving your lips. You may also just 
breathe out and visualise that the breath is flowing through the eye socket caressing and 
relaxing it. Repeat this several times. With every repetition more and more tension 
dissolves, and the eye sockets muscles are becoming softer and more relaxed. 
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Direct your awareness to your jaw. Throughout life tension may accumulate in the 
muscles of the jaw. Inhale fully, and as you exhale tell the muscles in your jaw: “relax!” 
Feel the tension in your jaw dissolving away. You may do this by whispering or simply 
by moving your lips. You may also just breathe out and visualise that the breath is 
flowing through the jaw caressing and relaxing it. Repeat this several times. With every 
repetition more and more tension dissolves, and the jaw muscles are becoming softer 
and more relaxed. 
Now let your whole body relax. Your whole body is becoming more and more 
relaxed. All your muscles are soft, limp, heavy. You are sinking down through the mat. 
Conclusion: Say to yourself: “I am practicing muscle relaxation. I am lying down 
on a mat in this room”. Take some time now to scan your body. How does your body 
feel now compared to how it felt in the beginning of the exercise? Is there still tension 
anywhere in your body? Where? Try to use the same technique to dissolve any 
remaining tension which you may have. 
 Slowly open your eyes. Slowly stretch your arms and legs. Move your fingers. 
Move your toes. Slowly support your weight and move to a sitting position.  Muscle 
relaxation practice has now come to its conclusion. Make sure you are completely 
awake and ready to return to daily activity. 
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Appendix 10.3 Yoga Nidra transcript 
Adapted from several Yoga Nidra protocols by Swami Satyananda Swaraswati, of the 
Bihar School of Yoga (Satyananda, 1976, pp. 81-150) 
Preparation: Please prepare yourself for the practice of Yoga Nidra. Please lie 
down on a mat, or a bed, or in a reclining chair.  If possible lie on your back with your 
feet slightly apart and the palms of your hands facing upwards. But if this is not possible 
please find a position which suits your physical condition. You may use a pillow or 
cushion or a folded blanket to keep your neck aligned with your spine. Cover yourself 
with a blanket to stay comfortably warm during the practice. Gently close your eyes. 
Keep your lips touching lightly, relax your jaws, and let the back of your neck relax. It 
is important that you be as comfortable as possible. So take some time to make yourself 
even more comfortable. Try to breathe in deeply and then breathe out with a big sigh. 
As you sigh, feel you are letting go of stress and tension. Repeat it two more times. 
Instructions: It is important that you maintain this position without movement 
throughout the practice. Say to yourself in your mind: “I will not move throughout the 
practice. I will be aware of my body but I will not move”. In Yoga Nidra you need to 
stay awake and alert. Do not fall asleep. All you have to do in Yoga Nidra is to listen to 
the teacher‟s voice. Do not analyse the words you hear or intellectualize. Do not try to 
concentrate too hard. Simply listen to the instructions and let your mind follow. From 
time to time a thought may come. That is OK. Do not try to stop the thoughts forcefully 
but do not react to them. Simply stay calm and alert and pay more attention to the 
instructions being called out in the moment. 
Relaxation: Say to yourself mentally: “I am becoming more and more relaxed”. 
With every breath you breathe out, feel the tension in your muscles dissolving more and 
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more. Relax your feet, toes, ankles, calves, knees, thighs, hamstrings, buttocks, lower 
middle and upper back muscles, shoulders, chest, arms, elbows, hands, fingers, head 
and neck. Relax the whole body. Your whole body is soft. It is melting into the mat. It is 
dissolving into the mat.  
Resolution to stay awake and aware: Say to yourself mentally with full 
intention: “I will now practice Yoga Nidra. I will be relaxed. I will stay wide awake. I 
will remain alert and attentive. I will be fully aware. I will not fall asleep.”  
Positive affirmation (The ‘Resolve’): It is now time to make a positive 
affirmation. It can be a life goal or it can be a wish for any positive change in any area 
of your life, such as health, relationships, work. Say it inside your mind with full 
conviction and passion. Say it from your heart. Feel as if what you ask for has already 
been granted to you. Repeat it three times. 
Rotation of awareness: We will now use our awareness to scan our body. We 
will rotate our awareness quickly from one body part to the next. Just listen to the 
instructions. Relax your mind and let it follow the instructions. Do not try to concentrate 
too hard. Repeat the body part which is mentioned mentally in your mind. Direct your 
mind to that body part and try to be aware of it and feel it with your senses. Just be 
aware of it do not try to concentrate too hard. If you cannot feel anything that is all 
right. Just direct your mind to that body part. If you miss an instruction or lose 
concentration for a second that is all right. Just stay calm and focus again on the 
instructions and direct your awareness there. 
 Maintain awareness. Maintain alertness. Stay awake. 
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Right side: Be aware of the right side of your body. You will now rotate your 
awareness through the right side of the body, part by part. Start with right thumb, be 
aware of your right thumb and repeat mentally right thumb, sense your right thumb. 
Rotate your awareness to the second finger, third finger, fourth finger, fifth finger. 
Sense all five fingers together. Right palm of the right hand, back of the right hand, 
right wrist, right forearm, feel the right elbow, upper right arm, right shoulder, right 
armpit, right chest, right ribcage, right waist, right hip, right buttock, right thigh, right 
hamstring, right knee, right calf, right ankle, right heel, sole of right foot, top of the 
right foot, right big toe, second toe, third toe, fourth toe, fifth toe, feel all five toes 
together. 
Left side: Now shift your awareness to the left side of your body. You will now 
rotate your awareness through the left side of the body part by part. Start with left 
thumb, sense your left thumb and repeat mentally left thumb. Rotate your awareness to 
the second finger, third finger, fourth finger, fifth finger. Sense all five fingers together, 
palm of the left hand, back of the left hand, left wrist, left forearm, feel the left elbow, 
upper left arm, left shoulder, left armpit, left chest, left ribcage, left waist, left hip, left 
buttock, left thigh, left hamstring, left knee, left calf, left ankle, left heel, left sole, left 
top of the foot, left big toe, second toe, third toe, fourth toe, fifth toe, feel all five toes 
together. 
Maintain awareness. Maintain alertness. Stay awake. 
Right to left: You will now direct your awareness skipping from the right side of 
the body to the left side and moving from top to bottom. Right heel, left heel, both heels 
together. Right ankle, left ankle, both ankles together. Right calf, left calf, both calves 
together. Right knee, left knee, both knees together. Right thigh, left thigh, both thighs 
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together. Right hamstring, left hamstring, both hamstrings together. Right buttock, left 
buttock, both buttocks together, right hip, left hip, both hips together. Waist, lower 
abdomen, upper abdomen, whole of the abdomen. Right side of the chest, left side of 
the chest, whole chest. Right collarbone, left collarbone, centre of the collarbones, 
throat. Right shoulder, left shoulder, right arm, left arm, right elbow, left elbow, right 
hand, left hand. Right thumb, second finger, third finger, fourth finger, fifth finger, all 
five fingers together, Palm of the right hand, back of the right hand. Left thumb, second 
finger, third finger, fourth finger, fifth finger, all five fingers together, palm of the left 
hand, back of the left hand. Right side of the back, left side of the back, lower back 
middle back, upper back. Back of the neck, front of the neck, the whole neck. Whole 
back. Be aware of the whole back. Sense the whole back. Chin, lower lip, upper lip, 
both lips together, teeth, tongue. Right cheek, left cheek, both cheeks. Right nostril, left 
nostril, both nostrils, tip of the nose, whole nose. Right eyelid, left eyelid, both eyelids, 
right eyeball, left eyeball, both eyeballs together. Right eyebrow, left eyebrow, both 
eyebrows. Right temple, left temple, forehead, back of the head, crown of the head. 
Whole face, be aware of whole head. Sense your whole head. 
 Right and left together: You will now direct your awareness symmetrically to 
both sides of the body at the same time moving quickly from bottom to top, starting 
from your toes up to the crown of the head. All the ten toes together. Both soles 
together, both heels, both ankles, both calves, both knees, both thighs, both buttocks, 
lower back, middle back, upper back, both shoulders, armpits, chest, ribcage. Sense all 
ten fingers together, both palms, back of the hands, both wrists, forearms, both  elbows, 
both arms, shoulders, neck, back of head, scalp, forehead, eye sockets, temples, nose, 
upper lip, lower lip, inside the mouth, tongue, chin. 
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Large body parts: You will now direct your awareness to larger body parts. 
Whole right arm, whole left arm, whole right leg, whole left leg, whole front of the 
body, whole back of the body, whole right side of the body, whole left side of the body. 
Whole body together, whole body together, whole body together. 
Maintain awareness. Maintain alertness. Do not fall asleep. 
Hot and cold Sensations: You will now direct your awareness to sensations of 
heat and cold in your body: First, try to feel the body becoming very hot. Try to feel 
heat sensation throughout the body. Recall a time when you felt very hot. Try to 
recreate the same sensation of heat now just as you have experienced it in the past.  
Now try to feel the opposite sensation: Try to feel the body becoming very cold. Try to 
feel cold sensation throughout the body. Recall a time when you felt very cold. Try to 
recreate the same sensation of cold now just as you have experienced it in the past. 
Heavy and light Sensations: You will now direct your awareness to sensations of 
heaviness and lightness in your body: First, try to feel the body becoming very heavy. 
Your whole body is so heavy you can‟t move. It is so heavy it is pressing down hard 
and sinking into the mat. Your muscles are heavy. Your whole body is heavy like lead. 
Now try to feel the opposite sensation: Try to feel the body becoming very light. Your 
whole body is so light you feel you are floating upwards. It is so light that it is floating 
off the mat. Your muscles are very light and loose. Your whole body is light like a 
helium balloon floating up and drifting in the wind. 
Pain and Pleasure Sensations: You will now direct your awareness to sensations 
of pain and pleasure in your body: First, try to feel pain somewhere in your body. Try to 
remember a time when you had pain somewhere in your body. Recreate that feeling of 
pain in your body.  
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Now try to feel the opposite sensation: Try to pleasure somewhere in your body. 
Try to remember a time when you had a pleasant sensation in your body. Recreate that 
feeling of pleasure in your body. 
Maintain awareness. Maintain alertness. Do not fall asleep. 
Breath Awareness: You will now direct your attention to your breath. We inhale 
and exhale all the time but most of the time we are not aware of it. You will focus your 
awareness on the breath now. 
Focus on abdomen: Now focus you attention on your lower belly. Notice what 
happens to it when you inhale and when you exhale. When you inhale, your belly rises 
and when you exhale it comes back down. Inhale and notice your belly rise. Exhale and 
notice it go down. As the belly is coming down count inwardly “18”. Then watch the 
belly going up again and when it comes back down count inwardly “17”. Keep counting 
down towards the end of each exhalation till you reach “1”. If you lose your count start 
again from “18”. 
 Focus on chest and rib cage: Now focus your attention on your chest and rib 
cage. Notice what happens to it when you inhale and when you exhale. When you 
inhale, the ribcage expands sideways and the chest expands up when you exhale the 
ribcage contracts towards the centre and the chest contracts down. As you exhale count 
inwardly “18”. Next exhalation say “17”. Keep counting down this way till you reach 
“1”. If you lose your count start again from “18”. 
Focus on throat: Now focus you attention on your throat. Notice what happens to 
it when you inhale and when you exhale. Notice the sensation and listen to the sound of 
air going through the throat as you inhale. Notice the sensation in the throat and listen to 
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the sound of air going through the throat as you inhale and exhale. As you exhale count 
inwardly “18”. Next exhalation say “17”. Keep counting down this way till you reach 
“1”. If you lose your count start again from “18”. 
Focus on nostrils: Now focus you attention on your nostrils. Notice what 
happens when you inhale and when you exhale. When you inhale, cooler air goes in 
through the nostrils and when you exhale warmer air goes out. As you exhale count 
inwardly “18”. Next exhalation say “17”. Keep counting down this way till you reach 
“1”. If you lose your count start again from “18”. 
Maintain awareness. Maintain alertness. Do not fall asleep. 
Focus on the inner space: Now you may stop counting. You may stop observing 
your breath. Just relax. Relax your whole body. Whole body is very relaxed. Direct your 
attention to the inner space just above the bridge of your nose and between your 
eyebrows. Just observe the inner space. Relax your eyes do not strain. Do not try to 
visualise anything. Just observe. Whatever you see there or don‟t see there is fine. Just 
watch your inner space. You may see colours. Your may see light. You may recall 
things that happened to you today or in the distant path. It does not matter. Just observe. 
Just relax. 
 Maintain awareness. Maintain alertness. Do not fall asleep.  
Rapid sequence of visualisations: Please maintain your focus on your inner 
space between your eyebrows. Relax your eyes do not strain. We will now go through a 
sequence of rapid visualisations. Listen to my voice. When I say a name of an object try 
to see the object in your inner space. Each object or scene will be called out three times. 
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Do not strain. Whether you see it clearly or vaguely or not at all – it does not matter. 
Just relax, listen to my voice and let your mind follow. 
 Pink Rose; Pink Rose; Pink Rose. 
 A golden egg; a golden egg; a golden egg. 
 A beach with golden sand; a beach with golden sand; a beach with golden 
sand. 
 Ocean waves breaking on the shore; Ocean waves breaking on the shore; 
Ocean waves breaking on the shore. 
 A sail ship on the horizon; a sail ship on the horizon; a sail ship on the 
horizon. 
 Golden sunset on the beach; Golden sunset on the beach; Golden sunset on 
the beach. 
 Evening sky with purple clouds; Evening sky with purple clouds; Evening 
sky with purple clouds;  
 Birds flying through evening skies; Birds flying through evening skies; Birds 
flying through evening skies. 
 Clear night skies filled with sparkling stars; clear night skies filled with 
sparkling stars; clear night skies filled with sparkling stars 
 Full moon; full moon; full moon; 
 Rain storm at night; rain storm at night; rain storm at night. 
 High mountains with snowy peaks; high mountains with snowy peaks; high 
mountains with snowy peaks. 
 A thick green forest; a thick green forest; a thick green forest. 
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 People gathering round a campfire; people gathering round a campfire; 
people gathering round a campfire. 
 People singing and laughing; People singing and laughing; People singing 
and laughing;  
 Sun rising; sun rising; sun rising. 
 White clouds in a blue sky; white clouds in a blue sky; white clouds in a blue 
sky; 
 Snow covered mountain peaks; Snow covered mountain peaks; Snow covered 
mountain peaks; 
 a cool breeze in the forest; a cool breeze in the forest; a cool breeze in the 
forest 
 A herd of horses galloping; a herd of horses galloping; a herd of horses 
galloping. 
 Clear mountain stream; clear mountain stream; clear mountain stream. 
 A waterfall; a waterfall; a waterfall. 
 Lonely house on top of a hill; lonely house on top of a hill; lonely house on 
top of a hill. 
 A beautiful rose garden; a beautiful rose garden; a beautiful rose garden. 
 A pink rose; A pink rose; A pink rose  
 A golden egg; A golden egg; A golden egg; 
 A beautiful diamond; A beautiful diamond; A beautiful diamond;  
 You sitting in meditation with friends; You sitting in meditation with friends; 
You sitting in meditation with friends;  
Maintain awareness. Maintain alertness. Do not fall asleep. 
409 
 
Repeating the auto-suggestion: It is now time to repeat the positive affirmation 
you made at the beginning of the practice. Your life goal, a wish for a positive change in 
your life, health, relationship etc. Say it silently inside your mind, with full conviction 
and passion. Say it from your heart. Feel as if what you ask for has already been granted 
to you. Repeat it three times. 
Conclusion: Say to yourself: “I am practicing yoga Nidra. I am lying down on a mat in 
this room”. Visualize yourself lying on the mat. Feel your whole body lying on the mat. 
Quickly scan your body from head to toe, and feel your whole body on the mat. 
Visualize the room around you. Become aware of your surroundings. Become aware of 
the sounds in the room. Become aware of sounds outside the room. Slowly open your 
eyes. Slowly stretch your arms and legs. Move your fingers. Move your toes. Slowly 
support your weight and move to a sitting position.  Yoga Nidra practice has now come 
to its conclusion. Make sure you are completely awake and ready to return to daily 
activity. 
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Appendix 11. Detailed statistical analysis  
Appendix 11.1  Subjective measures, Intention to Treat (ITT) analysis 
(Intervention versus control), Analysis of variance (ANOVA)  
Appendix 11.1.1 Karolinska Sleepiness Scale (KSS) (*) 
Scores on the Karolinska Sleepiness Scale (KSS) were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
A significant time by group interaction was found, Λ =.94, F(1,76)=5.21, p=.025, 
η2=.064 
 Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,76)=.40, p=.79, η2=.006 but a 
significant post-intervention group difference, F(1,76)=6.47, p=.013, η2=.078 
Further, the only significant pre- to post intervention change was seen in the control 
group which deteriorated significantly, Λ =.92, F(1,76)=6.88, p=.01, η2=.083 
There was a significant main effect for time, Λ =.95, F(1, 76)=4.39, p=.041, η2=.054  
There was no significant group main effect, F(1, 76)=2.31, p=.13, η2=.029 
Table App.11.1.1  
KSS scores - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 2.79 (1.35) 4.00 (1.93) 7.04 1,76 .01 .083 
intervention 3.02 (1.51) 2.96 (1.53) .033 1,76 .86 <.001 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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Appendix 11.1.2 Epworth Sleepiness Scale (ESS)  
Scores on the Epworth Sleepiness Scale (ESS) were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =1.00, F(1,80)=.20, p=.65, 
η2=.003 
 Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 80)=.047, p=.83, η2=.001 and no 
significant post-intervention group difference, F(1, 80)=.30, p=.37, η2=.004 
No significant pre  to post intervention change was seen with any of the  groups. 
There was no significant main effect for time, Λ =.96, F(1, 80)=3.55, p=.063, η2=.042  
nor was there a significant group main effect, F(1, 80)=.19, p=.67, η2=.002 
Table App.11.1.2  
ESS scores - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 7.00 (3.67) 7.85 (3.47) 1.97 1,80 .16 .024 
intervention 6.80 (3.88) 7.49 (3.83) 1.61 1,80 .21 .020 
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Appendix 11.1.3 Pittsburgh Sleep Quality Index (PSQI) - global score 
Scores on the Pittsburgh Sleep Quality Index (PSQI) global score were analysed using a 
2 x 2 mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =.97, F(1,64)=1.67, p=.20, 
η2=.025 
 Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,64)=.13, p=.72, η2=.002 and no 
significant post-intervention group difference, F(1,64)=2.12, p=.15, η2=.032  
Further, the only significant pre- to post intervention change was seen in the 
intervention  group which improved significantly, Λ =.90, F(1,64)=6.84, 
p=.011,η2=.097  
There was no significant main effect for time, Λ =.96, F(1,64)=2.75, p=.10, η2=.041  
nor was there a significant group main effect, F(1,64)=1.02, p=.32, η2=.016 
Table App.11.1.3 
PSQI global scores - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 10.14 (3.21) 10.00 (3.08) .057 1,64 .81 .001 
intervention 9.82 (3.49) 8.67 (3.62) 6.84 1,64 .011 .097 
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Appendix 11.1.4 PSQI - subjective sleep quality sub score 
Scores on the Pittsburgh Sleep Quality Index (PSQI) - subjective sleep quality sub score 
were analysed using a 2 x 2 mixed analysis of variance (ANOVA). The between-
subjects factor was group (intervention, control). The within-subjects factor was 
time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.98, F(1,78)=1.23, p=.27, 
η2=.016 Follow up analysis of simple main effects for this interaction revealed no 
significant difference among the groups at pre-intervention, F(1,78)=2.37, p=.13, 
η2=.030  but a significant post-intervention group difference, F(1,78)=12.22, p=.001 
η2=.13  
Further, the only significant pre- to post intervention change was seen in the 
intervention group which improved significantly, Λ =.89, F(1,78)=9.83, p=.002, η2=.11  
There was a significant main effect for time, Λ =.93, F(1,78)=5.74, p=.019,η2=.069 
There was also a significant group main effect, F(1,78)=1.02, p=.002, η2=.11 
Table App.11.1.4  
PSQI subjective sleep quality sub-scores -2 x 2 mixed ANOVA - Pre to Post intervention 
change by group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 1.84 (.62) 1.72 (.54) .59 1,78 .44 .008 
intervention 1.60 (.65) 1.27 (.52) 9.83 1,78 .002 .11 
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Appendix 11.1.5 Pittsburgh Sleep Quality Index (PSQI) - sleep latency sub score 
Scores on the Pittsburgh Sleep Quality Index (PSQI) - sleep latency sub score were 
analysed using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (intervention, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,62)=1.52, p=.11, 
η2=.002 
Follow up analysis of simple main effects for this interaction revealed a significant 
difference among the groups at pre-intervention, F(1,62)=6.57, p=.013, η2=.096  and  a 
significant post-intervention group difference, F(1,62)=4.06, p=.048, η2=.061 
A significant pre- to post intervention change was seen both with the intervention  
group, Λ =.80, F(1,62)=8.72, p=.004, η2=.16  and with the control,  Λ =.90, 
F(1,62)=6.50, p=.013, η2=.095, both improving significantly 
There was a significant main effect for time, Λ =.81, F(1,62)=14.41, p<.001,η2=.19 
There was a significant group main effect, F(1,62)=6.44, p=.014, η2=.094  
Table App.11.1.5  
PSQI sleep latency sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 2.45 (.67) 2.00 (.93) 6.70 1,62 .012 . 099 
intervention 1.86 (.98) 1.48 (1.02) 8.72 1,62 .004 .12 
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Appendix 11.1.6 Pittsburgh Sleep Quality Index (PSQI) - sleep duration sub score  
Scores on the Pittsburgh Sleep Quality Index (PSQI) - sleep duration sub score were 
analysed using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (intervention, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
A significant time by group interaction was found, Λ =.97, F(1,73)=4.96, 
p=.029,η2=.064  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,73)=.034, p=.85, η2<.001   
but a significant post-intervention group difference,  F(1,73)=5.66, p=.020, η2=.072 
Further, the only significant pre- to post intervention change was seen in the 
intervention group which improved  significantly, Λ =.94, F(1,73)=13.38, p=.042, 
η2=.055 
There was no significant main effect for time, Λ =1.00, F(1,73)=.004, p=.95, η2=.006 
There was a significant group main effect, F(1,73)=4.96,  p=.029, η2=.06  
Table App.11.1.6  
PSQI sleep duration sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 2.04 (.82) 2.26 (.75) 1.87 1,73 .17 .025 
intervention 2.00 (.99) 1.77 (.85) 4.29 1,73 .042 .055 
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Appendix 11.1.7 Pittsburgh Sleep Quality Index (PSQI) - sleep efficiency sub score  
Scores on the Pittsburgh Sleep Quality Index (PSQI) sleep efficiency sub score were 
analysed using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (intervention, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 A significant time by group interaction was found, Λ =.93, F(1,53)=4.21, p=.045, 
η2=.074 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,53)=.049, p=.82, η2=.001  
but a significant post-intervention group difference, F(1,53)=5.68, p=.021,η2=.097 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.93, F(1,53)=4.23, p=.045, 
η2=.074  
There was a significant main effect for time, Λ =1.00, F(1,53)=.001, p=.98,η2<.001  
There was no significant group main effect, F(1,53)=1.99, p=.16, η2=.036  
Table App.11.1.7  
PSQI sleep efficiency sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change 
by group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 1.50 (1.29) 1.86 (1.10) 1.41 1,53 .24 .026 
intervention 1.41 (1.22) 1.05 (1.09) 4.23 1,53 .045 .074 
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App.11.1.8 Pittsburgh Sleep Quality Index (PSQI) - sleep disturbance sub score  
Scores on the Pittsburgh Sleep Quality Index (PSQI) - sleep disturbance sub score were 
analysed using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (intervention, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,70)=.27, p=.61, 
η2=.004 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,70)=.25, p=.62, η2=.004  
and no significant post-intervention group difference, F(1, 70)=.009, p=.93,η2<.001 
There was no significant pre to post intervention change in any of the other groups. 
There was no significant main effect for time, Λ =1.01, F(1,70)=.27, p=.61 ,η2=.004 
nor was there a significant group main effect, F(1,70)=.060, p=.81, η2=.001 
Table App.11.1.8  
PSQI sleep disturbance sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change 
by group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 1.27 (.46) 1.27 (.63) .00 1,70 1.00 <.001 
intervention 1.34 (.56) 1.26 (.49) .87 1,70 .35 .012 
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App.11.1.9 Pittsburgh Sleep Quality Index (PSQI) sleep medication sub score (*) 
Scores on the Pittsburgh Sleep Quality Index (PSQI) sleep medication sub score were 
analysed using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (intervention, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,79)=.006, p=.94, 
η2<.001  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,79)=3.70, p=.058, η2=.045  
and no significant post-intervention group difference, F(1,79)=3.51, p=.065, η2=.043 
Further, no significant pre  to post intervention change was seen with any of the groups 
There was no significant main effect for time, Λ =1.00, F(1,79)=.20, p=.65, η2=.003  
There a significant group main effect, F(1,79)=4.03, p=.048, η2=.049 
Table App.11.1.9  
PSQI sleep medication sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change 
by group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 1.77 (1.18) 1.73 (1.15) .050 1,79 .82 .001 
intervention 1.38 (1.41) 1.33(1.41) .22 1,79 .64 .003 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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App.11.1.10 Pittsburgh Sleep Quality Index (PSQI) dysfunction sub score  
Scores on the Pittsburgh Sleep Quality Index (PSQI) dysfunction sub score were 
analysed using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (intervention, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,72)=.009, p=.93, 
η2<.001  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,72)=.44, p=.51, η2=.006  
but a significant post-intervention group difference, F(1,72)=.70, p=.040, η2=.010 
Further, no significant pre  to post intervention change was seen in any of the groups. 
There was no significant main effect for time, Λ =1.0, F(1,72)=.26, p=.61, η2=.004  
nor was there a significant group main effect, F(1,72)=.86, p=.36, η2=.012 
Table App.11.1.10  
PSQI dysfunction sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control .92 (.58) .88 (.68) .06 1,72 .80 .001 
intervention .80 (.76) .74 (.63) .28 1,72 .60 .004 
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App.11.1.11 Apnea probability score derived from MAP  
Apnea probability scores derived from MAP using an algorithm which incorporates age, 
gender, body mass index (BMI) and several MAP components,  were analysed using a 2 
x 2 mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,66)=.039, p=.84, 
η2=.001 Follow up analysis of simple main effects for this interaction revealed no 
significant difference among the groups at pre-intervention, F(1,66)=.40, p=.53, η2=.006 
nor a significant post-intervention group difference, F(1,66)=.62, p=.43, η2=.009 
Further, no  pre  to post intervention change was seen in any of the groups. 
 There was no significant main effect for time, Λ =1.00, F(1,66)=. 045, p=.83, η2=.001 
nor was there a significant group main effect, F(1,66)=.64, p=.42, η2=.010 
Table App.11.1.11  
MAP derived apnea probability scores 2 x 2 mixed ANOVA - Pre to Post intervention 
change by group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control .37 (.29) .36 (.29) .06 1,66 .80 .001 
intervention .42 (.31) .42 (.33) .32 1,66 .91 .005 
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App.11.1.12 Depression Anxiety Stress Scale (DASS) global score  
Depression Anxiety Stress Scale (DASS) global scores were analysed using a 2 x 2 
mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =1.00, F(1,71)=.12, p=.73, 
η2=.002 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,71)=.10, p=.75, η2=.001 
nor a significant post-intervention group difference, F(1,71)=.54, p=.46, η2=.008 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.91, F(1,71)=7.03, p=.010, η2=.09  
There was a significant main effect for time, Λ =.92, F(1,71)=6.21, p=.015,η2=.080  
There was no significant group main effect, F(1,71)=.29, p=.59, η2=.004  
Table App.11.1.12  
DASS global - scores 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) -post F df p η2 
control 23.48 (23.30) 19.86 (16.28) 1.61 1,71 .21 .022 
interven. 21.87 (17.32) 17.06 (14.03) 7.03 1,71 .010 .090 
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App.11.1.13   Depression Anxiety Stress Scale (DASS) - stress sub-score  
Depression Anxiety Stress Scale (DASS) stress sub-scores were analysed using a 2 x 2 
mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =1.00, F(1,73)=..99, p=.76 
η2=.07 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,73)=.18, p=.67, η2=.003 
nor a significant post-intervention group difference, F(1,73)=.62, p=.43, η2=.008 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.93, F(1,73)=5.64, p=.020, 
η2=.072  
There was a significant main effect for time, Λ =.93, F(1,73)=5.12, p=.027,η2=.66 
There was no significant group main effect, F(1,73)=.41, p=.52, η2=.006  
Table App.11.1.13  
DASS stress sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - 
post 
F df p η2 
control 10.50 (11.08) 8.91 (7.65) 1.35 1,73 .25 .018 
intervention 9.53 (7.90) 7.43 (7.27) 5.64 1,73 .020 .072 
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App.11.1.14 Depression Anxiety Stress Scale (DASS) anxiety sub-score  
Depression Anxiety Stress Scale (DASS) anxiety sub-scores were analysed using a 2 x 
2 mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =.99, F(1,76)=.52, p=.47, 
η2=.007 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,76)=.002, p=.96, η2<.001 
nor a significant post-intervention group difference, F(1,76)=.30, p=.58, η2=.004 
Further, the intervention group improved  pre  to post intervention but not significantly, 
Λ =.95, F(1,76)=3.66, p=.060, η2=.046 
There was no significant main effect for time, Λ =.98, F(1,76)=1.71, p=.19,η2=.022 
There was no significant group main effect, F(1,76)=.062, p=.80, η2=.001  
Table App.11.1.14  
DASS anxiety sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 7.00 (6.60) 6.68 (5.80) .12 1,76 .73 .002 
intervention 7.07 (5.72) 5.96 (4.96) 3.66 1,76 .060 .046 
 
  
424 
 
App.11.1.15 Depression Anxiety Stress Scale (DASS) depression sub-score  
Depression Anxiety Stress Scale (DASS) depression sub-scores were analysed using a 2 
x 2 mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =.99, F(1,72)=.62, p=.43, 
η2=.008 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,72)=.16, p=.69, η2=.002 
nor a significant post-intervention group difference, F(1,72)=1.66, p=.20, η2=.023 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.93, F(1,72)=5.77, p=.019, 
η2=.074 
There was no significant main effect for time, Λ =.96, F(1,72)=3.14, p=.080, η2=.042 
There was no significant group main effect, F(1,72)=.74, p=.40, η2=.010  
Table App.11.1.15  
DASS depression sub-scores 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 6.00 (6.86) 5.38 (5.43) .34 1,72 .56 .005 
intervention 5.34 (6.23) 3.74 (4.75) 5.77 1,72 .019 .074 
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App.11.1.16 Profile of Mood States (POMS) global score (*) 
Profile of Mood States (POMS) global scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,64)=.093, 
p=.76,η2=.001 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,64)=.53, p=.47, η2=.008  
nor a significant post-intervention group difference, F(1,64)=1.62, p=.21, η2=.025 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.90, F(1,64)=7.21, p=.009, η2=.10 
There was a significant main effect for time, Λ =.91, F(1,64)=6.64, p=.012, η2=.094 
There was no significant group main effect, F(1,64)=1.12, p=.29, η2=.017  
Table App.11.1.16  
POMS global scores - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 16.16 (25.65) 11.21 (20.86) 1.81 1,64 .18 .028 
intervention 11.96 (19.10) 5.68 (13.58) 7.21 1,64 .009 .10 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found 
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App.11.1.17 Profile of Mood States (POMS) depression sub - score (*) 
Profile of Mood States (POMS) depression sub - scores were analysed using a 2 x 2 
mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =.99, F(1,68)=.33, p=.57, 
η2=.005  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,68)=.88, p=.35, η2=.013 
nor a significant post-intervention group difference, F(1,68)=3.22, p=.077, η2=.045 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.94, F(1,68)=4.54, p=.037, 
η2=.063 
There was no significant main effect for time, Λ =.94, F(1,68)=3.10, p=.083,η2=.044 
There was no significant group main effect, F(1,68)=2.07, p=.16, η2=.029 
Table App.11.1.17  
POMS depression sub scores -2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 4.67 (6.37) 4.10 (4.71) .50 1,68 .48 .007 
intervention 3.47 (4.11) 2.35(3.24) 4.54 1,68 .037 .063 
* Homogeneity assumption not satisfied for this variable.  Homogeneity corrected using power 
transformation and ANOVA performed on transformed variable. Results as follows 
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App.11.1.18 POMS depression sub score (-2 power transformation) 
 (-2.0) power transformation of (POMS depression sub score +100) was performed. 
Homogeneity obtained on pre and post measures. Transformed scores were analysed 
using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects factor was 
group (intervention, control). The within-subjects factor was time/phase (pre versus 
post-intervention). 
 No significant time by group interaction was found, Λ =.99, F(1,68)=.62, p=.43, 
η2=.009  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,68)=.74, p=.34, η2=.011  
nor a significant post-intervention group difference, F(1,63)=3.30, p=.074, η2=.046 
There was no significant main effect for time, Λ =.99, F(1,68)=.62, p=.43, η2=.009  
There  was no significant group main effect, F(1,68)=1.99, p=.16, η2=.028 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly: 
Table App.11.1.18  
POMS transformed depression sub scores -2 x 2 mixed ANOVA - Pre to Post intervention 
change by group (intervention, control) 
group Λ F df p η
2
 
control 1.00 .30 1,68 .59 .004 
intervention .93 5.14 1,68 .027 .070 
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App.11.1.19 Profile of Mood States (POMS) tension sub - score  
Profile of Mood States (POMS) tension sub - scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,69)=.73, p=.79, 
η2=.001  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,69)=.35, p=.56, η2=.005 
nor a significant post-intervention group difference, F(1,69)=1.15, p=.29, η2=.016 
Further, no significant pre  to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.91, F(1,69)=2.33, p=.13,η2=.033 
nor was there a significant group main effect, F(1,69)=.79, p=.38, η2=.011  
Table App.11.1.19  
POMS tension sub scores - 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 6.14 (7.03) 5.41 (4.50) .58 1,69 .45 .008 
intervention 5.29 (4.86) 4.24 (4.09) 2.61 1,69 .11 .036 
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App.11.1.20 Profile of Mood States (POMS) anger sub - score  
Profile of Mood States (POMS) anger sub - scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
 A significant time by group interaction was found, Λ =.95, F(1,67)=3.31, p=.073, 
η2=.047 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,67)=1.01, p=.75, η2=.002 
but a significant post-intervention group difference, F(1,67)= 4.53, p=.037, η2=.063 
No significant pre  to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.97, F(1,67)=.56, p=.46,η2=.008  
nor was there a significant group main effect, F(1,67)=1.42, p=.24, η2=.021 
Table App.11.1.20 
POMS anger sub scores - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 4.70 (4.93) 5.15 (4.16) .41 1,67 .52 .006 
intervention 4.33 (4.20) 3.24 (3.00) 3.31 1,67 .073 .047 
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App.11.1.21 Profile of Mood States (POMS) fatigue sub - score  
Profile of Mood States (POMS) fatigue sub - scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =.96, F(1,72)=2.60, p=.11, 
η2=.035 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 72)=.20, p=.66, η2=.003 
nor a significant post-intervention group difference, F(1, 72)= 1.90, p=.17, η2=.026 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.91, F(1,72)=7.08 p=.010, η2=.089  
There was no significant main effect for time, Λ =.98, F(1, 72)=1.64, p=.20,η2=.022  
There was no significant group main effect, F(1, 72)=.20, p=.66, η2=.003  
Table App.11.1.21 
POMS – fatigue sub scores 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 4.59 (3.71) 4.73 (2.80) .04 1,72 .84 .001 
intervention 4.96 (3.06) 3.79 (2.62) 7.08 1,72 .010 .089 
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App.11.1.22 Profile of Mood States (POMS) confusion sub - score  
Profile of Mood States (POMS) confusion sub - scores were analysed using a 2 x 2 
mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
 No significant time by group interaction was found, Λ =.96, F(1,70)=2.57, p=.11, 
η2=.035 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 70)=.42, p=.52, η2=.006 
nor a significant post-intervention group difference, F(1, 70)=.97,  p=.33, η2=.014 
No significant pre  to post intervention change was seen with any of the groups.  
There was a significant main effect for time, Λ =1.00, F(1, 70)=.049, p=.82,η2=.001 
There was no significant group main effect, F(1, 70)=.007, p=.93, η2<.001  
Table App.11.1.22 
POMS – confusion sub scores 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 2.95 (3.00) 3.45 (2.63) .69 1,70 .41 .010 
intervention 3.45 (3.24) 2.82 (2.47) 2.72 1,70 .10 .037 
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App.11.1.23 Profile of Mood States (POMS) vigour sub - score  
Profile of Mood States (POMS) vigour sub - scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,69)=.28, p=.60, 
η2=.004 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 69)=.92, p=.34, η2=.013 
nor a significant post-intervention group difference, F(1, 69)=.52,  p=.47, η2=.007 
No significant pre  to post intervention change was seen with any of the groups.  
There was no significant main effect for time, Λ =.99, F(1, 69)=.38, p=.54, η2=.006 
There was no significant group main effect, F(1, 69)=.90, p=.35, η2=.013  
Table App.11.1.23 
POMS – vigour sub scores 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
control 8.33 (3.84) 10.52(8.86) 2.20 1,69 .14 .031 
intervention 9.94 (7.24) 10.00 (5.20) .007 1,69 .93 <.001 
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App.11.1.24   SF36 (Health Survey) global score 
SF36 (Health Survey) global scores were analysed using a 2 x 2 mixed analysis of 
variance (ANOVA). The between-subjects factor was group (intervention, control). The 
within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.96, F(1,61)= 2.71, p=.10, 
η2=.043 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 61)=.37, p=.55, η2=.088 
and no  significant post-intervention group difference, F(1, 61)=.36, p=.55, η2=.096 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.89, F(1,61)=7.54, p=.008, η2=.11  
There was a significant main effect for time, Λ =.97, F(1, 61)=1.87,  p=.18, η2=.030 
There was a significant group main effect, F(1, 61)<.001, p=.98, η2=.030 
Table App.11.1.24 
SF36 – global scores 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 68.16 (11.25) 67.82 (11.69) .03 1,61 .87 <.001 
intervention 66.21 (11.87) 69.90 (12.73) 7.54 1,61 .008 .11 
 
  
434 
 
 
App.11.1.25    SF36 (Health Survey) Physical functioning sub - score (*) 
SF36 (Health Survey) Physical functioning sub - scores were analysed using a 2 x 2 
mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
 No significant time by group interaction was found, Λ =.98, F(1,77)=1.43, p=.89, 
η2<001 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 77)=2.54, p=.11, η2=.032 
nor a significant post-intervention group difference, F(1, 77)=.47,  p=.50, η2=.006 
No significant pre  to post intervention change was seen with any of the groups 
There was no significant main effect for time, Λ =1.00, F(1, 77)=.20, p=.89,η2<.001 
There was no significant group main effect, F(1, 77)=1.42,  p=.24, η2=.018 
Table   App.11.1.25 
SF36 - Physical functioning sub - scores 2 x 2 mixed ANOVA - Pre to Post intervention 
change by group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 81.81 (11.22) 79.79 (14.41) .63 1,77 .43 .008 
intervention 75.05 (19.40) 76.64 (20.40) .91 1,77 .34 .012 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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App.11.1.26    SF36 (Health Survey) Role limitations due to physical health sub - 
score  
SF36 (Health Survey) Role limitations due to physical health sub - scores were analysed 
using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects factor was 
group (intervention, control). The within-subjects factor was time/phase (pre versus 
post-intervention). 
 A significant time by group interaction was found, Λ =.94, F(1,71)=4.60, p=.035, 
η2=.061 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 71)=1.31, p=.26, η2=.018 
nor a significant post-intervention group difference, F(1, 71)=.50,  p=.48, η2=.007 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.94, F(1,71)=4.64, p=.035, 
η2=.061  
There was no significant main effect for time, Λ =1.00, F(1, 71)=.75, p=.78,η2=.001 
There was no significant group main effect, F(1, 71)=.65,  p=.79, η2=.001 
Table   App.11.1.26 
SF36 – Physical Role limitations sub - scores 2 x 2 mixed ANOVA - Pre to Post 
intervention change by group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 65.22 (37.49) 57.61 (39.48) 1.26 1,71 .26 .08 
intervention 54.33 (37.95) 64.17 (35.60) 4.64 1,71 .035 .061 
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App.11.1.27     SF36 (Health Survey) body pain sub - score  
SF36 (Health Survey) body pain sub - scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
A significant time by group interaction was found, Λ =1.00, F(1,76)=.013, p=.91, 
η2<.001 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 76)=.65, p=.80, η2=.001 
nor a significant post-intervention group difference, F(1, 76)=.32,  p=.72, η2=.002 
No significant pre  to post intervention change was seen with any of the groups. 
There was no significant main effect for time, Λ =1.00, F(1, 76)=.038, p=.85, η2<.001 
There was no significant group main effect, F(1, 76)=.12,  p=.73, η2=.002 
Table    App.11.1.27 
SF36 – body pain sub - scores 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 65.78 (22.77) 64.96 (25.23) .033 1,76 .86 <.001 
intervention 67.25 (23.46) 67.04 (22.05) .006 1,76 .94 <.001 
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App.11.1.28   SF36 (Health Survey) general health sub - score  
SF36 (Health Survey) general health sub - scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,71)=.19, p=.66, 
η2=.003 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 71)=0.94, p=.76, η2=.001 
nor a significant post-intervention group difference, F(1, 71)=.39,  p=.53, η2=.006 
No significant pre  to post intervention change was seen with any of the groups. 
 There was no significant main effect for time, Λ =1.0, F(1,71)=.01, p=.75, η2=.001 
There was no significant group main effect, F(1, 71)=.22,  p=.62, η2=.003 
Table    App.11.1.28 
SF36 – general health sub - scores 2 x 2 mixed ANOVA - Pre to Post intervention change 
by group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 59.99 (19.45) 59.80 (14.05) .005 1,71 .94 <.001 
intervention 61.41 (16.85) 62.57 (17.70) .51 1,71 .47 .007 
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App.11.1.29    SF36 (Health Survey) vitality/energy sub - score  
SF36 (Health Survey) vitality/energy sub - scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(1,70)=.14, p=.87, 
η2=.004 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 70)=1.29, p=.28, η2=.036 
nor a significant post-intervention group difference, F(1, 70)=2.09,  p=.13, η2=.057 
A significant pre  to post intervention change was seen in the intervention group Λ =.94, 
F(1, 70)=3.86, p=.053, η2=.052  which improved significantly. 
There was a significant main effect for time, Λ =.94, F(1, 70)=4.25, p=.043, η2=.058 
There was no significant group main effect, F(1, 70)=2.11,  p=.13, η2=.058 
Table   App.11.1.29 
SF36 – vitality/energy sub - scores 2 x 2 mixed ANOVA - Pre to Post intervention change 
by group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 58.25 (17.50) 61.50 (18.36) .83 1, 70 .37 .012 
intervention 59.33 (17.35) 63.65 (17.84) 3 86 1, 70 .053 .052 
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App.11.1.30    SF36 (Health Survey) social functioning sub – score (*) 
SF36 (Health Survey) social functioning sub - scores were analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
 A significant time by group interaction was found, Λ =.93, F(1,77)= 5.96, p=.017, 
η2=.072 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1,77)=.63, p=.43, η2=.008 
and no significant post-intervention group difference, F(1, 77)=2.58, p=.11, η2=.032 
Further, the only significant pre  to post intervention change was seen in the 
intervention group which improved significantly, Λ =.94, F(1, 77)=4.91, p=.030, 
η2=.060  
There was no significant main effect for time, Λ =1.00, F(1, 77)=.003, p=.96,η2=.001 
nor was there a significant group main effect, F(1, 77)=.26, p=.61, η2=.003 
Table   App.11.1.30 
SF36 – social functioning sub - scores 2 x 2 mixed ANOVA - Pre to Post intervention 
change by group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 81.52 (21.93) 75.00 (22.61) 2.36 1,77 .13 .03 
intervention 77.45 (21.93) 83.70 (21.57) 4.91 1,77 .030 .060 
 * Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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App.11.1.31    SF36 Role limitations due to emotional function sub – score (*) 
SF36 (Health Survey) Role limitations due to emotional function sub – scores were 
analysed using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (intervention, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
A significant time by group interaction was found, Λ =.88, F(1,68)= 8.61, p=.005, 
η2=.11 
Follow up analysis of simple main effects for this interaction revealed a significant 
difference among the groups at pre-intervention, F(1, 68)=7.10, p=.009, η2=.11 
but  no significant post-intervention group difference, F(1, 68)=.26, p=.61, η2=.004 
Further, a significant pre  to post intervention change was seen both with the control 
group which deteriorated significantly, Λ =.94, F(1, 68)=4.61, p=.035, η2=.064 and the 
intervention group which improved significantly Λ =.94, F(1, 68)=4.25, p=.043, 
η2=.059 
There was no significant main effect for time, Λ =.99, F(1, 68)=.39, p=.53, η2=.006 
There was a significant group main effect, F(1, 68)=1.73, p=.14, η2=.09  
Table   App.11.1.31 
SF36 – emotional role limitations sub - scores 2 x 2 mixed ANOVA - Pre to Post 
intervention change by group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
control 86.36 (26.54) 68.18 (39.14) 4.61 1,68 .035 .064 
intervention 61.11 (40.29) 72.92 (35.57) 4.25 1,68 .043 .059 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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App.11.1.32    SF36 (Health Survey) emotional well being/mental health subscore 
SF36 (Health Survey) emotional well being/mental health sub - scores were analysed 
using a 2 x 2 mixed analysis of variance (ANOVA). The between-subjects factor was 
group (intervention, control). The within-subjects factor was time/phase (pre versus 
post-intervention). 
No significant time by group interaction was found, Λ =1.00, F(1,70)= .057, p=.81, 
η2=.010 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 70)=.83, p=.37, η2=.012 
but  a significant post-intervention group difference, F(1, 70)=.37, p=.54, η2=.025 
No significant pre  to post intervention change was seen with any of the groups. 
There was no significant main effect for time, Λ =.99, F(1, 70)=.74, p=.39, η2=.010 
There was a significant group main effect, F(1, 70)=.81, p=.37, η2=.011  
Table   App.11.1.32 
SF36 – emotional well being sub - scores 2 x 2 mixed ANOVA - Pre to Post intervention 
change by group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 67.00 (17.60) 69.65 (15.75) .42 1,70 .52 .006 
intervention 70.92 (15.92) 71.65 (17.22) .35 1,70 .56 .005 
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Appendix 11.2   Objective measures, Intention to Treat (ITT) analysis 
(Intervention versus control), Analysis of variance (ANOVA) 
App.11.2.1 Total time in bed (TTB)  
 „Total time in bed‟ was analysed using a 2 x 2 mixed analysis of variance (ANOVA). 
The between-subjects factor was group (intervention, control). The within-subjects 
factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.98, F(1,69)= 1.05, p=.31, 
η2=.015 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 69)=1.33, p=.25, η2=.019 
nor  a significant post-intervention group difference, F(1, 69)=.013, p=.91, η2<.001 
No significant pre - to post intervention change was seen with any group .  
There was no significant main effect for time, Λ =1.00, F(1, 69)=.019, p=.89, η2=.005 
There was no significant group main effect, F(1, 69)=.44, p=.51, η2=.006 
Table App.11.2.1 
Total time in bed - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 402.3 (91.43) 416.30 (73.98) .50 1,69 .48 .008 
YI 424.85 (70.33) 414.04 (78.31) .61 1,69 .44 .009 
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App.11.2.2 Total sleep time (TST) 
Total sleep time was analysed using a 2 x 2 mixed analysis of variance (ANOVA). The 
between-subjects factor was group (intervention, control). The within-subjects factor 
was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(1,68)= .52, p=.47, 
η2=.008 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 68)=1.34, p=.25, η2=.019 
nor  a significant post-intervention group difference, F(1, 68)=.005, p=.83, η2=.001 
Further, no significant pre - to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.16, F(1, 68)=.08, p=.99, η2<.001 
There was no significant group main effect, F(1, 68)=.73, p=.40, η2=.011 
Table App.11.2.2 
Total sleep time - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 355.91 (80.92) 363.78 (62.06) .20 1,68 .65 .003 
intervention 375.32 (57.24) 367.74 (74.57) .38 1,68 .54 .006 
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App.11.2.3  Sleep onset latency (SOL) [*] 
Sleep latency was analysed using a 2 x 2 mixed analysis of variance (ANOVA). The 
between-subjects factor was group (intervention, control). The within-subjects factor 
was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(1,69)=1.00, p=.32, 
η2=.014 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 69)=.010, p=.92, η2<.001 
nor  a significant post-intervention group difference, F(1, 69)=2.04, p=.16, η2=.029 
Further, no significant pre - to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.99, F(1, 69)=.54, p=.47, η2=.008 
There was no significant group main effect, F(1, 69)=1.33, p=.25, η2=.019 
Table App.11.2.3 
Sleep latency - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 9.11 (10.36) 8.39 (8.33) .027 1,69 .87 <.001 
intervention 9.46 (14.97) 14.07 (18.13) 2.33 1,69 .13 .033 
* Normality assumption not satisfied for this variable. No suitable transformation found. 
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App.11.2.4  Wake After Sleep Onset (WASO)  
Total wake time duration was analysed using a 2 x 2 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (intervention, control). The within-
subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.95, F(1,66)=3.78, p=.056, 
η2=.054 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 66)=2.80, p=.10, η2=.041 
nor  a significant post-intervention group difference, F(1, 66)=.59, p=.45, η2=.009 
Further, no significant pre - to post intervention change was seen with any of the 
groups, although both intervention groups improved and the control deteriorated but not 
significantly. 
There was no significant main effect for time, Λ =1.00, F(1, 66)=.003, p=.96, η2<.001 
There was no significant group main effect, F(1, 66)=.56, p=.45, η2=.008 
Table  App.11.2.4 
Total WASO - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, and control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 50.73 (18.14) 57.14 (19.79) 1.46 1,66 .23 .022 
intervention 59.80 (22.12) 53.74 (15.72) 2.76 1,66 .10 .040 
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App.11.2.5  Sleep Efficiency (SE)  
Sleep efficiency was analysed using a 2 x 2 mixed analysis of variance (ANOVA). The 
between-subjects factor was group (intervention, control). The within-subjects factor 
was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.97, F(1,66)=2.36, p=.13, 
η2=.034 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 66)=1.71, p=.31, η2=.025 
nor  a significant post-intervention group difference, F(1, 66)=.040, p=.23, η2=.012 
Further, no significant pre - to post intervention change was seen with any group 
There was no significant main effect for time, Λ =1.0, F(1, 66)=.23, p=.88, η2<.001 
There was no significant group main effect, F(1, 66)=.21, p=.64, η2=.003 
Table  App.11.2.5 
Sleep efficiency - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, and control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
Control .87 (.040) .87 (.030) 1.04 1,66 .31 .016 
intervention .86 (.004) .87 (.037) 1.48 1,66 .23 .022 
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App.11.2.6  Total light sleep duration  
Total Light Sleep duration was analysed using a 2 x 2 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (intervention, control). The within-
subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.98, F(1,68)=1.34, p=.25, 
η2=.019 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 68)=1.61, p=.21, η2=.023 
nor  a significant post-intervention group difference, F(1, 68)=.006, p=.74, η2<.001 
Further, no significant pre - to post intervention change was seen with any of the 
groups. 
There was no significant main effect for time, Λ =1.00, F(1, 68)=.004, p=.95, η2<.001 
There was no significant group main effect, F(1, 68)=.61, p=.44, η2=.009 
Table  App.11.2.6 
Total light sleep duration - 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 176.83 (55.30) 184.69 (47.48) .44 1,68 .51 .007 
intervention 192.59 (45.39) 183.82 (43.42) 1.13 1,68 .29 .016 
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App.11.2.7  Total Slow Wave stage (SWS) duration  
Total Slow Wave Sleep (deep sleep) duration was analysed using a 2 x 2 mixed analysis 
of variance (ANOVA). The between-subjects factor was group (intervention, control). 
The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(1,68)=.33, p=.57, 
η2=.005 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 68)=.001, p=.97, η2<.001 
but  a significant post-intervention group difference, F(1, 68)=.47, p=.49, η2=.007 
No  significant pre - to post intervention change was seen with any  group. 
There was no significant main effect for time, Λ =.99, F(1, 68)=.53, p=.47, η2=.008 
There was no significant group main effect, F(1, 68)=.19, p=.67, η2=.003 
Table  App.11.2.7 
Total SWS duration - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 106.74 (24.80) 107.44 (20.70) .009 1,68 .92 <.001 
intervention 106.49 (28.00) 112.34 (30.92) 1.28 1,68 .26 .019 
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App.11.2.8   Slow Wave stage (SWS) latency [*] 
Slow Wave stage (SWS) latency was analysed using a 2 x 2 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (intervention, control). The within-
subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(1,68)=.57, p=.45, 
η2=.008 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 68)=0.088, p=.80, η2=.001 
nor  a significant post-intervention group difference, F(1, 68)=1.78, p=.18, η2=.026 
Further, no significant pre - to post intervention change was seen with any of the groups 
There was no significant main effect for time, Λ =1.00, F(1, 68)=.001, p=.97, η2<.001 
There was no significant group main effect, F(1, 68)=.97, p=.33, η2=.014 
Table  App.11.2.8 
Total SWS latency - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
Control 18.61 (20.40) 15.39 (16.27) .19 1,68 .66 .003 
intervention 20.92 (34.46) 24.44 (30.34) . 47 1,68 .50 .007 
* Homogeneity assumption not satisfied for this variable.  Homogeneity corrected using power 
transformation and ANOVA performed on transformed variable. Results as follows: 
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App.11.2.9  Slow Wave stage (SWS) latency (-1 power transformation)  
Slow Wave stage (SWS) latency was transformed by using (-1) power transformation 
on (SWS latency +1) and then analysed using a 2 x 2 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (intervention, control). The within-
subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =1.00, F(1,68)=.082, p=.77, 
η2=.001 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 68)=.15, p=.70, η2=.002 
nor  a significant post-intervention group difference, F(1, 68)<.001, p=.99, η2<.001 
There was no significant main effect for time, Λ =.97, F(1, 68)= 1.92, p=.17, η2=.028 
There was no significant group main effect, F(1, 68)=.11, p=.74, η2=.002 
Further, no significant pre - to post intervention change was seen with any of the 
groups: 
Table  App.11.2.9 
Transformed SWS latency - 2 x 2 mixed ANOVA - Pre to Post intervention change by 
group (intervention, control) 
group Λ F df p η
2
 
Control .99 .45 1,68 .50 .007 
intervention .97 2.13 1,68 .15 .030 
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Appendix 11.2.10  Total Rapid Eye Movement stage (REM) duration  
Total Rapid Eye Movement stage (dream stage) duration was analysed using a 2 x 2 
mixed analysis of variance (ANOVA). The between-subjects factor was group 
(intervention, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =1.00, F(1,68)=.15, p=.70, 
η2=.002 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 68)=.008, p=.93, η2<.001 
nor  a significant post-intervention group difference, F(1, 68)=.10, p=.75, η2=.001 
Further, no significant pre - to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.99, F(1, 68)=.40, p=.53, η2=.006 
There was no significant group main effect, F(1, 68)=.027, p=.87, η2<.001 
Table  App.11.2.10 
Total REM duration- 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 70.43 (28.12) 69.39 (28.53) .023 1,68 .88 <.001 
intervention 71.04 (25.74) 66.72 (34.80) . 80 1,68 .37 .012 
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App.11.2.11  Rapid Eye Movement stage (REM) latency  
Rapid Eye Movement stage (dream stage) latency was analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.96, F(1,67)=2.52, p=.12, 
η2=.036 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 67)=.28, p=.60, η2=.004 
nor  a significant post-intervention group difference, F(1, 67)=1.38, p=.24, η2=.020 
Further, no significant pre - to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.99, F(1, 67)=.68, p=.41, η2=010 
There was no significant group main effect, F(1, 67)=.15, p=.70, η2=.002 
Table  App.11.2.11 
REM latency- 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 98.30 (44.25) 113.70 
(48.49) 
2.16 1,67 .15 .032 
intervention 104.61 
(47.80) 
99.72 (45.66) .44 1,67 .51 .007 
 
  
453 
 
App.11.2.12  Mean blood oxygen saturation (SPO2) during night 
Mean blood oxygen saturation level was analysed using a 2 x 2 mixed analysis of 
variance (ANOVA). The between-subjects factor was group (intervention, control). The 
within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =1.00, F(1,69)= .014, p=.61, 
η2=.004 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 69)<.001, p=.99, η2<.001nor  a 
significant post-intervention group difference, F(1, 69)=.35, p=.85, η2=.001 
Further, no significant pre - to post intervention change was seen with any group 
There was no significant main effect for time, Λ =1.00, F(1, 69)=.26, p=.61, η2<.001 
There was no significant group main effect, F(1, 69)=.011, p=.92, η2<.001 
Table  App.11.2.12 
Mean blood oxygen saturation level- 2 x 2 mixed ANOVA - Pre to Post intervention 
change by group (intervention, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
Control 97.13 (4.20) 96.87 (4.21) .057 1,69 .81 .001 
intervention 97.12 (4.82) 96.71 (2.95) .31 1,69 .58 .004 
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App.11.2.13   Respiratory Disturbance Index (RDI) [*] 
 Respiratory Disturbance Index (RDI) was analysed using a 2 x 2 mixed analysis of 
variance (ANOVA). The between-subjects factor was group (intervention, control). The 
within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(1,68)= .43, p=.51, 
η2=.006 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 68)=2.62, p=.10, η2=.037 
nor  a significant post-intervention group difference, F(1, 68)=3.23, p=.077, η2=.045 
Further, no significant change was seen with any of the  groups  pre  to post intervention  
There was no significant main effect for time, Λ =1.00, F(1, 68)=.025, p=.87, η2<.001 
There was no significant group main effect, F(1, 68)=3.22, p=.077, η2=.045  
Table  App.11.2.13 
 RDI - 2 x 2 mixed ANOVA - Pre to Post intervention change by group (intervention, 
control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 10.90 (6.45) 10.24 (5.55) .25 1,68 .62 .004 
intervention 14.92 (10.99) 15.32 (12.96) .19 1,68 .66 .003 
* Homogeneity assumption not satisfied for this variable. Homogeneity corrected using suitable power 
transformation (-1.939).  ANOVA performed on transformed variable. Results as follows: 
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App.11.2.14  Respiratory Disturbance Index (RDI) (-1.939 Power 
Transformation)  
Transformed Respiratory Disturbance Index (RDI) was analysed using a 2 x 2 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (intervention, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.98, F(1,68)=1 .07, p=.30, 
η2=.015 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 68)=.48, p=.49, η2=.007 
nor  a significant post-intervention group difference, F(1, 68)=.47, p=.49, η2=.007 
There was no significant main effect for time, Λ =.99, F(1, 68)=.40, p=.53, η2=.006 
There was no significant group main effect, F(1, 68)=.14, p=.71, η2=.002  
Further, no significant pre  to post intervention change was seen with any of the  groups:  
Table  App.11.2.14 
Transformed RDI - 2 x 2 mixed ANOVA - Pre to Post intervention change by group 
(intervention, control) 
group  F df p η
2
 
Control .99 .06 1,68 .81 .001 
intervention .97 2.11 1,68 .15 .030 
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App.11.2.15  Oxygen Desaturation Index (ODI) 
 Apnea Duration Index (ODI) was analysed using a 2 x 2 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (intervention, control). The within-
subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.91, F(1,69)= .096, p=.76, 
η2=.001 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(1, 69)=2.16, p=.15, η2=.030 
and  no significant post-intervention group difference, F(1, 69)=2.47, p=.12, η2=.035 
Further, no significant change was seen with any of the  groups  pre  to post intervention  
There was no significant main effect for time, Λ =1.00, F(1, 69)=.036, p=.85, η2=.001 
There was no significant group main effect, F(1, 69)=2.55, p=.11, η2=.036 
Table  App.11.2.15 
ODI - 2 x 2 mixed ANOVA - Pre to Post intervention change by group (intervention, 
control) 
group M (SD) - pre M (SD) - post F df p η2 
Control 7.82 (6.70) 7.74 (5.94) .005 1,69 .94 <.001 
YI 11.34 (10.45) 11.70 (11.33) .19 1,69 .66 .003 
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Appendix 11.3   Objective measures, Intention to Treat (ITT) analysis 
(Intervention versus control), Multivariate analysis of variance (MANOVA) 
App.11.3.1 Insomnia related multivariate analysis of variance (MANOVA)  
The data for the insomnia multivariate was analysed using a 2 x 2 mixed multivariate 
analysis of variance (MANOVA). The two-level between-subjects factor was group 
(intervention, and control) and the two-level within-subjects factor was phase (baseline 
versus post-intervention). The multivariate dependent variable was made up of four 
measures related to insomnia namely: sleep onset latency (SOL), wake after sleep onset 
(WASO), total sleep time (TST) and sleep efficiency (SE). 
Multivariate tests revealed no significant main effect for phase,  = .95, F(4, 63) =.78,  
p = .54, 2 = .047, no significant multivariate main effect for group,  = .93, F(4, 63) 
=1.17,  p = .33, 2 = .069,  and no significant multivariate interaction,  = .90, F(4, 
63)=1.71, p = .16, 2 = .098. 
When the sub-scales for the multivariate main effect for phase were considered 
separately, there was no significant univariate phase main effect, no significant 
univariate group main effect, and no significant univariate interaction. 
Examination of the marginal means showed that across all groups, for WASO and SE 
(sleep efficiency) remained without change, for TST improved, and for SOL 
deteriorated slightly from baseline to post-intervention. 
Analysis of the multivariate simple main effects for time/phase within group revealed a 
significant pre - to post-intervention change for the intervention group only: 
Table  App.11.3.1 
Insomnia related multivariate analysis of variance (MANOVA) - Pre to Post intervention 
change by group (intervention, control) 
group  F df p η
2
 
control .97 . 40 4, 63 . 81 . 025 
intervention .84 3.02 4, 63 .024 .16   
 Please continue to the next page  
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App.11.3.2   OSA related multivariate analysis of variance (MANOVA)  
The data for OSA was analysed using a 2 x 2 mixed multivariate analysis of variance 
(MANOVA). The two-level between-subjects factor was group (YI, control) and the 
two-level within-subjects factor was phase (baseline versus post-intervention). The 
multivariate dependent variable was made up of three measures related to OSA namely, 
RDI (transformed), ODI, and mean SPO2. Multivariate tests revealed no significant 
main effect for phase,  = .99, F(3, 66) = .26, p = .85, 2 = .012, no significant 
multivariate main effect for group,  = .95,  F(3, 66) =1.18,  p = .33, 2 = .051,  and no 
significant multivariate interaction   = .96, F(3, 66) =.91, p = .44, 2 = .040. When the 
sub-scales for the multivariate main effect for phase were considered separately, there 
was no significant univariate phase main effect, no significant univariate group main 
effect, and no significant univariate interaction. Examination of the marginal means 
showed a slight deterioration in SPO2 and ODI measures and slight improvement in 
RDI measure - across all groups from baseline to post-intervention. Analysis of the 
multivariate simple main effects for time/phase within group revealed no significant 
pre- to post-intervention change for any of the groups: 
Table  App.11.3.2 
OSA related multivariate analysis of variance (MANOVA) - Pre to Post intervention 
change by group (YI, control) 
group  F df p η
2
 
control .97 .077 3,66 .97 .004 
YI .93 1.63 3,66 .19 .069 
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App.11.3.3   Slow Wave Sleep (SWS) - multivariate analysis of variance (MANOVA)  
The data for the SWS was analysed using a 2 x 2 mixed multivariate analysis of 
variance (MANOVA). The two-level between-subjects factor was group (intervention, 
and control) and the two-level within-subjects factor was phase (baseline versus post-
intervention). The multivariate dependent variable was made up of two measures related 
to SWS, namely, SWS duration and SWS latency (transformed). Multivariate tests 
revealed no significant multivariate main effect for phase,  = .96, F(2,66)= 1.25, p = 
.29, 2 = .037, no significant multivariate main effect for group,  = .99, F(2, 66) =.27, 
p = . 76, 2 = .008, and no significant multivariate interaction,  = .99, F(2, 66) =.38, p 
= .69, 2 = .011 . 
When the sub-scales for the multivariate main effect for phase were considered 
separately, there was neither a significant univariate phase main effect, nor a significant 
univariate group main effect, nor a significant univariate phase by group. Examination 
of the marginal means showed that, for SWS duration, participants across all groups 
improved from baseline to post-intervention, but for SWS latency - remained 
unchanged from baseline to post-intervention. Analysis of the multivariate simple main 
effects for time/phase within group revealed no significant pre- to post-intervention 
change for any group: 
Table  App.11.3.3 
SWS related multivariate analysis of variance (MANOVA) - Pre to Post intervention 
change by group (intervention, control) 
group  F df p η
2
 
control .99 .23 2,66 .80 .007 
intervention .94 1.99 2,66 .14 .057 
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App.11.3.4   REM sleep - multivariate analysis of variance (MANOVA)  
The data for the REM sleep was analysed using a 2 x 2 mixed multivariate analysis of 
variance (MANOVA). The two-level between-subjects factor was group (intervention, 
and control) and the two-level within-subjects factor was phase (baseline versus post-
intervention). The multivariate dependent variable was made up of two measures related 
to REM, namely, REM duration and REM latency (transformed). 
Multivariate tests revealed no significant multivariate main effect for phase,  = .99, 
F(2,65)=.36, p = .70, 2 = .011, no significant multivariate main effect for group,  = 
1.00, F(2, 65) =.053, p = . 95, 2 = .002, and no significant multivariate interaction,  = 
.96, F(2, 65) =1.20, p = .31, 2 = .036. 
When the sub-scales for the multivariate main effect for phase were considered 
separately, there was neither a significant univariate phase main effect, nor a significant 
univariate group main effect, nor a significant univariate phase by group. 
Examination of the marginal means showed that, for REM duration, participants across 
all groups improved from baseline to post-intervention, but for REM latency 
deteriorated from baseline to post-intervention 
Analysis of the multivariate simple main effects for time/phase within group revealed 
no significant pre- to post-intervention change for any group. 
Table App.11.3.4 
REM related multivariate analysis of variance (MANOVA) - Pre to Post intervention 
change by group (intervention, control) 
group  F df p η
2
 
Control .97 1.06 2,65 .35 .032 
intervention .99 .25 2,65 .78 .008 
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 App.11.4  Subjective measures, ‘On treatment’ (OT) subset (low compliance 
versus high compliance versus control)– analysis of variance (ANOVA)  
App.11.4.1  Karolinska Sleepiness Scale (KSS) (*) 
Scores on the Karolinska Sleepiness Scale (KSS) were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
A significant time by group interaction was found, Λ =.90, F(2,75)=4.00, p=.022, 
η2=.096 
 Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,75)=.23, p=.79, η2=.006 but a 
significant post-intervention group difference, F(2,75)=5.36, p=.007, η2=.12 
Further, the only significant pre- to post intervention change was seen in the control 
group which deteriorated significantly, Λ =.91, F(1,75)=7.04, p=.01, η2=.086 
There was no significant main effect for time, Λ =.97, F(1, 75)=2.51, p=.12, η2=.032  
nor was there a significant group main effect, F(2, 75)=2.04, p=.14, η2=.052 
Table   App.11.4.1 
KSS scores - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - 
post 
F df p η2 
low comp. 2.96 (1.46) 3.46 (1.93) 1.20 1,75 .28 .016 
high comp. 3.07 (1.57) 2.57 (.97) 1.51 1,75 .22 .020 
control 2.79 (1.35) 4.00 (1.93) 7.04 1,75 .01 .086 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found.   
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App.11.4.2   Epworth Sleepiness Scale (ESS)  
Scores on the Epworth Sleepiness Scale (ESS) were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =1.00, F(2,79)=.13, p=.88, 
η2=.003 
 Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 79)=.91, p=.41, η2=.023 and no 
significant post-intervention group difference, F(2,79)=.82, p=.44, η2=.020 
No significant pre  to post intervention change was seen with any of the  groups. 
There was no significant main effect for time, Λ =.96, F(1,79)=3.45, p=.067, η2=.042  
nor was there a significant group main effect, F(2, 79)=1.01, p=.37, η2=.025 
Table   App.11.4.2 
ESS scores - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 6.08 (4.23) 6.69 (4.42) 1.04 1,79 .31 .013 
high comp. 7.43 (3.49) 7.78 (3.58) .60 1,79 .44 .008 
control 7.00 (3.67) 7.85 (3.47) 1.97 1,79 .16 .024 
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App.11.4.3   Pittsburgh Sleep Quality Index (PSQI) - global score 
Scores on the Pittsburgh Sleep Quality Index (PSQI) global score were analysed using a 
2 x 3 mixed analysis of variance (ANOVA). The between-subjects factor was group 
(low compliance, high compliance, control). The within-subjects factor was time/phase 
(pre versus post-intervention). 
A significant time by group interaction was found, Λ =.82, F(2,63)=6.80, p=.002, 
η2=.18 
 Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,63)=.62, p=.54, η2=.019 and no 
significant post-intervention group difference, F(2,63)=2.53, p=.088, η2=.074  
Further, the only significant pre- to post intervention change was seen in the high 
compliance  group which improved significantly, Λ =.77, F(1,63)=18.90, p<.001,η2=.23  
There was no significant main effect for time, Λ =.95, F(1,63)=3.36, p=.072, η2=.051  
nor was there a significant group main effect, F(2,63)=.56, p=.57, η2=.018  
Table  App.11.4.3 
PSQI global scores - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 9.17 (3.94) 9.72 (4.03) .74 1,63 .39 .012 
high comp. 10.26 (3.14) 7.96 (3.22) 18.90 1,63 <.001 .23 
control 10.14 (3.21) 10.00 (3.08) .057 1,63 .81 .001 
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App.11.4.4   Pittsburgh Sleep Quality Index (PSQI) - subjective sleep quality sub 
score 
Scores on the Pittsburgh Sleep Quality Index (PSQI) - subjective sleep quality sub score 
were analysed using a 2 x 3 mixed analysis of variance (ANOVA). The between-
subjects factor was group (low compliance, high compliance, control). The within-
subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.98, F(2,77)=.69, p=.50, 
η2=.018 Follow up analysis of simple main effects for this interaction revealed no 
significant difference among the groups at pre-intervention, F(2,77)=1.26, p=.29, 
η2=.032  but a significant post-intervention group difference, F(2,77)=6.04, p=.004, 
η2=.136  
Further, the only significant pre- to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.92, F(1,77)=6.66, p=.012, η2=.08  
There was a significant main effect for time, Λ =.90, F(1,77)=8.56, p=.005,η2=.1  
There was also a significant group main effect, F(2,77)=5.05, p=.009, η2=.12 
Table  App.11.4.4 
PSQI subjective sleep quality sub-scores -2 x 3 mixed ANOVA - Pre to Post intervention 
change by group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 1.56 (.71) 1.28 (.46) 3.23 1,77 .076 .04 
high comp. 1.63 (.61) 1.27 (.58) 6.66 1,77 .012 .08 
control 1.84 (.62) 1.72 (.54) .59 1,77 .44 .008 
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App.11.4.5  Pittsburgh Sleep Quality Index (PSQI) - sleep latency sub score 
Scores on the Pittsburgh Sleep Quality Index (PSQI) - sleep latency sub score were 
analysed using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (low compliance, high compliance, control). The within-subjects 
factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =.95, F(2,61)=1.52, p=.23, 
η2=.047  
Follow up analysis of simple main effects for this interaction revealed a significant 
difference among the groups at pre-intervention, F(2,61)=3.37, p=.041, η2=.10  and  a 
significant post-intervention group difference, F(2,61)=3.96, p=.024, η2=.11 
A significant pre- to post intervention change was seen in the high compliance  group, 
Λ =.84, F(1,61)=11.56, p=.001, η2=.16  and also with the control,  Λ =.90, 
F(1,61)=6.70, p=.012, η2=.099, both improving significantly 
There was a significant main effect for time, Λ =.82, F(1,61)=13.10, p=.001,η2=.177  
There was a significant group main effect, F(2,61)=4.22, p=.019, η2=.12  
Table  App.11.4.5 
PSQI sleep latency sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 1.94 (1.03) 1.82 (1.07) .35 1,61 .56 .006 
high comp. 1.80 (.96) 1.24 (.93) 11.56 1,61 .001 .166 
control 2.45 (.67) 2.00 (93) 6.70 1,61 .012 . 099 
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App.11.4.6  Pittsburgh Sleep Quality Index (PSQI) - sleep duration sub score  
Scores on the Pittsburgh Sleep Quality Index (PSQI) - sleep duration sub score were 
analysed using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (low compliance, high compliance, control). The within-subjects 
factor was time/phase (pre versus post-intervention). 
A significant time by group interaction was found, Λ =.83, F(2,72)=7.40, p=.001,η2=.17  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,72)=1.64, p=.20, η2=.044   
but a significant post-intervention group difference,  F(2,72)=3.12, p=.050, η2=.080 
Further, the only significant pre- to post intervention change was seen in the high 
compliance group which improved  significantly, Λ =.84, F(1,72)=13.38, p<.001,η2=.15 
There was no significant main effect for time, Λ =.99, F(1,72)=.41, p=.53, η2=.006 
nor was there a significant group main effect, F(2,72)=1.12, p=.33, η2=.03  
Table  App.11.4.6 
PSQI sleep duration sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 1.74 (1.10) 1.87 (.87) .67 1,72 .41 .009 
high comp. 2.21(.86) 1.69 (.85) 13.38 1,72 <.001 .16 
control 2.04 (.82) 2.26 (.75) 1.87 1,72 .17 .025 
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App.11.4.7  Pittsburgh Sleep Quality Index (PSQI) - sleep efficiency sub score  
Scores on the Pittsburgh Sleep Quality Index (PSQI) sleep efficiency sub score were 
analysed using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (low compliance, high compliance, control). The within-subjects 
factor was time/phase (pre versus post-intervention). 
 A significant time by group interaction was found, Λ =.88, F(2,52)=3.38, p=.042, 
η2=.11  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,52)=.22, p=.80, η2=.008  
but a significant post-intervention group difference, F(2,52)=3.23, p=.048,η2=.11 
Further, the only significant pre  to post intervention change was seen in the hi 
compliance group which improved significantly, Λ =.89, F(1,52)=6.75, p=.012, η2=.115  
There was no significant main effect for time, Λ =.99, F(1,52)=.44, p=.51,η2=.008  
nor was there a significant group main effect, F(2,52)=.98, p=.38, η2=.036  
Table  App.11.4.7 
PSQI sleep efficiency sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change 
by group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 1.28 (1.23) 1.22 (1.00) .044 1,52 .83 .001 
high comp. 1.52 (1.24) .91 (1.16) 6.75 1,52 .012 .11 
control 1.50 (1.29) 1.86 (1.10) 1.41 1,52 .24 .026 
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App.11.4.8  Pittsburgh Sleep Quality Index (PSQI) - sleep disturbance sub score  
Scores on the Pittsburgh Sleep Quality Index (PSQI) - sleep disturbance sub score were 
analysed using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (low compliance, high compliance, control). The within-subjects 
factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =.95, F(2,69)=1.70, p=.19, 
η2=.047  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,69)=.80, p=.45, η2=.023  
and no significant post-intervention group difference, F(2, 69)=.34, p=.71,η2=.01 
The only improvement pre to post intervention was seen with the hi compliance group 
although not significantly, Λ =.95, F(1,69)=3.49, p=.066, η2=.048 . There was no 
significant pre to post intervention change in any of the other groups as well. 
There was no significant main effect for time, Λ =1.01, F(1,69)=.28, p=.60 ,η2=.004 
nor was there a significant group main effect, F(2,69)=.048, p=.95, η2=.001 
Table   App.11.4.8 
PSQI sleep disturbance sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change 
by group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 1.24 (.54) 1.33 (.48) 5.3 1,69 .47 .008 
high comp. 1.41 (.57) 1.21 (.49) 3.49 1,69 .066 .048 
control 1.27 (.46) 1.27 (.63) .00 1,69 1.00 <.001 
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App.11.4.9  Pittsburgh Sleep Quality Index (PSQI) sleep medication sub score (*) 
Scores on the Pittsburgh Sleep Quality Index (PSQI) sleep medication sub score were 
analysed using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (low compliance, high compliance, control). The within-subjects 
factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =1.0, F(2,78)=.009, p=.99, 
η2<.001  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,78)=1.87, p=.16, η2=.046  
and no significant post-intervention group difference, F(2,78)=1.80, p=.17, η2=.044 
Further, no significant pre  to post intervention change was seen with any of the groups 
There was no significant main effect for time, Λ =1.00, F(1,78)=.25, p=.62, η2=.003  
nor was there a significant group main effect, F(2,78)=2.05, p=.13, η2=.05 
Table   App.11.4.9 
PSQI sleep medication sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change 
by group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 1.44 (1.39) 1.40 (1.41) .052 1,78 .82 .001 
high comp. 1.33 (1.45) 1.27 (1.48) .174 1,78 .68 .002 
control 1.77 (1.18) 1.73 (1.15) .050 1,78 .82 .001 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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App.11.4.10   Pittsburgh Sleep Quality Index (PSQI) dysfunction sub score  
Scores on the Pittsburgh Sleep Quality Index (PSQI) dysfunction sub score were 
analysed using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (low compliance, high compliance, control). The within-subjects 
factor was time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =.99, F(2,71)=.35, p=.71, η2=.01  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,71)=.69, p=.50, η2=.019  
nor a significant post-intervention group difference, F(2,71)=2.63, p=.079, η2=.069 
Further, no significant pre  to post intervention change was seen in any of the groups. 
There was no significant main effect for time, Λ =1.0, F(1,71)=.25, p=.62, η2=.003  
nor was there a significant group main effect, F(2,71)= 2.22, p=.12, η2=.059 
Table  App.11.4.10 
PSQI dysfunction sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. .91 (.81) .95 (.65) .71 1,71 .79 .001 
high comp. .71 (.71) .57 (.57) .89 1,71 .35 .012 
control .92 (.58) .88 (.68) .06 1,71 .80 .001 
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App.11.4.11   Apnea probability score derived from MAP  
Apnea probability scores derived from MAP using an algorithm which incorporates age, 
gender, body mass ratio (BMR) and several MAP components,  were analysed using a 2 
x 3 mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =.99, F(2,65)=.40, p=.67, 
η2=.012 Follow up analysis of simple main effects for this interaction revealed no 
significant difference among the groups at pre-intervention, F(2,65)=.20, p=.82, η2=.006 
nor a significant post-intervention group difference, F(2,65)=.69, p=.50, η2=.021 
Further, no  pre  to post intervention change was seen in any of the groups. 
 There was no significant main effect for time, Λ =1.00, F(1,65)=. 061, p=.81, η2=.001 
nor was there a significant group main effect, F(2,65)=.40, p=.67, η2=.012 
Table  App.11.4.11 
MAP derived apnea probability scores 2 x 3 mixed ANOVA - Pre to Post intervention 
change by group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. .42 (.31) .37 (.29) .44 1,65 .51 .007 
high comp. .42 (.32) .46 (.35) .32 1,65 .57 .005 
control .37 (.29) .36 (.29) .06 1,65 .80 .001 
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App.11.4.12   Depression Anxiety Stress Scale (DASS) global score  
Depression Anxiety Stress Scale (DASS) global score were analysed using a 2 x 3 
mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =.95, F(2,70)=1.88, p=.16, 
η2=.051 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,70)=.24, p=.79, η2=.007  
nor a significant post-intervention group difference, F(2,70)=.65, p=.53, η2=.018 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.87, F(1,70)=10.78, p=.002, η2=.13  
There was a significant main effect for time, Λ =.90, F(1,70)=7.48, p=.008,η2=.097  
There was no significant group main effect, F(2,70)=.14, p=.87, η2=.004  
Table  App.11.4.12 
DASS global - scores 2 x 3 mixed ANOVA - Pre to Post intervention change by group 
(low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 20.04 (19.21) 19.04 (13.08) .14 1,70 .71 .002 
high comp. 23.31 (15.86) 15.48 (14.77) 10.78 1,70 .002 .13 
control 23.48 (23.30) 19.86 (16.28) 1.67 1,70 .20 .023 
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App.11.4.13   Depression Anxiety Stress Scale (DASS) - stress sub-score  
Depression Anxiety Stress Scale (DASS) stress sub-scores were analysed using a 2 x 3 
mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =.97, F(2,72)=1.09, p=.34, 
η2=.03 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,72)=.27, p=.76, η2=.008  
nor a significant post-intervention group difference, F(2,72)=.43, p=.65, η2=.012 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.91, F(1,72)=7.50, p=.008, η2=.094  
There was a significant main effect for time, Λ =.92, F(1,72)=6.27, p=.015,η2=.079 
There was no significant group main effect, F(2,72)=.21, p=.81, η2=.006  
Table  App.11.4.13 
DASS stress sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change by group 
(low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 8.71 (7.86) 8.00 (7.13) .30 1,72 .59 .004 
high comp. 10.21 (8.01) 6.97 (7.48) 7.50 1,72 .008 .094 
control 10.50 (11.08) 8.91 (7.65) 1.37 1,72 .24 .019 
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App.11.4.14   Depression Anxiety Stress Scale (DASS) anxiety sub-score  
Depression Anxiety Stress Scale (DASS) anxiety sub-scores were analysed using a 2 x 
3 mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =.95, F(2,75)=1.78, p=.17, 
η2=.045 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,75)=.53, p=.59, η2=.014 
nor a significant post-intervention group difference, F(2,75)=.18, p=.84, η2=.005 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.92, F(1,75)=6.8, p=.011, η2=.083  
There was no significant main effect for time, Λ =.97, F(1,75)=2.67, p=.11,η2=.034 
There was no significant group main effect, F(2,75)=.14, p=.87, η2=.004  
Table  App.11.4.14 
DASS anxiety sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change by group 
(low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 6.19 (5.64) 6.15 (4.10) .002 1,75 .96 <.001 
high comp. 7.83 (5.78) 5.80 (5.67) 6.79 1,75 .011 .083 
control 7.00 (6.60) 6.68 (5.80) .12 1,75 .73 .002 
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App.11.4.15   Depression Anxiety Stress Scale (DASS) depression sub-score  
Depression Anxiety Stress Scale (DASS) depression sub-scores were analysed using a 2 
x 3 mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =.94, F(2,71)=2.2, p=.12, 
η2=.058 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,71)=.11, p=.89, η2=.003 
nor a significant post-intervention group difference, F(2,71)=2.03, p=.14, η2=.054 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.88, F(1,71)=9.67, p=.003, η2=.12 
There was a significant main effect for time, Λ =.94, F(1,71)=4.56, p=.034, η2=.060 
There was no significant group main effect, F(2,71)=.53, p=.59, η2=.015  
Table  App.11.4.15 
DASS stress sub-scores 2 x 3 mixed ANOVA - Pre to Post intervention change by group 
(low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 5.08 (7.41) 4.88 (5.91) .05 1,71 .83 .001 
high comp. 5.55 (5.18) 2.79 (3.34) 9.69 1,71 .003 .12 
control 6.00 (6.86) 5.38 (5.43) .35 1,71 .55 .005 
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App.11.4.16   Profile of Mood States (POMS) global score (*) 
Profile of Mood States (POMS) global scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =.99, F(1,63)=.38, 
p=.68,η2=.012 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,63)=.42, p=.66, η2=.013  
nor a significant post-intervention group difference, F(2,63)=.80, p=.46, η2=.025 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.91, F(1,63)=6.45, p=.014, η2=.028  
There was a significant main effect for time, Λ =.88, F(2,63)=8.16, p=.006, η2=.11 
There was no significant group main effect, F(2,63)=.60, p=.55, η2=.019  
Table  App.11.4.16 
POMS global scores - 2 x 3 mixed ANOVA - Pre to Post intervention change by group 
(low compliance, high compliance, control)  
group M (SD) - pre M (SD) - post F df p η2 
low comp. 10.05(17.27) 5.90 (12.46) 1.40 1,63 .24 .022 
high comp. 13.50 (20.67) 5.50 (14.65) 6.45 1,63 .014 .093 
control 24.89 (24.45) 11.21 (20.85) 1.80 1,68 .18 .028 
* Homogeneity assumption not satisfied for this variable. No suitable Power transformation found 
  
477 
 
App.11.4.17   Profile of Mood States (POMS) depression sub - score (*) 
Profile of Mood States (POMS) depression sub - scores were analysed using a 2 x 3 
mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(2,67)=.18, p=.83, 
η2=.005  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,67)=.50, p=.61, η2=.015 
nor a significant post-intervention group difference, F(2,67)=1.63, p=.20, η2=.046 
No significant pre  to post intervention change was seen with any group .  
There was a significant main effect for time, Λ =.94, F(1,67)=4.35, p=.041,η2=.061 
There was no significant group main effect, F(2,67)=1.08, p=.35, η2=.031 
Table  App.11.4.17 
POMS depression sub scores -2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 3.18 (4.33) 2.18 (3.98) 1.60 1,67 .21 .023 
high comp. 3.70 (4.00) 2.48 (2.56) 2.92 1,67 .09 .042 
control 4.67 (6.37) 4.10 (4.71) .50 1,67 .48 .007 
 
* Homogeneity assumption not satisfied for this variable.  Homogeneity corrected using power 
transformation and ANOVA performed on transformed variable. Results as follows 
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App.11.4.18   Profile of Mood States (POMS) depression sub score (-2.0) power 
transformation 
 (-2.0) power transformation of (POMS depression sub score +100) was performed. 
Homogeneity obtained on pre and post measures. Transformed scores were analysed 
using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects factor was 
group (low compliance, high compliance, control). The within-subjects factor was 
time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =.99, F(2,67)=.31, p=.73, 
η2=.009  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,67)=.47, p=.63, η2=.014  
nor a significant post-intervention group difference, F(2,63)=1.72, p=.19, η2=.049 
There was a significant main effect for time, Λ =.94, F(1,67)=4.40, p=.040, η2=.062  
There  was no significant group main effect, F(2,67)=1.10, p=.34, η2=.032 
Further, no significant pre  to post intervention change was seen with any group:  
Table  App.11.4.18 
Transformed POMS depression sub scores -2 x 3 mixed ANOVA - Pre to Post intervention 
change by group (low compliance, high compliance, control) 
group Λ F df p η
2
 
low comp. .97 1.96 1,67 .17 .028 
high comp. .96 3.12 1,67 .082 .044 
control 1.00 .29 1,67 .59 .004 
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App.11.4.19   Profile of Mood States (POMS) tension sub - score  
Profile of Mood States (POMS) tension sub - scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =.98, F(2,68)=.84, p=.43, 
η2=.024  
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,68)=.57, p=.57, η2=.017 
nor a significant post-intervention group difference, F(2,68)=.58, p=.56, η2=.017 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.94, F(1,68)=4.21, p=.04, η2=.09  
There was no significant main effect for time, Λ =.96, F(1,68)=.62, p=.96,η2=.040  
 
Table  App.11.4.19 
POMS tension sub scores - 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 4.52 (4.73) 4.35 (3.20) .034 1,68 .85 .001 
high comp. 5.96 (4.97) 4.15 (4.81) 4.21 1,68 .044 .058 
control 6.14 (7.03) 5.41 (4.50) .58 1,68 .45 .008 
 
  
480 
 
App.11.4.20   Profile of Mood States (POMS) anger sub - score  
Profile of Mood States (POMS) anger sub - scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 A significant time by group interaction was found, Λ =.92, F(2,66)=3.03, p=.05, 
η2=.084 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,66)=.86, p=.43, η2=.025 
nor a significant post-intervention group difference, F(2,66)= 2.24, p=.11, η2=.064 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.89, F(1,66)=8.28, p=.005, η2=.11 
There was no significant main effect for time, Λ =.97, F(1,66)=2.03, p=.16,η2=.03  
nor was there a significant group main effect, F(2,66)=1.06, p=.35, η2=.031 
Table  App.11.4.20 
POMS anger sub scores - 2 x 3 mixed ANOVA - Pre to Post intervention change by group 
(low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 3.48 (3.62) 3.17 (2.62) .22 1,66 .64 .003 
high comp. 5.08 (4.59) 3.31 (3.35) 8.28 1,66 .005 .11 
control 4.70 (4.93) 5.15 (4.16) .41 1,66 .52 .006 
 
  
481 
 
App.11.4.21   Profile of Mood States (POMS) fatigue sub - score  
Profile of Mood States (POMS) fatigue sub - scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =.96, F(2,71)=.39, p=.28, 
η2=.035 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 71)=.39, p=..68, η2=.011 
nor a significant post-intervention group difference, F(2, 71)= 1.46, p=.24, η2=.040 
Only the intervention groups showed improvement pre  to post intervention but not 
significantly. Low compliance: Λ =.95, F(1, 71)=3.51, p=.065,η2=.047, high 
compliance: Λ =.95, F(1, 71)=3.47, p=.067,η2=.047 
There was a significant main effect for time, Λ =.95, F(1, 71)=3.89, p=.02,η2=.052  
There was no significant group main effect, F(2, 71)=.63, p=.54, η2=.017  
Table  App.11.4.21 
POMS – fatigue sub scores 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 4.60 (3.19) 3.40 (2.36) 3.51 1,71 .065 .047 
high comp. 5.30 (2.96) 4.15 (2.84) 3.47 1,71 .067 .047 
control 4.59 (3.71) 4.73 (2.80) .04 1,71 .84 .001 
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App.11.4.22   Profile of Mood States (POMS) confusion sub - score  
Profile of Mood States (POMS) confusion sub - scores were analysed using a 2 x 3 
mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =.95, F(2,69)=1.76, p=.18, 
η2=.049 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 69)=.29, p=.75, η2=.008 
nor a significant post-intervention group difference, F(2, 69)=.66,  p=.52, η2=.019 
Only the high compliance group improved but not significantly, Λ =.95, F(1,69)=3.50, 
p=.066, η2=.05 
There was a significant main effect for time, Λ =.99, F(1, 69)=.62, p=.43,η2=.009 
There was no significant group main effect, F(2, 69)=.005, p=.99, η2<.001  
Table  App.11.4.22 
POMS – confusion sub scores 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 3.29 (3.33) 3.04 (2.20) .19 1,69 .67 .003 
high comp. 3.65 (3.20) 2.62 (2.73) 3.50 1,69 .066 .048 
control 2.95 (3.00) 3.45 (2.63) .69 1,69 .41 .010 
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App.11.4.23   Profile of Mood States (POMS) vigour sub - score  
Profile of Mood States (POMS) vigour sub - scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =.97, F(2,68)=1.10, p=.34, 
η2=.031 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 68)= 2.58, p=.083, η2=.070 
nor a significant post-intervention group difference, F(2, 68)=.65,  p=.53, η2=.019 
No significant pre  to post intervention change was seen with any of the groups.  
There was no significant main effect for time, Λ =.99, F(1, 68)=.97, p=.33, η2=.014 
There was no significant group main effect, F(2, 68)=1.78, p=.18, η2=.050  
Table  App.11.4.23 
POMS – vigour sub scores 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - 
pre 
M (SD) - post F df p η2 
low comp. 8.04 (5.19) 8.96 (5.85) .44 1,68 .51 .006 
high comp. 11.69 (8.45) 10.96 (4.40) .30 1,68 .58 .004 
control 8.33 (3.84) 10.52(8.86) 2.20 1,68 .14 .031 
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App.11.4.24   SF36 (Health Survey) global score 
SF36 (Health Survey) global scores were analysed using a 2 x 3 mixed analysis of 
variance (ANOVA). The between-subjects factor was group (low compliance, high 
compliance, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =.95, F(2,60)= 1.40, p=.25, 
η2=.045 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 60)=2.88, p=.064, η2=.088 
but  a significant post-intervention group difference, F(2, 60)=3.20, p=.048, η2=.096 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.92, F(1,60)=5.23, p=.03, η2=.08  
There was a significant main effect for time, Λ =.94, F(1, 60)=4.08,  p=.05, η2=.064 
There was a significant group main effect, F(2, 60)=3.34, p=.042, η2=.10  
Table  App.11.4.24 
SF36 – global scores 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 61.68 (9.67) 64.81 (11.88) 2.33 1,60 .13 .04 
high comp. 69.65 (12.39) 73.73 (12.19) 5.23 1,60 .030 .08 
control 68.16 (11.25) 67.82 (11.69) .03 1,60 .87 <.001 
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App.11.4.25  SF36 (Health Survey) Physical functioning sub - score (*) 
SF36 (Health Survey) Physical functioning sub - scores were analysed using a 2 x 3 
mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =.98, F(2,76)=.71, p=.50, 
η2=.018 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 76)=1.26, p=.29, η2=.032 
nor a significant post-intervention group difference, F(2, 76)=.23,  p=.79, η2=.006 
No significant pre  to post intervention change was seen with any of the groups 
There was no significant main effect for time, Λ =1.00, F(1, 76)=.74, p=.79,η2=.001 
There was no significant group main effect, F(2, 76)=.70,  p=.50, η2=.018 
 
Table  App.11.4.25 
SF36 - Physical functioning sub - scores 2 x 3 mixed ANOVA - Pre to Post intervention 
change by group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 75.31 (19.71) 76.82 (21.52) .37 1,76 .55 .005 
high comp. 74.83 (19.40) 76.50 (19.79) .54 1,76 .47 .007 
control 81.81 (11.22) 79.79 (14.41) .63 1,76 .43 .008 
 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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App.11.4.26  SF36 (Health Survey) Role limitations due to physical health sub - 
score  
SF36 (Health Survey) Role limitations due to physical health sub - scores were analysed 
using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects factor was 
group (low compliance, high compliance, control). The within-subjects factor was 
time/phase (pre versus post-intervention). 
 No significant time by group interaction was found, Λ =.94, F(2,70)=2.3, p=.11, 
η2=.062 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 70)=.88, p=.42, η2=.025 
nor a significant post-intervention group difference, F(2, 70)=.37,  p=.69, η2=.010 
No significant pre  to post intervention change was seen with any of the groups 
There was no significant main effect for time, Λ =.98, F(1, 70)=1.16, p=.28,η2=.016 
There was no significant group main effect, F(2, 70)=.25,  p=.78, η2=.007 
 
Table  App.11.4.26 
SF36 – Physical Role limitations sub - scores 2 x 3 mixed ANOVA - Pre to Post 
intervention change by group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 50.00 (38.73) 61.11 (38.04) 2.45 1,70 .12 .034 
high comp. 57.47 (37.75) 66.38 (34.25) 2.18 1,70 .14 .030 
control 65.22 (37.49) 57.61 (39.48) 1.26 1,70 .26 .08 
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App.11.4.27  SF36 (Health Survey) body pain sub - score  
SF36 (Health Survey) body pain sub - scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(2,75)=.036, p=.96, 
η2=.001 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 75)=.85, p=.43, η2=.022 
nor a significant post-intervention group difference, F(2, 75)=.63,  p=.54, η2=.016 
No significant pre  to post intervention change was seen with any of the groups. 
There was no significant main effect for time, Λ =1.00, F(1, 75)=.023, p=.88, η2<.001 
There was no significant group main effect, F(2, 75)=.94,  p=.39, η2=.024 
Table  App.11.4.27 
SF36 – body pain sub - scores 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 62.88 (25.23) 63.44 (21.76) .017 1,75 .90 <.001 
high comp. 70.90 (21.63) 70.03 (22.21) .048 1,75 .83 .001 
control 65.78 (22.77) 64.96 (25.23) .033 1,75 .86 <.001 
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App.11.4.28  SF36 (Health Survey) general health sub - score  
SF36 (Health Survey) general health sub - scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(2,70)=.14, p=.87, 
η2=.004 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 70)=1.62, p=.20, η2=.044 
nor a significant post-intervention group difference, F(2, 70)=2.39,  p=.099, η2=.064 
No significant pre  to post intervention change was seen with any of the groups. 
 There was no significant main effect for time, Λ =1.0, F(1,70)=.24, p=.62, η2=.003 
There was no significant group main effect, F(2, 70)=2.25,  p=.11, η2=.060 
Table  App.11.4.28 
SF36 – general health sub - scores 2 x 3 mixed ANOVA - Pre to Post intervention change 
by group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 56.94 (17.11) 57.58 (17.17) .072 1,70 .79 .001 
high comp. 65.39 (15.86) 67.02 (17.24) .53 1,70 .47 .007 
control 59.99 (19.45) 59.80 (14.05) .005 1,70 .94 <.001 
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App.11.4.29  SF36 (Health Survey) vitality/energy sub - score  
SF36 (Health Survey) vitality/energy sub - scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 No significant time by group interaction was found, Λ =1.00, F(2,69)=.14, p=.87, 
η2=.004 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 69)=1.29, p=.28, η2=.036 
nor a significant post-intervention group difference, F(2, 69)=2.09,  p=.13, η2=.057 
No significant pre  to post intervention change was seen with any of the groups. 
There was a significant main effect for time, Λ =.94, F(1, 69)=4.25, p=.043, η2=.058 
There was no significant group main effect, F(2, 69)=2.11,  p=.13, η2=.058 
Table  App.11.4.29 
SF36 – vitality/energy sub - scores 2 x 3 mixed ANOVA - Pre to Post intervention change 
by group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 55.21 (14.78) 58.40 (15.51) .96 1, 69 .33 .014 
high comp. 62.86 (18.89) 68.15 (18.73) 3.08 1, 69 .083 .043 
control 58.25 (17.50) 61.50 (18.36) .83 1, 69 .37 .012 
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App.11.4.30  SF36 (Health Survey) social functioning sub – score (*) 
SF36 (Health Survey) social functioning sub - scores were analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
 A significant time by group interaction was found, Λ =.85, F(2,76)= 6.68, p=.002, 
η2=.15 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2,76)=.31, p=.73, η2=.008 
but  a significant post-intervention group difference, F(2, 76)=4.64, p=.013, η2=.11 
Further, the only significant pre  to post intervention change was seen in the high 
compliance group which improved significantly, Λ =.86, F(1, 76)=12.09, p=.001, 
η2=.137  
There was no significant main effect for time, Λ =.99, F(1, 76)=.51, p=.48,η2=.007 
nor was there a significant group main effect, F(2, 76)=1.23, p=.30, η2=.031 
Table  App.11.4.30 
SF36 – social functioning sub - scores 2 x 3 mixed ANOVA - Pre to Post intervention 
change by group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 77.40 (19.69) 75.96 (26.20) .13 1,76 .72 .002 
high comp. 77.50 (20.86) 90.42 (13.80) 12.09 1,76 .001 .13 
control 81.52 (21.93) 75.00 (22.61) 2.36 1,76 .13 .03 
 * Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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App.11.4.31  SF36 (Health Survey) Role limitations due to emotional function sub 
– score (*) 
SF36 (Health Survey) Role limitations due to emotional function sub – scores were 
analysed using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects 
factor was group (low compliance, high compliance, control). The within-subjects 
factor was time/phase (pre versus post-intervention). 
A significant time by group interaction was found, Λ =.88, F(2,67)= 4.42, p=.016, 
η2=.12 
Follow up analysis of simple main effects for this interaction revealed a significant 
difference among the groups at pre-intervention, F(2, 67)=6.12, p=.04, η2=.15 
but  no significant post-intervention group difference, F(2, 67)=1.33, p=.27, η2=.04 
Further, the only significant pre  to post intervention change was seen in the control 
group which deteriorated significantly, Λ =.94, F(1, 67)=4.57, p=.04, η2=.06 
There was no significant main effect for time, Λ =1.0, F(1, 67)=.22, p=.64, η2=.003 
There was a significant group main effect, F(2, 67)=3.43, p=.04, η2=.09  
Table  App.11.4.31 
SF36 – emotional role limitations sub - scores 2 x 3 mixed ANOVA - Pre to Post 
intervention change by group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 47.37 (38.99) 63.16 (41.41) 2.92 1,67 .09 .04 
high comp. 70.11 (39.18) 79.31(27.33) 1.54 1,67 .22 .02 
control 86.36 (26.54) 68.18 (39.14) 4.57 1,67 .035 .06 
* Homogeneity assumption not satisfied for this variable. No suitable transformation found. 
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App.11.4.32 SF36 (Health Survey) emotional well being/mental health sub - score 
SF36 (Health Survey) emotional well being/mental health sub - scores were analysed 
using a 2 x 3 mixed analysis of variance (ANOVA). The between-subjects factor was 
group (low compliance, high compliance, control). The within-subjects factor was 
time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(2,69)= .46, p=.64, 
η2=.013 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 69)=1.61, p=.21, η2=.045 
but  a significant post-intervention group difference, F(2, 69)=3.38, p=.04, η2=.089 
No significant pre  to post intervention change was seen with any of the groups. 
There was no significant main effect for time, Λ =.99, F(1, 69)=.65, p=.42, η2=.009 
There was a significant group main effect, F(2, 69)=3.45, p=.037, η2=.091  
Table  App.11.4.32 
SF36 – emotional well being sub - scores 2 x 3 mixed ANOVA - Pre to Post intervention 
change by group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 67.17 (14.67) 66.12 (16.41) .08 1,69 .78 .001 
high comp. 74.14 (16.49) 77.82 (17.50) 1.12 1,69 .29 .016 
Control 67.00 (17.60) 69.65 (15.75) .42 1,69 .52 .006 
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App.11.5  Objective measures, ‘On treatment’ (OT) subset (low compliance 
versus high compliance versus control) analysis of variance (ANOVA) 
App.11.5.1  Total time in bed (TTB)  
 „Total time in bed‟ was analysed using a 2 x 3 mixed analysis of variance (ANOVA). 
The between-subjects factor was group (low compliance, high compliance, control). 
The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.94, F(2,68)= 1.98, p=.14, 
η2=.055 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 68)=.79, p=.46, η2=.023 
nor  a significant post-intervention group difference, F(2, 68)=1.28, p=.28, η2=.036 
Further, the only significant pre - to post intervention change was seen in the low 
compliance group which decreased significantly, Λ =.94, F(1,68)=4.31, p=.04, η2=.06 
There was no significant main effect for time, Λ =1.00, F(1, 68)=.20, p=.65, η2=.005 
There was no significant group main effect, F(2, 68)=.44, p=.64, η2=.013 
Table  App.11.5.1 
Total time in bed - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
YLC 431.70 (71.09) 393.30 (77.36) 3.27 1,68 .045 .046 
YHC 419.96 (70.68) 428.86 (76.93) .25 1,68 .62 .004 
Control 402.3 (91.43) 416.30 (73.98) .51 1,68 .47 .008 
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App.11.5.2  Total sleep time (TST)  
Total sleep time was analysed using a 2 x 3 mixed analysis of variance (ANOVA). The 
between-subjects factor was group (low compliance, high compliance, control). The 
within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.96, F(2,67)= 1.34, p=.27, 
η2=.038 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 67)=.66, p=.52, η2=.019 
nor  a significant post-intervention group difference, F(2, 67)=1.50, p=.23, η2=.043 
Further, no significant pre - to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.96, F(1, 67)=.18, p=.67, η2=.003 
There was no significant group main effect, F(2, 67)=1.53, p=.22, η2=.044 
Table  App.11.5.2 
Total sleep time - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - 
post 
F df p η2 
YLC 375.70 (68.72) 347.40 (72.75) 2.30 1,67 .13 .033 
YHC 375.04 (48.46) 382.81 (73.59) .23 1,67 .63 .003 
Control 355.91 (80.92) 363.78 (62.06) .20 1,67 .65 .003 
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App.11.5.3  Sleep onset latency (SOL) [*] 
Sleep latency was analysed using a 2 x 3 mixed analysis of variance (ANOVA). The 
between-subjects factor was group (low compliance, high compliance, control). The 
within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.98, F(2,68)=.54, p=.58, 
η2=.016 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 68)=.51, p=.60, η2=.015 
nor  a significant post-intervention group difference, F(2, 68)=1.12, p=.33, η2=.032 
Further, no significant pre - to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.98, F(1, 68)=1.35, p=.25, η2=.020 
There was no significant group main effect, F(2, 68)=.19, p=.31, η2=.034 
Table  App.11.5.3 
Sleep latency - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 7.10 (9.78) 12.80 (16.70) 1.46 1,68 .23 .02 
high comp. 11.14 (17.77) 14.98 (19.33) .93 1,68 .34 .01 
Control 9.11 (10.36) 8.39 (8.33) .027 1,68 .87 <.001 
* Normality assumption not satisfied for this variable. No suitable transformation found. 
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App.11.5.4  Total wake after sleep onset duration (WASO)  
Total wake time duration was analysed using a 2 x 3 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (low compliance, high compliance, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.94, F(2,65)=2.24, p=.11, 
η2=.064 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 65)=1.87, p=.16, η2=.054 
nor  a significant post-intervention group difference, F(2, 65)=.29, p=.75, η2=.009 
Further, no significant pre - to post intervention change was seen with any of the 
groups, although both intervention groups improved and the control deteriorated but not 
significantly. 
There was no significant main effect for time, Λ =.99, F(1, 65)=.56, p=.46, η2=.009 
There was no significant group main effect, F(2, 65)=.51, p=.61, η2=.015 
Table  App.11.5.4 
WASO - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, and control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 63.37 (23.91) 53.63 (16.03) 2.60 1,65 .092 .043 
high comp. 57.30 (20.86) 53.81 (15.68) .69 1,65 .47 .008 
Control 50.73 (18.14) 57.14 (19.79) 1.46 1,65 .23 .022 
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App.11.5.5  Sleep Efficiency (SE)  
Sleep efficiency was analysed using a 2 x 3 mixed analysis of variance (ANOVA). The 
between-subjects factor was group (low compliance, high compliance, control). The 
within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.96, F(2,65)=1.39, p=.26, 
η2=.041 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 65)=1.71, p=.19, η2=.025 
nor  a significant post-intervention group difference, F(2, 65)=.040, p=.67, η2=.012 
Further, no significant pre - to post intervention change was seen with any group 
There was no significant main effect for time, Λ =1.0, F(1, 65)=.22, p=.64, η2=.003 
There was no significant group main effect, F(2, 65)=.97, p=.37, η2=.029 
Table  App.11.5.5 
Sleep efficiency - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, and control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. .85 (.05) 87 (.04) 1.69 1,65 .20 .025 
high comp. .87 (.04) .87 (.05) .25 1,65 .62 .004 
Control .87 (.04) .87 (.03) 1.04 1,65 .31 .016 
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App.11.5.6  Total light sleep duration  
Total Light Sleep duration was analysed using a 2 x 3 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (low compliance, high compliance, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.98, F(2,67)=.93, p=.49, 
η2=.021 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 67)=.90, p=.41, η2=.026 
nor  a significant post-intervention group difference, F(2, 67)=.47, p=.62, η2=.014 
Further, no significant pre - to post intervention change was seen with any of the 
groups. 
There was no significant main effect for time, Λ =1.00, F(1, 67)=.26, p=.61, η2=.004 
There was no significant group main effect, F(2, 67)=.73, p=.49, η2=.021 
Table  App.11.5.6 
Total light sleep duration - 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - 
post 
F df p η2 
YLC 189.70 (41.57) 176.45 (41.44) .93 1,67 .39 .014 
YHC 195.44 (48.03) 189.30 (45.43) .32 1,67 .57 .005 
Control 176.83 (55.30) 184.69 (47.48) .44 1,67 .51 .007 
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App.11.5.7  Total Slow Wave stage (SWS) duration  
Total Slow Wave Sleep (deep sleep) duration was analysed using a 2 x 3 mixed analysis 
of variance (ANOVA). The between-subjects factor was group (low compliance, high 
compliance, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =.95, F(2,67)=1.86, p=.16, 
η2=.053 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 67)=.002, p=1.00, η2<.001 
but  a significant post-intervention group difference, F(2, 67)=3.17, p=.048, η2=.13 
Further, a significant pre - to post intervention change was seen in the high compliance 
group which improved significantly, Λ =.94, F(2,67)=4.30, p=.042, η2=.060 
There was no significant main effect for time, Λ =.99, F(1, 67)=.58, p=.49, η2=.009 
There was no significant group main effect, F(2, 67)=1.38, p=.26, η2=.040 
Table  App.11.5.7 
Total SWS duration - 2 x 3 mixed ANOVA - Pre to Post intervention change by group 
(low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
YLC 106.25 (24.59) 101.25 (23.64) .80 1,67 .52 .006 
YHC 106.67 (30.75) 120.56 (33.45) 4.30 1,67 .042 .060 
Control 106.74 (24.80) 107.44 (20.70) .009 1,67 .92 <.001 
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App.11.5.8  Slow Wave stage (SWS) latency [*] 
Slow Wave stage (SWS) latency was analysed using a 2 x 3 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (low compliance, high compliance, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(2,67)=.38, p=.68, 
η2=.011 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 67)=.22, p=.80, η2=.007 
nor  a significant post-intervention group difference, F(2, 67)=1.75, p=.18, η2=.050 
Further, no significant pre - to post intervention change was seen with any of the groups 
There was no significant main effect for time, Λ =1.00, F(1, 67)=.12, p=.72, η2=.002 
There was no significant group main effect, F(2, 67)=1.17, p=.32, η2=.034 
Table  App.11.5.8 
Total SWS latency - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 24.05(46.89) 31.27 (39.12) .52 1,67 .43 .009 
high comp. 18.61 (21.92) 20.11 (21.56) .049 1,67 .83 .001 
Control 18.61 (20.40) 15.39 (16.27) .19 1,67 .66 .003 
* Homogeneity assumption not satisfied for this variable.  Homogeneity corrected using power 
transformation and ANOVA performed on transformed variable. Results as follows: 
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App.11.5.9  Slow Wave stage (SWS) latency (-1.00 power transformation)  
Slow Wave stage (SWS) latency was transformed by using (-1) power transformation 
on (SWS latency +1) and then analysed using a 2 x 3 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (low compliance, high compliance, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(2,67)=.32, p=.72, 
η2=.010 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 67)=.074, p=.93, η2=.002 
nor  a significant post-intervention group difference, F(2, 67)=.96, p=.39, η2=.028 
There was no significant main effect for time, Λ =.96, F(1, 67)= 2.73, p=.10, η2=.039 
There was no significant group main effect, F(2, 67)=.52, p=.60, η2=.015 
Further, no significant pre - to post intervention change was seen with any of the 
groups: 
Table  App.11.5.9 
Transformed SWS latency - 2 x 3 mixed ANOVA - Pre to Post intervention change by 
group (low compliance, high compliance, control) 
group Λ F df p η
2
 
low comp. .97 2.31 1,67 .13 .033 
high comp. .99 .37 1,67 .54 .006 
Control .99 .45 1,67 .50 .007 
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App.11.5.10  Total Rapid Eye Movement stage (REM) duration  
Total Rapid Eye Movement stage (dream stage) duration was analysed using a 2 x 3 
mixed analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =.99, F(2,67)=.37, p=.69, 
η2=.011 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 67)=.10, p=.87, η2=.004 
nor  a significant post-intervention group difference, F(2, 67)=.10, p=.89, η2=.003 
Further, no significant pre - to post intervention change was seen with any group  
There was no significant main effect for time, Λ =.99, F(1, 67)=.81, p=.37, η2=.012 
There was no significant group main effect, F(2, 67)=.14, p=.97, η2<.001 
Table  App.11.5.10 
Total REM duration- 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 73.40 (31.35) 64.75 (34.66) 2.31 1,67 .13 .03 
high comp. 69.29 (21.17) 68.18 (35.49) .008 1,67 .93 <.001 
Control 70.43 (28.12) 69.39 (28.53) .023 1,67 .88 <.001 
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App.11.5.11  Rapid Eye Movement stage (REM) latency  
Rapid Eye Movement stage (dream stage) latency was analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =.96, F(2,66)=1.48, p=.23, 
η2=.043 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 66)=.34, p=.71, η2=.010 
nor  a significant post-intervention group difference, F(2, 66)=1.67, p=.20, η2=.048 
Further, no significant pre - to post intervention change was seen with any group  
There was no significant main effect for time, Λ =1.00, F(1, 66)=.044, p=.83, η2=001 
There was no significant group main effect, F(2, 66)=.19, p=.83, η2=.006 
Table  App.11.5.11 
REM latency- 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 99.32 (44.89) 88.39 (42.47) .90 1,66 .35 .019 
high comp. 108.33 
(50.22) 
107.68 
(46.90) 
.004 1,66 .95 <.001 
Control 98.30 (44.25) 113.70 
(48.49) 
2.16 1,66 .15 .032 
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App.11.5.12  Mean blood oxygen saturation (SPO2) during night 
Mean blood oxygen saturation level was analysed using a 2 x 3 mixed analysis of 
variance (ANOVA). The between-subjects factor was group (low compliance, high 
compliance, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =.99, F(2,68)= .42, p=.65, 
η2=.012 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 68)=.26, p=.77, η2=.008 nor  a 
significant post-intervention group difference, F(2, 68)=.10, p=.90, η2=.003 
Further, no significant pre - to post intervention change was seen with any group 
There was no significant main effect for time, Λ =1.00, F(1, 68)=.21, p=.65, η2=.003 
There was no significant group main effect, F(2, 68)=.054, p=.95, η2=.002 
Table  App.11.5.12  
 Mean blood oxygen saturation level- 2 x 3 mixed ANOVA - Pre to Post intervention 
change by group (low compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 96.55(5.07) 96.95 (2.52) .12 1,68 .73 .002 
high comp. 97.53 (4.69) 96.54 (3.25) 1.02 1,68 .31 .015 
Control 97.13 (4.20) 96.87 (4.21) .057 1,68 .81 .001 
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App.11.5.13  Mean Respiratory Disturbance Index (RDI) [*] 
Respiratory Disturbance Index (RDI) was analysed using a 2 x 3 mixed analysis of 
variance (ANOVA). The between-subjects factor was group (low compliance, high 
compliance, control). The within-subjects factor was time/phase (pre versus post-
intervention). 
No significant time by group interaction was found, Λ =.97, F(2,67)= .93, p=.40, 
η2=.027 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 67)=1.36, p=.26, η2=.039 
but  a significant post-intervention group difference, F(2, 67)=2.12, p=.13, η2=.060 
Further, no significant change was seen with any of the  groups  pre  to post intervention  
There was no significant main effect for time, Λ =1.00, F(1, 67)=.044, p=.83, η2=.001 
There was no significant group main effect, F(2, 67)=1.88, p=.16, η2=.053  
Table  App.11.5.13 
 RDI - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low compliance, 
high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
low comp. 15.53 (11.32) 17.22 (14.97) 1.41 1,67 .24 .021 
high comp. 14.47 (10.93) 13.92 (11.33) .20 1,67 .66 .003 
Control 10.90 (6.45) 10.24 (5.55) .25 1,67 .62 .004 
* Homogeneity assumption not satisfied for this variable. Homogeneity corrected using suitable power 
transformation (-1.939).  ANOVA performed on transformed variable. Results as follows: 
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App.11.5.14  Mean Respiratory Disturbance Index (RDI) (-1.939 Power 
Transformation)  
Transformed Respiratory Disturbance Index (RDI) was analysed using a 2 x 3 mixed 
analysis of variance (ANOVA). The between-subjects factor was group (low 
compliance, high compliance, control). The within-subjects factor was time/phase (pre 
versus post-intervention). 
No significant time by group interaction was found, Λ =.98, F(2,67)= .70, p=.50, 
η2=.021 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 67)=.46, p=.63, η2=.013 
nor  a significant post-intervention group difference, F(2, 67)=.52, p=.59, η2=.015 
There was no significant main effect for time, Λ =.99, F(1, 67)=.91, p=.34, η2=.013 
There was no significant group main effect, F(2, 67)=.41, p=.66, η2=.012  
Further, no significant change was seen with any of the  groups  pre  to post 
intervention: 
Table  App.11.5.14 
Transformed mean RDI - 2 x 3 mixed ANOVA - Pre to Post intervention change by group 
(low compliance, high compliance, control) 
group Λ F df p η
2
 
low comp. 1.00 .29 1,67 .62 .004 
high comp. .97 2.20 1,67 .14 .032 
Control 1.00 .06 1,67 .81 .001 
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App.11.5.15 Mean Oxygen Desaturation Index (ODI)  
 Apnea Duration Index (ODI) was analysed using a 2 x 3 mixed analysis of variance 
(ANOVA). The between-subjects factor was group (low compliance, high compliance, 
control). The within-subjects factor was time/phase (pre versus post-intervention). 
No significant time by group interaction was found, Λ =1.00, F(2,68)= 0.80, p=.92, 
η2=.002 
Follow up analysis of simple main effects for this interaction revealed no significant 
difference among the groups at pre-intervention, F(2, 68)=1.74, p=.18, η2=.049 
and  no significant post-intervention group difference, F(2, 68)=1.66, p=.20, η2=.047 
Further, no significant change was seen with any of the  groups  pre  to post intervention  
There was no significant main effect for time, Λ =1.00, F(1, 68)=.075, p=.78, η2.001 
There was no significant group main effect, F(2, 68)=1.86, p=.16, η2=.052 
Table  App.11.5.15 
Mean ODI - 2 x 3 mixed ANOVA - Pre to Post intervention change by group (low 
compliance, high compliance, control) 
group M (SD) - pre M (SD) - post F df p η2 
YLC 13.17 (12.05) 13.28 (12.84) .91 1,68 .93 <.001 
YHC 10.03 (9.15) 10.57 (10.22) 1.80 1,68 .62 .004 
Control 7.82 (6.70) 7.74 (5.94) <.001 1,68 .94 <.001 
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App.11.6  Objective measures, ‘On treatment’ (OT) subset (low compliance 
versus high compliance versus control) Multivariate Analysis of Variance 
(MANOVA) 
App.11.6.1 Insomnia related objective multivariate analysis of variance 
(MANOVA)  
The data for the insomnia multivariate was analysed using a 2 x 3 mixed multivariate 
analysis of variance (MANOVA). The three-level between-subjects factor was group 
(high compliance, low compliance and control) and the two-level within-subjects factor 
was phase (baseline versus post-intervention). The multivariate dependent variable was 
made up of four measures related to insomnia namely: sleep onset latency (SOL), wake 
after sleep onset (WASO), total sleep time (TST) and sleep efficiency (SE) 
Multivariate tests revealed no significant main effect for phase,  = .91, F(4, 62) = 1.53,  
p = .20, 2 = .090, no significant multivariate main effect for group,  = .85, F(8, 124) 
=1.28,  p = .26, 2 = .076,  and no significant multivariate interaction,  = .88, F(8, 124) 
=.98, p = .45, 2 = .06. 
When the sub-scales for the multivariate main effect for phase were considered 
separately, there was no significant univariate phase main effect, no significant 
univariate group main effect, and no significant univariate interaction. 
Examination of the marginal means showed that, for WASO and TST, participants 
across all groups improved, for SOL deteriorated and for sleep efficiency remained 
without change from baseline to post-intervention. 
Analysis of the multivariate simple main effects for time/phase within group revealed 
no significant pre - to post-intervention change for any of the groups:   
Please continue to next page  
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Table  App.11.6.1 
Insomnia related objective 2 x 3 mixed - multivariate analysis of variance (MANOVA)  
Pre to Post intervention change by group (low compliance, high compliance, control) 
group  F df p η
2
 
low comp. .92 1.29 4,62 .28 .077 
high comp. .89 1.99 4,62 .11 .11 
Control .97 .39 4,62 .81 .025 
 
App.11.6.2  Obstructive Sleep Apnea (OSA) - multivariate analysis of variance 
(MANOVA)  
 The data for the OSA was analysed using a 2 x 3 mixed multivariate analysis of 
variance (MANOVA). The three-level between-subjects factor was group (high 
compliance, low compliance and control) and the two-level within-subjects factor was 
phase (baseline versus post-intervention). The multivariate dependent variable was 
made up of three measures related to OSA, including, RDI (transformed), ODI and 
SPO2. 
Multivariate tests revealed no significant main effect for phase,  = .97,  F(3, 65) = .62, 
p = .60, 2 = .028, no significant multivariate main effect for group,  = .93, F(6, 130) 
=.85,  p = .53, 2 = .038,  and no significant multivariate interaction   = .93, F(6, 130) 
=.61,  p = .22, 2 = .034. 
When the sub-scales for the multivariate main effect for phase were considered 
separately, there was no significant univariate phase main effect, no significant 
univariate group main effect, and no significant univariate interaction. 
Examination of the marginal means showed a slight deterioration of SPO2 measure and 
improvement in ODI and small improvement in RDI measures - across all groups from 
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baseline to post-intervention. 
Analysis of the multivariate simple main effects for time/phase within group revealed a 
significant pre- to post-intervention change for the high compliance group but not for 
the other groups. 
Table  App.11.6.2 
OSA related objective 2 x 3 mixed - multivariate analysis of variance (MANOVA)  Pre to 
Post intervention change by group (low compliance, high compliance, control) 
group  F df p η
2
 
YLC. 1.00 .094 3,65 .96 .004 
YHC. .90 2.16 3,65 .10 .091 
Control 1. 00 .078 3,65 .97 .004 
 
App.11.6.3  Slow Wave Sleep (SWS) - multivariate analysis of variance (MANOVA)  
The data for the SWS was analysed using a 2 x 3 mixed multivariate analysis of 
variance (MANOVA). The three-level between-subjects factor was group (high 
compliance, low compliance and control) and the two-level within-subjects factor was 
phase (baseline versus post-intervention). The multivariate dependent variable was 
made up of two measures related to SWS, namely, SWS duration and SWS latency 
(transformed). 
Multivariate tests revealed no significant multivariate main effect for phase,  = .95, 
F(2,65)= 1.65, p = .20, 2 = .048, no significant multivariate main effect for group,  = 
.92, F(4, 130) = 1.36, p = . 25, 2 = .040, and no significant multivariate interaction,  = 
.89, F(4, 130) = 1.92, p = .11, 2 = .056 . 
When the sub-scales for the multivariate main effect for phase were considered 
separately, there was neither a significant univariate phase main effect, nor a significant 
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univariate group main effect. Only the SWS duration univariate phase by group 
interaction test generated a significant outcome, F(2, 66) = 3.3, p = .043, 2 = .091. 
Examination of the marginal means showed that, for SWS duration, participants across 
all groups improved from baseline to post-intervention, but for SWS latency - remained 
unchanged from baseline to post-intervention 
Analysis of the multivariate simple main effects for time/phase within group revealed a 
significant pre- to post-intervention change for the high compliance group only: 
Table  App.11.6.3 
SWS related objective 2 x 3 mixed - multivariate analysis of variance (MANOVA) Pre to 
Post intervention change by group (low compliance, high compliance, control) 
group  F df p η
2
 
low comp. .96 1.50 2,65 .23 .044 
high comp. .89 4.05 2,65 .022 .11 
Control .99 .23 2,65 .80 .007 
 
App.11.6.4  Rapid Eye Movement sleep multivariate analysis of variance 
(MANOVA)  
The data for the REM was analysed using a 2 x 3 mixed multivariate analysis of 
variance (MANOVA). The three-level between-subjects factor was group (high 
compliance, low compliance and control) and the two-level within-subjects factor was 
phase (baseline versus post-intervention). The multivariate dependent variable was 
made up of two measures related to REM, namely, REM duration and REM latency 
(transformed). Multivariate tests revealed no significant multivariate main effect for 
phase,  = 1.00, F(2,64)=.096, p = .91, 2 = .003, no significant multivariate main 
effect for group,  = .97, F(4, 128) =.47, p = . 75, 2 = .015, and no significant 
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multivariate interaction,  = .95, F(4, 128) =.81, p = .52, 2 = .025 . When the sub-
scales for the multivariate main effect for phase were considered separately, there was 
neither a significant univariate phase main effect, nor a significant univariate group 
main effect, nor a significant univariate time by group interaction, Examination of the 
marginal means showed that, for both measures, participants across all groups 
deteriorated very slightly from baseline to post-intervention. Analysis of the 
multivariate simple main effects for time/phase within group did not reveal a significant 
pre- to post-intervention change for any of the group: 
Table  App.11.6.4 
REM related objective 2 x 3 mixed - multivariate analysis of variance (MANOVA) Pre to 
Post intervention change by group (low compliance, high compliance, control) 
group  F df p η
2
 
low comp. .98 .67 2,64 .51 .021 
high comp. 1.00 .012 2,64 .99 <.001 
Control .97 1.05 2,65 .36 .032 
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App.11.7  Testing for relationships between variables 
App.11.7.1  Testing for Relationship between OSA degree and compliance level 
Pearson‟s Chi Square test revealed no statistically significant relationship between OSA 
degree, (none, mild, moderate, severe) and between compliance level, 2  (3, N = 58) = 
1.94, p = .58 
App.11.7.2  Testing for Relationship between OSA degree, and MAP derived apnea 
probability score 
Pearson’s Chi Square test revealed no statistically significant relationship between OSA 
degree, (none, mild, moderate, severe) and between pre intervention apnea probability 
calculated from pre intervention MAP, 22 (192, N = 65) = 195.0, p = .43 
Pearson’s Chi Square test revealed no statistically significant relationship between OSA 
degree, (none, mild, moderate, severe) and between post intervention apnea probability 
calculated from post intervention MAP, 22 (183, N = 62) = 186.0, p = .42 
App.11.7.3  Testing for Relationship between compliance level and age 
Pearson’s Chi Square test revealed no statistically significant relationship between 
compliance level and age, 22 (23, N = 59) = 24.46, p = .38 
App.11.7.4  Testing for Relationship between OSA degree and change pre to post 
intervention in subjective measure scores  
Pearson’s correlation test was used to determine whether a relationship exists between 
OSA degree (none, mild, moderate, severe), diagnosed post study, and between change 
pre to post in subjective and objective measure scores in control and intervention 
groups. Results are given in the following four tables 
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Table  App.11.7.4.1  
Pearson’s correlation test between OSA degree and pre to post change in subjective 
measures in the intervention group 
Pre to Post change  r p  N Note 
KSS score change .15 .28 54  
ESS score change .13 .35 56  
MAP score change .16 .27 46  
MAP apnea probability score change .22 .093 58  
PSQI global score change .34 .023 45 #1 
PSQI subjective sub score change .037 .79 55  
PSQI latency sub score change .16 .30 42  
PSQI duration sub score change .31 .026 52  
PSQI efficiency sub score change .52 .001 41 #1 
PSQI disturbance sub score change .006 .97 50  
PSQI medication sub score change .089 .52 55  
PSQI dysfunction sub score change .009 .95 50  
DASS global score change .14 .31 52  
DASS stress sub score change .10 .46 53  
DASS anxiety sub score change .16 .23 56  
DASS depression sub score change .13 .35 53  
POMS global score change .012 .94 49  
POMS tension sub score change .29 .043 49 #2 
POMS depression sub score change .24 .10 49  
POMS anger sub score change .19 .19 49  
Continued on next page   
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Table continued from previous page:     
Pre to Post change  r p  N Note 
POMS fatigue sub score change .24 .088 52  
POMS confusion sub score change .23 .10 50  
POMS vigour sub score change .16 .26 50  
SF36  physical function sub score change -.009 .95 55  
SF36  role limitations (physical) change -.38 .007 50 #1 
SF36  body pain  sub score change .17 .22 55  
SF36  general health sub score change -.21 .13 53  
SF36  vitality sub score change -.026 .86 52  
SF36  social function sub score change -.29 .03 56 #1 
SF36  role limitation (emotional) change -.46 .001 48 #1 
SF36  mental health sub score change -.19 .18 52  
SF36  global score change -.33 .032 42 #1 
Notes:  
#1 Significant correlation found and ANOVA test revealed significant pre to post change in this measure 
#2 Significant correlation found however ANOVA test revealed no significant pre to post change in 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
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Table  App.11.7.4.2  
Pearson’s correlation test between OSA degree and pre to post change in subjective 
measures in the control group 
Pre to Post change  r p  N Note 
KSS score change .18 .44 20  
ESS score change .06 .81 21  
MAP score change -.01 .96 19  
MAP apnea probability score change .43 .052 21 #2 
PSQI global score change -.25 .33 17  
PSQI subjective sub score change -.28 .23 20  
PSQI latency sub score change .05 .83 18  
PSQI duration sub score change -.14 .59 18  
PSQI efficiency sub score change -.50 .11 11  
PSQI disturbance sub score change .25 .31 19  
PSQI medication sub score change -.25 .27 21  
PSQI dysfunction sub score change .28 .23 20  
DASS global score change .07 .80 17  
DASS stress sub score change -.05 .84 18  
DASS anxiety sub score change .10 .69 18  
DASS depression sub score change .12 .63 17  
POMS global score change -.30 .22 18  
POMS tension sub score change -.003 .99 18  
POMS depression sub score change -.07 .79 17  
POMS anger sub score change -.09 .75 16  
Table continued on next page   
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Table continued from previous page:     
Pre to Post change  r p  N Note 
POMS fatigue sub score change -.06 .80 18  
POMS confusion sub score change .03 .91 18  
POMS vigour sub score change -.22 .39 17  
SF36  physical function sub score change .18 .45 19  
SF36  role limitations (physical) change -.09 .70 19  
SF36  body pain  sub score change -.40 .09 19  
SF36  general health sub score change -.13 .64 16  
SF36  vitality sub score change .05 .85 16  
SF36  social function sub score change -.03 .91 19  
SF36  role limitation (emotional) change -.18 .46 18  
SF36  mental health sub score change -.008 .98 16  
SF36  global score change -.43 .11 15  
Notes:  
#1 Significant correlation found and ANOVA test revealed significant pre to post change in this measure 
#2 Significant correlation found however ANOVA test revealed no significant pre to post change in 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
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Table  App.11.7.4.3 
Pearson’s correlation test between OSA degree and pre to post change in objective 
measures in the intervention group 
Pre to Post change  r p  N Note 
 Mean blood oxygen saturation level 
(SPO2) 
-.22 .13 47  
 Respiratory disturbance index (RDI) -.22 .13 46  
Total de-saturations .091 .54 47  
Sleep onset latency (SOL) -.172 .25 47  
REM latency .019 .90 46  
SWS latency -.062 .68 47  
Total time in bed (TTB) .092 .54 47  
Total sleep time (TST) .093 .54 46  
Total wake time after sleep onset (WASO) .17 .26 45  
Total light sleep duration -.040 .79 46  
Total REM duration  .00 1.00 46  
Total SWS duration .19 .19 46  
Sleep efficiency (SE) -.14 .33 47  
Notes:  
#1 Significant correlation found and ANOVA test revealed significant pre to post change in this measure 
#2 Significant correlation found however ANOVA test revealed no significant pre to post change in 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
  
519 
 
Table  App.11.7.4.4 
Pearson’s correlation test between OSA degree and pre to post change in objective 
measures in the control group 
Pre to Post change  r p  N Note 
 Mean blood oxygen saturation level  -.037 .87 21  
 Respiratory disturbance index (RDI) -.26 .26 21  
Total de-saturations -.01 .96 21  
Sleep latency .48 .028 21 #2  
REM latency .053 .82 20  
SWS latency .028 .91 20  
Total time in bed -.18 .44 21  
Total net sleep time -.09 .70 21  
Total wake time after sleep onset -.28 .21 21  
Total light sleep duration .18 .42 21  
Total REM duration  -.33 .15 21  
Total SWS duration -.31 .18 21  
Sleep efficiency (SE) -.27 .23 21  
Notes:  
#1 Significant correlation found and ANOVA test revealed significant pre to post change in this measure 
#2 Significant correlation found however ANOVA test revealed no significant pre to post change in 
measure 
N- number of cases, r-Pearson‟s correlation, p - Significance (2 tailed) 
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11.8 Analyses of WLC subset matched to themselves as YI subset  
Table 11.8.1 QoL scores of WLC subset– matched to themselves as YI subset. Paired 
samples  t test.  
Measure M (SD) - pre M (SD) - post t df p 
DASS global score 32.37 (21.30) 15.47 (8.85) 3.95 14 .001 
DASS stress  14.10 (8.93) 7.13 (4.82) 4.09 14 .001 
DASS anxiety  8.87 (5.12) 7.56 (3.44) 2.66 15 .018 
DASS depression  8.59 (6.82) 3.94 (3.11) 3.28 15 .005 
POMS global score 27.07 (18.80) 13.50 (10.34) 2.18 13 .048 
POMS tension  17.036 (21.79) 5.28 (10.22) 2.45 14 .028 
POMS depression  5.32 (5.67) 2.21 (2.66) 2.075 13 .058 
POMS anger  5.13 (3.86) 3.07 (2.58) 2.79 14 .014 
POMS fatigue  4.90 (2.89) 2.80 (2.18) 3.41 14 .004 
POMS confusion  3.40 (2.53) 2.07 (1.79) 2.55 14 .023 
POMS vigour  8.96 (3.34) 9.79 (4.06) -.75 13 .47 
SF36 physical function  81.26 (15.11) 85.11 (16.77) -1.73 14 .10 
SF36 physical role  64.06 (36.76) 70.31(40.02) -1.52 15 .15 
SF36 physical pain  65.87 (22.20) 71.50 (20.67) -1.51 15 .15 
SF36 general health  63.22 (13.60) 67.03 (15.24) -1.41 14 .18 
SF36 vitality  61.41 (16.10) 67.19 (17.41) -1.17 15 .26 
SF36 social function  76.17 (20.57) 90.62 (14.79) -3.79 15  .002 
SF36 emotional role  72.92 (29.11) 85.42 (24.25) -1.69 15 .11 
SF36 mental health  66.53 (12.16) 69.25 (22.89) -.54 15 .60 
SF36 global score  68.69 (10.00) 73.37 (10.37) -1.74 14 .10 
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Table 11.8.2  
Subjective Sleep quality measures scores of WLC subset group – matched to themselves as 
YI subset group. Paired samples t test.  
Measure M (SD) - pre M (SD) - post t df p 
KSS 3.44 (.96) 2.94 (1.00) 1.62 15 .13 
ESS 7.78 (2.83) 7.31 (3.38) .61 15 .55 
PSQI Global score 9.80 (2.53) 8.07 (3.77) 2.31 14 .037 
PSQI subjective sleep quality 1.53 (.34) 1.37 (.62) 1.00 15 .33 
PSQI sleep latency 2.00 (.71) 1.36 (.93) 3.63 13 .003 
PSQI sleep duration 2.17 (.70) 1.73 (.88) 2.69 14 .017 
PSQI sleep efficiency 1.18 (1.12) 1.07 (1.33) .27 13 .79 
PSQI sleep disturbances 1.34 (.51) 1.19 (.40) 1.32 15 .21 
PSQI medication .78 (1.12) .75 (1.24) 1.74 15 .86 
PSQI daytime dysfunction 1.03 (.72) .69 (.70) 1.70 15 .11 
MAP – apnoea probability .35 (.26) .44 (.34) -1.09 14 .29 
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Table 11.8.3  
Objective sleep quality measures scores of WLC subset group – matched to themselves as 
YI subset group. Paired samples t test.  
Measure M (SD) - pre M (SD) - post t df p 
Total time in bed (TTB) 421.36 (65.25) 449.14 (84.16) -1.40 13 .18 
Total sleep time (TST) 377.88 (51.00) 398.08 (89.67) -.99 12 .34 
SOL 7.59 (6.17) 12.86 (12.88) -1.24 13 .24 
WASO 53.86 (16.00) 54.14 (19.88) -.067 12 .95 
Sleep efficiency .88 (.069) .87 (.047) .65 12 .53 
light sleep duration 188.077 (40.24) 202.077 (47.74) -.96 12 .36 
SWS duration 113.23 (17.30) 126.85 (32.64) -1.51 12 .16 
SWS latency 17.54 (17.43) 20.07 (19.70) -.30 13 .77 
REM sleep duration 74.19 (23.99) 66.46 (39.26) .65 12 .52 
REM sleep latency 117.30 (29.22) 102.54 (54.48) 1.08 13 .30 
blood oxygen saturation 93.29 (1.85) 93.11 (1.28) .38 13 .71 
RDI 9.47 (5.73) 9.99 (5.73) -.49 12 .63 
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Appendix 12.  Advertisements 
App.12.1  Advertisement  (English version) 
A study of yoga for improving sleep in the elderly 
Sponsored by Shaare Zedek Medical Center, Israel Yoga Teachers 
Organization, Australia Israel Scientific Exchange Foundation, RMIT 
University – School of Health Sciences 
 Insomnia (disturbed sleep, non restorative sleep), is very common in the elderly 
population  
 Insomnia may cause tiredness, health problems and reduced quality of life, 
impaired cognitive ability, accidents and falls.  
 sedative-hypnotic drugs can have serious negative side effects  
 Yoga includes movement, stretches, relaxation, and meditation 
 Yoga has been shown to improve conditions such as hypertension, stress, anxiety, 
chronic pain etc. Some research suggests that yoga also helps with insomnia. 
 Our research program was designed to improve sleep and life quality. 
 For 3 months participants will train with a yoga teacher twice a week) Jerusalem 
metropolitan area) and use a special relaxation CD at home. All FREE! 
 If you are 60+ and feel your sleep quality is lacking you are invited to join the 
study.  
 
 For details please contact:  
Jonathan on 02-6666319 or email  sleepyoga@gmail.com 
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תכנית מחקר יוגה / הרפיה לשיפור איכות שינה וחיים לבני 06 ומעלה – ללא תשלום! 
הקרן לחילופי , ארגון מורי היוגה בישראל, בחסות המרכז הרפואי שערי צדק ירושלים
 TIMR ישראל ואוניברסיטת  –מדע אוסטרליה 
 גיל' בקרב שכיחה בריאות בעיית היא) מספקת לא שינה, שינה הפרעות(' אינסומניה' 
  .'הזהב
  .ונפילות תאונות, לעייפות, והתפקוד המחשבה בכושר לירידה גורמת' אינסומניה' 
 לתאונות סיכון גורם המהווה ,טשטוש כולל, לוואי בתופעות כרוך – תיתרופה הטיפול
  .ונפילות
  .ומדיטציה רגיעה, נשימה תרגילי, הרפיה, שחרור, מתיחות, תנועה כוללת יוגה
 ,אסטמה, לב מחלות, דם לחץ על חיוביות השפעות יוגה שלתרגול הראו מחקרים
  'וכו, חרדה, מתח, סכרת
  .השינה בפרטותכנית המחקר נבנתה לשיפור איכות חיים בכלל  .
 במשך בשבוע פעמיים הזהב לגיל מותאמת' רכה' יוגה יתרגלו המשתתפים
 רגיעה לתרגל ילמדו וכן יוני מחודש החל הכרם בית באזור חדשים שלשה
 והרפיה בבית בעזרת תקליטור מיוחד. ללא תשלום.
 בני 06 ומעלה מוזמנים להצטרף.
  לקבלת פרטים / להרשמה נא צרו קשר עם: יהונתן בטלפון 9136666-20
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  5אבחון ניסיוני/ות למחקר רפואי הכולל טיפול/ות מתנדבים/דרושים
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